Participants Catalog

Transcription

Participants Catalog
H2020 European Health Brokerage Event – Paris 2016
Powered by B2Match ©
Page 1 of 487
Cameroon
237health
18
Request: Traditional e-health market, Request for technical, pedagogical and commercial collaboration
France
3M France
19
Request: Understand and meet
France
4Clinics
20
Offer: Vaccine and Immunotherapeutics Development
Belgium
A-MEDICA
21
Offer: Funding & operational support
Turkey
Afyon Kocatepe University, School of Medicine, Cardiology Department.
22
Offer: Cardiology Projects
Czech Republic
AGEL Research a.s.
24
Offer: Offering clinical expertise, patient data
France
Agence Nationale de la Recherche
26
Austria
Agency for European Integration and economic Development
27
Offer: User centered policy support for innovative health care solutions
Ukraine
Agency of European Innovation
29
Offer: Antibiotics Big Data System
Offer: Preparation of joint proposals for H2020 Calls with leading Ukrainian organizations in the field
HEALTH
Request: Preparation of joint proposals for H2020 Calls with leading Ukrainian organizations in the field
HEALTH
Request: Project proposal for topic SC1-PM-21-2016: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries
Offer: Project proposal for topic SC1-PM-21-2016: Implementation research for scaling-up of evidence
based innovations and good practice in Europe and low- and middle-income countries
Ukraine
Agency of European Innovations
33
Offer: Preparation of joint proposals for H2020 Calls with leading Ukrainian organizations in the field
HEALTH
Request: Preparation of joint proposals for H2020 Calls with leading Ukrainian organizations in the field
HEALTH
Request: Project proposal for topic SC1-PM-21-2016: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries
Offer: Project proposal for topic SC1-PM-21-2016: Implementation research for scaling-up of evidence
based innovations and good practice in Europe and low- and middle-income countries
Austria
AIT - Austrian Institute of Technology
37
Offer: Bioinformatics and computational biology (Big data, NGS, omics, systems biology)
Request: Project partner in Horizon 2020
Request: Vaccine development for malaria and neglected infectious diseases
Offer: Bioinformatics for rare and undiagnosed diseases
Offer: Partner in PM-03-2017 - Diagnostic characterization of rare diseases
Austria
AIT - Austrian Institute of Technology GmbH
39
Request: Biomarker development and validation for patient stratification & companion diagnostics
adressing age related diseases (Focusing on: SC1-PM-02-2017)
Offer: SC1-PM-02-2017, New concepts in patient stratification - Rheumatoid Arthritis
Request: SC1-PM-02-2017, New concepts in patient stratification - rheumatoid arthritis
Austria
AIT Austrian Institute of Technology
42
Offer: We are your Research partner in the field User Experience, User-Centered Design, Prototyping
and Evaluation
Austria
44
Offer: Development of EEG based sleep monitoring for self assesment and home application
Jordan
Al-Balqa Applied University + Scientific Food Center + Scientific FACTS Center
46
Page 2 of 487
Request: Scientific Food Center in Jordan established with EU funds
France
Alaxia
47
Request: Thinking outside the box
Portugal
ALERT Life Sciences Computing
48
Request: Commercial and innovation cooperation
France
Altran research
50
Offer: E-health smart solutions conception
France
Ambassade du Luxembourg en France
52
Offer: Echanges France-Luxembourg et mises en relations entre sociétés et institutions françaises et
luxembourgeoises.
Turkey
ankara university
55
Request: Health problems, diseases and ICT program development
Turkey
Ankara University
57
Offer: Ankara University Stem Cell Institude
Turkey
Ankara University
60
Offer: A multicenter, placebo controlled, phase I/II trial comparing autologous bone marrow-derived
mononuclear and human umbilical cord stroma derived multipotent stromal cells with critical limb ischemia.
Turkey
ankara university
61
Request: HEALTH EDUCATION PROBLEMS, USING ICT FOR HEALTH EDUCATION, MULTIDISCIPLINARY
STUDIES FOR HEALTH PROBLEMS
Offer: HEALTH EDUCATION PROBLEMS, USING ICT FOR HEALTH EDUCATION, MULTIDISCIPLINARY STUDIES FOR HEALTH PROBLEMS
Turkey
Ankara University Faculty of Medicine
63
Request: Improvement of quality of life in children and young adults with visual impairment and prevention of potentially blinding diseases in childhood
Turkey
Ankara University, Faculty of Health Sciences, Department of Healthcare Management
64
Offer: The impact of low health literacy on the medical costs: How can we measure?
Offer: Cost-effectiveness analysis of renal replacement therapy for end-stage renal disease: How to use
the development of health policy?
France
AnyGenes
66
Offer: Signaling pathways analysis, biomarkers identification&patients stratification
France
AP-HP
68
France
AP-HP
69
France
APROVA
70
Offer: A CRO with the experience of European-funded consortiums to manage your clinical trials
France
Ariana Pharma
72
Offer: Statistical and data mining analysis expertise -- Bio-computing tools and decision support systems (DSS) development
Belgium
Artialis
74
Offer: Innovative Biomarkers, preclinical studies, and clinical trials in musculoskeletal field
United
Kingdom
Aseptika Ltd
76
Request: Personalised medicine
Request: BuddyWOTCH - wearable medical monitor for those with chronic respiratory disease
Spain
Asphalion S.L.
Offer:
Offer:
Offer:
Offer:
78
Scientific and Regulatory Services
Feasibility assessments during Drug development
Regulatory Strategy
Roadmaps: CMC, Non-clinical and clinical development plans
Page 3 of 487
Offer: Scientific advice (EMA, EU-NCAs, FDA,..)
Offer: Writing regulatory documentation: IMPD, IB, CTA, Orphan Drug Designation (ODD) application,
Paediatric Investigation Plan (PIP) and a lot more…
Offer: SME application to EMA
Spain
Asphalion S.L.
79
Offer: Scientific and Regulatory Services
Offer: Feasibility assessments during Drug development
Offer: Regulatory Strategy
Offer: Roadmaps: CMC, Non-clinical and clinical development plans
Offer: Writing regulatory documentation: IMPD, IB, CTA, Orphan Drug Designation (ODD) application,
Paediatric Investigation Plan (PIP) and a lot more…
Spain
Asserta Global Healthcare Solutions
80
Offer: Experts in Pharmacology and eHealth
Offer: eHealth solutions
France
Association E-SENIORS
81
Offer: As an “end-user group” representative, we can have a specific role with deep implication during
the whole project
Turkey
Association of Public Hospitals Northern Anatolian Region Of Istanbul
83
Request: Big Data Solutions and Pilot applications - Health Literacy
Belgium
AXINESIS
85
Request: Partnership in multi technological stroke & brain injuries patient care
Offer: Clinical and research partnership in the filed of brain injured patients
Request: Distribution partnerships in european countries
Spain
AZIERTA CONTRACT SCIENTIFIC SUPPORT CONSULTING SL
86
Offer: Scientific Consultancy Services in Biopharmaceutical drugs: From candidate to the approval
Offer: Consultancy Services in Medical Devices: From prototype to the market
Offer: Quality Systems services in Biomedical Research
Spain
87
Romania
BEIA Consult International
88
Request: Telemetry M2M / IoT Applications across a Distributed Cloud Platform
Turkey
Bilims
91
Request: Real-Time e-Problem Based Learning
France
BIO-MODELING SYSTEMS
92
Offer: CADI Discovery to decipher diseases' mechanisms and propose robust solutions
Offer: CADI Discovery for neurology, metabolism, inflammation
Offer: CADI Discovery for neurodegenerative diseases (Creutzfeldt-Jakob’s, Parkinson’s & Alzheimer’s
diseases), psychiatry, autism, cancer, diabetes, longevity/aging, infections, dermatology, skincare and
cosmetics.
Netherlands BioActor
96
Request: Nutritional solutions to prevent chronic disease
France
BIOASTER
97
Offer: Development and use of innovative technologies and approaches in multi-omics data generation,
predictive modeling and data integration and analysis covering vaccines, therapies, antimicrobial resistance and microbiota
France
BIOMODEX
99
Offer: SURGICAL SIMULATION
Request: SURGICAL SIMULATORS FOR INDUSTRY
Switzerland Biopack Medical SA
100
Offer: Exploitation of the Major H2020 Calls
Offer: Consulting Advisory Role, Design of a Project, Project Management, Exploitation, Dissemination
Page 4 of 487
and Communication of the H2020 Calls
Request: Seeking for Clinical Partners
Request: Seeking Clinical Partnerships
Request: Centers for Epidemiology and Health Policy Analysis
Request: SMEs & Big Compamies
Offer: Big Data Expertise
France
Biosims Technologies
102
Offer: Protein biomarker validation
France
BRAIN e-NOVATION
103
Request: BRAIN e-NOVATION
France
CAP DIGITAL
105
Offer: Interested in joining a consortium for the HCO10 Support for Europe’s leading Health ICT SMEs
Offer: interested in joining a consortium for the call gaming and gamification
France
CARDIAWAVE
106
Request: Noninvasive ultrasound therapy for heart valve disease
Switzerland CARDIOCENTRO TICINO
107
Offer: CELL THERAPIES
Offer: CARDIAC ELECTROPHYSIOLOGY
Offer: RARE CARDIOVASCULAR DISEASES: PREVENTION, DIAGNOSIS AND TREATMENT
Poland
CAS MED TECH sp. z o.o.
108
Request: CAS - Active nano-tropocollagen - looking for investor
Spain
Catalan Institute of Oncology, IDIBELL
110
Offer: Cancer therapeutic resistance
Portugal
CCG - Center for Computer Graphics
112
Offer: Computer Vision Interaction and Graphics
Offer: Engineering Process Maturity and Quality
Offer: Perception, Interaction and Usability (Human Factors)
France
CEA Institut de biologie et de technologie de Saclay
115
Offer: Searching for SME partners to set up a Eurostar project on diagnostics
France
CEA LIST
116
Offer: INFRAIA-02: European Research Infrastructure in the field of Radiation Therapy and Medical Imaging: management and optimization of the patient dose in medicine
France
Cell&Co
118
Offer: Sample management ; Biobanking ; and Biorepository
Offer: Biobanking / Biorepository
France
Cellvax
120
Offer: Preclinical studies in Cancer and Osteoarthritis (OA) fields
France
Centre Collaborateur de l'OMS pour la recherche et la formation en santé mentale
122
Offer: Empowerment of mental health services users and carers
Portugal
CHLO-Hospital S. Francisco Xavier
124
Offer: Co-operation in Personalised Medicine and Active Ageing H2020 Projects
France
CHU de Dijon
125
Request: Improving cervix cancer prevention: understanding the hurdles in order to overcome them.
Request: PREVENTION OF CERVICAL CANCER IN WOMEN REFRACTORY TO CERVICAL CANCER SCREENING
Offer: national network of Clinical Research Centers for obstetrics and Gynecology
Portugal
CIAFEL-FADEUP
127
Offer: Exercise- and health-related outcomes
Poland
Clinical Communication Centre, Kazimierz Wielki University in Bydgoszcz, Poland
129
Poland
Clinical Communication Centre, Kazimierz Wielki University in Bydgoszcz, Poland
130
Page 5 of 487
Request: Clinical communication research an effective way to ensure high quality health care across
Europe and beyond
France
CNRS - UMR 7244
132
Request: Ethical and legal aspects while storing, sharing and working with biomedical data from human
individuals
Offer: Multiplexed analysis of biological samples for diagnostic purposes using nano-gold sensors, spectrometric imaging and/or NMR spectrometry associated to multivariate statistical analysis
France
CNRS UMR8258
134
Offer: Applications for engeneered nanoparticles
Poland
Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy
135
Request: research projects in the fields of medicine
France
CONSEIL DEPARTEMENTAL DES YVELINES
136
Offer: DomYcile gathering and exploitation of health services data for agieng people receiving home
care
Request: DomYcile gathering and exploitation of health services data for agieng people receiving home
care
France
138
Offer: DomYcile gathering and exploitation of health services data for agieng people receiving home
care
Switzerland Cytel, Inc.
140
Offer: Cytel Inc.
Czech Republic
Department of Biomedical Engineering, Brno University of Technology
141
Offer: (Bio)medical data processing
Offer: Bioinformatics – genomic and proteomic data processing
Offer: Live cell imaging and analysis
Bulgaria
Diavita Ltd
143
France
Diverchim SA
144
Offer: Valorisation of Matriochka chemical library
Norway
DNV GL
145
Request: Alarm management
Request: Safety and efficiency at lower cost when developing and finalising medical devices
Request: Big data: Pharma, medical devices and patient safety
Offer: Safety, quality and risk management increasing patient safety
Turkey
Dokuz Eylul University Faculty of Medicine Department of Family Medicine
147
Request: E-health for screening, diagnosing, therapy and monitoring of hypertension and type 2 diabetes in primary care based on clinical decision support system for physicians and patients.
Offer: Clinical expert in Ehealth of chronical disease, active aging in primary health care
Offer: Clinical expert and researcher in adolescent health in primary care
France
E-Seniors Association
149
Offer: End-user expertise and deep implication in the users' studies and pilot testing of the final product
during the whole project
Request: Project partners for Horizons2020
Belarus
Educational Institution "Gomel State Medical University"
151
Offer: Project "Gender Sensitive e-Health Promotion and Prevention"
France
Embassy of Hungary
152
Offer: Big data supporting public health policies
Turkey
Erciyes University
154
Offer: Online Holter Device
Turkey
Erciyes University
156
Page 6 of 487
France
Eukarys
158
Offer: Non-viral gene therapy for human or non human disorders based on the C3P3 technology
Offer: C3P3 Technology for protein bioproduction
Portugal
Fac Medicine Univ Porto
160
Offer: Portuguese academic/research medical faculty 300-staff strong, 100 of which clinical (twenty
IF>10 papers/year: ALLERGY, CARDIAC & CARDIOVASCULAR SYSTEMS, GASTROENTEROLOGY & HEPATOLOGY); 20 international patents
Switzerland FHNW - IMA
162
Offer: Bio-signals Sensors Systems
Offer: Sensors Systems for assisted surgery, active implants and robotics
Offer: Implant Development
France
FHU SUPORT (SUrvival oPtimization in ORgan Transplantation
164
Request: Partnership for translational projects
Request: Information on research funding
Offer: The platform network of the FHU SUPORT
Offer: Research platforms for experimental surgery and preclinical investigations
Germany
Fraunhofer IAIS
166
Offer: Big Data Analytics in Healthcare
Spain
Fundació Sant Joan de Déu
Offer:
Offer:
Offer:
ment
Offer:
Turkey
168
Active ageing and Self-Management of Health
Rare Diseases: Diagnostic Characterization of rare Diseases and New Therapies for rare Diseases
Impulsivity and Compulsivity and the Link with Nutrition, Lifestyle and the Socio-Economic EnviroClinical Trials, Chronic Diseases
Gazi University
171
Request: Pharmacogenetic and pharmacogenomic studies on drug toxicity and efficacy; personalised
medicine I would like to be partner one of projects.
United
Kingdom
GeneFirst
173
Offer: Detecting ultra-rare, cancer gene mutations in circulating cell-free DNA in blood using a novel
NGS technology
Offer: a novel multiplex realtime PCR for infectious disease detection
Offer: a novel multiplex realtime PCR for cancer mutation detection
France
GENOPOLE
175
Request: GENOPOLE, leading biocluster of biotech companies in Health, is looking for partners in the
field of personalized therapeutic interventions, malaria, biomarkers, rare and chronic diseases, ICT and
management of "omics" data
Spain
GIRONA BIOMEDICAL RESEARCH INSTITUTE (IDIBGI)
177
Request: Managing population Big Data and Active and healthy ageing
France
Greenpharma S.A.S.
178
Offer: Clinical evaluation of a new patented composition against addiction to drugs and alcohol
Offer: Drug discovery -- hit-to-lead optimisation
Offer: Valorisation of natural products, side-products and wastes for cosmetic, functional food, veterinary industries and crop protection
Turkey
Hacettepe University
180
Offer: regenerative medicine, A multicentre, phaSe 1/2 clinical trial compAring bone marrow mononuclear and umbilical cord-deriVed multipotent stromal cElls in critical LIMB ischemia
Request: cardiovascular surgery
Netherlands Hanze University of Apllied Sciences
182
Offer: 5G Fieldlab
Offer: Independent Living Business & Information Modelling & Solutions
Page 7 of 487
Turkey
Hayriya Teknoloji Ltd
184
Offer: IoT HealthCare Information Systems
Request: A Self-Management Health Care Project
United
Kingdom
High Force Research
186
Offer: Chemical Synthesis Services
Offer: Novel Fluorescent Retinoids with applications in stem cell chemistries
Spain
Hospital Consorci Sanitari de Terrassa
188
Offer: Health organization offers big capabilities of recruitment for e-health devices deployment at
homes for healthy aging solutions
Offer: SFS-38-2016 Impulsivity and compulsivity and the link with nutrition, lifestyle and the socio-economic environment
Offer: Empowering patients
Spain
Hospital Vall d'Hebron - Institute of Research
191
Offer: As a partner PM-06-2016 - Vaccine for malaria/neglected infectious diseases
Switzerland Huperion Pharmaceuticals
193
Offer: Drug discovery and development company willing to participate in project involving drug therapy
and with relevance for epigenetic processes and Histone Methyl Transferases (HMTs)
France
Hôpital Saint Louis, APHP ,Hla &Medecine
195
Offer: Personalized immunology and immunogenetics in transplantation and regenerative medicine
France
i Sonic Medical
196
Request: MINIATURISATION OF TONOMETER DEVICE
Request: FINANCING
Luxembourg IBBL (Integrated Biobank of Luxembourg)
198
Offer: Biobanking and biomarker validation partner for consortium research projects
Luxembourg IBBL (Integrated Biobank of Luxembourg)
200
Offer: Biobanking, sample processing & analysis, biomarker validation, biospecimen research
France
ID2Santé
202
Request: European network for oncology research in blood biomarkers
Offer: mHealth Diagnostics and therapy monitoring
Offer: Organic compounds analysis by infrared optical fiber
Offer: Non-clinical and clinical studies
Offer: Healthcare data management
Spain
IESE Business School
204
Offer: Support to Business Concept Development / Market Deployment for Innvoative Technologies
Belgium
Ile-de-France Europe
206
France
IMAGENE
207
Offer: Clinical reference material and standards - offer for technical and/or commercial collaboration
Offer: Innovative Biobanking at room temperature
France
IMSTAR S.A.
209
Offer: Innovative High-Content Cellular Imaging proprietary solutions for cost effective biomarkers’
quantification in Oncology preclinical research, assisted Cyto-Pathology and large scale DNA damage assessment
France
Inato
212
Offer: Disruptive clinical trials
France
Inato
214
Portugal
INEB - Instituto de Engenharia Biomédica/i3S - Instituto de Investigação e Inovação em Saúde
216
Offer: Competences available
Spain
INNAXIS Foundation
218
Offer: Modelling complex biomedical challenges through networks and data analysis
Page 8 of 487
France
INRA
219
Offer: Metabolic Phenotype, Nutrition & Modeling
Request: Epidemiologists with prospective cohorts
Request: Integrative approaches/systems biology
Request: Clinician/Physician with expertise in obesity and type 2 diabetes
France
INRA
221
Offer: Metabolic phenotype, nutrition and modeling
Request: Integrated approaches / Systems biology
Request: Physician with expertise in obesity and type 2 diabetes
France
Inria
Offer:
Offer:
Offer:
Offer:
France
223
ORPHAMINE (Data mining platform for Orphan diseases)
Shanoir (Sharing NeurOImaging Resources)
Shanoir (Sharing NeurOImaging Resources)
Examples videos.
Inserm
225
Request: Infection and Inflammation
France
INSERM
227
France
INSERM U1034
228
Offer: A complete panel of experts on a bright health challenge
France
Inserm U1163 - Human lymphohematopoiesis Laboratory
229
Request: Optimization of conditioning regimen before transplantation of hematopoietic stem cells or Tcell progenitors in order to favor engraftment in the bone marrow and in the thymus.
France
INSERM, US14 - Orphanet
231
Offer: Orphanet: providing data and an ontology for rare disease research
Spain
Inspiralia Tecnologia Avanzada SL
233
Offer: H2020 collaboration
France
Institut Carnot CALYM
235
Offer: Lymphoma expertise, from non-clinical to phase III clinical studies
France
Institut du Cerveau et de la Moelle Epinière
237
Offer: Research program on population stratification and rewiring of the brain
France
Institut du Cerveau et de la Moelle épinière (ICM)
238
France
Institut Pasteur
240
Offer: Milieu Intérieur: multi-disciplinary consortium dissecting the interplay between genetics, environment and impact on a healthy immune response
France
United
Kingdom
Institut Pasteur
242
Institute of Bio-Sensing Technology
243
Request: New concepts in patient stratification – biosensors for identifying patient groups
Offer: Chronic diseases therapies – biosensors to monitor effectiveness of therapeutic interventions
Offer: Effectiveness of healthcare interventions for adult population – home use biosensors
Offer: Quality control for regenerative medicine
Offer: eHealth innovations for the patient (PCP) – home diagnostics front end
Offer: Standardisation of procedures for in-vitro diagnostics
United
Kingdom
Offer:
Offer:
Offer:
Offer:
245
New concepts in patient stratification – biosensors for identifying patient groups
Chronic diseases therapies – biosensors to monitor effectiveness of therapeutic interventions
Effectiveness of healthcare interventions for adult population – home use biosensors
Quality control for regenerative medicine
Page 9 of 487
Request: Standardisation of procedures for in-vitro diagnostics
France
Institute of Cardiometabolism and Nutrition (ICAN)
247
Offer: Translational research towards innovative personalized medicine for cardiometabolic diseases
Czech Republic
Croatia
Institute of Experimental Medicine - Academy of Sciences Czech Republic
250
Institute of Public Health for the Osijek-Baranya County
251
Offer: Institute’s expertise
Request: Managing of bacterial resistance to antibiotics in real time
Belarus
Institute of Radiobiology of the National Academy of Sciences of Belarus
253
Offer: Comparing the effectiveness of existing healthcare interventions in the adult population
Portugal
Instituto Pedro Nunes (Las) and Ageing@Coimbra
255
Offer: eVida – Digital Social Innovation Platform
Spain
Intelligent Pharma, S.L.
257
Offer: Molecular modeling
Italy
Intelsint srl
259
Request: Full automation for sample prep in Histolabs
Portugal
IPMA
260
Offer: Bioprospection of marine bioative compounds with health benefits
France
ISoft
262
Offer: Innovative technology dedicated to the management and the processing of massive and heterogeneous biological data
Turkey
Istanbul Sehir University
264
Request: Research collaboration is sought in personalized medicine
Turkey
266
Offer: I am an expert on Translational Cancer Research Using Computational Techniques and I seek Biologists and MDs for collaborations
Turkey
Istanbul Technical University
267
Request: Research and Development on personalised coaching for well-being and big data supporting
public health policies
Turkey
269
Offer: Health Economist
Turkey
272
Offer: Understanding the mechanisms of complex diseases for prevention and treatment
Turkey
273
Request: Research and Development on personalised coaching for well-being and big data supporting
public health policies
Italy
ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST)
275
Offer: Cytometry and CTCs Lab
Offer: : A new method for CTC-based patient stratification and personalized medicine
Request: Research center and Small and Medium Enterprise (SMEs)
Request: Oncology Research institutes
Italy
ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI, IRST SRL (IRST)
277
Offer: Oncology Research institute-Cytometry and CTC Lab
Offer: A new method for CTC-based patient stratification and personalized medicine
Poland
ITTI
279
Offer: Distant health monitoring platform - MedStar.co
France
JDRF
281
Page 10 of 487
Request: Diabetes type 1 in Microbiome - Autoimmunity - Vaccine areas
Belgium
Johanniter International
283
Offer: Experienced Proposalwriters and End User Connection
Offer: Europeanwide Test facilities and network
Offer: European Policy Making and large scale trials
Turkey
Kadir Has University
285
Offer: Smart position and movement monitoring using iBeacons
Offer: Interest to participate in a consortium: Smart data processing for Big Health Data
France
Keyrus Biopharma
287
Offer: CRO Partnering for your projects
France
Leads To Development
289
France
290
Offer: Preclinical and non-clinical development support
Offer: Preclinical and non-clinical development support (regulatory, production, toxicology and quality)
Spain
LEITAT Technological Center
Offer:
Offer:
Offer:
Offer:
France
292
BIOMED Division
Safety & Sustainability Division
Devices & Design & Engineering (D2E) Division
Advanced Materials Division
LIVANOVA SORIN CRM
295
Offer: Active implantable medical devices
Luxembourg Luxembourg Institute of Health
296
Request: Research and developpment of a RNA-based diagnostic tool to predict outcome of acute cardiovascular disease
Request: Research and developpment of a molecular diagnostic tool based on RNA detection in blood
cells
Portugal
MD Tour - Medical Tourism and Medical Innovation
298
Offer: MD tour Medical Tourism , Medical innovation
Request: MD tour Medical Tourism , Medical innovation
France
Medclinik
300
Offer: Clincally validated Virtual Nurse for Treatment adherence
Request: Clinical and techno partner for H2020 project on patient self management in cardio / transplant care
Turkey
MedLab Health Solutions
302
Turkey
303
Request: MedLab Solutions for Monitoring Patient
France
MedTrucks
305
Request: Partnership for deploying Mobile Dialysis Unit in remote area.
France
MethodCO
306
Request: Weight Management and weight loss program
Turkey
Ministry of Health, Turkey
307
Request: General Directorate of Health Information Systems
Turkey
309
Offer: Turkish Ministry of Health, General Directorate of Health Information Systems
France
MITOLOGICS
311
Offer: Mitochondrial dysfunction
Offer: Mitochondrial targeting in oncology
Poland
Mossakowski Medical Research Centre of the Polish Academy of Sciences - MMRC
313
Offer: partner in rare diseases - chronic diseases - regenerative medecine projects
Belgium
MULTITEL
315
Page 11 of 487
Offer: Development of multi-modal optical imaging from visible to THz.
Request: Applications of novel biomolecular sensors
Offer: Optical sensors and instruments for labeled or label-free assays
France
mydoctool
317
Request: Health care follow up protocol design and test
Netherlands MyLife Technologies BV
319
Request: Smart microneedle patches for dermal drug delivery
Switzerland NANOGALENIX Sàrl
Offer:
Offer:
ability
Offer:
Offer:
Hungary
321
Mesoporous silica nanoparticles fot theranostics
Nano/micro drug delivery systems for the enteral administration route with enhanced bioavailOENE: oxygen entrapped nano-emulsions for local delivery of oxygen to cells, tisssues and organs
Antibiotics from the natural pool active on multiresistant bacterial strains
National Healthcare Service Center
323
Offer: Data analysis and policy concept making
Request: SC1-PM-21 Implementation research
Hungary
National Healthcare Service Center (NHSC)
325
Offer: Unmet needs and validation
Offer: National Healthcare Service Center (NHSC) colleagues and NHSC hospitals are interested in joining consortium looking for end-user of research
Request: Looking to partner with National Healthcare Service Center (NHSC) and NHSC hospitals
Belgium
NCP-Wallonie
327
Offer: NCP in Belgium / Identifying and selecting the best Belgian partners for your project.
Turkey
Nesne Elektronik Danışmanlık Ltd. Şti
329
Offer: Interested in development of Exo-skeleton systems
United
Kingdom
Northumbria University
330
Offer: Integrated approach to modelling of health and disease with links to ageing
Norway
Norwegian University of Science and Technology (NTNU)
331
Offer: Large population registry seeking partners for cooperation in PM-18 and PM-10
Offer: One of the largest total population based helath
Offer: One of the largest total population based longitudinal health surveys, The HUNT Study, Norway
Norway
333
Norway
335
Offer: Exploitation of a unique population data repository for public health policy development, forecasting of health trends, impacts and comparing effectiveness of interventions. Challenge: PM-18-2016 - Big
Data supporting Public Health policies
Request: Treating and managing diseases PM-10-2017 - Effectiveness of healthcare interventions for
adult population
Belgium
Novadip
338
Offer: Clinical development of Novadip Biosciences (Regenerative Medicine)
Germany
Nurogames GmbH
340
Offer: Nurogames GmbH Research and Innovation Profile
Germany
Nuromedia GmbH
342
Offer: ICT: development of cross-platform ehealth & mhealth applications and games
France
OpenHealth Company
344
Offer: Meet H2020 Healthcare data challenge through value creating EU partnerships
Spain
OPESVAL European Health Projects Office- Valencia Region
345
Offer: The European Health Projects Office- Valencia Region
Page 12 of 487
Czech Republic
OR-CZ
347
Offer: Developing information systems for healthcare
Request: CS1-PM12-2016: PCP eHealth innovation in empowering the patient
Request: SC1-PM18-2016 Big data supporting public health policies
Request: SC1-PM19-2017 PPI for uptake of standards for the exchange of digitalised healthcare records
Offer: We developed own information systems for archiving, viewing and sharing radiology data (imaging pictures) in DICOM format.
Offer: Secure and guarantee big data archiving.
France
Orange Healthcare
349
France
ORPHELIA Pharma
350
Request: Looking for partners in the neuro-paediatric and metabolic diseases fields
Norway
Oslo and Akershus University College
351
Request: Medicines and patients safety
Norway
Oslo medtech
353
Norway
Oslo Medtech
355
Request: Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
France
PARTNERS
357
Offer: Research cooperation / clinical development plan design and clinical research execution
France
Pasteur Institute
359
Offer: NGS and analysis research platform for genomic, metagenomics and proteomic studies
United
Kingdom
PCI Pharma Services
361
Offer: Supply chain services
Switzerland PKNM Solutions Sarl - CH
362
Offer: Exploitation of the Major H2020 Calls of PKNM Solutions’ Interests (as described above)
Offer: Consulting Advisory Role, Design of a Project, Project Management, Exploitation, Dissemination
and Communication of the H2020 Calls
United
Kingdom
Plymouth Graduate School of Management
364
Offer: Developing an Innovative Big Data Approach and Dedicated Platform to support Future Healthcare Organisations
Switzerland Polygene AG
366
Offer: State-of-the-art technologies for the generation of animal models of human disease
Request: Forming consortia and projects, which need customized animal models of human disease, e.g.
within the call "Diagnostic characterisation of rare diseases"
France
Polytech Orleans
368
Request: Computer models for living organs: Diagnostic and Drug treatments
United
Kingdom
Public Health England
370
Request: PM-07-2017 Mental Health and Wellbeing in the Young
Request: Participating in active ageing and self-management of health programme calls
Portugal
Raríssimas - Associação Nacional de Deficiências Mentais e Raras
372
Offer: CASA DOS MARCOS - RESOURCE CENTRE FOR RARE DISEASES
Portugal
Raríssimas - Portuguese National Association for Rare and Mental Disorders
373
Page 13 of 487
Poland
Rehabilitatus
375
Offer: Markerless telerehabilitation system to be integrated in comprehensive program/platform of services dedicated to ageing population
Turkey
Research Center for Rejenerative and Restorative Medicine (REMER) in Istanbul Medipol University 376
Offer: Identification of novel causative genes and therapies for autosomal recessive rare diseases
Offer: Discovery of novel genetic factors, molecular mechanisms and new therapies for Alzheimer's disease
Request: Systems Medicine: Integration of genomics data with other omics-data for the risk assesment,
prevention and treatment of common diseases
Request: Personalised Medicine for Heart: Integration of clinical, genetic and life-style information for
risk assessment, tailored prevention and therapy of heart diseases
Romania
ROPARDO
380
Offer: ZivaCare : Cloud Health Parameter Monitoring System
United
Kingdom
ROYAL Society for Public Health
382
Request: Youth health Champions
Offer: Health Champions
France
Sanofi
384
Request: Identify assets within companies dedicated to e-health and integrated care solutions.
Switzerland Saphetor
385
Offer: Next generation sequencing (NGS) data analysis, germline and somatic human variants discovery, annotation and classification.
France
SAS REVINAX
387
Offer: enhance training technic
France
Semperego
389
Offer: Technology for stabilisation / preservation of biomolecules at room temperature
France
Skappy
390
Request: Commercial ans scientific cooperation
France
SLEEP APNEA BIOTECH INNOVATION
392
Request: Evaluation of clinical potentiel of biomarkers
France
SOCOSUR Chem
393
Offer: H2020-SMEINST-2016-2017 - Active Pharmaceutical Ingredients supply solutions for H2020 projects
Request: SC1-PM-09-2016 - H2020 partnership for new MoA in OsteoArthritis clinical trials
France
Soladis
395
Offer: Clinical and Statistical services
France
Sorbonne Universities, University Pierre and Marie Curie
397
Offer: Scalable biomedical imaging/engineering for massive data analytics
Request: Parallel computing for high-content imaging (big data)
Request: Medical challenge and knowledge
Offer: Massive Data Analysis
France
Sparks & Co
399
Offer: Impact - Communication and Dissemination of your research
Spain
SPECIPIG
Offer:
Offer:
choice
Offer:
choice
France
401
CRO Pre-clinical Services, Breeding center (miniature pigs) for biomedical research
SPECIPIG as partner for Pre-clinical research in therapeutic areas in which miniature pig is a
model:
SPECIPIG as partner for Pre-clinical research in therapeutic areas in which miniature pig is a
model:
STAB XTOM
403
Offer: Smart healthcare devices provider
Page 14 of 487
Spain
Starlab Barcelona SLU
404
Request: Starlab Barcelona: Your SME partner for electrophysiology, BigData, and neurotechnology
France
Stimul
406
Offer: Digital health service enabling online behaviour therapies helping lifestyle modifications (inactivity/weight-loss)
France
Stimul
407
United
Kingdom
France
Strata Health Europe
408
Strata Health Solutions Europe
409
Request: Strategic partnership to build an integration logic to improve care coordination across a regional care ecosystem
Offer: Resource Matching and eReferral technology
France
STREAMVISION
411
Request: Looking for e-health partners and players
France
STREAMVISION
413
Switzerland SUPSI
414
Request: Big Data for Social Health
France
SWAF
416
Offer: Hydration solution
Poland
SWPS University of Social Sciences and Humanities
417
Request: Relieving stress to enhance reproduction: Cognitive Behavior Therapy and blended intervention for the treatment of Functional Hypothalamic Amenorrhea. A randomized clinical trial with reproductive hormone measures as outcomes.
Germany
Synchem UG & Co. KG
419
Offer: Synthesizing new molecules for the research on active substances
France
Systematic Paris Region
420
Offer: Collaboration with partners working in ICT and Healthcare technologies within H2020 projects
France
Team8
422
Request: Team8, the connectable watch for kids for fun, health and safety.
France
tebu-bio
423
Request: Generic technologies for in vitro assays and physiological fluid analysis
Offer: In vitro alternatives to animal models
Spain
Tecnologias Avanzadas Inspirala SL
425
Offer: Financing your project with the leader - H2020 Framework Program for SME´s in HEALTHCARE
Turkey
Teknopar
426
Request: Telemedicine, telehealth and home care services
Turkey
Teknopar
427
Request: ICT solutions for active and healthy ageing and management of health data
United
Kingdom
The University of Manchester
429
Request: Looking to partner with the University of Manchester
Offer: Universty of Manchester colleagues are interested in joining a consortium for SC1-PM-02-2017:
New concepts in patient stratification;
France
TheFamily
431
Request: The Future Of Aging Care
Ireland
Tonix Pharma Limited
432
Request: Partnership in European Clinical Trials for CNS Disorders
Page 15 of 487
United
States
Tonix Pharmaceuticals Holding Corp.
433
Finland
TraceRay Oy
434
Request: Sophisticated technological platform for bone regeneration in humans and animals
Spain
Traza consultores
435
Offer: PM-15-2017 - Personalised coaching for ageing population
Spain
Traza consultores
437
Offer: PM-07-2017 - Mental health and well-being in the young
Germany
TU Darmstadt
439
Offer: Application-specifc computing architectures
Turkey
TUBITAK
441
Offer: TUBITAK
Turkey
TUBITAK MARMARA RESEARCH CENTER
443
Request: Suport of Turkish Initiative on Human Biomonitoring on European Initiative
Portugal
UCP - CREATING HEALTH - Research and Innovation Funding
445
Offer: Ophiomics - an SME Partner for SC1-PM-01-2016: Multi omics for personalised therapies addressing diseases of the immune system
Offer: HELP U2B IT, LDA (HUBIT) - A Partner for research and development of machine learning for correlations between health improvement programs and health outcomes, promoting healthier lifestyles.
France
UK Science and Innovation Network
448
France
Umanlife
449
Request: Umanlife, platform of prevention to follow and manage his health and wellbeing
France
UNICANCER
450
Offer: Real life data
Offer: Clinical trial for cancer
Offer: interoperable electronic health record for translational research
Portugal
UNINOVA-CTS
453
Offer: UNINOVA
Spain
Universidad complutense
455
Offer: Advise on Health systems cohesión mechanisms
Request: Access to Health
France
University Hospital of Montpellier
457
Offer: Persistent Immune Activation in patients followed-up for a chronic disease and emerging comorbidities
Switzerland University of Applied Sciences Northwestern Switzerland
458
Request: Additive Manufacturing of Smart Implants
Italy
University of Bologna
459
Offer: Societal challenges. Health, demographic change and wellbeing
Spain
University of Deusto
461
Offer: Collaboration in the areas of Personalised Medicine, ICTs for Health and Wellbeing, and Active
Ageing
Request: Seeking partners interested in projects on Machine Learning, Data Mining and Biomedical Signal Processing
Spain
463
Offer: Collaboration in the areas of Personalised Medicine, ICTs for Health and Wellbeing, and Active
Ageing
Request: Seeking partners interested in projects on Machine Learning, Data Mining and Biomedical Signal Processing
Switzerland University of Geneva
466
Page 16 of 487
Offer: S-Mouse for Cognitive Charge Measurement
Request: AAMI
Offer: Interactive social avatar/robots
Offer: Smart Home devices and Internet of Things
United
Kingdom
University of Reading
468
Request: University of Reading interested in proposal on call SC1-PM-09-2016 New therapies for Chronic diseases
United
Kingdom
University of Sheffield - Medical Advanced Manufacturing Research Centre
469
Request: mechanical and electrical design, prototyping and verification, design for manufacture, and visualisation
United
Kingdom
University of Southampton
471
Offer: SC1-PM-02-2017: New concepts in patient stratification; SC1-PM-16–2017: In-silico trials for developing and assessing biomedical products; SC1-PM-17–2017: Personalised computer models and in-silico
systems for well-being
Offer: SC1-PM-16–2017: In-silico trials for developing and assessing biomedical products
Offer: Computational engineering and design of cardiovascular devices
Offer: Microfluidic Based Wearable Tissue-fluid / Blood Chemical Analyser for Continuous Monitoring of
Body Chemicals
Request: Constitutive modelling of biological tissues and biomaterials: mathematical and computational models
Belgium
Université catholique de Louvain – Louvain Bionics
Offer:
Offer:
Offer:
Offer:
Offer:
Offer:
France
473
Design and control of robots for the rehabilitation of the upper limbs
Design and control of robotic prostheses for the lower limb
Design and optimization of assisted surgical procedures
Design of virtual/augmented reality interfaces
Modelling and experimental characterization of motor control and human motion
Identification and analysis of ethical issues within the human / robot interaction
Université Claude Bernard Lyon 1
475
Offer: Research cooperation in pharmacoepidemiology - Research tools: French Claims and Hospitalizations data; Electronic Health Records (eg: disease analyzer); patient reported outcomes
France
Université Paris Sud
477
Offer: European desk of Universite paris sud can help you to find the relevant academic research team
in your collaborative EC project
Romania
UTI Grup
479
Offer: Ms. Alina Manea
Ukraine
Uzhgorod National University
481
Request: Research of diagnostic, prognostic and predictive markers of malignant gliomas
Austria
Vienna Biocenter Core Facilities, GmbH
483
Offer: SC1-PM-03–2017, SC1-PM-02-2017: offer of advanced optical microscopy solutions for clinical applications
Offer: Offer of expertise in Bioinformatics & Scientific Computing
Offer: SC1-PM-02-2017, SC1-PM-03–2017: offer of Next Generation Sequencing services
Offer: SC1-PM-08–2017: New therapies for rare diseases - glutaric acidemia type I, maple syrup urine
disease
Offer: SC1-PM-01-2016 - offer of preclinical phenotyping services - mouse models
Offer: SC1-PM-06–2016: collboration offer in the field of protein technologies and CRISPR/Cas9 genome
engineering technology for genome engineering
Italy
world federation of Hydrotherapy and climatotherapy FEMTEC
486
Offer: the impact of thermal therapy on people’s wellbeing
Page 17 of 487
Cameroon
237health
Organisation Name
Country
Cameroon
City
Yaoundé
Street
Mvan
Website
Phone
Organisation Type
R&D Institution
Person
Name
eric frank Moukon A Kibeng
Email
[email protected]
Job Position
Organisation Details
The 237health joint venture (237health) is a specialized R&D laboratory that is concerned with ICT innovative solutions for fragile populations. It was established on 25 february 2014, headquartered in Yaoundé, Cameroon. The constitution of the 237health joint venture had been signed by about a hundred of health care providers on July 2015.
Since its creation, it has played a leading role in the census of both formal and informal health actors around our
country. in order to improve their abilities and their litigious capacities (mainly through e-learning workshops plus
"masterclasses").
In terms of health services, 237health looks to improve governance, financing, staffing and management, and the
availability and quality of evidence of local traditional medecines to guide policy making. It also strives to "ensure improved access, quality and use of medical products and technologies". 237health working with donor agencies and
national governments can improve their use of and their reporting about their use of our data.
Its current priorities are eHealth innovations for the population, throughout a better value chain organisation of traditionnal medecines, in particular destined to pregnant women and aggeing people, specificaly with our innovative initiatives for the medical appointment reminders
Areas of Activity
Active ageing and self-management of health
• PM-12-2016 - eHealth innovations for the patient
(PCP)
• PM-15-2017 - Personalised coaching for ageing
population
Coordination activities
• HCO-16-2016 - ICT for Active and Healthy Ageing
Cooperation Profiles
Request: Traditional e-health market, Request for technical, pedagogical and commercial
collaboration
SOLUTION OR EXPERTISE SOUGHT
Currently we are setting up our traditionnal e-health market and are looking for : 1) Training / educational partners to
identify key competencies for health (informal) actors through the practice of their profession 2) safety (and/or efficacy) testing partners of traditional medicines 3) establishment of clinical trials on all medicines, most popular first 4)
Expertise Partner on obligations displays of drugs compositions for sale
TYPE OF PARTNER SOUGHT
For our Cameroonian traditionnal e-health market, we are looking for european experts and firms : 1) European experts/consultant in training of health actors 2) European laboratory of drug tests 3) European specialized organism in
medicines labeling
Page 18 of 487
France
3M France
Organisation Name
Country
France
City
CERGY PONTOISE
Street
Bd de l'oise
Website
Phone
01 30 31 80 90
Organisation Type
Large Company
Person
Name
LENTZ Adeline
Email
[email protected]
Job Position
Government Affairs Manager
3M multi sectors innovative industry Interested by H2020 projects on digital health, existing corsortiums for improving healthcare, and leading companies in Europe on the subject.
Areas of Activity
Treating and managing diseases
• PM-09-2016 - Chronic diseases therapies
(PCP)
• PM-13-2016 - ICT solutions for ageing population
(PPI)
Methods and data
• PM-16-2017 - In-silico trials for biomedical products
• PM-19-2017 - Exchange of digitalised healthcare
records (PPI)
Health care provision and integrated care
• PM-21-2016 - Up-scaling of evidence based innovations and best practices
• HCO-07-2017 - Global Alliance for Chronic Diseases (GACD)
• HCO-10-2016 - Support for Europe's leading
Health ICT SMEs
• HCO-12-2016 - Digital health literacy
Request: Understand and meet
Understand H2020 scope of opportunity in digital health Understand which are the active existing consortiums in EU
and in France for Digital health Meet key stakeholders to move forward
Coordinators of consortium in Digital Health or active members Leaders of H2020 projects in Digital Health Studies on
trasformation of healthcare through digital pain points on Digital health
People helping to understand above
Page 19 of 487
France
4Clinics
Organisation Name
Country
France
City
Paris
Street
8 Rue de la Terrasse
Website
Phone
Organisation Type
Other
Person
Name
Mehdi CHELBI
Email
[email protected]
Job Position
Director Business Development
4Clinics provides clinical operations, data management, biostatistics, medical & scientific writing, regulatory affairs
and scientific communication services.
Through the educational background of our staff, extensive on-the-job training and experience inside the pharmaceutical industry, 4Clinics have accumulated considerable expertise within the different domains of clinical, observational
and epidemiological studies in a broad range of therapeutic areas with well-known expertise in vaccine, cell therapy and immunology studies.
Areas of Activity
Preventing disease
• PM-06-2016 - Vaccine for malaria/neglected infectious diseases
• PM-08-2017 - Rare diseases therapies
• PM-11-2016-2017 - Regenerative medicine
Offer: Vaccine and Immunotherapeutics Development
4Clinics specialises in vaccines and immunotherapeutics studies with dedicated experts with the support of a scientific board. 4Clinics has considerable experience in vaccine and immunology representing more than 70% of the clinical,
observational and epidemiological studies managed by 4Clinics. 4Clinics built a sustainbale and long-term relationships with top 20 Pharma companies specialized in vaccine and immunotherapies and several biotech companies.
With the support of its scientific board and its considerable experience, 4Clinics proposes to support and manage all
or any part (statistics, data management, writing...) of clinical development and post-marketed studies in the field.
INNOVATIVE ASPECTS AND MAIN ADVANTAGES
- Access to clinical expertise in vaccines, immunology and cell therapies - Access to combined expertise in Biometry
and Medical Writing capabilities with experience in vaccines, immuno-ocology and clle therapies - No need to set-up
and train internal teams to biostatistics, data management and/or medical writing - No need to aquire any software
for e-CRF and statistical analysis - Direct access to clinical know-how and input from the pre-clinical stages
MARKET APPLICATION
- Prophylactic Vaccines - Therapeutic Vaccines - Cell Therapies - Gene Therapies - Immuno-oncology products
Expertise (Sample size calculation, Stattsicial power, Protocol development, Data Management Plan...) Insourced staff
Tasks to be outsourced (Writing of Protocole, statistical analysis on SAS, data management...) Fully integrated services including tools and tasks (Biometry platform) Training in biostatistics and medical writing
Page 20 of 487
Belgium
A-MEDICA
Organisation Name
Country
Belgium
City
Brussels
Street
Avenue des Saisons 100
Website
www.a-medica.com
Phone
Organisation Type
SME
Person
Name
Michael ROSEN
Email
[email protected]
Job Position
A-Medica enabling medical technology projects – with operational support and where relevant also funding package:
* Bridging from prototype to revenues phase
* Product launch and expanding revenues internationally
Areas of Activity
Offer: Funding & operational support
A-MEDICA enables medical technology projects – with operational support and where relevant also funding package: ?
Bridging from prototype to revenues phase ? Product launch and expanding revenues internationally
A-MEDICA enables health-tech & medtech projects to evolve from prototype stage (TRL 3-5) to business stage (TRL 9)
internationally. A-MEDICA mobilizes a range of funding instruments, grants & subsidies, public loans & bank guarantees, deferred payments and / or “sweat equity” type of arrangements, funding from private-public Industrial Programs, as well as possibly public and / or private local venture capital in host country, and other. A-MEDICA amongst
other also supports projects to secure U.S. Food & Drugs Administration (FDA) approval for medical devices, like the
"510(k)".
MARKET APPLICATION
A-MEDICA has hands-on experience from a range of territories like EU, US, Gulf States, ... Application wise, A-MEDICA
has or is engaged on devices for cardiovascular, neurology, organ preservation, vital signs monitoring, ... procedures.
Emerging health-tech & medtech projects having a prototype, in need of enabling and accelerating their development
towards commercial stage EU - wide Animal models; human trials; CE-marking; contract-manufacturing; distribution
Page 21 of 487
Turkey
Afyon Kocatepe University, School of Medicine, Cardiology
Department.
Organisation Name
Country
Turkey
City
Afyonkarahisar
Street
Izmir Yolu
Website
Phone
Organisation Type
University
Person
Name
Ersel Onrat
Email
[email protected]
Job Position
Chief of Department
We are very youg cardiology clinic, it is 16 years old. There are 7 doctotrs in department, two of them are Cardiology
Professor. We are interested in Cardiology Disease, Treatment, Intervention, New Pathophysiology of Some Unknown
Disease, Genetic Polymorphism. There are four national projects which are going on in our department. One of these
projects is about the differentiatial diagnosis of idiopathic dilated cardiomyopathy and ischemic dilated cardiomyopathy. The others are about genetic polymorphism of some cardiac disease. Cardiology Department and Biochemistry
Department and Genetic Departments collobrate very well in our faculty. Also we have some experience about cardiac rehabilitation. In the future, we want to investigate new device for home based cardiac rehabilitation device for our
country. There are one echocardiography labratory, one arrhythmia labratory and one catheterization labratory in our
clinic.
Areas of Activity
Understanding health, well-being and disease
• PM-02-2017 - New concepts in patient stratification
• PM-03-2017 - Diagnostic characterization of rare
diseases
• PM-10-2017 - Effectiveness of healthcare interventions for adult population
Preventing disease
• PM-05-2016 - The European Human Biomonitoring
Initiative
Offer: Cardiology Projects
We are ready all kind of cardiology projects. Especially interested in atrial fibrillation pathophysiology, and new treatment based pathophysiology. We have patients with idiopathic, ischemic or diabetic cardiomyopathy patients. Some
experience in cardiac rehabilitation. Diagnosis of cardiac arrhythmia and ablation treatment in electrophysiology
labratory
Investigating the molecular bases of cardiac disease
MARKET APPLICATION
For the molecular biology company, Cardiac rehabilitation devices,
Page 22 of 487
Turkey
No expertise up to now, University, compay Any Country,
Page 23 of 487
Czech Republic
AGEL Research a.s.
Organisation Name
Country
Czech Republic
City
Ostrava
Street
Zalužanského 1192/15
Website
research.agel.cz
Phone
+420739034298
Organisation Type
Large Company
Person
Name
Martina Urbankova
Email
[email protected]
Job Position
Manager of International Projects
AGEL Research is a memer of AGEL Group, the largest private healthcare provider in the CEE region. AGEL operates hospitals, outpatient centers, service and distribution companies, a research entity and a foundation both in
the Czech Republic and Slovakia. All hospitals in the Czech Republic run on our own HIS in which information about 2
000 000 patients is available in a real time.
AGEL in numbers:
•
•
•
•
•
39 Centers, 13 Hospitals (9 CR, 4 SR), 6 Out-patient Centers
5 300 Beds
170 000 Hospital In-patient Treatments Annually
2 000 000 Hospital Out-patient Treatments Annually
9 000 Employees
We offer our partners:
• Ability to assist from research stage to market implementation;
•
• Access to a diverse pool of patients and experts;
•
• Experience with Horizon 2020 and nationally funded research projects;
•
• Expertise relevant to Horizon 2020 topics;
•
• Experience with many clinical studies;
•
• Own HIS – information about 2 000 000 patients in a real time;
•
• Support to research and innovation collaborations across the board.
Areas of Activity
Methods and data
Page 24 of 487
Czech Republic
(PCP)
population
• PM-18-2016 - Big Data supporting Public Health
policies
Offer: Offering clinical expertise, patient data
We are able to contribute expertise of our clinicians, conduct product validation, do data mining and integrate ICT applications on our own HIS.
Page 25 of 487
France
Agence Nationale de la Recherche
Organisation Name
Country
France
City
PARIS
Street
50, avenue Daumesnil
Website
Phone
Organisation Type
Authority/Government
Person
Name
Loreline ROBBE
Email
[email protected]
Job Position
ANR provides funding for project-based research in all fields of science - for both basic and applied research - to public research organisations and universities, as well as to private companies (including
SMEs). Employing a method based on competitive peer reviews compliant with international standards,
ANR provides the scientific community with instruments and programmes promoting creativity and
openness, and stimulate new ideas and partnerships, particularly between academia and industry. Its
activity also contributes to enhancing the competitiveness and the influence of French research in Europe and across the world.
Since 2010, ANR has also been the lead manager of the Investments for the Future programme in the
field of higher education and research, in charge of project selection, funding and monitoring.
Areas of Activity
Preventing disease
• PM-07-2017 - Mental health and well-being in the
young
Methods and data
policies
• PM-20-2017 - Economic evaluation and measures
in the health sector
(PCP)
Page 26 of 487
Austria
Agency for European Integration and economic Development
Organisation Name
Country
Austria
City
Vienna
Street
Bräunerstrasse 11a
Website
www.aei.at
Phone
Organisation Type
Person
Name
Karin Rainer
Email
[email protected]
Job Position
project manager
With the active involvement in public-private partnerships (PPP), training activities and research, user focused development and counselling services, AEI, the Agency for European Integration and economic Development settled its
portfolio and thus facilitates and represents a professional interface between its members, relevant Ministries and
public bodies, stakeholders in international public administration and policy, research and business.
The AEI has successfully conducted more than 150 leveraged international projects with a total volume of over
100 million € since its inception.
The AEI has many years of experience in facilitating and leading projects in the framework of various funding programs.
Our main activities cover the fields
•
•
•
•
•
•
finance, border management and taxation,
security and police cooperation,
training and vocational education,
health, environment and societal challenges,
data protection and privacy issues,
labour market and business development.
The AEI was founded in 2003 by the Federal Ministry of Finance and approved by the European Commission as
"fully mandated body" to create an inter-ministerial platform to support Twinning activities in new and future member states of the European Union with Austrian expertise and knowledge.
Apart from the core mission of internationally promoting the common legal requirements of the EU, and fostering
modern and efficient administration via partnership projects, AEI soon broadened its focus. AEI implemented a more
flexible and service-oriented approach covering the professional administration, management and implementation of
a wider area of international projects was the result.
As implementing agency representing Austria at the EUNIDA, the European Network of Implementing Development Agencies, the mandate of AEI evolved to support international development activities on behalf of the EU.
Areas of Activity
• PM-04-2016 - Networking of population cohorts at
EU level
Methods and data
policies
Preventing disease
Page 27 of 487
Austria
young
(PCP)
(PPI)
• PM-14-2016 - EU-Japan cooperation in ICT Robotics
population
records (PPI)
• HCO-08-2017 - Actions to bridge the divide in European health research
Health ICT SMEs
Offer: User centered policy support for innovative health care solutions
As a relevant, inter-ministerial project management platform, AEI, the Agency for European Integration and economic
Development, offers high-level expertise and networks in national and international policy cycles. Policy support and
the approach of public-private-partnerships (PPP) for innovative health care solutions are an important growth and
sustainability factors. These, together with multi level user- and beneficiary-aspects, are the core offer of AEI. Workshop design, knowledge transfer, training and dissemination activities are adding up to the holistic approach and supporting activities of AEI.
Innovative health care solutions are - until now focused on technical feasibility and in recent times also on first level
user-requirements - still lacking the transfer potential to broad, public implementation. Due to the specifically in this
field still weak, but compulsory connection to public bodies relevant to foster strategic inclusion of novel health care
solutions, services and processes, AEI brings in the multi level user- and beneficiary approach. Thus, including not only first level users at home or in special care institutions, care provider but above all policy maker and stakeholder are
in the focus of AEI. Besides traditional forms of communication and dissemination, AEI also involves high-level players
and international opinion leaders to strengthen this approach to embrace and support the outcomes of research and
development projects and pilots.
MARKET APPLICATION
public private partnerships
Strong coordinators and consortia from all countries, coordination
Page 28 of 487
Ukraine
Agency of European Innovation
Organisation Name
Country
Ukraine
City
Lviv
Street
Petra Pancha 11/3
Website
http://aei.org.ua
Phone
+380509292396
Organisation Type
R&D Institution
Person
Name
Ivan Kulchytskyy
Email
[email protected]
Job Position
President
The main aim of NGO AEI is increasing cooperation between Ukraine and EU in ICT, Renewable Energy, Agricultural,
Food, Health R&D areas within FP7/HORIZON2020, ENI and others EU-programmes.
The Agency supports Universities, R&D Institutions, SMEs, NGOs governmental and local authorities in preparation
and implementation of common international projects for the above mentioned cooperation programmes within the
activity as a Western Regional Contact Point of Scientific-Technical Cooperation with EU and NCP ICT&SME of Ukraine.
AEI monitor changes in the Health policy in EU and Ukraine, as well as the implementation of new process technologies in the Health area
Since 2010, AEI annually organize a delegation of leading medical scientist and representatives of hospitals and innovative SMEs in medicine to International Forum for Innovative Technology for Medicine IT MED
(http://bestofeast.mwci.eu/pl/itmed.aspx)
MAIN CAPACITY & EXPERTISE
•
•
•
•
•
Innovation intermediary with experience in Ukraine and Europe
Experience in FP6&FP7 projects
Direct contacts with leading R&I organizations in Ukraine and Europe
The developed network of contacts with innovative SMEs
Sound knowledge of matchmaking activities to research and industrial organisations with a view to
foster strategic partnerships at national and international level.
• Great experience in organising cooperation building (networking, twinning events and meetings) as
well as awareness raising events (info-days, dissemination conferences).
• Experience in using the social and professional networks (such as Facebook, LinkedIN, Twitter) to
disseminate information; organization discussion; the formation of thematic groups and increase of
contacts with the target groups who are interested in development the international cooperation between EaP countries and the EU.
• AEI administers LinkedIn group «Ukraine in the Horizon2020 and other EU-programs» with more
than 600 members and is actively used for the development of cooperation between the EU and
Ukraine in the field of R&D&I.
Ivan Kulchytskyy is a president of the AEI. He manages international projects, coordinates NCP ICT&SME of HORIZON2020 in Ukraine as well as ICT-cluster of Ukrainian national technology platform “AGRO-FOOD” in ETP network
“FOOD FOR LIFE”. He is a vice chairman of International Forum for Innovative Technology for Medicine IT MED. Moreover, he is experienced in WP-leader duties performance in a FP6-project ATVN-EU-GP (Academic Internet Television
Network Showcases the best of good practice activities), WP "Dissemination and promotion"; FP7-project SCUBE-ICT,
WP “Collaboration Potential Assessment”, FP7-project PICTURE, WP "Support to policy dialogue", FP7-project
EECA-2-HORIZON, WP "Strengthen cooperative research links – Partnership building actions and Advanced Support
Page 29 of 487
Ukraine
Services . He acted as regional expert of the EU project JSO-ERA in 2008-2011. He has an extensive experience in international events preparation and conducting as well as in broadening contacts of UA organizations with potential
partners from EU. Ivan Kulchytskyy is a coordinator of WG10 “Industrial, scientific and technical cooperation, intellectual property protection, information society” Ukrainian part of Civil Society Platform on Implementation of the Agreement on EU-Ukraine Association.
See details in the profile in LInkedIN
http://ua.linkedin.com/in/ivankulchytskyy
Areas of Activity
Preventing disease
young
Methods and data
• PM-17-2017 - Personalised computer models and
in-silico systems for well-being
policies
population
Health ICT SMEs
Offer: Antibiotics Big Data System
Project idea for topic SC1-PM-18–2016: Big Data supporting Public Health policies Developing of support clinical decision system AntiBidS (Antibiotics Big Data System) to standardize approaches to informed choice of antibiotics in the
treatment of patients with surgical infection and collecting new antibiotics data in the Internet. Project objectives:
simplify and improve the process of personalization antibiotic treatment of patients; give doctors tools for finding
medical information with similar characteristics diseases and prescribed treatment; analysis of medical records and
prediction of the dynamics of change for certain categories of patients.
The main issues are: 1) processing of big medical data; 2) medical letters parsing (information extraction); 3) search
of dependencies between illness, personal data and antibiotics; 4) personalized of patients' data; 5) make recommendations for prevention. -========== Concept and approach: 1)Development of open and compatible components
for a flexible effective infrastructure of system based on cloud computing. 2) Develop tools for managing, sharing and
use of vast amounts of data about preparations for making complex decisions about antibiotic therapy. 3) Collection
of data about medications, identification of key characteristics with regard to language description. 4) Modeling logic
reasoning doctor based on the patient's personal data and indications or contraindications of medications. 5) Expert
System will offer one or more variants of antibiotics, information obtained from the Internet. 6) Can consider the financial capacity of the patient.
MARKET APPLICATION
Our project will have the following expected results: Raising awareness of physicians with new medicines allow decrease in time spent for searching for information about them. Improving the quality of medical treatment by personalizing treatment schemes Ability to use the program not only to antibiotic therapy, but doctors can use for other
fields that will increase the quality of medical care Providing hospitals the proposed information system for the rational antibiotic therapy for diseases caused by different types of surgical infection The inclusion of large amounts of da-
Page 30 of 487
Ukraine
ta into useful information for planning authorities in the field of public health and implementation approach "health in
all policies".
Consortium - partnership required: Competences & Skills wanted - Content analysis, - Big Data synthesis and analysis,
- Technical. Types of partners sought - Universities, including medical, - Medical clinics of EU and Eastern Europe, Pharmaceutical companies, - Business structures. Work to be performed - Technologies innovative services in medicine, - Personalising of patients’ data, - Programming and Web-technologies.
Offer: Preparation of joint proposals for H2020 Calls with leading Ukrainian organizations
in the field HEALTH
The majority of announced Calls have the interdisciplinary nature. Project proposals should be based on: existing
state-of-the art knowledge on biological, psychological and social determinants of mental well-being such as societal,
cultural, work life, lifestyle, epidemiological, economic and environmental perspectives. Our organization collaborates
with many leading Ukrainian research groups and innovative SMEs. We also prepare analytical materials and proposals for policy makers. We are interested in the preparation of project proposals in the following topics:
SC1-PM-07–2017: Promoting mental health and well-being in the young SC1-PM-10–2017: Comparing the effectiveness of existing healthcare interventions in the adult population SC1-PM-15-2017: Personalised coaching for well-being and care of people as they age SC1-PM-18–2016: Big Data supporting Public Health policies SC1-PM-17–2017: Personalised computer models and in-silico systems for well-being SC1-PM-20-2017: Development of new methods and
measures for improved economic evaluation and efficiency measures in the health sector SC1-PM-21-2016: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries SC1-HCO-01-2016: Valorisation of FP7 Health and H2020 SC1 research results SC1-HCO-08–2017: Actions to bridge the divide in European health research and innovation SC1- HCO-10-2016 - Support for Europe's leading Health ICT SMEs SC1-HCO-12–2016: Digital health literacy
Depending on the topic and the specific tasks in each project proposal we can create interdisciplinary group of leading scientists and experts who can bring significant benefits to the project consortium. Ukraine is a big European
country and is open to different sort of reforms. Reform of the health sector is one of the greatest challenges for the
government of Ukraine and leading organizations in Ukraine. Therefore, new project proposals for H2020 calls may include testing and validation of the best European examples in the Ukraine.
MARKET APPLICATION
New successful project proposals for H2020 Calls
University, Research Organization, SME, Innovation intermediary, Agency, Consulting organization
Request: Preparation of joint proposals for H2020 Calls with leading Ukrainian organizations in the field HEALTH
Page 31 of 487
Ukraine
Request: Project proposal for topic SC1-PM-21-2016: Implementation research for scalingup of evidence based innovations and good practice in Europe and low- and middle-income countries
Topic description see on Participation portal https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/3056-sc1-pm-21-2016.html Ukraine is a middle-income country. Reform of the health sector is one
of the greatest challenges for the government of Ukraine and leading organizations in Ukraine. Ukraine is a big country and a neighbor of Europe. Therefore it is logical to consortium of project proposal for topic SC1-PM-21-2016 to has
at least one partner from Ukraine. We can generate interdisciplinary group of leading scientists and experts that can
ensure the successful implementation of the project. An interesting feature of the inclusion of Ukraine is a research of
cross-border cooperation between Poland and Ukraine on the transfer of best European practices in the field of Health
Inclusion of representatives of Ukraine in the consortium of project on transfer of best European practices in the field
of Health to low- and middle-income countries provides an opportunity to analyze the effectiveness of different ways
and instruments for the transfer of such experience, for instance: exchange of experience among leading health organizations, especially in the context of cross-border Poland-Ukraine cooperation; Health-policy change at the regional
level through better contacts with European countries in the western regions of Ukraine; impact instruments on the
improvement of Health-policy at the national level, discussion of problems and their solutions together with key stakeholders and policy makers; features of the use of European experience in the regions with higher disease level (eastern regions of Ukraine);
Offer: Project proposal for topic SC1-PM-21-2016: Implementation research for scaling-up
of evidence based innovations and good practice in Europe and low- and middle-income
countries
MARKET APPLICATION
Good successful proposal and access to the Ukrainian market
Page 32 of 487
Ukraine
Agency of European Innovations
Organisation Name
Country
Ukraine
City
Lviv
Street
Petra Pancha 11/3
Website
aei.org.ua
Phone
Organisation Type
R&D Institution
Person
Name
Oles Kulchytskyy
Email
[email protected]
Job Position
project manager
The main aim of NGO Agency of European Innovations (AEI) is increasing cooperation between Ukraine and EU in ICT,
Renewable Energy, Agricultural, Food, Health R&D areas within HORIZON2020, ENI and others EU-programmes.
MAIN CAPACITY & EXPERTISE
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Western Regional Contact Point of Scientific-Technical Cooperation with EU;
National Contact Point of ICT&SME of Ukraine;
Developed network of contacts with innovative SMEs;
Direct contacts with leading R&D&I organizations in Ukraine and Europe;
AEI acts as Innovation Bridge between science, business and authorities in areas of Health, ICT, Renewable
Energy.
Experience in organising cooperation building (networking, twinning events and meetings) as well as
awareness raising events (info-days, dissemination conferences);
Organization of trainings, seminars and conferences in Health topics;
We monitor changes in the Health policy in EU and Ukraine, as well as the implementation of new process
technologies in the Health area
AEI prepared the analysis of economic situation in Healthcare in Lviv region within IncoNet EaP grant;
Since 2010, AEI annually organize a delegation of leading medical scientist and representatives of hospitals
and innovative SMEs in medicine to International Forum for Innovative Technology for Medicine IT MED;
Experience in projects under the FP6 and FP7; the program «Polish Aid» Ministry of Foreign Affairs of
Poland; Science and Technology Days of Poland-East; CBC programme «Poland-Belarus-Ukraine»;
Our team implemented two FP7-ICT projects: PICTURE “Policy dialogue in ICT to an Upper level for Reinforced EU-EECA Cooperation” and EECA-2-HORIZON “Bringing the EU-EECA cooperation and policy dialogue
in ICT in the HORIZON 2020 era”.
AEI cooperate with the Lviv national medical university, Lviv Railway Hospital
AEI performs a coordinating role within a cluster ICT of Ukrainian national technology platform “AGROFOOD”.
AEI closely cooperates with Lviv State Centre of Science, Innovations and Informatization (LvCSII);
AEI administers web-portal «Innovative entrepreneurship: Lviv, Ukraine» with more than 7000 subscribers including medical scientists and innovative SMEs in Health area;
AEI administers LinkedIn group «Ukraine in the Horizon2020 and other EU-programs» with more than
600 members and is actively used for the development of cooperation between the EU and Ukraine in the
field of R&D&I. «
AEI has a status of research organization.
Areas of Activity
Page 33 of 487
Ukraine
Health ICT SMEs
population
Methods and data
policies
Preventing disease
young
Offer: Preparation of joint proposals for H2020 Calls with leading Ukrainian organizations
in the field HEALTH
MARKET APPLICATION
New successful project proposals for H2020 Calls
Request: Preparation of joint proposals for H2020 Calls with leading Ukrainian organizations in the field HEALTH
measures for improved economic evaluation and efficiency measures in the health sector SC1-PM-21-2016: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-in-
Page 34 of 487
Ukraine
come countries SC1-HCO-01-2016: Valorisation of FP7 Health and H2020 SC1 research results SC1-HCO-08–2017: Actions to bridge the divide in European health research and innovation SC1- HCO-10-2016 - Support for Europe's leading Health ICT SMEs SC1-HCO-12–2016: Digital health literacy
Request: Project proposal for topic SC1-PM-21-2016: Implementation research for scalingup of evidence based innovations and good practice in Europe and low- and middle-income countries
Offer: Project proposal for topic SC1-PM-21-2016: Implementation research for scaling-up
of evidence based innovations and good practice in Europe and low- and middle-income
countries
MARKET APPLICATION
Good successful proposal and access to the Ukrainian market
Page 35 of 487
Ukraine
Page 36 of 487
Austria
AIT - Austrian Institute of Technology
Organisation Name
Country
Austria
City
Vienna
Street
Muthgasse 11
Website
Phone
+43 664 88390686
Organisation Type
R&D Institution
Person
Name
Stephan Pabinger
Email
[email protected]
Job Position
R&D, Scientist
Molecular Diagnostics (AIT, HE Department) develops tailored biomarkers, biosensors and rapid point of care test
applications for life threatening diseases.
Our bioinformatics team uses and develops innovative statistical and bioinformatics methods and offers statistical support in validation studies.
Our services range from experimental design, feature selection and assay standardisation to the development
of decision support systems. A major focus of our research is on the analysis of sequencing data. We have comprehensive experience in analysing data obtained with various sequencing methods and can thus provide optimal support in this field.
More information: http://www.ait.ac.at/bioinformatics
Areas of Activity
• PM-01-2016 - Multi-omics addressing diseases of
the immune system
diseases
EU level
(PPI)
Methods and data
Preventing disease
Initiative
Offer: Bioinformatics and computational biology (Big data, NGS, omics, systems biology)
We have a strong background in biomarker identification and validation (e.g., various cancer types) and large experience in big data analysis (DNASeq, RNASeq, MethylationSeq, ...).
Bioinformatics, Sequence data analysis, Customized modules for biomarker identification and validation, High
throughput methods
Page 37 of 487
Austria
Research organizations, clinicians, industry
Request: Project partner in Horizon 2020
We are actively searching for partners to cooperate in H2020 health projects
Research organizations, clinicians, industry, SME
Request: Vaccine development for malaria and neglected infectious diseases
AIT is looking for additional partners completing a consortium for PM-06-2016 vaccine development for malaria and
neglected infectious diseases. Targets are West Nile Virus, RVF or Hanta virus. Not finally selected yet. Current Partners *) AIT (initiator and current coordinator AUT Diagnostics Development Intents to transfer coordinator role to vaccination specialist) *) Protobios (LOI) EST Improved Epitope Selection Technology *) University Nottingham (LOI) GBR
In-vitro Testing System for Vaccine Development *) Brigham & Women’s Hospital (LOI) USA In-vitro Testing System for
Vaccine Development *) Harvard Medical School *) Antibodybcn (LOI) ESP Antibody Production for Diagnostic Systems
*) Steinbeis-europe DEU Administration, Management & Dissemination *) (under negotiation Themis Biosiences) AUT
Vaccination Technology
*) Institution for In-Vivo Animal Testing *) Institution for Vaccine Production *) Institution for Human Vaccine Testing
Vaccine Production Animal Testing Human Vaccine Testing
Offer: Bioinformatics for rare and undiagnosed diseases
We have already created a bioinformatics toolkit for rare and undiagnosed diseases. In the upcoming H2020 call
PM-03-2017 - Diagnostic characterization of rare diseases we want to extend and employ this toolkit.
MARKET APPLICATION
Research, Clinical applications
Clinical partners, ...
Offer: Partner in PM-03-2017 - Diagnostic characterization of rare diseases
We will offer bioinformatics support based on existing national projects for the diagnosis and elucidation of rare and
undiagnosed diseases
Clinical partner, Research partner, Large-infrastructure partner
Page 38 of 487
Austria
Organisation Name
Country
Austria
City
Vienna
Street
Muthgasse 11/2
Website
http://www.ait.ac.at/departments/health-environment/molecular-diagnostics/
Phone
+43 50550 4441
Organisation Type
R&D Institution
Person
Name
Walter Pulverer
Email
[email protected]
Job Position
R&D
The AIT Austrian Institute of Technology GmbH is Austria’s largest non-university research institute with over 1,100
employees working in five departments. The Health & Environment Department focuses on the two strategic research
areas Biomedical and Biomolecular Health Solutions and Resource Exploitation and Management and is organised in
four business units. The goal of our business unit Molecular Diagnostics is to identify effective ways for early diagnosis
of age-related diseases, such as diabetes, cancer and fibrotic diseases as well as infection diagnostics. We develop
biomarkers based on nucleic acids and proteins (especially autoantibodies, DNA methylation patterns, pathogen
genotyping and antibiotic resistance testing), and highly sensitive and specific biosensor systems for medical diagnostics which can be integrated into portable devices. The group currently comprises a team of about 50 scientists
with interdisciplinary expertise in biology, physics, chemistry and electrical engineering
Health & Environment
The Health & Environment Department has core expertise in nano and sensor technologies, system integration, molecular biological omics technologies, modelling and simulation, and addresses customers in the health care, environmental and agricultural sectors. Our researchers solve challenges associated with demographic change, resource scarcity and environmental pollution backed by longstanding experience and excellent research infrastructure.
Molecular Diagnostics (HMD)
The Business Unit Molecular Diagnostics develops tailored biomarkers, biosensors and rapid point of care test applications for life threatening diseases. Collaborative R&D projects have been successfully performed with leading industry
and academic organizations. Our long-term vision is to become a key-player for saliva based diagnostics and generate minimal invasive IVD assays for early disease detection and therapy monitoring in clinical drug development programs.
The focus is on the development of nucleic acid and autoantibody-based biomarker panels and ranges from screening
and biomarker validation through to the development of customised diagnostic tests for clinical and industrial partners. Data analysis is supported by HMD's own bioinformatic division, which developes innovative statistical approaches and bioinformatics methods biological data.
Areas of Activity
the immune system
Page 39 of 487
Austria
diseases
Request: Biomarker development and validation for patient stratification & companion diagnostics adressing age related diseases (Focusing on: SC1-PM-02-2017)
The advent of novel technologies lead to major advances in understanding disease related pathologic mechanisms in
the post-genomic era, but still the benefit of a considerable number of all drugs is restricted to a limited number of
patients. Therefore establishing protocols for knowledge-based patient stratification and companion diagnostics is of
great interest from a clinical point of view. We use our expertise in biomarker development and bioinformatics revealing new concepts and approaches to pave the way for improved patient stratification strategies based on molecular
pathological mechanism of the underlying disease (colon cancer, prostate cancer, lung cancer, diabetes Type2, metabolic syndrome, Alzheimer's disease and other neurodegenerative diseases etc.).
1) partners with profound expertise in molecular mechanisms of the underlying disease (colon cancer, prostate cancer, lung cancer diabetes Type2, metabolic syndrome, Alzheimer's disease and other neurodegenerative diseases
etc.) 2) technology partners for technical assay validation 3) partners for clinical trials
Research institutes skilled in research & development & commercialization of molecular assays, clinical partners with
expertise in patient stratification and companion diagnostics.
Offer: SC1-PM-02-2017, New concepts in patient stratification - Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease that affects the joints of the body with
episodes of painful Inflammation. It can result in life threatening complications. Treatment needs to be ongoing, even
lifelong in some cases. The most successful treatment plans usually administer disease modifying anti-rheumatic
drugs (DMARDs) and various biologics in different treatment regimens. However, many patients fail therapy and alternative biologics must be used to improve response. This causes a high economic and patient’s health burden, which
would be best avoided by using objective measures via biomarkers to define a patient’s susceptibility to a specific
therapy. However, currently no biomarkers are available to predict therapy response.
We aim to use a longitudinal patient-sample cohort to discover and confirm biomarkers suitable for distinguishing responders versus non-responders to biologics. Targeting the two mechanistic molecular key-components of RA, we will
profile serum autoantibodies and inflammatory molecules in the serum of responders and non-responders along treatment. The outcome will be a validated biomarker signature as well as a diagnostic assay to predict responsiveness to
RA-therapy.
MARKET APPLICATION
Pharma, disease prevention, Patient stratification
Clinicians/biologists dealing with rheumatoid Arthritis all over Europe companies for product development and assay/
kit distribution all over Europe
Request: SC1-PM-02-2017, New concepts in patient stratification - rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease that affects the joints of the body with
episodes of painful inflammation. It can also affect other organs and, in severe cases, can result in life threatening
complications. Treatment needs to be ongoing, even lifelong in some cases. The most successful treatment plans usually administer disease modifying anti-rheumatic drugs (DMARDs) and various biologics in different treatment regimens. However, many patients fail therapy and alternative biologics must be used to improve response. This causes a
high economic and patient’s health burden, which would be best avoided by using objective measures via biomarkers
to define a patient’s susceptibility to a specific therapy. However, currently no biomarkers are available to predict
therapy response.
We aim to use a longitudinal patient-sample cohort to discover and confirm biomarkers suitable for distinguishing responders versus non-responders to biologics. Targeting the two mechanistic molecular key-components of RA, we will
profile serum autoantibodies and inflammatory molecules in the serum of responders and non-responders along treatment. The outcome will be a validated biomarker signature as well as a diagnostic assay to predict responsiveness to
RA-therapy.
Page 40 of 487
Austria
clinicians with expertise in rheumatoid arthritis and with existing sample cohorts
Page 41 of 487
Austria
Organisation Name
Country
Austria
City
Vienna
Street
Giefinggasse 2
Website
Phone
Organisation Type
R&D Institution
Person
Name
Markus Garschall
Email
[email protected]
Job Position
The AIT Austrian Institute of Technology GmbH is Austria´s largest non-university research institute. The Business Unit
Technology Experience (Dept Innovation Systems) consists of an interdisciplinary research team, headed by Prof. Dr.
Manfred Tscheligi, an expert in the field of Human Computer Interaction, which aims to research, design and improve
the user experience and interaction with innovative technology, goods and services. The team has long-time experience in the development and execution of national and international (e.g. more than 25 European Projects, some of
which have been coordinated by the team) research and cooperation projects. The AIT Technology Experience Laboratory, a flexible facility spanning over 110m², facilitates user experience and interaction research, as it includes cutting
edge technology tools, audio, video, and digital data streams capturing systems.
Areas of Activity
Preventing disease
young
Methods and data
policies
Health ICT SMEs
(PCP)
(PPI)
population
Offer: We are your Research partner in the field User Experience, User-Centered Design,
Prototyping and Evaluation
The AIT Austrian Institute of Technology is Austria's largest non-university research institute. The Business Unit Technology Experience (Department Innovation Systems) consists of an interdisciplinary research team, headed by Prof.
Dr. Manfred Tscheligi, an expert in the field of Human Computer Interaction, which aims to research, design and improve the user experience and interaction with innovative technology, goods and services. The team has long-time
Page 42 of 487
Austria
experience in the development and execution of national and international (e.g. more than 25 European Projects,
some of which have been coordinated by the team) research and cooperation projects.
One of our main fields of expertiese is the design and development of assistive technologies for vulnerable groups,
ageing people and eHealth applications. In addition, we are active in sustainability and mobility research. If you are
looking for a reliable and renowned partner in the fields User Experience, User-Centered Design, Prototyping and Evaluation, we should meet up. Our AIT Technology Experience Laboratory, a flexible facility spanning over 110m², facilitates user experience and interaction research, as it includes cutting edge technology tools, audio, video, and digital
data streams capturing systems.
MARKET APPLICATION
Our know-how on the methods for user-driven innovation can be applied to any product or service in the fields of Active and healthy ageing and eHealth. At the moment we are specifically (but nut exclusively) searching for cooperations on the development of assistive solutions for people with dementia (or their caregivers).
We are interested in supporting the design, development and evaluation of your R&D project in the fields of Active
and healthy ageing and eHealth. We would be happy to support you with our longstanding experience in the fields of
User Experience research, User-Centered Design, Prototyping and Evaluation. In addition we have strong links to Austrian and European care organisations for the involvement of users and patients from various target groups.
Page 43 of 487
Austria
Organisation Name
Country
Austria
City
Vienna
Street
Donau-City-Strasse
Website
www.eeg-vienna.at, www.ait.ac.at
Phone
+436648251397
Organisation Type
R&D Institution
Person
Name
Hannes Perko
Email
[email protected]
Job Position
The AIT takes a leading position in the Austrian innovation system and a key role in Europe as Research and Technology Organizations (RTO). As a national and international network node at the interface of science and industry, the AIT
enables innovation through its scientific-technological expertise, market experience, tight customer relationships and
high quality research infrastructure.
Hannes Perko is a member of the biosignal research group consisting of about 10 persons with well proven expertise
in signal processing, neurophysiology and computer science. Since the group was founded, we developed computer
assisted analysis and diagnostic tools for assisting clinicians in their daily work. Important fields of interest were the
epilepsy monitoring unit and the intensive care unit. Our medically certified software packages are currently integrated in the recording software of several EEG manufacturers and are used in the daily routine work by clinicians. Our vision is to constantly extend our expertise and portfolio with medical solutions for the automatic analysis of neurological data. We are aiming to further establish the AIT biosignal processing group as a worldwide leading competence
center in this field. We think in general that providing computational biosignal analysis as an external service will
have a huge impact in the future.
Areas of Activity
diseases
(PCP)
(PPI)
Methods and data
policies
Offer: Development of EEG based sleep monitoring for self assesment and home application
We plan to develop a sleep monitoring device for the application by patients themself in their home enviroment. The
system will provide direct feedback to the patient as well as an interface to the hospital.
home based sleep monitoring for screening for - sleep disorders - sleep quality - direct patient feedback - remote diagnosis/feedback from medical centers key innovations: - easy to use unobstrousive sensors - algorithms for measuring key features
Page 44 of 487
Austria
MARKET APPLICATION
The Austrian Association of Sleep Medicine lists 32 accredited sleep laboratories, for Germany 314 accredited sleep
laboratories can be found at the German Association for sleep medicine. Based on these numbers we estimate about
2.000 accredited sleep laboratories in Europe.
Open tasks: - development of EEG recording hardware - patient organizations
Page 45 of 487
Jordan
Al-Balqa Applied University + Scientific Food Center + Scientific FACTS Center
Organisation Name
Country
Jordan
City
AMMAN
Street
AMMAN -SALT
Website
www.facts-center.com
Phone
Organisation Type
R&D Institution
Person
Name
Hanee Al-Dmoor
Email
[email protected]
Job Position
Prof of Food Science and Technology at Nutrition and Food Processing Department in Al-Balqa Applied University.
Prof Al-Dmoor an international expert in Food Science and Technology , has published more than 40 papers in reputed
journals and has been serving as an editorial board member of repute. He has established the Scientific Food Center which is a private research & developments center focus to serve broad categories of food businesses worldwide
from farm to the fork. The center provides many scientific services such as analysis, consultation, research, developments, and assessment for accreditation for certifications such as ISO, HACCP, GMP and training. Also Prof. Al-Dmoor
has established the Scientific FACTS Center which is a private research, developments & Training center as one of
the most non profits organization in Jordan.
Areas of Activity
EU level
Request: Scientific Food Center in Jordan established with EU funds
Have a nice time , We are a Scientific Food Center in Jordan established with EU funds. We want to tell you our Center
is working as a privet research center in Jordan ; agriculture , Food- water and environment ,health science & technology , Food Defense, Food protection , Food safety, Food analysis , Food quality , consultation, research, training ISO &
HACCP , conferences and others of center services . Please to take some information about my research center and
interests , just open the attached presentation For looking for partnership and future cooperation . Please open my
partner call ; https://www.linkedin.com/pulse/20140612164614-69031716-looking-for-partners-forhorizon-2020?trk=mp-reader-card If you have a 5 mints watch our center in YouTube ; https://www.youtube.com/
watch?v=htk4vyIGID0 Our research center ( Scientific Food Center) in Jordan is looking and planning for conducting
researches, dear we have a good chance to work as team work as ( partners) . My center interests in many ; - Food allergen - Olive oil - Aflatoxins occurrence , detection and limitations - Hormone, antibiotic residues - Pesticides residues
GM FOOD detection Food and cancer - Bisphenol A ,and or any of compounds … in food and drinks from plastic packaging materials - OTHERS Please if you have any interest of any of these or more , Thanks for forwarding this email to
any do you think who is interesting for research . Best regards, Prof. Hanee M. Al-Dmoor Scientific Food Center
Tel:053500038 -- Fax:053500083 Mob: 00962 796493068 P.O.BOX: 142935-AMMAN-11814-JORDAN www.facts-center.com - [email protected] Skype; hanidmoor
Page 46 of 487
France
Alaxia
Organisation Name
Country
France
City
Lyon
Street
60 Avenue Rockefeller
Website
www.alaxia-pharma.eu
Phone
Organisation Type
SME
Person
Name
Philippe Bordeau
Email
[email protected]
Job Position
VP Innovation
Alaxia is a French private biotech company developing therapeutic solutions for respiratory diseases based on its proprietary peroxidase platform. The most advanced drug candidate, ALX-009, is an antimicrobial innovative compound
aiming at treating cystic fibrosis, rare disease, including the most resistant bacterial strains even aggregated in
biofilm.
Areas of Activity
Request: Thinking outside the box
If you are not thinking inside the box, feel free to contact
Page 47 of 487
Portugal
ALERT Life Sciences Computing
Organisation Name
Country
Portugal
City
VN Gaia
Street
R. Daciano Batista Marques, 245
Website
www.alert-online.com
Phone
+351228328980
Organisation Type
SME
Person
Name
Maria Azeredo
Email
[email protected]
Job Position
Head of Business Development
Clinical software company fully dedicated to product development and innovation, with operations in 13 countries,
looks for research and innovation projects for Horizon 2020.
Areas of Activity
Preventing disease
Initiative
(PCP)
(PPI)
population
Methods and data
policies
records (PPI)
Health ICT SMEs
Request: Commercial and innovation cooperation
Commercial cooperation for ALERT products distribution and implementation in Europe (ALERT is widely implemented
in hospitals in Europe, LATAM, and MiddleEast). Innovation and research cooperation for EU projects under Horizon
2020 or other cooperation programes.
ALERT products are deeply compreehensive for hospital clinical settings and it is a result of a R&D projet launched in
Portugal. ALERT was shortlisted for the EU IST Prize for its innovative features. Commercial and implemenation capabilities within the healthcare sector are requested. ALERT is very interested in participating actively in research and
Innovation projects and its is open to cooperate both with other companies and research groups on eHealth, Ageing,
Personalized medicine and other related topics.
Page 48 of 487
Portugal
Commercial cooperation is sought for the European market. Companies must have relevant activity within the healthcare sector. Regarding Innovation projects, we are open to cooperate with any expertise and type of partners for research projects related to eHealth, Ageing, Personalized medicine or other related topics.
Page 49 of 487
France
Altran research
Organisation Name
Country
France
City
vélizy-villacoublay
Street
2 rue paul dautier
Website
Phone
+33674254417
Organisation Type
Large Company
Person
Name
Gabrièle Breda
Email
[email protected]
Job Position
E-health program manager
As global leader in innovation and high‐tech engineering consulting, Altran has accompanied its clients in the creation
and development of their new products and services for thirty years to key players in the Aerospace, Automotive, Energy, Railways, Finance, Healthcare and Telecoms sectors. Covering every stage of project development from strategic planning to manufacturing, Altran solutions capitalize on the Group’s technological know-how in five key areas: Innovative Product Development, Intelligent Systems, Lifecycle Experience, Mechanical Engineering, and Information
Systems. In 2014, the Group generated revenues of €1.756bn. Altran now has a staff of around 23,000 employees in
more than 20 countries.
Special expertise for health and e-health projects relies on :
• Operational activities : development of disease management tools for public or private health insurances,
high-tech software for medical products,...
• Research & Innovation: since 2009, Altran Research is the French research department of Altran for the development of new knowledge on six core areas: E-Health, Aeronautics and Space, Transport and Mobility, Energy,
complex systems, Industry and future services. Regarding e-health, Altran has engaged in several collaborative R&D projects: DISDEO (smart pill dispenser solution), PiCADo (domomedicine platform), EclairAge (ICT
based services for health and autonomy),...
Areas of Activity
(PCP)
(PPI)
population
Methods and data
records (PPI)
Offer: E-health smart solutions conception
Altran multidisciplinary teams can design and assess innovative technology-based solutions for e-health at several
steps: - design (including "design thinking" approach), augmented conception - architecture definition taking into account regulatory and standard constraints of the Health sector - development and tests - operation and maintenance -
Page 50 of 487
France
support in usage evaluation and medico-economic assessment (incuding technical constraints) Specific expertises
such as artificial intelligence, image analysis, Internet of Things, can be mobilized to define smart and innovative solutions.
As a multi-sectorial and international Group, Altran offers the advantage of being able to mobilize a number of specific expertises and to give the opportunity of cross-sectorial innovation, with international BtoB sales forces. Altran has
been in charge of large disease managements programs deployment for public and private insurances, of smart software solutions for innovative medical devices for innovative SMEs and large industrial Groups. Altran has also participated in several collaborative R&D projects in different countries to develop home monitoring solutions, observance
tools, services and information platforms, etc.
MARKET APPLICATION
Health insurance Pharmaceutical and medical device
Academic laboratories or SMEs looking for a partner able to support them to conceive and/or industrialize their solution Partners looking for specific engineering expertise (e.g. artificial intelligence, image analysis, Internet of Things,
etc.) (non exhaustive)
Page 51 of 487
France
Organisation Name
Country
France
City
Paris
Street
33 avenue Rapp
Website
http://paris.mae.lu/fr
Phone
0145551337
Organisation Type
Person
Name
Laurence SDIKA
Email
[email protected]
Job Position
Attachée économique et
commerciale & Secrétaire
générale du BCFL
- Representation of the Luxembourg Embassy in France.
- Representation of the Luxembourg Chamber of Commerce in France.
- Representation of the BCFL (Business Club France-Luxembourg): More than 220 French and Luxembourgish
members, including some in the sectors of health and e-health.
MISSIONS:
• Promotion of Luxembourg's innovation policy.
• Promotion of Luxembourg's economic diversity.
• Search for partners (technological or commercial) for Luxembourgish and French companies seeking assistance towards the neighbour's market.
• Provision of information on conditions for access to French and Luxembourg markets.
• Facilitation of a network of leading actors from business and R&D relevant to increase bilateral trade in volume and
value.
More details
Business Club France-Luxembourg
Portail de l'innovation et de la recherche au Luxembourg
Luxembourg BioHealth Cluster
Letzbio.lu
House of BioHealth
Chambre de Commerce du Grand-Duché de Luxembourg
Areas of Activity
(PCP)
Health ICT SMEs
Page 52 of 487
France
(PPI)
EU level
Methods and data
policies
records (PPI)
Offer: Echanges France-Luxembourg et mises en relations entre sociétés et institutions
françaises et luxembourgeoises.
Science and health technologies have boomed in Luxembourg in recent years. The country is specialist in personalized medicine, diagnostics, bioinformatics and medical informatics. The development of the health sector is supported
by an ambitious National Action Plan which aims to make the Grand Duchy an attractive destination for research and
innovation. Personalised medicine is becoming a reality for a variety of diseases. A more individually targeted care
will fundamentally change healthcare services and open new opportunities for the industry. Luxembourg has been at
the field’s forefront since 2008, when it teamed with world-renowned research institutes to kick-start three projects as
part of a new government-backed initiative: an international bio-banking infrastructure, a centre for systems biomedicine and research cooperation to validate biomarkers for lung cancer. To support research and to make the country a
global leader in incorporating personalised medicine into a national healthcare system, Luxembourg created the Personalised Medicine Consortium (PMC), which includes the IBBL (Integrated BioBank of Luxembourg), the Centre de
Recherche Public – Santé (CRP – Santé) - now called Luxembourg Institute of Health - and the Luxembourg Centre for
Systems Biomedicine (LCSB) at the University of Luxembourg. Since its creation in 2010, the consortium has supported research programmes in personalised healthcare, specifically in cancer, diabetes and Parkinson’s disease. The
country's appeal to the biomedical sector has further increased with the opening of the House of Biohealth, a unique
hosting facility with office and lab spaces, for both established and start-up companies in the field of biotech, cleantech and ICT.
- Located in the heart of Europe, Luxembourg provides a unique gateway into the continent, be it for research or business. The success of Luxembourg has long been attributed to its long-term government policies that are committed to
developing business friendly environments while promoting research and innovation. But there is definitely more to
the story: - A Biohealth cluster has been set up to build and nurture a life science community encompassing venture
capitalists, dedicated life science incubators, the Personalised Medicine Consortium and others. The University of Luxembourg is a thriving, robust engine for growth with its effective recruitment process attracting top researchers. Dedicated financing institutions are in place such as the National Research Fund (FNR). Luxembourg has established a cornerstone of public investment in London-based Advent Ventures, which invests in first and best-in-class ventures in
Europe and the US ensuring flow into Luxembourg. - Luxembourg boasts 7.6 researchers for every 1,000 workers (the
EU average being 6) with 82% of these being expatriates. Less than an hour away are universities and 14,000 medical students, high-profile biomedical research institutes and international research consortia. - Commitment to Europe (Founding member of the European Union, Council of Europe, besides others such as OECD). - Strategic location
(Direct access to major European markets with a high level of cross-border trade and employment). - Politically stable
(Continuity in policy initiatives with easy access to key authorities and quick decision making processes). - Friendly
business environment (Long-standing experience in attracting international companies with a suitable market size to
operate commercialisation processes with opportunities to centralise the company’s group functions and assets in
Luxembourg). - Favourable tax regime (Lowest VAT rates in the EU and a favourable tax regime). - Efficient financial
Platform (With one of the lowest levels of national debt in Europe, there is a guarantee of fiscal stability. The financial
sector is diversified and Luxembourg is the second largest domicile in the world for asset management). - Priority for
research and development (Availability of state subsidies and a dedicated public incentive framework for R&D to support innovative companies). - Excellent ICT infrastructure (Luxembourg is ranked first among the OECD countries in
terms of communication access). - Efficient logistics network (Logistics is a thriving and growing sector with the latest
addition of pharma logistics).
Page 53 of 487
France
MARKET APPLICATION
Luxembourgish companies - often SMEs - and public research bodies work in various fields such as biomedical analysis, the discovery of compounds and biomarkers, dental and orthopedic implants, laboratory equipment and hospital
equipment and computer applications related to health. Among the companies active in this sector are particularly
Advanced Biological Laboratories , Ketterthil, Laboratoires Réunis, WaferGen Biosystems Europe and innovative startups as Ai Mediq.
French companies and institutions interested in discovering or cooperating with the Luxembourg players .
Page 54 of 487
Turkey
ankara university
Organisation Name
Country
Turkey
City
ankara
Street
Dögol street Tandoğan
Website
Phone
Organisation Type
University
Person
Name
NERİMAN ARAL
Email
[email protected]
Job Position
ACADEMIC STAFF
The mission of Ankara University is to educate individuals that will guide the society in the fields of science and arts
through a universal perspective, and to contribute to the production of science, technology and arts with its distinctive and qualified research in the light of Atatürk’s saying, “Science is the most reliable guide in life.”Through the associate degree, undergraduate, and graduate programs it conducts, Ankara University educates individuals who can
examine, question, and solve problems, who are self-confident, open-minded, and free of prejudices, respecting social
and universal values, aware of the fact that ‘one who knows is strong’.At the same time, Ankara University offers the
accumulation of knowledge and technology acquired through the wide range of research and application centres within its body focused on various scientific fields.
Areas of Activity
EU level
Health ICT SMEs
(PPI)
population
Request: Health problems, diseases and ICT program development
Health problems play a major role for every age and for everybody in our life. Especially children and adolescents who
are the next future, need to have more information about diversity of diseases. Giving information and developing different programs through ICT programs are important for people to be aware of diseases. Effectiveness research in
children and adolescents is required which is targeted, designed, conducted, and reported in ways that include clinically important differences in the type and course of disease in children. We as a department of child development,
especially work on developing programs for children and adolocents to be aware of their health problems. Through
the programs it can also be planned to increase the level of education and adherence of individuals, patients. Under
the Health, demographic change and wellbeing program, we are looking for cooperation with different ICT program
developers and also develop new international health care programs.
Under the scope of the project we need to work with ICT program developers. Because we are developing programs
for patient children to be aware of their health problems. ICT program developers can help us to transfer our pro-
Page 55 of 487
Turkey
grams on ICT dimension. Also we are looking for people who work on ICT health programs, develop programs for different diseases, patients, measure their impact analyses and support patients' empowerement by developing programs.
ICT experts, program developers can be partner of us to develop new programs. With these experts, we can develop
new programs for patients and these programs can be used internationally.
Page 56 of 487
Turkey
Ankara University
Organisation Name
Country
Turkey
City
Ankara
Street
Dikimevi / Mamak
Website
Phone
+903125957349
Organisation Type
University
Person
Name
Erden Atilla
Email
[email protected]
Job Position
MD
Ankara University is a public university in Ankara, the capital city of Turkey. It was the first higher education institution founded in the Turkish Republic. Ankara University provides education through associate (two-year) degree programs, and undergraduate (Bachelor’s Degree) programs through its 15 faculties, 9 vocational schools, 1 school of
foreign languages and 1 conservatory. Education and research programs are carried out by its 4 institutes, 9 graduate
schools and 37 research centers. There are also 36 associate degree and 99 undergraduate programs. 1809 faculty
members are employed in Ankara University, of whom 1189 are professors, 287 are associate professors and 333 are
assistant professors. The total number of faculty members and adjunct faculty members is 3445. In addition, Ankara
University employs 5496 administrative and support staff. The current number of associate students is 5339 and that
of undergraduate students is 39778. Moreover, most of the graduates work at different universities in Turkey and employ the skills they have acquired at Ankara University in various sectors of society. They are all competent graduates
who are confident and internationally qualified and who can think creatively, independently and objectively.
Ankara University has 460 Erasmus agreements with a total of 285 universities from 25 European countries and 96
academic cooperation protocols with various universities. In accordance with these protocols, there are academic research projects and student and academic staff exchange programs. Ankara University encourages students to study
and do internships abroad as part of their education, and academic staff and administrative staff to visit partner universities.
Ankara University has 32 libraries which contain 727000 books, 75 databases, 30761 electronic journals, 72000 ebooks, 17000 manuscripts and 562 printed journal subscriptions.
Ankara University Stem Cell Institude
Overview and Objectives
In 2009, Ankara University announced the establishment of the Ankara University Stem Cell Institute (AU-SCI) upon
the resolution of Council of Ministers, issued 2009/15561, which was published in the 27412 edition of the Official
Gazette, November 20th 2009. To date, Ankara University Stem Cell Institute is the first and only existing institute
that serves in this field in Turkey.
With the foundation of world-class GMP labs at Cevizlidere campus, a technical and scientific work source, which is
able to function in teams, specialized in disease/problem-based multi-disciplinary studies will be trained. Achieving
this, it will be possible to contribute to the national strategies for improvement in the field of medicine and economy.
Construction of clean room facilities will be completed soon and will serve as the heart of our translational research
activities. The infrastructure will be completed for processing and preservation of cells and tissue engineering methods according to good manufacturing practices, good laboratory practices and good tissue practices. Furthermore, we
aim to establish imaging and tracking systems for stem/progenitor cells in experimental models; immunophenotyping, DNA analysis, high-flow cell separation and characterization systems; infrastructures for advanced molecular biology, genetic and proteomic characterization for the investigation of the cells at gene and protein level; characteriza-
Page 57 of 487
Turkey
tion and production systems for advanced regenerative biomaterials; high-standard units for experimental animals. Finally, developing cures for still-incurable diseases in the light of regenerative medicine is a goal that is of paramount
importance for mankind.
Mission and Vision
Mission of Ankara University Stem Cell Institute is to bring together the leading basic scientists, researchers, physicians and surgeons in a multidisciplinary fashion to collectively work in the fields of regenerative medicine and translational research. We aim to develop projects provided by teams working for specific disease areas that will serve as a
“Bridging the Gap” between academic research and patients with incurable diseases. Foundation of Ankara University
Stem Cell Institute was planned to improve the existing research projects, services and education on stem cell applications; in order to contribute to science and society at the highest level, and with the most efficient quality assurance program.
Objectives of Ankara University Stem Cell Institute are; to execute research projects that has potential to compete on
an international level; application and investigation of new developments on human stem cell biology; development
of new areas of diagnostic and therapeutic utilization; development of animal models, and later on, conduction of preclinical and clinical studies. In this sense, the institute accepts, the better understanding of stem and primary tissuespecific cells, research on national and international scale to utilize the potential (basic sciences, tissue engineering,
experimental and clinical studies), undertaking of educational and consultant activities, and providing grounds for the
treatment of human diseases using advanced regenerative medicine practices with regard to general medical practices and ethical values.
Ankara University School of Medicine, Hematology Department & Bone Marrow Transplantation Unit
Ankara University Department of Hematology and Bone Marrow Transplantation Unit started education and treatment
in 1982. Bone Marrow Transplantation Unit is one of the oldest in all over Turkey, first transplantation had performed
in 1988. Department's bed capacity is 66, 16 of them are for Bone Marrow Transplantation Unit. In our accredited
hematology laboratory several molecular test, HLA analysis as well flow cytometric analysis were held. Ankara University Department of Hematology serves hematology fellowship education program. It is the well known Hematology
referance center in Turkey.
Areas of Activity
Offer: Ankara University Stem Cell Institude
As an institution that welcomes change and development, which adopts a management approach based on innovation and diversity, Ankara University (AU) undertakes a scientific R&D mission that is considering the development
and progress of the society and country. With its activities in research and development, education and application
over the years, AU continues its leading position in Restorative and Regenerative Medicine. Such that; the first and
only “Stem Cell Institute” in Turkey was established for stem cell related research, services and education, in order to
maximize the benefit to science and society. Herein, we request a support for the preparation of a strategic plan document for the organization of the related units under the same roof in order to form R&D sub-groups for the interdisciplinary cooperation and increase the R&D potential. 5 sub-headings formed in accordance with the 5-year plan are as
follows; (1) Cell therapy products and clinical application, (2) Tissue and organ engineering, (3) Tissue banking, (4)
Cancer vaccines and stem cell differentiation treatments, and (5), Master cell development for recombinant drug development.
A.U. Faculty of Medicine, Hematology Department Bone Marrow Transplantation Unit’s 30 years & 2000 transplantation experience made the basis of stem cell treatment strategies in our university. Stem cell therapy, which is the
treatment of health problems or illnesses targets specific delivery of stem cell-based regenerative products. AU Stem
Cell Institute is a multidisciplinary organization which aims to develop therapy products and clinical applications for
Phase I-II studies using, peripheral hematopoietic stem cells, dermal fibroblasts, bone marrow and adipose stem cells,
umbilical mesenchymal stem cells. With the support, we aim to initiate studies investigating safety and effectivity of
programmed T cells and human multipotent stem cells in developing therapies for the diseases that are not currently
Page 58 of 487
Turkey
treatable. Ankara University “Tissue/Organ Engineering and Regenerative Medicine Research Group” was founded in
1993, under Biochemistry Department at the Faculty of Science. The group has performed many pioneering regenerative and translational studies with the present technical and physical infra-structure. Some end-results of which constitute firsts in Turkey and around World. With a support for the R&D strategy document we aim to prepare, the research conducted in the tissue/organ engineering and regenerative medicine research group is going to gain pace.
Tissue banks are cryogenic storage facilities for the storing of cells and tissues. “AU Cord Blood Bank” is the first and
only unrelated cord blood bank in Turkey, and it has started to provide stem cells for different transplantation centers
country-wide. With the proposed R&D strategy document, firstly we aim to fund studies for the treatment of various
diseases, by tissue processing and storage for cardiovascular, muscle and scelatal systems, eye, skin and other tissues. For those tissues progenitor cell analysis, we aim to compare, develop and standardize analytic and functional
methods R&D investigations on are planned. For the five-year term, cancer vaccine and stem cell differentiation studies, we aim to develop dendritic-cell and peptide vaccines. Therapy approaches that target cancer stem cells are going to play an important role in the treatment of metastatic development and prevent dramatic losses and the financial burden, while also benefiting the economy considerably. One other R&D focus is Phase II studies for the monitoring of early-stage and low-tumor-load patients and their initial results and conducting multi-center Phase III studies for
side-effect and cost analysis. Ankara University has prioritized the important subject of producing master cells’ production for the development of recombinant drugs in its vision and mission statement. Production of monoclonal antibodies and recombinant proteins are examples of AU target R&D sub-titles.
MARKET APPLICATION
Research in 5 sub-heading will be conducted by the faculty members of our university, who are recognized and established scientists in their respective fields. The potential benefits of studies in R&D titles in national and international
scale are apparent. With the R&D strategy document which is going to be developed, AU will gain pace as the leading
institution in regenerative and restorative medicine R&D. With the support, it will be possible to increase the capacity
for conducting original pre-clinical and early clinical (Phase I-II) research. AU Stem Cell Institute currently provides services with its “GMP Center for Human Tissue and Cell Production,” which is the most important multidisciplinary infrastructure funded by the internal resources of AU. According to AU mission statement and the basis of our vision; we
aim to take part in scientific ethical committees and providing consultancy services for the public policy-makers, in
subjects that need specific expertise such as, stem cell research, tissue/organ engineering, tissue banking, cancer
vaccines and master cell production for recombinant drug development.
Herein, we offer a collaboration for the preparation of a strategic plan document for the organization of the related
units under the same roof in order to form R&D sub-groups for the interdisciplinary cooperation and increase the R&D
potential. 5 sub-headings formed in accordance with the 5-year plan are as follows; (1) Cell therapy products and clinical application, (2) Tissue and organ engineering, (3) Tissue banking, (4) Cancer vaccines and stem cell differentiation treatments, and (5), Master cell development for recombinant drug development. We are seeking partners expertised in these 5 sub-headings. No country priority is required.
Page 59 of 487
Turkey
Ankara University
Organisation Name
Country
Turkey
City
Ankara
Street
Ankara University School of Medicine
Website
www.medicine.ankara.edu.tr
Phone
+903125958169
Organisation Type
University
Person
Name
Alp Can
Email
[email protected]
Job Position
Head of Depatment
Ankara University School of Medicine is the first medical school of Turkish Republic founded in 1945. It provides a
6-year graduation program for the medical school students with a 550 faculty members and 1250 staff members. It is
distributed into three manin campus in the heart of Ankara with a capacity of 2450 patient beds.
Areas of Activity
Offer: A multicenter, placebo controlled, phase I/II trial comparing autologous bone
marrow-derived mononuclear and human umbilical cord stroma derived multipotent stromal cells with critical limb ischemia.
The purpose of this project (HUC-BMC CLI TRIAL) is to evaluate the therapeutic efficacy and safety of human umbilical
cord-stroma derived multipotent (mesenchymal) allogeneic stem cells (HUC-MSCs) and autologous bone marrow-derived mononuclear cells (BMC) in patients with critical limb ischemia in a phase 1/2 multicenter, placebo controlled
clinical trial. We will examine the effect of combined intra-arterial and intramuscular cell transplantation with no option critical limb ischemia (NO-CLI).
Regenerative medicine by using progenitor cells has shown promising improvements in NO-CLI. While the search for
progenitor cells that can readily engraft within damaged tissue and differentiate into functioning tissues continues, regenerative therapy using BMCs and more recently mesenchymal stem cells (MSCs) has shown considerable promise
in many pre-clinical and important clinical studies with a small number of patients. Here, we propose a randomised,
controlled (two independent study group), phase 1/2 clinical trial with many clinical and laboratory parameters that
will be precisely monitored during a 2-year follow-up period after transplantation. Concomitantly, clinical-grade HUCMSCs that have been isolated and expanded in GMP (good manufacturing practice) conditions will also be taken into
extensive cell and genome analyses in order to demonstrate if any correlation exists between the cellular/genome parameters and the clinical outcomes. After a careful patient selection procedure based on strict inclusion and exclusion
criteria, all patients will be taken to cellular transplantation and strict follow up protocol.
MARKET APPLICATION
Stem cell production.
Seeking partners expertised in cellular therapy and vascular surgery. No country priority is required.
Page 60 of 487
Turkey
ankara university
Organisation Name
Country
Turkey
City
ankara
Street
Dögol street Tandoğan
Website
Phone
Organisation Type
University
Person
Name
ece ozdogan ozbal
Email
[email protected]
Job Position
academic staff
The mission of Ankara University is to educate individuals that will guide the society in the fields of science and arts
through a universal perspective, and to contribute to the production of science, technology and arts with its distinctive and qualified research in the light of Atatürk’s saying, “Science is the most reliable guide in life.”Through the associate degree, undergraduate, and graduate programs it conducts, Ankara University educates individuals who can
examine, question, and solve problems, who are self-confident, open-minded, and free of prejudices, respecting social
and universal values, aware of the fact that ‘one who knows is strong’.At the same time, Ankara University offers the
accumulation of knowledge and technology acquired through the wide range of research and application centres within its body focused on various scientific fields.
Areas of Activity
Health ICT SMEs
(PPI)
population
Request: HEALTH EDUCATION PROBLEMS, USING ICT FOR HEALTH EDUCATION, MULTIDISCIPLINARY STUDIES FOR HEALTH PROBLEMS
Health management need to be addressed in a holistic approach, from healthy lifestyle, dietary habits interlinked with
disease management, and adherence to medical plans, placing the patient in the centre and putting increased emphasis on health education, patient empowerment, secondary prevention and self-management of individual conditions, including co-morbidities and frailty. So we need to work with different diciplines. I am especially working on using ICT for health education and giving information patients about health problems and causes of health. We are planning to develop different educational programs for ICT and this programs can help patients from different aspects. We
are looking for ICT health program developers to develop programs for different diseases and patients and to measure their impact analyses and to support patients' empowerement.
The meetings which provide to work multidisciplinary and include topics about ICT health programs meet my needs.
Under the scope of the program, we are planning to apply with a Project that using ICT Health programs to empowerd
the patients and to create awareness about the disease and their potentials. New Technologies on ICT topics also important for our project.
Page 61 of 487
Turkey
New Technologies on ICT and develeoping ICT programs is important for our Project application. So people who are
looking for is work on technology on ICT, ICT Health program development and ICT effects.
Offer: HEALTH EDUCATION PROBLEMS, USING ICT FOR HEALTH EDUCATION, MULTIDISCIPLINARY STUDIES FOR HEALTH PROBLEMS
Health management need to be addressed in a holistic approach, from healthy lifestyle, dietary habits interlinked with
disease management, and adherence to medical plans, placing the patient in the centre and putting increased emphasis on health education, patient empowerment, secondary prevention and self-management of individual conditions, including co-morbidities and frailty. So we need to work with different diciplines. I am especially working on using ICT for health education and giving information patients about health problems and causes of health. We are planning to develop different educational programs for ICT and this programs can help patients from different aspects. We
are looking for ICT health program developers to develop programs for different diseases and patients and to measure their impact analyses and to support patients' empowerement.
The meetings which provide to work multidisciplinary and include topics about ICT health programs meet my needs.
Under the scope of the program, we are planning to apply with a Project that using ICT Health programs to empowerd
the patients and to create awareness about the disease and their potentials. New Technologies on ICT topics also important for our project.
MARKET APPLICATION
HEALTH CARE EDUCATION
HEALTCARE EDUCATION-TURKEY
Page 62 of 487
Turkey
Ankara University Faculty of Medicine
Organisation Name
Country
Turkey
City
Ankara
Street
Mamak cad
Website
Phone
90-312-5957253
Organisation Type
University
Person
Name
Huban Atilla
Email
[email protected]
Job Position
Our Ophthalmology department is affiliateted to Ankara University Faculty of Medicine. It has subspecialty clinics for
retina, glaucoma, uveitis, pediatric ophthalmology and strabismus, contact lenses, oculoplastics and low vision, Apart
from four operating theaters with facilities for every ocular surgery (including vitreoretşnal, keratoplasty, phacoemulsification, etc) there are both inpatient (50 patient capacity) and outpatient clinics. Our department is also a center
for ESASO and also there is colloboration with ANkara University Stem Cell Institute. Our Eye Banking department is
one of the first eye bank in our country.
Areas of Activity
the immune system
diseases
EU level
Preventing disease
young
(PCP)
population
Request: Improvement of quality of life in children and young adults with visual impairment and prevention of potentially blinding diseases in childhood
Our organization is a university clinic and we would like to participate in health and well being and demographic
change projects. We wish to participate projects as associate country.
As we have a relatively young population, we would like to work on preventive measures for ophthalmology related
projects especially in visually impaired children and young adults.
Also to increase quality of life in adult patients with visual impairment, we would like to participate in projects related
to improve well being of people with low vision.
Page 63 of 487
Turkey
Ankara University, Faculty of Health Sciences, Department
of Healthcare Management
Organisation Name
Country
Turkey
City
Altindag/Ankara
Street
Sukriye Mah. Plevne Cad. No:5
Website
www.ankara.edu.tr
Phone
Organisation Type
University
Person
Name
Yasemin Akbulut
Email
[email protected]
Job Position
Academic staff
Ankara University is a public university in Ankara, the capital city of Turkey. It was the first higher education institution founded in the Turkish Republic. Ankara University provides education through associate (two-year) degree programs, and undergraduate (Bachelor’s Degree) programs through its 15 faculties, 9 vocational schools, 1 school of
foreign languages and 1 conservatory. Education and research programs are carried out by its 4 institutes, 9 graduate
schools and 37 research centers. There are also 36 associate degree and 99 undergraduate programs. 1809 faculty
members are employed in Ankara University, of whom 1189 are professors, 287 are associate professors and 333 are
assistant professors. The total number of faculty members and adjunct faculty members is 3445. In addition, Ankara
University employs 5496 administrative and support staff. The current number of associate students is 5339 and that
of undergraduate students is 39778. Moreover, most of the graduates work at different universities in Turkey and employ the skills they have acquired at Ankara University in various sectors of society. They are all competent graduates
who are confident and internationally qualified and who can think creatively, independently and objectively.
Ankara University has 460 Erasmus agreements with a total of 285 universities from 25 European countries and 96
academic cooperation protocols with various universities. In accordance with these protocols, there are academic research projects and student and academic staff exchange programs. Ankara University encourages students to study
and do internships abroad as part of their education, and academic staff and administrative staff to visit partner universities.
Ankara University has 32 libraries which contain 727000 books, 75 databases, 30761 electronic journals, 72000 ebooks, 17000 manuscripts and 562 printed journal subscriptions.
Areas of Activity
(PCP)
Methods and data
policies
records (PPI)
Page 64 of 487
Turkey
Offer: The impact of low health literacy on the medical costs: How can we measure?
Health literacy defined as “The degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.” Studies have shown that patients
with low levels of health literacy receive fewer preventive services, frequently fail to follow medication instructions,
and have worse health outcomes. Moreover, patients with low health literacy skills are more likely to have higher utilization of health care services. For these reasons, low health literacy is a major source of economic inefficiency in
healthcare systems. The aim of the study is to examine the impact of low health literacy on medical care use and
costs.
Despite the growing research base documenting the extent and impact of low health literacy, there has been a paucity of data examining the financial costs associated with health literacy. In this regard, we care about capacity of measurement methodology for health literacy and medical cost.
MARKET APPLICATION
Other research institutes with skills in research & development of health literacy and cost. The concept will be implemented on different countries which need to develop new health policies.
Offer: Cost-effectiveness analysis of renal replacement therapy for end-stage renal disease: How to use the development of health policy?
The number of patients with chronic kidney disease worldwide is rising markedly. Providing renal replacement therapy
for end-stage renal disease patients is very critical. The three options varied in the proportion of patients allocated to
haemodialysis, peritoneal dialysis, and renal transplant. Despite growing evidence and findings on the cost-effectiveness of renal replacement therapy, health policy studies which using these findings are scarce. The aim of this study
is to assess the evidence on cost-effectiveness of continuous renal replacement therapy, develop new health policies
based on current evidence and provide how to use evidence to inform decisions about public health policies.
According to medical and economic literature, capacity of economic evaluations of hemodialysis, peritoneal dialysis,
and kidney transplantation is crucial.
MARKET APPLICATION
Other research institutes with skills in research & development of cost for renal replacement therapy or cost effectiveness analysis in health sector. The concept will be implemented on different countries which need to develop new
health policies for renal replacement therapy.
Page 65 of 487
France
AnyGenes
Organisation Name
Country
France
City
PARIS
Street
HÔPITAL TENON, 4 RUE DE LA CHINE
Website
www.anygenes.com
Phone
Organisation Type
SME
Person
Name
Ben-Youssef NAIMI
Email
[email protected]
Job Position
CEO
Established in France, Paris (TENON Hospital) since 2007, AnyGenes® is privately owned biotechnology company
(SME). Involved in research and development and production of signaling pathways for biomarkers discovery and validation. Our fast growing databases of over thousands of validated factors are now available. They represent signaling
pathways of different cellular processes (cell cycle, apoptosis, autophagy, inflammation, drug resistance&metabolism...), and for severe disease (cancer, neurodegenerative disease, autoimmune diseases…). Specifically designed to be analysed by high-throughput technology (HTqPCR), Fluidigm technology, and dedicated (home
designed) software data analysis.
AnyGenes® also offers services of integrated approaches based on a broad range of technologies for cellular processes analysis and drug development including drug screening and testing in in vitro cell culture, mechanism of action,
search of biomarkers, data analysis and patient stratification. Our goal is to help in the efficient development of new
personalized drugs by developing innovative tools, which allow selecting patients most likely to respond to a developed targeted therapy.
Areas of Activity
the immune system
Preventing disease
young
diseases
Offer: Signaling pathways analysis, biomarkers identification&patients stratification
Established in France, Paris (TENON Hospital) since 2007, AnyGenes® is privately owned biotechnology company
(SME). Involved in research and development, manufacturing, production of signaling pathways for biomarkers discovery and validation. Our fast growing databases of over thousands of validated factors are now available. Thanks to
our data-mining department, they are classified on various signaling pathways of different cellular processes (cell cycle, apoptosis, autophagy, inflammation, drug resistance&metabolism...), and for severe disease (cancer, neurode-
Page 66 of 487
France
generative disease, autoimmune diseases…). Data generated by using our signaling pathways system can be
analysed by our home designed software.
Our strength is based on proprietary experimental platform, biocomputers data analysis and a large collection of signaling pathways that can be used in a high-throughput analysis in an iterative manner to identify a specific biomarkers signature. AnyGenes® has its own i) laboratories with well equipped platform and validated technology for mutation detection, copy number variation, gene expression ii) data-mining platform for specific pathways design, data
analysis and software development: ➢ With the possibility of using different type of biological samples: biopsies, cell
lines, PBMC, FFPE… ➢ Using cutting edge technologies: Next Generation Sequencing (NGS), digital PCR… ➢ While taking charge of the whole process from sample reception to report of complete data analysis. ➢ With algorithms which
are adapted to the data interpretation and statistical analysis
MARKET APPLICATION
Biomarkers identification and validation, patients stratification, drug development, targeted therapies, clinical tests
Industry, public collaboratif projects, european H2020 projects in the topics: SC1-PM-01-2016 : Multi omics for personalised therapies addressing diseases of the immune system SC1-PM-02-2017 : New concepts in patient stratification
SC1-PM-03-2017 : Diagnostic characterisation of rare diseases SC1-PM-08-2017 : New therapies for rare diseases
SC1-PM-09-2016 : New therapies for chronic diseases
Page 67 of 487
France
AP-HP
Organisation Name
Country
France
City
Paris
Street
Rue Velle Faux
Website
Phone
01 44 84 17 28
Organisation Type
Other
Person
Name
Francis Bassompierre
Email
[email protected]
Job Position
R&D Direction
Assistance Publique - Hôpitaux de Paris (AP-HP) is the public hospital system of the city of Paris and its suburbs. It provides healthcare, teaching, research, prevention, education and emergency medical service in 52 branches of medicine; it employs more than 92 000 people (practitioners and administrative staff) in 44 hospitals. AP-HP is linked with
the University of Paris and its seven colleges of medicine, two of odontology and two of pharmacy. It is the largest
hospital system in Europe and the most important group of hospitals in France, including numerous expert centers
with international reputations.
Currently managing more than 100 European projects, AP-HP has developed a vast experience in the management of
European projects funded under FP7, including European studies where AP-HP is the sponsor (promoter) of clinical trials.
Since 2009, 2 departments (International promotion and European affairs) work in close collaboration with investigators, researchers and clinical research units to ensure the follow up of clinical trials promoted by AP-HP when involved
as coordinator or as partner in FP7 funded projects.
Areas of Activity
the immune system
diseases
EU level
Page 68 of 487
France
AP-HP
Organisation Name
Country
France
City
Paris
Street
10 Av.Claude Vellefaux
Website
Phone
Organisation Type
R&D Institution
Person
Name
Nabila LAAJAIL
Email
[email protected]
Job Position
European project manager
Assistance Publique - Hôpitaux de Paris (AP-HP) is the public hospital system of the city of Paris and its suburbs. It provides healthcare, teaching, research, prevention, education and emergency medical service in 52 branches of medicine; it employs more than 92 000 people (practitioners and administrative staff) in 44 hospitals. AP-HP is linked with
the University of Paris and its seven colleges of medicine, two of odontology and two of pharmacy. It is the largest
hospital system in Europe and the most important group of hospitals in France, including numerous expert centers
with international reputations.
Currently managing more than 100 European projects, AP-HP has developed a vast experience in the management of
European projects funded under FP7, including European studies where AP-HP is the sponsor (promoter) of clinical trials.
Since 2009, 2 departments (International promotion and European affairs) work in close collaboration with investigators, researchers and clinical research units to ensure the follow up of clinical trials promoted by AP-HP when involved
as coordinator or as partner in FP7 funded projects.
Page 69 of 487
France
APROVA
Organisation Name
Country
France
City
Boulogne-Billancourt
Street
4, rue Barthélémy Danjou
Website
www.aprova-cro.com
Phone
0671440190
Organisation Type
Large Company
Person
Name
Patrice Le Guen
Email
[email protected]
Job Position
Head of Operations
APROVA is a Contract Research Organization (CRO) specialized in the management of clinical studies for drugs and
medical devices for 20 years. Our teams located all over Europe can take in charge the regulatory submissions, the
project management, the monitoring (site identification, site initiation and training, site monitoring), the project management, the data management (paper-based or eCRF), the statistics (calculation of sample size, methodology and
design of the study including adaptive design, randomization, SAP, SAS programming of the analysis, statistical report) and the vigilance.
APROVA can be the CRO in charge of the management of the clinical trials part of your projects and has acquired the
experience of European projects as a member of consortiums or subcontractor for years with projects funded within
the framework of FP5, FP7 and Horizon 2020 programs.
APROVA can be involved as a French, Belgian or Czech companies, which have all their own PIC number.
Areas of Activity
Offer: A CRO with the experience of European-funded consortiums to manage your clinical
trials
APROVA is a Contract Research Organization (CRO) specialized in the management of clinical studies for drugs and
medical devices for 20 years. Our teams located all over Europe can take in charge the regulatory submissions, the
project management, the monitoring (site identification, site initiation and training, site monitoring), the project management, the data management (paper-based or eCRF), the statistics (calculation of sample size, methodology and
design of the study including adaptive design, randomization, SAP, SAS programming of the analysis, statistical report) and the vigilance. APROVA can be the CRO in charge of the management of the clinical trials part of your projects and has acquired the experience of European projects as a member of consortiums or subcontractor for years
with projects funded within the framework of FP5, FP7 and Horizon 2020 programs. APROVA can be involved as a
French, Belgian or Czech companies, which have all their own PIC number.
Experience of more than 20 years in the management of clinical trials for drugs and medical devices, European coverage, global offer of services (Clinical operations, Monitoring, Submissions, data Management, eCRF, Statistics, Vigilance
MARKET APPLICATION
Clinical trials
Page 70 of 487
France
APROVA can be the CRO of your consortium in charge of the management of the tasks related to your clinical trials all
over Europe.
Page 71 of 487
France
Ariana Pharma
Organisation Name
Country
France
City
Paris
Street
28 rue du Docteur Finlay
Website
http://www.arianapharma.com/
Phone
+33144371700
Organisation Type
SME
Person
Name
Julie Miralves
Email
[email protected]
Job Position
Project Manager
Ariana® Pharmaceuticals, a French SME based in Paris, offers software tools and services for identifying the best therapies for specific patients. Ariana uses innovative data analysis technologies that find the most-likely clinical responders and optimal biomarker signatures. Ariana’s advanced patient stratification and data mining technology KEM®
(Knowledge Extraction and Management) systematically explores combinations of markers from multiple sources, producing shorter and more effective biomarker signatures for personalized medicine. In this way, Ariana helps diagnostics companies develop multi-parametric diagnostic tests, and enable pharma and biotech companies to identify their
best patient responder sub-populations as well as patients at high risk of adverse events.
Ariana is currently developing a pipeline of software for treatment selection in oncology (Onco KEM®) and different algorithms embedded in personalized medicine products and diagnostic tools.
Areas of Activity
the immune system
Methods and data
(PCP)
(PPI)
Offer: Statistical and data mining analysis expertise -- Bio-computing tools and decision
support systems (DSS) development
Ariana Pharma develops and provides innovative data analysis and testing solutions. Ariana’s expertise in data mining
and signature optimization spans multiple technical issues and functional areas such as: • Patients characterization
and stratification through clinical data analysis: identification of best patient responder sub-groups and populations at
risk of adverse events. • Complex biomarker signatures identification and validation (i.e. multi-parametric data analysis combining the most relevant combinations of patient characteristics and biomarkers) combining multiple sources
of information: genomic, transcriptomic, proteomic, histological, pharmacological, biochemical, metabolomic and clinical data. • Predictive, diagnostic and/or prognostics biomarkers identification. • Lead optimization identifying particular combinations of chemical features that help a compound to fulfill multiple objectives and suggesting specific modifications to optimize compounds.
Page 72 of 487
France
Data mining and machine learning technologies -- Multi-parametric and multi-objective data analyses -- Complex biomarkers/features signatures identification and validation -- Patient or population stratification -- Bio-computing tools
and software development -- Decision support systems and software development -- Personalised medicine products
and diagnostic tools --
Page 73 of 487
Belgium
Artialis
Organisation Name
Country
Belgium
City
Liège
Street
avenue de l'Hôpital 11
Website
www.artialis.com
Phone
+3242427727
Organisation Type
SME
Person
Name
Myriam Gharbi
Email
[email protected]
Job Position
Value Stream Director
Artialis is a small company of 20 employees with complementary expertise. The company was founded in 2010 on the
initiative of Professor Yves Henrotin as a start-up from the Bone and Cartilage Research Unit of the University of Liège.
Artialis specializes in the development and validation of biomarkers specific of musculoskeletal disorders such as sarcopenia and osteoarthritis. Measured from a simple blood sample, these biomarkers allow, among others, to monitor
disease progression and treatment efficacy.
As a company specializing in the musculoskeletal field, Artialis provides services to pharmaceutical companies and researchers developing innovative and more effective therapeutic approaches, both in humans and animals. The company provides a complete and customized solution to preclinical and clinical studies including innovative biomarkers,
medical imaging techniques, and functional tests. The company is certified to ISO9001: 2008 for all its activities including its clinical and preclinical research activities and works in compliance with good clinical practices.
Areas of Activity
Offer: Innovative Biomarkers, preclinical studies, and clinical trials in musculoskeletal field
Artialis is a company of 20 employees with complementary expertise. Pioneer, Artialis specializes in the development
and validation of specific biomarkers of musculoskeletal disorders such as sarcopenia and osteoarthritis. Measured
from a simple blood test, these biomarkers allow, among others, to monitoring the evolution of the disease and a
treatment efficacy.
Imaging biomarkers to assess structural changes in osteoarthritis: -measurement of the cartilage loss based on MRI to
detect small changes over time considering each structure of the joint (WORMS) -biochemical composition of cartilage
from images by MRI providing sensitive information about the content of proteoglycans in cartilage (dGEMRIC) Soluble
biomarkers to asses disease evolution and/or predict treatment efficacy: - Artialis offers a panel of biomarkers that allow to consider different aspects of the disease as inflammation, cartilage degradation, and bone remodeling. - Artialis uses MSD technology providing high sensitive and accurate quantification of biomarkers using single or multiplex immunoassays. -Artialis is able to develop new customized biomarkers for partner from design to companion kit
Artialis offers all-in-one solution of preclinical & clinical services including imaging services and biomarkers.
MARKET APPLICATION
As specializing in the musculoskeletal field, Artialis offers services to pharmaceutical companies and researchers developing innovative and more effective therapeutic approaches, both in human and in animal. The company provides
a complete and customized solution of preclinical studies and clinical trials including innovative biomarkers, medical
Page 74 of 487
Belgium
imaging, and functional tests. Artialis is compliant with ISO9001: 2008 for its clinical and preclinical research activities.
Page 75 of 487
United Kingdom
Aseptika Ltd
Organisation Name
Country
United Kingdom
City
Huntingdon
Street
14 Elizabeth Drive
Website
www.activ8rlives.com
Phone
01480352821
Organisation Type
SME
Person
Name
Kevin Auton
Email
[email protected]
Job Position
Managing Director
Aseptika Limited is a healthcare technology company developing and marketing an integrated suite of self-monitoring
devices and services under the Activ8rlives brand. We are developing integrated systems which can be used by consumers and their healthcare service providers to better self-manage long-term health conditions (LTHC) through selfmonitoring.
The Company’s goal is to provide everyone with tools (and the understanding of how to apply them) so that most of
us can keep healthy and well for most of the time. Self-management through self-monitoring is the motivation driving
what we do.
Activ8rlives is unusual in that we are device agnostic, incorporating sensors and monitors ranging from consumer accessories to in vitro diagnostics (IVDs) with a focus on respiratory disease. All data is held together and can be cross
analysed in the Cloud to provide forecasts and learning for the user and clinician.
The Company gained the UK patent in 2013 protecting the invention of a test for biomarkers of Pseudomonas aeruginosa (PA) in the sputum of patients, which can be used to detect the on-set of an exacerbation and profile the efficacy
of antibiotic treatment for each patient.
Aseptika won first place in a competition earlier in 2014 to reward the most “Promising eHealth EU SME” eHealth solution 2014 developed by an early-stage European SME. The 2014 Competition was organized by TICBioMed and had
the endorsement of the Health and Wellbeing Unit of DG CONNECT of the European Commission. The judges commended Aseptika for the integrated approach it was taking in the support of patients with long-term respiratory disease, providing the platform to self-manage their illness through self-monitoring. Central to the Company’s “hospitalat-home” concept, is a test in which the patient measures the level of virulence of the bacteria living in their lungs
which from time to time, flare into a full and repeated chest infections.
Aseptika was a shortlisted finalist for the Cambridge News Top Innovations 2014 and AXA PPP Health Tech & You
Awards. Winner of the Discovery Start-up 2014 Competition run by Cambridge Wireless and Winner of the Hunts Post
Huntingdonshire Business Innovation Awards 2014. Named on Global Digital Health 100 Award list, reflecting the importance of mobile and digital solutions.
Wearable Technology Awards 2015 Aseptika was shortlisted in three categories: Best Innovation, Overall Wearable
Winner and was placed third in the Best Medical Device category.
Aseptika was granted a patent in the United States and New Zealand protecting its invention for a test for respiratory
infections early in 2015.
Aseptika has been short-listed as one of twenty semi-finalists for the Cisco British Innovation Gateway (BIG) Awards,
selected from over 150 entries from across the UK.
Page 76 of 487
United Kingdom
For more information on Aseptika Ltd, Activ8rlives and products, please visit: www.Activ8rlives.com
Areas of Activity
(PCP)
(PPI)
population
Seeking clinical partners to deploy our patent-protected test to profile Pseudomonas aeruginosa in sputum
Clinical partners with ability to undertake a RCT in the hospital setting.
Hospital, Clinical Research Centre not in the UK or in Spain
Request: BuddyWOTCH - wearable medical monitor for those with chronic respiratory disease
Lookng for clinical partners.
Ability to undertake clinical trials with large population groups.
Clinical Trial expertise
Page 77 of 487
Spain
Asphalion S.L.
Organisation Name
Country
Spain
City
Barcelona
Street
Via Augusta, 59
Website
www.asphalion.com
Phone
Organisation Type
SME
Person
Name
Lidia Cánovas
Email
[email protected]
Job Position
Asphalion is an International Scientific and Regulatory Affairs consultancy firm based in Barcelona and Munich.
Founded in 2000, Asphalion has consistently grown and now consists of over 70 professional consultants with backgrounds in Pharmacy, Chemistry, Biology, Biochemistry, Biotechnology, Medicine and Veterinary Medicine. ASPHALION offers comprehensive services for Drug Development and Regulatory Affairs to Pharma, Biotech and Medical
Devices companies. Asphalion can manage EU, US, Latin American and selected RoW procedures.
Asphalion has its own experienced US agents in the fields of Pharma/Biotech, Medical Devices and In Vitro Diagnostics.
Asphalion supports research consortia as SME Regulatory Expert Partner:
•
•
•
•
Experience in proposal preparation and application process
First successful grant agreement in 2013 (iHIVARNA)
Participation in a total of 5 research consortia
Overall potential funds of over 24 million euros
Areas of Activity
the immune system
diseases
Preventing disease
Offer: Writing regulatory documentation: IMPD, IB, CTA, Orphan Drug Designation (ODD)
application, Paediatric Investigation Plan (PIP) and a lot more…
Page 78 of 487
Spain
Asphalion S.L.
Organisation Name
Country
Spain
City
Barcelona
Street
Via Augusta, 59
Website
www.asphalion.com
Phone
Organisation Type
SME
Person
Name
Anna Graupera
Email
[email protected]
Job Position
Asphalion is an International Scientific and Regulatory Affairs consultancy firm based in Barcelona and Munich.
Founded in 2000, Asphalion has consistently grown and now consists of over 70 professional consultants with backgrounds in Pharmacy, Chemistry, Biology, Biochemistry, Biotechnology, Medicine and Veterinary Medicine. Asphalion
offers comprehensive services for Drug Development and Regulatory Affairs to Pharma, Biotech and Medical Devices
companies. Asphalion can manage EU, US, Latin American and selected RoW procedures.
Asphalion has its own experienced US agents in the fields of Pharma/Biotech, Medical Devices and In Vitro Diagnostics.
Asphalion supports research consortia as SME Regulatory Expert Partner:
•
•
•
•
Experience in proposal preparation and application process
First successful grant agreement in 2013 (iHIVARNA)
Participation in a total of 5 research consortia
Overall potential funds of over 24 million euros
Areas of Activity
the immune system
diseases
Preventing disease
Offer: Writing regulatory documentation: IMPD, IB, CTA, Orphan Drug Designation (ODD)
application, Paediatric Investigation Plan (PIP) and a lot more…
Page 79 of 487
Spain
Asserta Global Healthcare Solutions
Organisation Name
Country
Spain
City
Badalona
Street
Av. Dels Vents 9-13
Website
www.asserta.net
Phone
Organisation Type
SME
Person
Name
Anaïs Le Corvec
Email
[email protected]
Job Position
International Research
Strategist
We are a team of professionals with years of experience in clinical practice, health management, teaching and research, who are putting their knowledge and expertise at the service of improving processes and results in the healthcare area. We have developped several Health data management system over the years. Our team also include experts in planning and strategic management, quality management and information and communication technologies,
togehter with experts in EU and international research.
Areas of Activity
Preventing disease
young
Offer: Experts in Pharmacology and eHealth
We are a young SME but with very experienced team in the use of eTools to enhance a better management of hospital
pharmacies. This can be very relevant in project where consortium are looking for a very key expertise in developing
software and bringing together various sets of data in relation to drug prescription and the whole systems behind it.
We can be a key partner in several calls ( example: PM02 or PM04)
Offer: eHealth solutions
As part of our skills, we work together with a large set of eHealth companies and association that would be interested
in becoming partners in PM12, as providers of new solutions together with the public procurers.
Page 80 of 487
France
Association E-SENIORS
Organisation Name
Country
France
City
PARIS
Street
19 CITE DE PHALSBOURG
Website
www.e-seniors.asso.fr
Phone
+33624396434
Organisation Type
Patients associations
Person
Name
MONIQUE EPSTEIN
Email
[email protected]
Job Position
Director
E-Seniors is a non-profit non-governmental organization, founded in 2005 by Monique Epstein, the general manager
of the association. E-Seniors aims at fighting e-exclusion by providing access to and training in ICT to seniors and/or
disabled people. Its main objectives are:
• Bridging the digital gap between generations,
• Encouraging seniors’ participation and involvement,
• Opening new horizons for efficient use of free time.
Since its creation, E-Seniors has provided courses in ICT usage for seniors in various public locations and the association is constantly opening new locations all over the region in order to provide a “proximity” service that takes into
account the rhythm, interests and needs of its potential audience. Through its work for elderly people and with them
the organization also tries to increase awareness about the importance of ICT solutions in everyday life. E-Seniors also
proposes interactive gaming activities in residences for elders, retirement homes and day-care centres. E-Seniors is
aware of the challenges that healthy or dependant elders face and then invests resources in the development of new
applications and services to enable independent living and help maintain physical and mental health.
E-Seniors has experience in projects related to ICT-tools designed for seniors and for active and healthy ageing. The
past and current European projects of E-Seniors are:
• AAL project “NACODEAL”: creating a mobile device which will help seniors to easily perform everyday life
tasks.
• AAL project “STIMULATE”: providing a complete platform to plan travels and execution functions, associated
with personalized assistance dedicated to senior citizens.
• AAL project “ASSISTANT”: assisting seniors in their use of public transport by an application available on PCs
and Smartphones.
• AAL project “SONOPA”: developing a social network for inactive seniors encouraging them to carry out more
daily activities.
• AAL project “TOPIC”: providing an integrated set of online-shared spaces and services to support the physical
and mental care ability of informal caregivers in their daily needs.
• FP7-ICT Project “ALFRED”: developing a Virtual Butler for elderly, a service that is available on mobile devices.
• ICT-PSP project “SEACW”: creating an Ecosystem that provides training, informing and promoting activities
in the field of New Technologies reinforcing healthy and active ageing.
Page 81 of 487
France
• Grundtvig Multilateral project “ SenApp”: aiming at developing a Training App for seniors in four European
countries to support them effectively and individually to become competent ICT user.
• H2020-PHC20 project “ehcoBUTLER”: targeting population ageing by developing an ICT technological platform with both leisure and care apps.
In addition, ESE is a member of the French node in the EIT Health KIC, a European consortium operating in the
framework of the European Institute of Innovation and Technology (EIT), that has the mission to promote entrepreneurship and develop innovations in healthy living and active ageing.
Areas of Activity
(PCP)
(PPI)
population
Offer: As an “end-user group” representative, we can have a specific role with deep implication during the whole project
E-Seniors intervenes in activities such as: 1. In the first stages of the project - advice and assistance for: • Identifying
target user groups • Analyzing user needs, acceptance and requirements: usability and accessibility problems • Advice and guidance about characteristics of tests in regard to users and project objectives • Designing: scenarios and
usage definitions 2. In the stage of production/ project development: • Generating content adapted to users • Translating and localizing 3. Practical field tests and user feedback/validation: • Setting up user groups: interview/filtering •
Carrying out tests • Validating pilot application and prototype interfaces and issuing recommendations with regards to
specific approaches more adapted to a senior public • Gathering conclusions from users feedback in order to make
recommendations improving product design 4. During the whole project (together with all partners): • Addressing ethical Issues: informing and monitoring – together with other user groups (if exist) • Disseminating information about
the project(s)
We are also specialized on the subjet of ELSI (ethical, legal and social implications) and of RRI (responsible research
and innovation. We are partner in the EIT health KIC consortium. We have quite a lot of ideas for new projects and
would be happy to shere them in a consortium
MARKET APPLICATION
We represent all kind of seniors users, the ones living at home as well as people in retirement homes, in day care centers or even in hospitals.
We are looking for a coordinator but also all kind of other relevant partners, depending on the subject of the call.
Page 82 of 487
Turkey
Association of Public Hospitals Northern Anatolian Region Of
Istanbul
Organisation Name
Country
Turkey
City
Istanbul
Street
E-5 Highway over
Website
Phone
Organisation Type
Person
Name
Neslihan Ozturk
Email
[email protected]
Job Position
Project Coordinator
Association of Public Hospitals Northern Anatolian Region Of Istanbul, which was established in 2012, is an authority
on health services which depend on the Ministry of Health Turkey (MOH). Our Association have totally 17 health institutions and 14.000 personel who works in these institutions which give health services both Turkısh and foreing citizens with quality medical and technological equipments. Association of Norhern Anatolian Region is responsible
from implementation of national health strategies through programs and direct provision of health services in accordance with MOH strategies.
In this direction, we are doing many projects on health informatics technologies in order to develop quality of health
service given by our hospitals. The Decision Support System (DSS) is one of the long-running projects that has being
developed by the Northern Anatolian Association of Public Hospitals. It is the DSS's purpose to use the present medical data more efficiently, create a hybrid model by associating multiple data, optimize the associated organizations
more easily and increase governance. DSS gathers the medical data of the organizations on the proper database and
turns it into an effective platform for the decision-makers. The system is built on a multi functional structure. The
managers can simply choose which data they would like to see, provided that it is their area of responsibility, and see
the analyzed data.
Tele-Medicine System is also used by our physicians in radiology clinics. This project which allows to use of the clinical
data of patients forever by integrating to central system, is intended to accelerate the exchange of information between hospitals and so, provide more quality health services. The physicians are being offered the possibility of online
consultation via this system and can see old tests which before applied other hospitals. Thus, patients do not need to
make unnecessary tests and analysis for their treatments.
Areas of Activity
(PCP)
(PPI)
population
Methods and data
policies
EU level
Page 83 of 487
Turkey
Request: Big Data Solutions and Pilot applications - Health Literacy
Association of Public Hospitals Northern Anatolian Region Of Istanbul is the first institution which has developed advance Decision Support system in Turkey and gives more importance to health informatics technologies in the increase of the quality of health services. Besides the projects which we are conducting, we aim to use the personal
health systems more effectively with approaches focused on diagnosis as improving alternative applications with appropriate partners for chronic diseases therapies, digital health literacy, personalised coaching for ageing population,
eHealth innovations for the patient (PCP).
We would like to attend this meeting to establish appropriate partnerships on projects such as advanced big data solutions especially in case of personal healthcare, cronic disesase management, anti aging, clinical decision support
system.
Association of Public Hospitals Northern Anatolian Region Of Istanbul is an union which improving itself on health informatics technologies to use health data beneficially. The partners which we are looking for, should be experienced
in the information technology especially health fields.
Page 84 of 487
Belgium
AXINESIS
Organisation Name
Country
Belgium
City
Louvain-la-Neuve
Street
Place du Levant 2
Website
www.axinesis.com
Phone
+32 10 472 512
Organisation Type
SME
Person
Name
Eric Hanesse
Email
[email protected]
Job Position
CEO
Axinesis, a spin-off of the Université catholique de Louvain (UCL), is an innovative medtech company with a mission
to improve functional recovery of the upper limbs following brain injuries. The company has developed an ergonomic,
interactive and auto-adaptive device, REAplan, combining robotics and virtual reality to improve the rehabilitation of
impaired upper limbs. REAplan differentiates from existing solutions by offering real time automated personalized assistance of arm movements.
Areas of Activity
Request: Partnership in multi technological stroke & brain injuries patient care
Industrial partnership offered in the field of rehabilitation solutions dedicated to brain injured patients, combining robotics, exoskeletons, virtual reality, serious games, algorithms and big data.
Offer: Clinical and research partnership in the filed of brain injured patients
Research partner and/or clinical partner requested to develop further studies (clinical partnership) and medical devices developments (research partnership) in new specific fields of rehabilitation of brain injured patients, adults as
well as children.
Request: Distribution partnerships in european countries
Distribution partnership requested in european-countries to develop sales expansion of our first product, a rehabilitation robotic device dedicated to upper-limbs rehabilitation of stroke adults and cerebral palsy children.
Page 85 of 487
Spain
Organisation Name
Country
Spain
City
Pozuelo de Alarcón
Street
Francisco Gonzalez Leal 2
Website
http://www.azierta.eu/
Phone
0034 912771076
Organisation Type
SME
Person
Name
María Ángeles Munoz
Email
[email protected]
Job Position
Strategic Commercial Director
Based in Madrid and Barcelona, AZIERTA provides international scientific and regulatory compliance services to Life
Sciences sector (Pharma, Biotech, Medical Devices and others) helping companies during the Drug Development to
the submission and post-market.
Azierta Science provides sole services focused on key aspects related to Preclinical, Clinical and Regulatory aspects
for small molecules and biopharmaceutical drugs (from drug candidate to approval). We provide targeted solutions
for your products and company (European and non European companies). This is our commitment to excellence.
Areas of Activity
Health ICT SMEs
Offer: Scientific Consultancy Services in Biopharmaceutical drugs: From candidate to the
approval
Roadmaps: CMC, Preclinical and Clinical development plans Support on programs from early development beginning
until phase I clinical trials. Scientific advice (EMA, EU-National Agencies) SME Applications to EMA
MARKET APPLICATION
Pharma and Biotech companies
Azierta Science provides sole services focussed on key aspects related to Preclinical, Clinical and Regulatory aspects
for small molecules and biopharmaceutical drugs (from drug candidate to approval). We provide targeted solutions for
your products and company (European and non European companies). This is our commitment to excellence.
Offer: Consultancy Services in Medical Devices: From prototype to the market
CE Mark integral support Clinical evaluation (MEDEV 2.7/1) Product Design advise Classification Risk Analyses Notified
Body selection and relationship
Offer: Quality Systems services in Biomedical Research
Global support on Quality Systems in R&D Departments (GCP, GLP, ISO 15189...) Design, implementation and maintenance on GxP; Strategic Plan, Risk Analyses, Computer System Validation Audits in R&D environment (CRO's, preclinical laboratories, Phase I Units, Data Managements...)
Page 86 of 487
Spain
Organisation Name
Country
Spain
City
Pozuelo de Alarcón
Street
Francisco Gonzalez Leal 2
Website
http://www.azierta.eu/
Phone
0034 912771076
Organisation Type
SME
Person
Name
Chelo Tudela
Email
[email protected]
Job Position
Senior Preclinical and Clinical Regulatory specialist
Based in Madrid and Barcelona, AZIERTA provides international scientific and regulatory compliance services to Life
Sciences sector (Pharma, Biotech, Medical Devices and others) helping companies during the Drug Development to
the submission and post-market.
Azierta Science provides sole services focused on key aspects related to Preclinical, Clinical and Regulatory aspects
for small molecules and biopharmaceutical drugs (from drug candidate to approval). We provide targeted solutions
for your products and company (European and non European companies). This is our commitment to excellence.
Areas of Activity
Health ICT SMEs
Page 87 of 487
Romania
BEIA Consult International
Organisation Name
Country
Romania
City
Bucharest
Street
Str. Peroni Nr. 16
Website
http://www.beiaro.eu
Phone
+40213323006
Organisation Type
SME
Person
Name
George Suciu
Email
[email protected]
Job Position
IT&C Solutions Manager
Our organisation type is: SME
We are active in the following Technologies: Service innovation, Hardware, sensors, actuators, Information technologies, data storage and processing (back end), Interfaces, software (front end), Integration, Communication technologies / Tele-systems, Learning & Training, Standardization, Communication / Dissemination / Marketing, Business
development, Project management
Applications: Health & wellness, Home care, Information and learning, Mobility, Safety, security, privacy, Skills enhancement, Social interaction, Supply with goods & chores, Work
Beia Consult International is a R&D performing SME, founded in 1991, and it is one of the leading providers of
telecommunications equipment and solutions in Romania for enterprise cloud communications and telemetry. The
company’s references include over 5,000 turn-key projects for advanced IT and communications solutions. BEIA is
certified ISO 9001, 14001, 18001 and 27001.
BEIA has many partnerships in Romania with industrial manufacturers, academics, large enterprises and SMEs including, University “Politehnica” of Bucharest, Research Institute for Artificial Intelligence (Romanian Academy), Romanian
Space Agency, National Institute for Research and Development in Electrical Engineering. And finally, Beia is a member of various professional organizations such as ARIES, PMI, IEEE, AHK, IPMA.
Expertise & Competences
BEIA has R&D expertise in Cloud and embedded M2M (Machine 2 Machine) telemonitoring applications, one of the
R&D results consist in “IP-Wireless-Telemetry” experimental system: Remote Terminal Unit (RTU stand alone, GPS location, data acquisition and processing, command and control, GPRS/CDMA on-line data transmission with TCP/IP embedded); Field Interface Unit – communications server; client application (fleet management, data monitoring and
command), human machine interface.
BEIA develops an agriculture monitoring platform for monitoring ecological parameters and environmental telemetry.
BEIA has experience in sensor networks for real-time monitoring (including seismic activity, radioactivity, tsunamis,
marine/maritime activities) and with telemetry systems for Irrigation Management (including sensors for measuring
soil moisture, monitor water uptake and calculate evapotranspiration), Accurate Water Data (watersensors for hydrographical purposes, from precipitation to water level monitoring of lakes, rivers, wells) and Efficient Water Management (leak and burst detection, pressure, flow, level and well monitoring).
Also BEIA has experience with software for Energy Remote Management System and manages an ongoing project
"TELE-GREEN / Telemonitoring System equipment, installations and facilities for the production of clean energy" co-financed by the European Regional Development Funding.
Page 88 of 487
Romania
BEIA has completed more than ten National and EU R&D projects which have resulted in international projects such as
“REDICT”, a FP7 EU-financed project, projects financed from the “National Plan for Research, Development and Innovation” including: TERRA_RO, LOCOMAX, MITEAPL, SAWHAU, SEDCC and finally, projects financed through the “Research of Excellence Programme”: ARTEMIS, RO-IP-Wireless-Telemetry, HIBRIVOLT, PRO-EURO-TIC.
Also BEIA has started the EU projects "CLOUD CONSULTING", “FAIR” and “NMSDMON” in the field of Cloud and IoT (Internet of Things) that will serve to industrialize the cloud communications solutions.
More projects can be found on our projects website : http://www.beiaro.eu
Products and services
Contact/Call Centers, Enterprise Communications (IT&C integration hardware, software, network), Local telephone
and data networks, Small Office and Home Office Communications (PABX, phones), PCM and XDSL transmission, Telemonitoring (IP / Wireless SCADA), Structured Cabling and other Network Construction Elements, R&D for complete ITC
Projects, Communication Solutions : PABX, voice mail, IVR, softphone, Call Centre applications, VoIP services, ERP/CRM
development and integration, Text-To-Speech, Automatic Speech Recognition, Technical testing, Testing of market related features, Implementation, and Managed Services & System Integration.
Ongoing projects (know-how can be used for current requirements - develop hardware and/or software and adapt
these tools to Horizon 2020, Eureka and other calls)
SARAT-IWSN : Scalable Radio Transceiver for Instrumental Wireless Sensor Networks
COMMCENTER : Developing of a “cloud communication center" by integrating a call/contact center platform with unified communication technology, CRM system, “text-to-speech” and “automatic speech recognition” solutions in different languages (including Romanian)
NMSDMON : Network Management System Development and Monitoring
FAIR : "Friendly Application for Interactive Receiver" is a tool to provide the mobile user with reviews, ratings and detailed online information services.
ACCELERATE: A Platform for the Acceleration of go-to market in the ICT industry
MobiWay: Mobility Beyond Individualism: an Integrated Platform for Intelligent Transportation Systems of Tomorrow
EV-BAT: Redox battery with fast charging capacity as a main source of energy for electric autovehicles
Carbadetect: Imuno-biosensors for fast detection of carbamic pesticide residues (carbaryl, carbendazim) in horticultural products
SWITCH: Software Workbench for Interactive, Time Critical and Highly self-adaptive Cloud applications
Speech2Platform: Smart, natural language semantic analyser platform to process oriented back-ends
Power2SME: Cloud Platform for intelligent energy use by SMES
Areas of Activity
(PCP)
(PPI)
population
Methods and data
Health ICT SMEs
Page 89 of 487
Romania
policies
records (PPI)
Request: Telemetry M2M / IoT Applications across a Distributed Cloud Platform
Beia Consult International is a R&D performing SME, founded in 1991, and it is one of the leading providers of
telecommunications equipment and solutions in Romania for enterprise cloud communications and telemetry. The
company’s references include over 5,000 turn-key projects for advanced IT and communications solutions. BEIA is
certified ISO 9001, 14001, 18001 and 27001. BEIA has many partnerships in Romania and can provide a full sub-consortium, including industrial manufacturers, academia, large enterprises and SMEs including, University “Politehnica”
of Bucharest, Research Institute for Artificial Intelligence (Romanian Academy), Romanian Space Agency, National Institute for Research and Development in Electrical Engineering. And finally, Beia is a member of various professional
organizations such as ARIES, PMI, IEEE, AHK, IPMA. INNOVATIVE ASPECTS: BEIA Consult International has delivered
several R&D projects where cloud and wireless heterogeneous network technologies are studied and experimented.
BEIA develops an agriculture monitoring platform for monitoring ecological parameters and environmental telemetry:
We use different types of RTUs and Sensors that monitor and transmit important information such as temperature,
precipitation, wind speed, soil condition and leaf wetness from selected locations. The RTUs will transmit sensor data
to our cloud platform where we can conveniently process the site-specific weather and soil data in near real-time, display it in our web-based visualization application and get detailed recommendations when and where to spray and
how much to irrigate - resulting in optimized yield, quality and income. In previous approaches RTUs were implemented in most cases on a local server and no company could aggregate enough sensor data to consider automating the
treatment process. Furthermore, BEIA is developing sensor networks for real-time monitoring (including seismic activity, radioactivity, tsunamis, marine/maritime activities, floods) and manages an ongoing project “SaRaT-IWSN” (Scalable Radio Transceiver for Instrumental Wireless Sensor Networks) to design and to validate at experimental model
level a new generation of WSN for neutrino detection and alerting. Also Beia manages two ongoing projects following
Eureka programme in the field of Cloud and IoT: FAIR (Friendly Application for Interactive Receiver) and NMSDMON
(Network Management System Development and Monitoring). Currently, BEIA is developing a M2M Telemetry for basic
Water Monitoring on the Danube river (water level and temperature monitoring) that is crucial for ensuring an efficient management of the Danube river navigation. The previous situation of monitoring efforts has resulted in experimental data logging equipment that does not fulfil requirements of reliable GSM transmission and sustainable power
supply. Furthermore, the existing equipment is scattered in few locations and more professional remote telemetry
units are required. The sensors utilised are those for: Air temperature, Air Humidity, Leaf wetness, Precipitation intensity, Wind speed, Solar radiation Moreover, BEIA has experience with software for Energy Remote Management System and manages an ongoing project "TELE-GREEN / Telemonitoring System equipment, installations and facilities for
the production of clean energy" co-financed by the European Regional Development Funding.
Wanted Expertise: M2M, telemetry, tele-monitoring equipment manufacturer, sensors provider
Expertise in AAL, any type, country Tasks to be performed: Integration of eHealth solution
Page 90 of 487
Turkey
Bilims
Organisation Name
Country
Turkey
City
Izmir
Street
Inciralti
Website
www.bilims.com
Phone
Organisation Type
SME
Person
Name
Onur Keskin
Email
[email protected]
Job Position
CEO
Bilims starts its journey as an academic based startup company. But in 2 years now we can define ourself as a R&D
centric company. Our main activity area is developing secure, smart and small devices for Big Data. The device definition can change, sometimes it can be a hardware or a software according to the project.
Areas of Activity
Request: Real-Time e-Problem Based Learning
We are developing scenario based on real time e-learning platform for multidisciplinary education such as medical or
engineering. Because we want to overcome memory based traditional learning with experience based learning with
intelligent objective feedbacks.
We are looking for medical institutes, pharmacy companies, educators to enlarge our platform's capacity.
Medical and/or education technique related university departments and/or companies to expand the application areas
of the platform in other countries, languages and sectors.
Page 91 of 487
France
BIO-MODELING SYSTEMS
Organisation Name
Country
France
City
PARIS
Street
3 RUE DE L'ARRIVEE
Website
ww.bmsystems.net
Phone
+33683061272
Organisation Type
SME
Person
Name
MANUEL GEA
Email
[email protected]
Job Position
Co-founder & CEO
BMSYSTEMS' MANAGEMENT SUMMARY
Download our full corporate presentation with the 9 POCs and our Scientific Presentation.
BMSystems, the world’s first Mechanisms-Based Medicine Company, invented CADI™* Discovery in 2004 to:
• propose robust decision making support for R&D and Business, and
• discover cost-effective, lower risk, patentable novel integrated solutions.
for medicine, health technologies, nutrition and cosmetics.
CADI™ Discovery is, since 2004, the first and only to date operational "Mechanisms-based Medicine" platform, that
addresses two of the major life sciences issues:
• the complexity of life’s mechanisms with its “Architectural Principle”
• the significant unreliability of scientific and clinical publications through its “Negative Selection Principle”.
Using CADI™ Discovery, our biologists extract contextualized smart data from heterogeneous scientific, medical,
health & patients’ information to create novel & pertinent medical meanings embodied by externally validated & directly exploitable first in class heuristic, non-mathematical, mechanistic models.
With its dual contractual & collaborative business model, BMSystems, created in 2004 and profitable since 2006,
thanks to our recurrent clients, already achieved a world’s first in neurodegenerative diseases, 2 therapeutic spin-offs
in phase II-II, 4 patents delivered, 7 publications, 4 programs ready for external validation.
You have a R&D issue or a decision to make, we may have a solution for you.
BMSystems’ science at a glance
• Correct understanding of disease/disorder/syndrome mechanisms is the first objective. Finding the
most pertinent biomarkers and therapeutic solutions is the necessary consequence of the first objective.
• CADI™ Discovery was invented in 2002 by Dr. François IRIS, geneticist, physiologist & molecular biologist. Our IT people, from the digital world, developed the platform to “help” our biologists work.
• CADI™ Discovery addresses the recurrent causes of failures of the “dominant thinking” systems biology programs due to the issues of “life mechanisms complexity” and publications unreliability.
Page 92 of 487
France
• We combine the strengths of human and artificial intelligences in the right order.
• CADI™ Discovery is operated by biologists to generate and destroy the maximum of working hypotheses before starting the experimental validation phase.
• Our biologists build heuristic non-mathematical models to generate novel disruptive physiological/
medical meanings from scientific, medical & health smart data.
• CADI™ Discovery, our proprietary CADI™ Knowledge Database of mechanisms & interactions and our
CADI™ domains cross-fertilization process cannot be compared to classical systems biology or bioinformatics. Only discovery processes already delivering novel therapies should be the benchmarks.
• Highly productive, we already conducted R&D programs in the fields of neurology, inflammation, metabolism,
immunology, addressing neurodegenerative diseases (Creutzfeldt-Jakob’s, Parkinson’s & Alzheimer’s diseases), psychiatry, autism, cancer, diabetes, longevity/aging, infections, dermatology, skincare and cosmetics
(see the 9 POCs).
BMSystems’ Group at a glance
• Independent Private Company incorporated in 2004. 100% owned by its founders.
• Profitable since 2006, thanks to our clients, we only sell the results of the R&D programs
• 100% biology driven company focused on discovery.
• Proprietary CADI™ Knowledge Database of mechanisms & interactions.
• Not domain-dependent, but information-dependent.
• Markets: Pharma, Cosmetics, Nutrition, Health Technologies, Connected health,
• Highly productive 24 FTE* of which 9 FTE on CADI™ Discovery programs only.
• Strong & long term strategic R&D collaborations (>100 people collaborating).
• Dual business model : Contractual and/or Collaborative R&D programs.
• Outstanding internal pipeline of programs ready for collaborations.
• 2 therapeutic spin-offs, 4 patents, 7 publications, 4 programs ready for validation.
Areas of Activity
the immune system
diseases
EU level
Preventing disease
Initiative
(PCP)
(PPI)
population
Methods and data
Page 93 of 487
France
young
policies
Health ICT SMEs
Offer: CADI Discovery to decipher diseases' mechanisms and propose robust solutions
CADI™ Discovery is the world’s first and, to date, only operational platform that addresses life’s mechanisms complexity and the unreliability of scientific and clinical publications by combining the strengths of human and artificial intelligences in the right order.
"Correct understanding of disease/disorder/syndrome mechanisms is the first objective. Finding the most pertinent
biomarkers and therapeutic solutions is the necessary consequence of the first objective. " CADI™ Discovery was invented in 2002 by Dr. François IRIS, geneticist, physiologist & molecular biologist. Our IT people, from the digital
world, developed the platform to “help” our biologists work. CADI™ Discovery addresses the recurrent causes of failures of the “dominant thinking” systems biology programs due to the issues of “life mechanisms complexity” and
publications unreliability. We combine the strengths of human and artificial intelligences in the right order. CADI™ Discovery is operated by biologists to generate and destroy the maximum of working hypotheses before starting the experimental validation phase. Our biologists build heuristic non-mathematical models to generate novel disruptive
physiological/ medical meanings from scientific, medical & health smart data. CADI™ Discovery, our proprietary
CADI™ Knowledge Database of mechanisms & interactions and our CADI™ domains cross-fertilization process cannot
be compared to classical systems biology or bioinformatics. Only discovery processes already delivering novel therapies should be the benchmarks. Highly productive, we already conducted R&D programs in the fields of neurology, inflammation, metabolism, immunology, addressing neurodegenerative diseases (Creutzfeldt-Jakob’s, Parkinson’s &
Alzheimer’s diseases), psychiatry, autism, cancer, diabetes, longevity/aging, infections, dermatology, skincare and
cosmetics (see the 9 POCs).
MARKET APPLICATION
Pharma, diagnostic, cosmetics: Red/biomedical Biotech. Chemistry: White/Industrial biotech. Environment: Yellow/environmental Biotech. Energy: Renewable Energy Biotech.
BMSystems' answers to clients / partners needs: Physiological / Diseases Mechanisms understanding Multi-Systems
mechanisms Multi-Scale mechanisms description Targets discovery & validation. Signatures of biomarkers discovery &
validation. Marketing strategies rational support Adaptive clinical trials rational support Market Access rational support New therapeutic / diagnostic / cosmetics strategies, New associations of molecules & devices New associations of
existing molecules Molecules / Devices Mechanisms of action R&D / Molecules / clinical programs evaluation: Next
Phase GO / NO GO decision Novel Clinical phases end points / processes Drug (re) positioning /(re) profiling Rare diseases drugs repositioning Drug side effects analysis for rescue Chemical entities safety issues (Allergy, PE, etc…) BMSystems' markets: All applications linked to life sciences
Offer: CADI Discovery for neurology, metabolism, inflammation
BMSystems, the world’s first Mechanisms-Based Medicine Company, invented CADI™* Discovery in 2004 to: - propose
robust decision making support for R&D and Business, and - discover cost-effective, lower risk, patentable novel integrated solutions, for medicine, health technologies, nutrition and cosmetics. Using CADI™ Discovery, our biologists
extract contextualized smart data from heterogeneous scientific, medical, health & patients’ information to create
novel & pertinent medical meanings embodied by externally validated & directly exploitable first in class heuristic,
non-mathematical, mechanistic models. With its dual contractual & collaborative business model, BMSystems, created in 2004 and profitable since 2006, thanks to our recurrent clients, already achieved a world’s first in neurodegenerative diseases, 2 therapeutic spin-offs** in phase Ib and I/II, 4 patents delivered, 7 publications, 4 programs ready
for external validation. You have a R&D issue or a decision to make, we may have a solution for you.
Page 94 of 487
France
CADI™ Discovery is, since 2004, the first and only to date operational "Mechanisms-based Medicine" platform, that
addresses two of the major life sciences issues: - the complexity of life’s mechanisms with its “Architectural Principle”,
- the significant unreliability of scientific and clinical publications through its “Negative Selection Principle”.
MARKET APPLICATION
Not domain dependant
Worldwide
Offer: CADI Discovery for neurodegenerative diseases (Creutzfeldt-Jakob’s, Parkinson’s &
Alzheimer’s diseases), psychiatry, autism, cancer, diabetes, longevity/aging, infections,
dermatology, skincare and cosmetics.
BMSystems, the world’s first Mechanisms-Based Medicine Company, invented CADI™* Discovery in 2004 to: - propose
robust decision making support for R&D and Business, and - discover cost-effective, lower risk, patentable novel integrated solutions, for medicine, health technologies, nutrition and cosmetics.
Using CADI™ Discovery, our biologists extract contextualized smart data from heterogeneous scientific, medical,
health & patients’ information to create novel & pertinent medical meanings embodied by externally validated & directly exploitable first in class heuristic, non-mathematical, mechanistic models. CADI™ Discovery is, since 2004, the
first and only to date operational "Mechanisms-based Medicine" platform, that addresses two of the major life sciences issues: the complexity of life’s mechanisms with its “Architectural Principle”, the significant unreliability of scientific and clinical publications through its “Negative Selection Principle”.
Page 95 of 487
Netherlands
BioActor
Organisation Name
Country
Netherlands
City
Maastricht
Street
Oxfordlaan 70
Website
Bioactor.com
Phone
Organisation Type
SME
Person
Name
Hans Van der Saag
Email
[email protected]
Job Position
CEO
BioActor develops proprietary health ingredients for use in functional foods, medical nutrition and dietary supplements. All ingredients address chronic health concerns, such as diabetes, osteoporosis, and cardiovascular disease,
which would benefit from preventive dietary measures. BioActor’s product development strategy relies on three simple principles: health effects must be clinically proven; ingredients must be from a natural and renewable source; a
new health ingredient must be based on a patentable scientific discovery.
The company is based in the BioPartner Center, on the Maastricht University Health Campus. BioActor's offices are
next to the Maastricht University Medical Centre and the research school NUTRIM, the expert research group on nutrition and health in the Netherlands.
Areas of Activity
Preventing disease
young
Request: Nutritional solutions to prevent chronic disease
BioActor develops innovative health ingredients for nutrition. The aim is to contribute to prevention through targeted
nutrition. We have already 3 bioactives on the market and are interested in collaborative research projects to develop
new bioactives for sarcopenia, arthritis, sleep, cognitive performance. BioActor has an in-house clinical research team
and carries-out 2-3 clinical studies p.a and a collaboration would ideally combine an early lead with in-vitro/in-vivo data with a translational clinical project to be carried out by BioActor.
leads of natural bioactive substances with potential for sarcopenia, arthritis, sleep or cognitive performance
SME's or universities.
Page 96 of 487
France
BIOASTER
Organisation Name
Country
France
City
Lyon
Street
40 avenue Tony Garnier
Website
www.bioaster.org
Phone
Organisation Type
R&D Institution
Person
Name
Corentin Chaboud
Email
[email protected]
Job Position
Head of European Affairs
BIOASTER conducts innovative technological research projects in four major application fields in health-relalated microbiology and infectious: vaccines, antimicrobials, diagnosis and microbiota. Each applied research project, involving academics, SMEs and industrials partners, is undertaken by a team of high-level scientists and engineers integrating state-of-the-art technological equipment and expertise.
BIOASTER, an independent non-profit organization, is one of eight French Technology Research Institutes created in
2012 at the initiative of Institut Pasteur and Lyonbiopôle. It was founded by CEA, CNRS, INSERM, Danone Nutricia Research, Mérieux Institute and Sanofi Pasteur, and is supported by 40 SMEs in the Lyon and Paris regions as well as the
French government, through the “Investments for the future” program, and by the Grand Lyon, La métropole and the
Rhône-Alpes region.
With offices and laboratories in Lyon and Paris, BIOASTER has today more than 100 employees including 80 worldclass scientists and engineers originating from 16 different countries involved in collaborative projects.
Areas of Activity
the immune system
Preventing disease
Offer: Development and use of innovative technologies and approaches in multi-omics data generation, predictive modeling and data integration and analysis covering vaccines,
therapies, antimicrobial resistance and microbiota
BIOASTER has developed seven technology units that actively participate in the development of new technologies
and approaches in multi-omics data generation, predictive modeling and data integration and analysis. : 1. Biocollections & Microbiology: Single point of access to various biological sample with different partner collections and a
unique web based software to ensure fast and secure request of the biological specimens 2. Genomics & Transcriptomics: New generation sequencing data production and analysis (MiSeq, Illumina barcoding 384 capabilities) 3. Immunomonitoring: Mass cytometry (CyTOF) and array of classical flow cytometry 4. Protein & expression system engineering: Expression system optimization, protein engineering and characterization 5. Animal models & imaging:, Controlled microbiota and infectious disease mouse models (BSL 2/BSL 3 facilities and gnotobiology unit) 6. Data man-
Page 97 of 487
France
agement & Analyses: High throughput analyses, computing farm in collaboration with cc-IN2P3 (CNRS) (cloud computing facility, with appropriate environment for the design of specific analytical workflows) 7. Metabolomics & Proteomics: Targeted and non-targeted proteomics and metabolomics (NMR 600 MHRZ and HR-MS, CE-MS capabilities)
Collaboration with and for the industry and academic partners to unlock technological bottlenecks is at the core of
BIOASTER. BIOASTER's heads of technological units all have proven experience and expertise working with private
partners and spent significant time of their career in the pharma or biotech industry, in Europe and worlwide. The
combination of people’s skills and experience with state-of-the art infrastructures designed to answer the needs of industry and complementary to academia's offer, in the Lyon and Paris health-related R&D intensive area makes
BIOASTER a tailor-made partner for collaborative European projects.
MARKET APPLICATION
Vaccines, diagnostics, drug/biomarker discovery, microbiota
Academic partners, SMEs, Consortium coordinators, industry, patients association
Page 98 of 487
France
BIOMODEX
Organisation Name
Country
France
City
Paris
Street
96 bis boulevard Raspail
Website
http://www.biomodex.com
Phone
Organisation Type
SME
Person
Name
Thomas Marchand
Email
[email protected]
Job Position
CEO
BIOMODEX is a surgical simulation company using 3D printing technologies. We develop surgical simulators from raw
patient data to high fidelity anatomical 3D printed model.
Areas of Activity
Methods and data
Offer: SURGICAL SIMULATION
BIOMODEX is a french startup that develops and manufactures 3d printed surgical simulators from CT scan.
Our models allows a unique surgical simulation experience for education training or pre-operative patient-specific
surgeries.
MARKET APPLICATION
MEDTECH
We need to develop new applications with the Medtech Industry.
Request: SURGICAL SIMULATORS FOR INDUSTRY
BIOMODEX is a french startup that develops and manufactures 3d printed surgical simulators from CT scan.
We're looking to meet the MEDTECH INDUSTRY to develop new simulators on their applications.
MEDTECH INDUSTRY R&D & MARKETING.
Page 99 of 487
Switzerland
Biopack Medical SA
Organisation Name
Country
Switzerland
City
Lausanne (VD)
Street
Rue de la Paix 6
Website
http://biopackmedical.ch/
Phone
+41 21 213 03 17
Organisation Type
SME
Person
Name
Helene Wegmuller
Email
[email protected]
Job Position
CEO Biopack Medical SA CH
Biopack Medical was founded in 2006 by a multidisciplinary scientific & managerial team at the Swiss Federal School
of Engineering (EPFL) in Lausanne.
Our incentive was to gather our skills in order to develop our two main businesses:
Identifying innovative medical products in order to launch them on a national and international level.
Providing medical companies or centers with strategic consulting in order to answer their needs in:
Optimizing marketing
Geographic expansion / internationalization
Optimizing distribution
Developing new business models
Nowdays, Biopack has been entered to the Russian market by getting the
Specialized in diagnostic, reeducation and high definition imaging systems, BioPack Medical distributes the latest
technologies for a complete offer to the practitioner. The company has also developed reputation in the aesthetic
medicine industry.
Thanks to our established network of key opinion leaders and biomedical engineers, we are constantly assessing the
market potentials to optimize the uptake of new innovative medical devices. Recently we havee established a strong
collaboration into the Russian market by getting the needed acreditation and by developing a strong network.
Areas of Activity
EU level
(PCP)
(PPI)
Methods and data
policies
Page 100 of 487
Switzerland
Offer: Exploitation of the Major H2020 Calls
Biopack Medical S.A. is primarily a distribution company of innovative diagnostic devices and solutions throughout Europe & Russia. Based on great outcome indicators, Biopack Medical developed a strong knowledge of the needs of the
medical landscape. Furthermore, Biopack Medical has recently focused on the development and implementation of innovative approaches on International and European research, development and innovation support programs such as
Horizon 2020. Its emphasis is primarily on projects in the life and health sciences, natural sciences, information and
communication technologies (ICT), environment and energy sectors, and in the areas of security and big data, as well
as in supporting SMEs development. Biopack Medical S.A. has incorporated a new strategic planning on the R&D of
medical and biotechnology fields worldwide, based on its know how and expertise mentioned above.
Offer: Consulting Advisory Role, Design of a Project, Project Management, Exploitation,
Dissemination and Communication of the H2020 Calls
We have a long experience on participation as a partner or subcontractor for professional project management. Identifying a reliable partner for (EU) Project Management, is one of the most difficult or risky tasks on EU or any other
Funding Schemes / Calls. We assume responsibility for administration, reporting, finances; the organization of meetings and a vast variety of other needed or required tasks, according to clients’ wishes. To fulfill gaps of our clients’ Complementary skills is one of our assets, by providing a proper and accurate exploitation and dissemination scheme. We
act as your project officer or your strategic policy maker. However, we are quite often involved as a catalytic research
partner. Commitment, Experience and Know-How have been important to reach our goals and create a satisfactory
environment for our clients. In the area of research and development funding, we identify the masked rules that have
a significant importance for the success. Translational Analysis and Implementation of the “idea” to the real “working
scenario & consortium” is our important advantage in this competitive field. If you need an assistance on issues like
“how” to write a project proposal for Horizon 2020 or another EU funding scheme we would be delighted to provide
the solutions immediately. Based on the long lasting experience of successful proposal writing in different research areas and industries, we can create real competitive R&D tailor made scenarios.
Seeking for Clinical Partners
Novel Treatments for Chronic Diseases
Interesting for all the Calls that we are involved for the H2020
Development & Validation of Innovative Biomedical Technology in novel Therapeutic Areas
A Network of Excellence on Big Data Science
Page 101 of 487
France
Biosims Technologies
Organisation Name
Country
France
City
Rouen
Street
75 Route de Lyons la foret
Website
Phone
Organisation Type
SME
Person
Name
Christine Heuclin
Email
[email protected]
Job Position
CEO
Biosims is dedicated to the development & manufacturing of high-performance analytical tools for Life Science Industries. Our core technology is Dynaxi.
Biosims is opening up a new class of research and monitoring thanks to Dynaxi, its core technology, which allows the
multiplex quantification of analytes down to the lowest abundances.
Dynaxi Immunoassays are designed to unlock research projects in the fields of disease biomarkers, drug discovery,
pre-clinical studies and drug development.
Biosims solutions range from supplying instruments and assay kits to customized prototyping with specific assays.
Areas of Activity
the immune system
diseases
Offer: Protein biomarker validation
Protein biomarker validation We would be delighted to discuss with you the outcomes of your research activity with
the purpose of integrating them into our devices as we have already done with other research organizations. The principle of the licensing-in partnership is to have your work recogneized and actually applied and to reward your organization with the royalties it generates.
The Dynaxi detection platform enables quantification of target molecules through ultra-highly sensitive and multiplex
immunoassays on microarray devices. The technology consists in a new innovative immunoassay approach : No light
/ No fluorescence / No amplification but Digital Counting, allowing extremely low amounts of multiple targets in a
sample to be monitored, at a level never reached so far on a chip device. The platform displays ionization spectrometry to detect a proprietary chemical named Symtag that is conjugated with the detection antibodies. This non-optical
detection system enables a more reproducible and robust digital quantification of analytes without any interference. It
will detect and quantify all protein analytes (Biomarkers) and will help to stratify clinical populations in human applications or in animal models thanks to a very low demand in sample volume.
Academics needing biomarker validation
Page 102 of 487
France
BRAIN e-NOVATION
Organisation Name
Country
France
City
Paris
Street
47 boulevard de l'Hôpital
Website
www.brainenovation.com
Phone
0157274666
Organisation Type
Other
Person
Name
Alexandra Chukas
Email
[email protected]
Job Position
operational manager
The Common Laboratory BRAIN e-NOVATION has been set up to share medical expertise from ICM – Brain & Spine
Institute – and expertise in Information and Communication Technologies (ICT) related to Health from GENIOUS
Group to design health innovation products and processes for therapists and patients.
Through BRAIN e-NOVATION, GENIOUS Group and ICM – Brain & Spine Institute – plan to design new e-health applications (notably therapeutic serious games), assess their clinical efficicacy and bring these solutions
onto tomorrow’s digital drugs' market.
Areas of Activity
(PCP)
(PPI)
Health ICT SMEs
Request: BRAIN e-NOVATION
The Common Laboratory BRAIN e-NOVATION has been set up to share medical expertise from ICM – Brain & Spine Institute – and expertise in Information and Communication Technologies (ICT) related to Health from GENIOUS Group,
to design health innovation products and processes for therapists and patients. Through BRAIN e-NOVATION, GENIOUS
Group and Brain & Spine Institute plan to design new e-health applications (notably therapeutic serious games), assess their clinical efficacy and bring these solutions onto tomorrow’s digital drugs market. Therapeutic Serious Games
have proven their efficacy in a number of nervous system disorders. We are going to adapt existing e-Health solutions
(serious games) from our pipeline to new pathologies, create new games, measure their clinical efficacy, test solutions in diverse environments to readjust and then commercialize them. At the same time we develop a comprehensive system/platform www.curapy.com allowing remote interactions “patient-therapist-family”, with accurate record of
disease progression, and efficient strategies of rehabilitation in institution and at home. Finally our aim is to promote
e-Health solutions in the society and enhance our collaborations with foreign partners. Necessary steps: creation, validation of the game, pilot study, clinical trials in Partner organizations, dissemination of results.
Required skills and Expertise: - Ability to conduct a clinical trial in the neurosciences domain, - Ability to launch, follow
a pilot study in the field of serious games for reeducation, - Access to the end-user, - Experience in market, pre-commercial activities and commercialization in the field of serious games, - Dissemination / communication capacities.
Page 103 of 487
France
Description of work to be carried out by the partner(s) sought: - Clinical trials, pilot studies in living labs, research centers, - End-user inclusion, co-creation, - Market study, business model for distribution in the foreign markets, - Dissemination / communication.
-End-user organizations to a) perform pilots in diverse environments, b) co-create games with the end user and facilitate acceptance of the technology, -Research institutes and hospitals to perform clinical trials, -Private market players
to facilitate pre-commercial activities and commercialization, -Other types of partners, which might be complementary with our expertise.
Page 104 of 487
France
CAP DIGITAL
Organisation Name
Country
France
City
Paris
Street
14 rue Alexandre Parodi
Website
Phone
Organisation Type
Other
Person
Name
Nadia ECHCHIHAB
Email
[email protected]
Job Position
Cap Digital is the French business cluster for digital transformation in the Paris Region, created in 2005, we count
1000 members; mostly SMEs but also large companies, academics and policy makers. We provide our members with
intelligence, training, matchmaking/networking, funding solutions, project reviews, business development and internationalization services.
Cap Digital is well involved in the field of connected health; we can reach out 82 members working in Health (65 SME,
5 major companies, 10 research labs/Universities and 2 private investors).
Areas of Activity
(PPI)
Health ICT SMEs
Offer: Interested in joining a consortium for the HCO10 Support for Europe’s leading
Health ICT SMEs
Cap Digital has access to more than 150 companies active in the field of ICT & health (telemedicine, connected
health, e-health etc.). we can organize workshops notably at Futur en Seine, the International digital festival to take
place every year in June. We can disseminate information and be the gateway to French SMEs.
Offer: interested in joining a consortium for the call gaming and gamification
Page 105 of 487
France
CARDIAWAVE
Organisation Name
Country
France
City
75017
Street
12 rue Albert Roussel
Website
Phone
Organisation Type
SME
Person
Name
BENJAMIN BERTRAND
Email
[email protected]
Job Position
CEO
Cardiawave, located in Paris, France, develops a unique non-invasive, real-time image-guided medical device for heart
valve disease treatment using a cutting-edge histotripsy technology with no thermal injury. We treat calcified aortic
stenosis (CAS), one of the world’s main causes of cardiovascular death. CAS affects 2-13% of the population aged 65
and over: it has become a major public health concern because of the ageing Western population (by 2030 1 person
in 3 will be over the age of 65 in Europe).
Areas of Activity
Request: Noninvasive ultrasound therapy for heart valve disease
Cardiawave develops a non-invasive, real-time image-guided medical device for heart valve disease treatment mainly CAS - using a cutting-edge histotripsy technology. Cardiawave is a spin-off from the French-based Langevin Institute (CNRS/INSERM).
1) Preclinical study: development of animal models with aortic stenosis 2) 3D printing or any artefact of aortic valve
for in vitro testing 3) Novel imaging techniques and expertise for cardiac tissue analysis before and after our therapy
treatment 4) Development of a support arm for our medical device 5) OEM imaging plateform and probes 6) OEM system for ECG 7) Customized electronic cards 8) Clinical centers in Europe for First-in-Men clinical trial
Partnerships or subcontracting in Germany, Great Britain, Belgium, Switzerland and Italy.
Page 106 of 487
Switzerland
CARDIOCENTRO TICINO
Organisation Name
Country
Switzerland
City
Lugano
Street
Via Tesserete 48
Website
www.cardiocentro.org
Phone
+41918053977
Organisation Type
University
Person
Name
Maria Montilla
Email
[email protected]
Job Position
Grant Manager
CARDIOCENTRO TICINO PARTNER SEARCH - HORIZON 2020 HEALTH
Cardiocentro Ticino (CCT) is a nonprofit organization leader in specialized health care service in Cardiology, Cardiac
Surgery and Cardiac anesthesia in Canton Ticino, Switzerland. It is also considered as a Research Center (according to
article 5 of the Swiss Federal Act on the Promotion of Research and Innovation RIPA).
WHAT WE DO
Every year at CCT more than 2,800 patients are treated with increasingly less invasive surgical procedures, as well as
the most advanced cardiac catheterization procedures. CCT also conducts several clinical, traslational and basic research studies.
Areas of Activity
Offer: CELL THERAPIES
CCT is implementing several studies on cardiovascular cell therapies and on the use of extracellular vesicles (EVS) to
improve cardiac function after MI. Since the safety and efficacy of cell therapies may be significantly influenced by
cell production protocols, our research groups are working on the development of innovative ideas for cell cultures
technologies. Likewise, CCT research groups are exploring non-cellular therapeutic approaches by studying exosomes
as key mediators of intercellular communication in the heart and as therapeutic candidates for heart disease.
Offer: CARDIAC ELECTROPHYSIOLOGY
Cardiocentro Ticino is leading a series of next generation projects that entail the design of a mathematic model of the
human heart’s electrical activity; in this way, it will be possible to simulate the electrical and mechanical alterations
occurring in heart failure patients treated with pacemakers or cardiac stimulators. It will thus be possible, in a not too
distant future, to offer every patient a fully customized electrical treatment.
Offer: RARE CARDIOVASCULAR DISEASES: PREVENTION, DIAGNOSIS AND TREATMENT
To offer patients in Italian Switzerland a programme for the prevention, diagnosis and quality treatment of Marfan
syndrome and related disorders, Cardiocentro Ticino and its Heart Surgery Department have organised a special service, expressly focused on these pathologies that have a serious impact on the cardiovascular system.
Page 107 of 487
Poland
CAS MED TECH sp. z o.o.
Organisation Name
Country
Poland
City
Mrowino
Street
ul. Poznańska 50
Website
Phone
+48600090080
Organisation Type
SME
Person
Name
Bohdan Baszuk
Email
[email protected]
Job Position
Member of board
Cas Med Tech sp. z o.o. is a producer of active nano-tropocollagen. Active nano-tropocollagen - a protein derived from
a particular type of fish skins. This source of raw materials caused due to good compatibility of the collagen to human
epidermis. Fish collagen, unlike cows and pigs collagen, is hypoallergenic and do not pile up.
Nano tropocollagen:
- active particles
- “basement” for regeneration
- “transport” for medications
Tropocollagen nanoparticles are sized with length of 150-200 nm and diameter of 1.5-3 nm. These dimensions
allow collagen to penetrate into the deeper layers of the human epidermis, and restore its elasticity.
As a first step CAS started sales tropocollagen as cosmetics.
We started a project to elaborate a new medical treatment and products which will serve in venous leg treatment Collran. The project was started and grand funding received from NCBiR (polish research and development public institution).
CAS cooperates with:
- Medical University in Poznan,
- Adam Mickiewicz University on Poznan,
- Medical University in Bydgoszcz,
- University of Life Sciences in Poznan,
- Polytechnic University in Poznan,
- University in Gdansk.
Why invest in CAS?
- Unique technology of nano-tropocollagen production
- Access to prominent Polish professors
- Multifunctional usage of tropocollagen (“drug transport”)
- First step to “personalized medicine”
Areas of Activity
Page 108 of 487
Poland
(PCP)
Request: CAS - Active nano-tropocollagen - looking for investor
CAS - developed a technology of production of Tropocollagen nanoparticles (length of 150-200 nm and diameter of
1.5-3 nm). In the first phase we are looking for 2-4 mln EUR
Planning investments: - boosting sales of tropocollagen as cosmetics - contribution in two medical projects - involve
scientists and professors for development of new uses of tropocollagen (as it is and in combination with nanoparticle
of silver, gold, zinc, cerium dioxide and in combination with drugs as nano-tropocollagen has an excellent penetration
ability).
Private inwestor, venture fund, start-up investor
Page 109 of 487
Spain
Catalan Institute of Oncology, IDIBELL
Organisation Name
Country
Spain
City
L'Hospitalet del Llobregat
Street
Gran via 199
Website
Phone
+34932607952
Organisation Type
R&D Institution
Person
Name
Miguel Angel Pujana
Email
[email protected]
Job Position
The Institut Català d’Oncologia (ICO, Catalonia, Spain; http://ico.gencat.cat/en) is a public health center
working exclusively in the field of cancer. Its approach to the disease is comprehensive, combining care, prevention,
research and specialized training in one organization. Currently, the ICO is the oncology referral center for approximately 50% of the adult population of Catalonia, which represents around 3.5 million individuals.
In this scenario, the ICO has launched a new research program, ProCURE. The program is led by the attending investigator Miguel Angel Pujana Ph.D., expert in the field of cancer bioinformatics and systems biology (PubMed). The
Mission of ProCURE is to make a significant contribution to “reducing the impact of cancer”; through a global, multidisciplinary approach to the questions of why resistance to current (and future) cancer treatments develops and how
it can be impaired.
Areas of Activity
the immune system
diseases
EU level
Methods and data
policies
Offer: Cancer therapeutic resistance
The major referral cancer institute in Catalonia has launched a new research program who's overall aim is "to produce
quality multi-disciplinary research in resistance to therapy, leading to a significant improvement in cancer patient
care". Through the coordinated activity of eight research groups, ProCURE is leading multi-disciplinary studies on cancer resistance, using advanced cellular and animal (particularly ortho-xenografts) models, and performing pre-clinical
evaluations of novel therapeutic approaches.
We research for patients. Our research is focused on patients, from diagnosis to treatment and/or progression. The
target population consists on thousands of cancer cases diagnosed every year at our institute. We work in multi-disciplinary teams. Our cancer research is carried out in complementary multi-disciplinary teams, addressing various
Page 110 of 487
Spain
types of cancer and employing a variety of experimental approaches. We are committed to knowledge transfer. We
transfer knowledge with a view to improving clinical care and quality of life, and to support wealth creation for the
benefit of society as a whole. Three spin-offs have already been launched from the ProCURE research groups; for the
application of oncolytic virus and immunotherapy; for the application of metabolomics and stem cell therapy; and for
the application of personalized ortho-xenograft murine models.
MARKET APPLICATION
-Personalized cancer risk profiles and models -Personalized cancer therapy profiles and models -Prediction of therapy
efficacy or resistance -Data integration and modeling
-Protein structure modeling and target prediction. -High-throughput screens: for drugs, and molecular and/or cellular
assays. -Advanced sequencing approaches: single cell and from FFPE samples. -Tumor heterogeneity understanding,
including evolution. -Functional assays of defined oncogenes and/or tumor suppressors. -CRISPR functional screens, in
cell and animal models.
Page 111 of 487
Portugal
CCG - Center for Computer Graphics
Organisation Name
Country
Portugal
City
Guimarães
Street
Campus de Azurem
Website
www.ccg.pt
Phone
Organisation Type
R&D Institution
Person
Name
Luís Guimarães
Email
[email protected]
Job Position
CCG has a wide experience regarding development and implementation of projects, in which its activity is targeted to
Domains of applied research.
CVIG: Computer Vision, Graphics and Interaction
•
•
•
•
•
Computer Vision
Computer Graphics
Human Machine Interaction
Virtual Reality
Augmented Reality
EPMQ: Engineering Process, Maturity & Quality
•
•
•
•
•
Modeling approaches for analysis and design
Process and project management
Business and location-enhanced database systems
Web-based systems interoperability
Metadata and ontologies for the semantic Web
PIU: Perception, Interaction & Usability
•
•
•
•
Human Factors R&D activities in applied fields such as health, safety, transportation and entertainment
GUI (Graphical User Interface) analysis
Prototype testing and Functional interface analysis
User-centred solutions, ergonomics and functional design
UMC: Urban and Mobile Computing
•
•
•
•
•
Pervasive and Ubiquitous Computing
Intelligent Transport Systems
Urban Computing
Visualization of mobility flows and urban space
Mobile Solutions and Location Based Services
Areas of Activity
Preventing disease
Initiative
Methods and data
Page 112 of 487
Portugal
(PCP)
(PPI)
policies
Offer: Computer Vision Interaction and Graphics
Domain of applied research, intrinsically linked to computer vision and computer graphics. The integration of both of
these scientific domains allows the study and development of technological innovative solutions, across all the development cycle, from the signal acquisition to its interpretation and correspondent output action. The CVIG team as a
vast experience in R&D and counts several successful projects in its fields of appliance. CVIG is supported by three
key topics of expertise: Computer Vision; Computer Graphics; Human-Machine Interaction. To which we add and highlight three technological modules: Virtual Reality Augmented reality Virtual Actors
In Computer Vision relevant information is extracted from images. CVIG works mainly in the following subjects: Electronic Surveillance (detection, tracking, and recognition of people or vehicles), Medical Image, Object Recognition and
Industry applications; In computer graphics, the development of virtual actors (avatars), serious games, and virtual
reality navigation solutions are the main topics of choice. Human-Machine Interaction using natural user interfaces as
input and avatars as output are two of the most important human-machine interfaces to CVIG. In a world more and
more virtual every day, CVIG explores the virtual reality concept through the development of immersive experiences,
experienced by virtual reality goggles (e.g.: oculus RIFT), adapting the real to the virtual world. CVIG develops augmented reality applications. These, either targeting PCs or mobile devices, allow the simulation of real world objects
by means of virtual models imposed in the world surrounding us. Virtual Actors represent a natural way to communicate information and to position the interaction from machines to people in a much more natural perspective. CVIG
has developed through the course of the last years, the technologies needed to generate/createvisually high quality
virtual actors for different scenarios, including its application to low end devices. At CCG, CVIG implements R&D in
straight cooperation with other R&D laboratories and universities. This cooperation allows the adoption of a strongly
committed approach focused on the resolution of multidisciplinary problems found in several projects, at the same
time that new R&D challenges are identified for and by the researchers.
MARKET APPLICATION
Smart Retail, Education, Simulation, Training
SME's
Offer: Engineering Process Maturity and Quality
Domain of applied research in engineering process maturity and quality. For that matter, EPMQ has strategically defined that its research must be objective and that its applicability must be validated in an industrial environment. EPMQ is composed by a multidisciplinary team, in thigh collaboration with research groups and academia, namely Group
SEMAG: Centro ALGORITMI from University of Minho, which have interests in state of the art on information systems
based in software engineering and management.
Complex product prototyping Product and process diagnosing Information systems architectures, by defining, modeling, designing, diagnosing, implementing, optimizing, maturity, evaluation and improvement of products and processes. We provide solutions services and development, at consulting and software engineering level. IT development:
analysis, design, implementation, test and delivery of software products. IT project management: software engineering process improvement process modeling software project management development methods ISO/OMG/SEI-based
requirements engineering multi-model environments high matured levels and assessment roadmaps Support in products/services normalization and certification: Process definition, evaluation, diagnosing, optimizing and improvement.
Delivering IT products and services modeling : information systems and software development processes business
analysis, requirements elicitation, business model descriptions IT process and products business modeling and architecture design IT integration and interoperability: : Development of architectural models, that represent mechanisms
for technological artifacts, standards, protocols Testing and Certification (conformity and interoperability assessment
in order to ease tested/certified products insertion on external Markets) Development of methods, techniques and
processes for product integration Requirements, models and integration concerns as references to integration tools
Page 113 of 487
Portugal
Integration assurance and product quality assessment Cloud Computing (SaaS and IaaS) architectures : Business
models analysis and development for SaaS and IaaS Business and functional requirements specification for SaaS and
IaaS Architecture design for SaaS and IaaS SaaS prototype and product development SaaS and IaaS system integration with other systems (e.g. ERPs) SaaS billing mechanisms implementation Business support components implementation Service provisioning components implementation Decision-support systems: : Development of decisionsupport systems (DSS) for gathering and storing of business data using analysis tools Complex prototype development using Business Intelligence, Business Analytics, Dashboards, Data Mining and Data Warehouse tools.
MARKET APPLICATION
Organizations working with Big Data.
Industry (from system development business) – on a company or organization’s need to innovate. It is our purpose to
create conditions to industry to innovate, without having to invest in the creation of their own means of research,
which would have high costs, and take years to acquire scientific maturity and productivity that can be found in academia. Research & Development members (from the same research interests) – on a specific work validation from one
of our doctorate researchers. For that matter, we develop projects for skills reinforcement, as well for serving companies/organization’s needs.
Offer: Perception, Interaction and Usability (Human Factors)
domain of applied research within CCG, with a dedicated team that studies human perception, behavior, adaptation,
and interaction with his/her surroundings. In the field of perception, PIU develops research in basic perception
processes, mainly processes of multimodal integration and perception-action in the visual, audiovisual, audio-motor,
visual-motor, and, recently, olfactory modalities. Regarding interaction PIU has developed projects on the frontier between science and technology, focusing mainly on the user’s adaptation to new interfaces, devices, and motor interaction. This acquired knowledge can be applied in areas such as biomechanics, rehabilitation, sports, entertainment,
and assisted living. As for usability, PIU faces it as the applied area of knowledge that gathers ergonomics, functional
design, accessibility, and the general development of user-centered design solutions.
PIU has at its disposal cutting edge technology in a space equipped with a virtual and augmented reality system,
namely a CAVE-like (Cave automatic Virtual Environment) system, a real-time auralization system, and a motion capture Vicon® system. The main goal is to provide users with an immersive environment that is highly configurable in
order to be used in simulation, prototyping, and interaction evaluation in a very realistic scenario. This domain of applied research has strong connections with the Laboratory of Visualization and Perception (LVP) from the University of
Minho. Besides having services concerning the utilization of the CAVE and inherent technical support, PIU’s team has
already developed different applied projects in several areas, such as: Studying road pavements that are acoustically
comfortable for road users; Calibrating audiovisual interfaces for assisted living; Evaluation of technologies and interactions; Driving simulation, interfaces for driver support, road safety; Biomechanical studies and products for motor
rehabilitation; Analysis of comfort/ergonomic indicators (consulting); Usability tests for product certification (consulting); Collection and reproduction of 3D audio (noise studies, entertainment, modeling); Psychophysical studies for the
aromatization of spaces.
MARKET APPLICATION
Technology producers.
The main goal of PIU is to develop human-centered studies and to participate in the creation of new products that
contribute to a more adaptive, usable, and comfortable utilization, as well as products that help with health/rehabilitation, safety, and entertainment.
Page 114 of 487
France
CEA Institut de biologie et de technologie de Saclay
Organisation Name
Country
France
City
GIF/YVETTE
Street
BAT 532 PC 103
Website
http://dsv.cea.fr/dsv/english/
Phone
Organisation Type
R&D Institution
Person
Name
Isabelle PHILIPPE
Email
[email protected]
Job Position
Research funding services
The Institute of Biology and Technology Saclay conducts research projects in genetics, molecular and cellular biology, structural biology, protein engineering, pharmacology, organic and inorganic chemistry, bioenergy, and biosecurity. This research is supported by the development of methodologies such as metabolomics, spectroscopy (NMR,
Raman, EPR, etc.), high-throughput screening, immunoanalysis and isotopic labeling.
Areas of Activity
the immune system
diseases
Methods and data
• HCO-02-2016 - Standardisation of procedures for
in-vitro diagnostics
Preventing disease
Initiative
Offer: Searching for SME partners to set up a Eurostar project on diagnostics
Our institute has developed commercialization projects that proved particularly successful (Prion or bioterrorism
agents dosage, for example) by the realization of numerous contractual studies or collaborative research with industrial partners in pharmaceuticals and diagnostics for over twenty years ("spin-off" from our developments).The existence of a strong quality policy also contributes to the identity of our service: the presence of two full-time quality
professionals, accreditation of Good Laboratory Practices (ANSM) of LEMM and iso9001 certification of SPI obtained on
December 2014. Lately we developped the eZYSCREEN test on ebola in partnership with INSERM Jean Mérieux Lyon.
We are now searching for partnerships with SMEs in order to submit H2020 projects.
SMEs
Page 115 of 487
France
CEA LIST
Organisation Name
Country
France
City
Gif-sur-Yvette
Street
DIGITEO Saclay Bât 565
Website
www.plateformedoseo.com
Phone
Organisation Type
R&D Institution
Person
Name
Carole SENTEIN
Email
[email protected]
Job Position
European Manager
DOSEO: a reference platform dedicated to radiotherapy technologies
www.plateformedoseo.com/
DOSEO is an open platform to all actors of the radiotherapy and the imaging, and it’s a cluster for innovative therapies and advanced technologies in healthcare.
Working on a non-clinical basis (say without hospital constraints), its activities are focus on innovation applied to
various steps of the radiotherapy workflow, on academic education and users training, on increased control of the
treatment delivery (metrology, quality control, protocols comparison), and on tests / demonstration of industrial
products.
DOSEO will ensure connexions between various partners as well (clinics / users, universities and research institutes,
industry, metrology laboratory, quality control institutions and regulatory entities …), providing them with a unique
opportunity to meet through the platform.
DOSEO is a 2 400 m2 center dedicated to R&D and training with 1000 m2 reception area (all, offices, meeting
rooms), 400 m2 training space and 1000 m2 technological area which comprises two medical accelerators (ELEKTA
VERSA HD and VARIAN TrueBeam), one scanner (GE Discovery CT750HD), a computed server, brachytherapy sources
and 60Co irradiator as well as room for meetings and education, offices, conventional lab.
Some expertises in simulation software, metrology, instrumentation and imaging reconstruction methods are available.
Offer: INFRAIA-02: European Research Infrastructure in the field of Radiation Therapy and
Medical Imaging: management and optimization of the patient dose in medicine
The offer would be to propose some tools (software, instrumentation, exchange of best practices, training, definition
of standards, and better standardization of practices…) to manage dose due to ionizing radiation used in medicine.
One example of federating target could be the setting up of a shared database of patient records to manage all doses
received by the patient. In matter of radiotherapy, another example is the development of a new tool, which would
compare different radiotherapy protocols and possibly allow the best choice. Such a tool would take into account the
patient's personal data but also some other parameters, to enable personalized radiotherapy treatment. Also the development of new methods (software or/and instrumentation) to optimize the in-vivo dosimetry and quality controls
are of interest. The ultimate goal of these services is to improve patient care and quality of life after radiotherapy.
DOSEO is a unique research platform in the field of radiotherapy and aims at being a reference centre for French and
foreign partners dedicated to radiotherapy technologies.
Page 116 of 487
France
Similar platforms in the field of proton therapy, radiology, CT scanners... Manufacturers of radiotherapy and protontherapy equipments
Page 117 of 487
France
Cell&Co
Organisation Name
Country
France
City
Pont-Du-Château
Street
ZAC de champ Lamet Rue de Chambussière
Website
http://www.cell-and-co.com/
Phone
Organisation Type
SME
Person
Name
Florent Belon
Email
[email protected]
Job Position
CEO
Cell&Co Biorepository – Your partner for the management and secure storage of your biological samples
Cell&Co offers a complete one-stop-shop solution for managing biological and clinical samples for public organizations
and private companies involved in life sciences and clinical research.
As the sole eco-biobank in Europe, Cell&Co processes the samples in compliance with the relevant quality standards
(GLP, GMP, GCP, ISO 9001 and NF S 96-900) and maintains the cold chain throughout their lifecycle: collection, transportation, receipt, storage, retrieval and disposal.
In order to offer a complete solution, Cell&Co also supports its customers by managing:
Sample processing (extraction, aliquoting, fractionation, etc.) and bioanalysis;
Sampling kits design, production and supply;
Logistics of materials and equipment (cryovials, labels, freezers, barcode scanners etc.);
Biospecimen provision;
Storage of paper archives and electronic data related to their samples.
Located in France and in the USA, Cell&Co is well placed to handle for European and international projects. Regardless of the size, location and complexity of the project, Cell&Co commits to offering a competitive service focused on
speed, simplicity and flexibility. With the capacity to store over 10 million samples, from ambient to cryogenic temperatures, Cell&Co handles resources of any origin: human, animal, plant, microbial or biochemical.
Aiming to improve sample quality and security, Cell&Co also develops and offers innovative systems such as our sealing systems, over-wrapping systems and our web-based sample management software on which our clients can control their samples and data. Our commitment to innovation ensures that your valuable resources will be managed to
extremely high standards.
Learn more about our offers on: www.cell-and-co.com
Areas of Activity
EU level
Methods and data
records (PPI)
Page 118 of 487
France
(PCP)
Health ICT SMEs
Offer: Sample management ; Biobanking ; and Biorepository
Our teams manages the security, confidentiality, traceability and quality of your biological samples, offering short,
medium or long-term storage.
Sealed over wrapping and sealing systems : to label samples for traceability
MARKET APPLICATION
Biotech , Pharmaceutical labs, Master Cell banks ...
Offer: Biobanking / Biorepository
Biobanking
Sealed and over wrapping systems traceability for secure storage
MARKET APPLICATION
Pharmaceutical Labs and biotech / CRO
Clinical trials
Page 119 of 487
France
Cellvax
Organisation Name
Country
France
City
Romainville
Street
102 avenue Gaston Roussel
Website
Phone
Organisation Type
SME
Person
Name
Ming Wei
Email
[email protected]
Job Position
Cellvax, founded in 2001, is a French SME which provides complete preclinical innovating drug validation studies both
in vitro and in vivo (rodents and non-rodents) allowing to accelerate the drug development process for unmet needs
related to severe human diseases, mainly in Cancer and Osteoarthritis (OA) fields.
Based on a technological platform and on our expertise in fields of molecular biology, cellular cultures in primo-culture (freshly established tumor cells from human biopsies) and in established lines, an original Nodule system, original animal tumor models (S.C. and/or orthotopic), angiogenesis and metastasis test, Rabbit ACLT model, Guniea pig
model for spontaneous Osteoarthritis development, in vivo imaging, toxicity, Toxicity studies in rodents and non-rodents, Bio-distribution/PK, histological analysis …, we are able to provide customized services for all academic and/or
industrial laboratories. These services allow to speed up the development of drug candidates in different fields by reducing cost of development.
Since its foundation in 2001, Cellvax has achieved a significant progress as a service company, especially in different
cancer models and OA models in mice, rats and other animal species, angiogenesis models in vitro and in vivo. Cellvax is actively developing scientific collaborations within European communities. From the beginning of its foundation,
Cellvax has successfully collaborated with different European companies and academic laboratories (France, Germany, Belgium, UK, Israel, etc.). Numerous contracts have been signed and successfully achieved. In 2007, Cellvax
has successfully launched a EUREKA project in cancer field for a total amount of 2.0 million €. In 2011, Cellvax has
successfully obtained a 2nd FP-7 grant for a total amount of 2.4 million €. The FP-7 projects not only allow for Cellvax
to develop its R&D activity, but also allow increasing its visibility in European countries, thus greatly beneficial for Cellvax’s development.
Areas of Activity
Offer: Preclinical studies in Cancer and Osteoarthritis (OA) fields
Cellvax, founded in 2001, is a French SME which provides complete preclinical innovating drug validation studies both
in vitro and in vivo (rodents and non-rodents) allowing to accelerate the drug development process for unmet needs
related to severe human diseases, mainly in Cancer and Osteoarthritis (OA) fields.
Page 120 of 487
France
Based on a technological platform and on our expertise in fields of molecular biology, cellular cultures in primo-culture (freshly established tumor cells from human biopsies) and in established lines, an original Nodule system, original animal tumor models (S.C. and/or orthotopic), angiogenesis and metastasis test, Rabbit ACLT model, Guniea pig
model for spontaneous Osteoarthritis development, in vivo imaging, toxicity, Toxicity studies in rodents and non-rodents, Bio-distribution/PK, histological analysis …, we are able to provide customized services for all academic and/or
industrial laboratories. These services allow to speed up the development of drug candidates in different fields by reducing cost of development.
MARKET APPLICATION
All pharmaceutical, biotechnological companies and/or public research laboratories.
Cellvax is looking for establishing partnerships or acts as a service provider (fees fro services) with drug discovery
companies.
Page 121 of 487
France
Centre Collaborateur de l'OMS pour la recherche et la formation en santé mentale
Organisation Name
Country
France
City
Hellemmes
Street
211 rue Roger Salengro
Website
Phone
Organisation Type
Person
Name
Berenice Staedel
Email
[email protected]
Job Position
chargée de mission programme médiateurs de
santé-pairs
The French World Health Organisation Collaborating Center for Research and Training in Mental Health (WHOCC Lille,
France) is a functional organization bringing together a network of actions, skills and programmes, related to the
mental health policy of WHO.
It is one of the 46 WHO Collaborating Centers in the world specializing in mental health (the only one in France) and
one of the four french speaking centres with Casablanca, Genève et Montréal.
The WHOCC gathers hospitals, research centres and universities that participate in implementing this work plan.
The Center is constituted by a network of qualified human resources and a consultative scientific council that share
common values. It organizes on-site trainings and visits of community based mental health services for professionals,
politicians, NGOs. It coordinates international and national trainings. The WHOCC provides technical assistance to
countries wishing to develop community based mental health services, and it provides technical assistance to relevant French speaking
countries in implementing their mental health local councils.
•
Areas of Activity
Preventing disease
young
Health ICT SMEs
(PCP)
Offer: Empowerment of mental health services users and carers
WHOCC participates, with WHO Europe and the European Commission, in the promotion of indicators of empowerment of citizens and users of mental health services. It contributes to the collection and dissemination of good prac-
Page 122 of 487
France
tices and facilitate exchanges. It participates in the development of the WHO QualityRights Toolkit to promote the
rights of desabled people, based on the United Nations Convention on the Rights of Persons with Disabilities.
Page 123 of 487
Portugal
CHLO-Hospital S. Francisco Xavier
Organisation Name
Country
Portugal
City
LISBON
Street
Estrada do Alto do Duque
Website
www.hsfxavier.min-saude.pt
Phone
+351210431000
Organisation Type
Other
Person
Name
Ana Ribeiro da Cunha
Email
[email protected]
Job Position
Consultant of Internal Medicine
Big Central Hospital in the center of Lisbon
Emergency room
internal Medicine
General Surgery
Ortopedics
Central Lab
ICU etc
Takes Medical care of 300.000 patients in the area of Lisbon
Areas of Activity
the immune system
(PCP)
(PPI)
Offer: Co-operation in Personalised Medicine and Active Ageing H2020 Projects
As a general central Hospital unit, integrated in the West Lisbon Hospital Centre, EPE; the Hospital de São Francisco
Xavier (HSFX) is well known a reference hospital for several prestigious emergency units in the areas of general emergency, pediatrics emergency and obstetrics emergency. Its internal medicine professionals are interested in integrating projects in the fields of personalized medicine and active ageing.
Page 124 of 487
France
CHU de Dijon
Organisation Name
Country
France
City
Dijon
Street
14, rue Gaffarel, BP77908
Website
Phone
Organisation Type
Other
Person
Name
Marc Bardou
Email
[email protected]
Job Position
Head of Clinical Research
Centre
The CHU is a teaching hospital. Within my institution I am running a clinical research centre.
I am running a clinical research center that, despite being multi-thematic has a specific focus on women and children
health.
I am leading the French Network of INSERM-Granted clinical research centers working on obstetrics and gynecology
(reseau GO-CIC, http://www.reseaugocic.fr), in close partnership with the GROG (research group on obstetrics and gynecology).
I am now focusing on access to care, particularly in the underserved women.
Areas of Activity
Request: Improving cervix cancer prevention: understanding the hurdles in order to overcome them.
This project is intended to assess, in a randomized clinical trial, mean to improve adherence to cervix cancer screening guidelines, and to further determine, in an observational comparison management of women with abnormal pap
smears finding, and factors likely to be associated with suboptimal management.
I need to find partners that have a specific interest in cancer prevention, and more specifically in cervical cancer prevention, with tools to identify women not adherent to guidelines, with a specific interest in underserved (or low income) women.
I am looking for experts in cervical cancer prevention, in modelling, in cost-effectiveness analysis, in public health
policies, in qualitative and socio-economic studies I don't have a real specific request for selected European countries,
but I would like to have countries with different size, different health care systems, and different social organisation
Page 125 of 487
France
Request: PREVENTION OF CERVICAL CANCER IN WOMEN REFRACTORY TO CERVICAL CANCER SCREENING
The idea is to prospectively assess interventions aimed at improving cervical cancer screening in women not adherent to screening policies, to assess management after abnormal Pap smear, to analyses barriers to screening, to build
model in order to adapt the best approaches across Europe according to socio-economic, health cares, prevalence
and other factors that can differ from one country to the others.
We will thus need epidemiologists, economists, statisticians, clinicians, sociologists, specialists of health care system
and policies, patient representative.
I am looking for partners all across Europe, including but not retrictive to, Belgium, UK, Ireland Germany, Poland, Bulgaria, Finland, Denmark, Sweeden.
Offer: national network of Clinical Research Centers for obstetrics and Gynecology
The GO-CIC network (http://www.reseaugocic.fr) is a unique partner, constituted of 15 academic ObGyn departments
and INSERM granted clinical research centers. It has a close relationship with the GROG (Groupe de Recherche en Gynecology and Obstetric). The GO-CIC network provides both scientific, logistic and administrative support.
MARKET APPLICATION
Drugs and medical devices for women health. Any other research in the field of women health.
Page 126 of 487
Portugal
CIAFEL-FADEUP
Organisation Name
Country
Portugal
City
Porto
Street
Rua DR Plácido Costa, 91
Website
http://ciafel.fade.up.pt
Phone
+351222504245
Organisation Type
University
Person
Name
Jorge Mota
Email
[email protected]
Job Position
Full professor-CIAFEL Director
The University of Porto is the largest university in Portugal and the nation’s leader in scientific papers. Housing Portugal’s largest number of students, faculties, and courses, the university alone was responsible for over 22% of all scientific papers produced in the country. The University of Porto is also a leader in community outreach as well as establishing international networks to enrich its student’s education. The scope of the Faculty of Sport (FADEUP) and Research Centre in Physical activity Health and Leisure (CIAFEL) at the University of Porto, is to promote basic and applied research on health-related physical activity field, valuing the relationships between physical activity and sports
with health and leisure. Promoting and collaborating in basic and applied research projects at national and international level on health-related physical activity issues, which express timely and important questions dealing with the
relationship between health (mainly chronic diseases), physical activity and leisure. PU was also project partner in the
European EUNAAPA, PASEO and IMPALA projects. In addition, FADEUP through CIAFEL offers a Physical Activity community program for the elderly and for obese children. UP is also an active member of the HEPA Europe network and
was involved in the pilot phase of the HEPA PAT project.
Areas of Activity
EU level
Preventing disease
young
(PPI)
population
Offer: Exercise- and health-related outcomes
CIAFEL is a Health Science Research Unit supported by the Fundação para a Ciência e a Tecnologia (FCT) and is hosted by the Faculty of Sport at the University of Porto, Portugal. The scope of the CIAFEL is to promote basic and applied
research in the health-related physical activity field, valuing the relationships between physical activity, health, and
leisure. Non-communicable diseases (NCD) such as obesity, diabetes and cardiovascular diseases (CVD) are major
public health problems in our society and are strongly linked to common lifestyle determinants such as physical inactivity and poor dietary habits. This research program is aiming to provide additional knowledge which will allow us to
develop strategies that counteract NCD trends and epidemics by identifying the primary lifestyle as well as the bio-
Page 127 of 487
Portugal
logical and psycho-social determinants and by evaluating efficient ways to improve lifestyle in the context of chronic
disease management.
Execute in vitro and in vivo studies to relate and optimize exercise with several disease conditions (Research): CIAFEL
seeks to promote and collaborate in basic and applied research projects of health-related physical activity issues at
the national and international levels. The CIAFEL research projects and activities are organized based on the scope
and objectives of the unit, which address timely and important questions dealing with the relationship of physical activity in primary and secondary prevention of chronic diseases (e.g. cardiovascular disease; metabolic disorders; aging) as well as the role of physical and leisure activities (e.g. quality of life and environmental characteristics) in population well-being.
Project leader in which exercise might fit as an appropriate issue.
Page 128 of 487
Poland
Clinical Communication Centre, Kazimierz Wielki University
in Bydgoszcz, Poland
Organisation Name
Country
Poland
City
Bydgoszcz
Street
ul. Staffa 1
Website
http://www.ukw.edu.pl
Phone
+48502715340
Organisation Type
University
Person
Name
Magdalena Lewandowska
Email
[email protected]
Job Position
The Clinical Communication Centre (CCC) is an education and research inter-university unit based in Poland. Its
mission is to improve health outcomes through a wide range of activities. Among its priority projects are conducting
research in the field of clinical communication. Our activities focus on two areas: 1) research on the quality of communication between healthcare professionals and patients to help us identify the areas that need improvement and 2)
teaching and training healthcare professionals in order to meet the standards of personalized medicine and developing communication skills teaching standards for healthcare professionals. The CCC is also the centre-point of the
EACH Poland Network for Communication Teaching and Research the aim of which is to provide support for teachers
and researchers of communication throughout Poland. It now serves a s a platform of cooperation for 10 out of 12
medical universities in Poland and has circa 100 active members. The CCC also cooperates with the teaching committee of the European Association for Communication in Healthcare. It hosts and helps organize conferences, trainings
and meetings of health care professionals to encourage the sharing of best practice and exchange of knowledge in
the field of clinical communication.
We offer:
• access to two University hospitals
• access to a diverse pool of patients, highly qualified medical personnel and medical infrastructure at our University hospitals
• access to a nation-wide network of scientists, researchers and teachers of clinical communication in Poland
• administrative base for all researchers and teachers of clinical communication in Poland.
We are currently working on the Polish adaptation of Health Professionals Communication Skills Scale (HP-CSS).
Areas of Activity
EU level
Page 129 of 487
Poland
Clinical Communication Centre, Kazimierz Wielki University
in Bydgoszcz, Poland
Organisation Name
Country
Poland
City
Bydgoszcz
Street
ul. Staffa 1
Website
http://www.ukw.edu.pl
Phone
+48502715340
Organisation Type
University
Person
Name
Anna Ratajska
Email
[email protected]
Job Position
Assistant professor, Rector's proxy
for the Clinical Communication
Centre
The Clinical Communication Centre (CCC) is an education and research inter-university unit based in Poland. Its
mission is to improve health outcomes through a wide range of activities. Among its priority projects are conducting
research in the field of clinical communication. Our activities focus on two areas: 1) research on the quality of communication between healthcare professionals and patients to help us identify the areas that need improvement and 2)
teaching and training healthcare professionals in order to meet the standards of personalized medicine and developing communication skills teaching standards for healthcare professionals. The CCC is also the centre-point of the
EACH Poland Network for Communication Teaching and Research the aim of which is to provide support for teachers
and researchers of communication throughout Poland. It now serves a s a platform of cooperation for 10 out of 12
medical universities in Poland and has circa 100 active members. The CCC also cooperates with the teaching committee of the European Association for Communication in Healthcare. It hosts and helps organize conferences, trainings
and meetings of health care professionals to encourage the sharing of best practice and exchange of knowledge in
the field of clinical communication.
We offer:
• access to two University hospitals
• access to a diverse pool of patients, highly qualified medical personnel and medical infrastructure at our University hospitals
• access to a nation-wide network of scientists, researchers and teachers of clinical communication in Poland
• administrative base for all researchers and teachers of clinical communication in Poland.
We are currently working on the Polish adaptation of Health Professionals Communication Skills Scale (HP-CSS).
Areas of Activity
EU level
Page 130 of 487
Poland
Request: Clinical communication research an effective way to ensure high quality health
care across Europe and beyond
We are keen to join forces with individuals/ institutions doing research in the wider clinical communication field. We
are particularly interested in doctor–patient communication, communication among health care team members and
health care professionals and patients. Research evidence indicates that improved communication enhances quality
of health care services and health outcomes. This is particularly important in the Central European Countries where
clinical communication skills teaching has to date not been mandatory. We are also interested in doing research into
patients with chronic somatic illnesses. We want to study similarities and differences among chronically ill patients in
different countries and develop most effective methods of communication with patients (e.g. heart failure patients).
Developing communication skills means good medical practice and this translates to increased patients’ satisfaction
and lower healthcare costs.
We are keen to join researchers that have • experience in coordinating research projects in the field • experience with
Horizon 2020 • experience in coordinating the EU funded projects
We are pioneering research activities into clinical communication in Poland and in order to bring about structural
changes driven by evidence-based outcomes, we need logistical support and know-how of more experienced EU partners . We aim at long-term cooperation.
Page 131 of 487
France
CNRS - UMR 7244
Organisation Name
Country
France
City
Villetaneuse
Street
Institut Galilée, Université Paris 13, 99 avenue JB
Clément
Website
http://www.univ-paris13.fr/cspbat/
Phone
33 (0)1 49 40 33 46
Organisation Type
Person
Name
Danielle GELDWERTH
Email
[email protected]
Job Position
senior scientist
Teams involved in Health engineering research. Applying macromolecular and organic chemistry, physics, physicalchemistry and biology to the development of prosthetic biomaterials, tissue engineering, bio-nano-materials, diagnostic and therapeutic imaging compounds, innovative biosensors, spectrometry (Raman & NMR) and spectrometric
imaging approaches for multi-scale analysis of biological media and diagnosis.
Areas of Activity
the immune system
diseases
Methods and data
policies
Request: Ethical and legal aspects while storing, sharing and working with biomedical data from human individuals
Our REQUEST for a collaboration concerns expertise in dealing with ethical and legal aspects while storing, sharing
and working with biomedical data of patients from geographically distributed areas (scattered medical centers sharing through common repository infrastructures). We are currently building a cloud-based computer infrastructure
meant to be used by a network of widespread users and contributors, and respective of ethical concerns and european regulatory requirements.
Technical means of anonymisation compatible with : longitudinal follow up of patients; use of distributed computer
infra-structures. Expertise on respects of european ethical concerns and regulatory requirements.
- Ethical, legal and regulatory expertise in sharing human biomedical data - Producers of biomedical data concerned
by sharing their data sets, and by participating to multicenter data (meta)analysis (particularly on distant biomedical
image annotations)
Page 132 of 487
France
Offer: Multiplexed analysis of biological samples for diagnostic purposes using nano-gold
sensors, spectrometric imaging and/or NMR spectrometry associated to multivariate statistical analysis
Our collaboration profile for research collaborations is based on OFFERING new means of individual biomedical diagnosis for personalized medicine, by using : innovative single or multiplexed bio-sensors (using nanogold substrates
and based on vibrational spectroscopies, Nanomedicine approach); multi-parameters detection/quantification dedicated to metabolome studies of biological samples (fluids and tissue biopsies) as allowed by Nuclear Magnetic Resonance Spectrometry and multivariate statistical analysis; multi-scale spectrometric imaging (confocal fluorescence
imaging and Raman spectrometry, fluorescence and signal correlation spectroscopy, atomic force microscopy). Such
approaches are complementary of other means of biomedical analysis at/by different modalities and scale (like biological phenotyping and/or multi-modal imaging studies at the cellular, organ, tissue and individual levels). We are also able to develop specific nanostructures in solution for theranostic approaches and applications in nanomedicine
(imaging, therapy...).
Our approaches are complementary of other means of biomedical analysis at/by different modalities and scale (like
biological phenotyping and/or multi-modal imaging studies at the cellular, organ, tissue and individual levels). Strong
innovative aspects in our research developments; high physical, physico-chemical and statistical expertise within our
team; Previous experience of setting up and conducting a european multi partner collaboration
MARKET APPLICATION
Diagostics and follow up of medical cohorts
Page 133 of 487
France
CNRS UMR8258
Organisation Name
Country
France
City
PARIS
Street
Faculty of Pharmacy, 4 avenue de l'observatoire
Website
http://www.upcgi.cnrs.fr/spip.php?rubrique10
Phone
01537439581
Organisation Type
Person
Name
Nathalie Mignet
Email
[email protected]
Job Position
Team leader
Team involved in nanoparticles for targeted therapy and imaging. Microbubbles for gene delivery, liposomes delivering under ultrasound, hydrogels temperature dependant, luminescent nanoparticles. Preformulation, calorimetric
analyses, In vitro and in vivo studies.
Areas of Activity
Offer: Applications for engeneered nanoparticles
From our expertise, we can offer several types of nanoparticles for Imaging or delivering that we can provide from our
set or conceive according to you application. We already have in hand microbubbles for ultrasound Imaging, responsive to ultrasound for delivery; luminescent nanoparticles which can be imaged in vivo without any tissue background
and can be re-excited at will; Albumin-like nanoparticles for Imaging and targeting with a specific process tjat we
patented earlier.; Hydrogels for local and long-term delivery. Bimodal MRI and optical Imaging.
The different formulations and vectors that we propose have been patented and can be developped for new applications for patent extension. Each formulation has been developped thanks to a special expertise within the team.
MARKET APPLICATION
These are technologies for health which can be helpful for diagnosis or delivery.
The expertise which would be complementary from ours would be chemists who developped a molecule of interest
which would request a formulation to provide solubilisation or a longer term effect. Another expertise of interest who
be biologists with a clear question and model to answer to whom we could provide nanoparticles for Imaging target or
drug delivery.
Page 134 of 487
Poland
Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy
Organisation Name
Country
Poland
City
Bydgoszcz
Street
Jagiellońska 13-15
Website
Phone
Organisation Type
University
Person
Name
Paulina Gyrkow
Email
[email protected]
Job Position
Collegium Medicum was previously known as the Ludwik Rydygier Medical University, which was established by the
Seym (the lower chamber of the Polish parliament) on 21st July 1984. In October of the same year, the Rector, prof. dr
hab. Jan Domaniewski, inaugurated the youngest medical university in Poland.
In 2004, the Medical University in Bydgoszcz was incorporated into the Nicolaus Copernicus University in Toruń and
renamed as the Ludwik Rydygier Collegium Medicum in Bydgoszcz. Since then, it has been providing academic education as part of NCU.
Currently, Collegium Medicum in Bydgoszcz provides education in the Polish language in 15 fields of study offered by
three faculties Faculty of Medicine, Faculty of Pharmacy, Faculty of Health Sciences.
Two teaching hospitals function at Collegium Medicum as the institutional base for education, scientific research and
highly specialised diagnostic, medical and rehabilitation services:
• the Antoni Jurasz University Hospital No. 1 in Bydgoszcz
• the Jan Biziel University Hospital No. 2 in Bydgoszcz
Areas of Activity
(PCP)
(PPI)
population
Request: research projects in the fields of medicine
As CM NCU has a broad offer in the research fields the cooperation may include most of the medical branches.
Research Insitutions Enterprises with expereince in the medical field other
Page 135 of 487
France
Organisation Name
Country
France
City
Versailles
Street
2 Place André Mignot
Website
https://www.yvelines.fr/
Phone
Organisation Type
Person
Name
SADI-HADDAD FARIDA
Email
[email protected]
Job Position
Le conseil départemental est l'assemblée délibérante élue au suffrage universel d'un département. Le Conseil départemental a pour mission de régler par ses délibérations les affaires du Département. En ce sens, il est en charge
du service public et de son amélioration dans les domaines dont il a la compétence.
Les principales compétences du Conseil départemental sont :
• l'aide sociale (forme légale d'assistance) : protection de l'enfance dont la protection maternelle et infantile,
aide sociale à l'enfance et prévention, insertion des personnes en difficulté, RSA, aide aux personnes âgées et
handicapées et prévention sanitaire,
• la voirie : gestion des routes départementales et routes nationales d'intérêt local, des transports et des transports scolaires par autocar
• l'éducation : gestion matérielle des collèges
• la culture : archives départementales, bibliothèque départementale de prêt, patrimoine architectural et
muséal
• le développement local : aides aux associations et aux communes.
• le tourisme
• une partie du financement des sapeurs-pompiers.
Le Conseil départemental emploie plus de 4000 personnes.
Areas of Activity
(PPI)
Offer: DomYcile gathering and exploitation of health services data for agieng people receiving home care
DomYcile is a multi users ITC plateform dedicated to health service providers and the ageing people receiving home
care. It provides: - a better folllow-up of the different interventions of multiple service providers for the same user
(better coordination and organisation of home care) - for isolated people, an opportunity for the family to monitor the
cares received - easy access for the health service providers (physician, nurses, social services, emergency services...) of the relevant health information about the patient
Domycile is a portable piece of hardware that is gathering datas regarding the ageing patient situation and the home
care services he's receiving. Domycile is an open system on which other application with value for the patient (considering also services outside of the health care field) could connect (telepresence for example)
Page 136 of 487
France
MARKET APPLICATION
Public collectivities in charge of organising home care for ageing people
Application developpers, public health care services, public collectivities
Request: DomYcile gathering and exploitation of health services data for agieng people
receiving home care
Page 137 of 487
France
Organisation Name
Country
France
City
Versailles
Street
2 Place André Mignot
Website
https://www.yvelines.fr/
Phone
Organisation Type
Person
Name
NAVARRE Jean-Francois
Email
[email protected]
Job Position
Le conseil départemental est l'assemblée délibérante élue au suffrage universel d'un département. Le Conseil départemental a pour mission de régler par ses délibérations les affaires du Département. En ce sens, il est en charge
du service public et de son amélioration dans les domaines dont il a la compétence.
Les principales compétences du Conseil départemental sont :
• l'aide sociale (forme légale d'assistance) : protection de l'enfance dont la protection maternelle et infantile,
aide sociale à l'enfance et prévention, insertion des personnes en difficulté, RSA, aide aux personnes âgées et
handicapées et prévention sanitaire,
• la voirie : gestion des routes départementales et routes nationales d'intérêt local, des transports et des transports scolaires par autocar
• l'éducation : gestion matérielle des collèges
• la culture : archives départementales, bibliothèque départementale de prêt, patrimoine architectural et
muséal
• le développement local : aides aux associations et aux communes.
• le tourisme
• une partie du financement des sapeurs-pompiers.
Le Conseil départemental emploie plus de 4000 personnes.
Areas of Activity
(PPI)
Offer: DomYcile gathering and exploitation of health services data for agieng people receiving home care
Page 138 of 487
France
MARKET APPLICATION
Application developpers, public health care services, public collectivities
Page 139 of 487
Switzerland
Cytel, Inc.
Organisation Name
Country
Switzerland
City
Geneva
Street
Route de Pré-Bois 20 C.P. 1839
Website
www.cytel.com
Phone
+41 22 761 70 20
Organisation Type
R&D Institution
Person
Name
Rachel Madec
Email
[email protected]
Job Position
Senior Manager
Cytel is an international biometrics CRO offering a range of innovative solutions for all phases of drug, biologic and
device development. Our unrivaled knowledge in biostatistics and trial implementation capabilities supports our software, consulting and clinical research services. We help clients uphold high standards of scientific rigor, statistical validity and data quality in their engagements.
Areas of Activity
Preventing disease
young
Offer: Cytel Inc.
Cytel is a premier provider of biometrics support to the pharmaceutical, biotechnology and device industry and academia. Cytel offers a full range of biometrics services: Strategic Consulting (Trial Design, Program and Portfolio Optimization, Interactions with Regulatory Agencies ..), Data Management (including EDC), Biostatistics (including IDMC
Support, Statistical Programming), CDISC Migration and Integrated Analysis, Randomisation, Medical Writing. Cytel also provides statistical software for trial design and implementation. The www.cytel.com website describes our activities and a selection of our experiences. One of Cytel’s specialisations is the design and implementation of adaptive
trials. With a goal to improve the Probability of Success of your development efforts, we’ve supported numerous successful programs resulting in approved products across a range of therapeutic areas including but not restricted to
oncology, cardiovascular, CNS, gastric/intestinal. Several of these programs were in rare, orphan disease indications.
We value excellence in implementation, with an emphasis on obtaining maximum information value and enabling the
best decisions to be made about the candidate drug, biologic or device. We are committed to a collaborative style of
working and helping our customers and/or partners (including among others many academic and medical centres as
well as government and regulatory agencies worldwide) to uphold the highest standards of scientific rigor, statistical
validity, and data quality in all our engagements. Convinced by the innovative strength and the scientific added-value
of the consortium, we would be delighted to be part of a consortium. Please don't hesitate to contact Caroline Morgan
([email protected]) or Rachel Madec ([email protected]) for further information about Cytel.
Page 140 of 487
Czech Republic
Department of Biomedical Engineering, Brno University of
Technology
Organisation Name
Country
Czech Republic
City
Brno
Street
Technická 12
Website
www.vutbr.cz
Phone
+420603151437
Organisation Type
University
Person
Name
Ivo Provazník
Email
[email protected]
Job Position
head
The Department of Biomedical Engineering of BUT integrates a range of scientific and engineering disciplines to create next-generation diagnostics devices and signal/image analysis software with the help of our clinical partners. First,
we specialise in the areas of cardiovascular diseases (electrocardiography), neurology (neuroimaging, EEG-fMRI
analysis, ...), orthopaedy (CT, calcification, ...), ophtalmology (glaucoma, ...), biological laboratory equipment (spectrometry, fluorescence microscopy, circulating mRNA analysis, ...). We are also involved in development of point-tocare laboratory devices for personalised healthcare from idea through IP rights protection to a final product for competitive market. Second, we specialise in machine learning approaches in bioinformatics for processing of large
amount of omics data, de novo genome assembly, phylogenetic comparative analyses, metagenomics, 3D QSAR
pharmacophore modeling (eg. in multiple drug resistance studies, ...).
Our methods and devices assist in the diagnosis of diseases, as well as monitoring its progression. We are interested
in partnering in proposals seeking devices to diagnose diseases as well as monitor therapeutic response during personalised treatment.
Areas of Activity
the immune system
diseases
Methods and data
Offer: (Bio)medical data processing
Department of Biomedical Engineering (DBME) is oriented towards development of methods for analysis of biological
signals (ECG, EEG, EMG, EOG), ultrasound images, ophthalmic image data, 3D MRI and fMRI data, CT and x-ray images, microscopic images, and genomic/proteomic data. The scope of DBME covers these challenging applications: •
Signal and image processing, analysis and feature extraction - analysis of polysomnographic signals, ECG, EGG, EMG.
Page 141 of 487
Czech Republic
Image processing focused on CT, MRI, ultrasound, and retinal modalities. • Video-based monitoring of basic physiological signals - estimation of heart rate, HRV assessment, respiratory rate, blood oxygen saturation. • Mathematical and
computer modelling of biological systems - mathematical description of different biological systems (cardiovascular
system, respiratory system, compartment-based approaches, epidemiological models) with respective numerical solutions, development of neural connectivity models for fMRI. • Feature extraction and feature reduction techniques - applications in the area of bio-signals (ECG, EEG, EMG) and bio-image (retina, iris, cell microscopy, MRI) processing that
cover feature extraction and feature reduction (ICA, PCA, wrapper and filter based techniques). • Analysis of biological
signals aimed at stress factors monitoring - statistical analysis of environmental data, prediction models. • Biofeedback applications and biofeedback based rehabilitation – methods based on utilization of EEG and EMG signals, and
respiratory and heart rate parameters. • Biomedical signal analysis for biometric applications – development of face
and eye recognition methods and systems, evaluation of current biometric characteristics • Genomic signal processing - efficient and fast large genome assembly
Offer: Bioinformatics – genomic and proteomic data processing
Department of Biomedical Engineering (DBME) is oriented towards Further orientation of DBME is towards development of methods and efficient algorithms for analysis of DNA and proteins and drug discovery. This field includes following research activities: • Phylogenetic comparative analyses • Metagenomics • 3D QSAR pharmacophore modeling • de novo genome assembly
Offer: Live cell imaging and analysis
Department of Biomedical Engineering (DBME) is oriented towards development of unique technology and methodology for measurement and imaging of electrical and mechanical activity of cells (such as for cardiomyocytes viability
measurements and cell dynamic parameters analysis): • Double-camera double-dye fluorescence microscopy to acquire video sequences of cell • Patch clamp techniques • Microelectrode array for simultaneous recording across cell
membrane • Standard confocal microscopy, fluorescence microscopy and bright field microscopy
Page 142 of 487
Bulgaria
Diavita Ltd
Organisation Name
Country
Bulgaria
City
Varna
Street
68 Br. Miladinovi str. entr. G
Website
www.diavita.org
Phone
Organisation Type
SME
Person
Name
Dimiter Dimitrov
Email
[email protected]
Job Position
Diavita Ltd. is a SME company based in Bulgaria and focused on translational bioinformatics and systems medicine.
Areas of Activity
the immune system
diseases
EU level
Methods and data
policies
records (PPI)
Projects that need SME in translational bioinformatics and systems medicine.
Page 143 of 487
France
Diverchim SA
Organisation Name
Country
France
City
Roissy CDG Cedex
Street
6 rue du noyer, Roissy-en-France
Website
www.diverchim.com
Phone
+33130119550
Organisation Type
SME
Person
Name
Lionel COLLIANDRE
Email
[email protected]
Job Position
Chemoinformatic and Data
Manager
Founded in 2000, DIVERCHIM is the leading French company for organic synthesis of original molecules bringing its
customers a top level expertise. DIVERCHIM is a Contract Research Organisation (CRO) in organic chemistry.
Our teams combine experience in drug discovery and process development, medicinal chemistry, parallel synthesis, biochemical tools and fine chemicals to deliver you with unique chemistry solutions to achieve your requirements. Diverchim specifies in complex multi-steps synthesis, low temperature chemistry, asymmetric,
organometallic, cyclopropane, pyrrolidine, oxetane chemistry... Besides Diverchim can scale-up existing processes or
develop a new process for existing products. Our Custom Synthesis capabilities range from mg to cGMP kilogram
scale.
DIVERCHIM offers reference products for screening and building blocks for discovery (catalog) and pilot plant production under cGMP compliance (ANSM certificate in 9/2015)
Cooperation sought : screening of our collection, development of Matriochka concept in drug discovery, developement of functional dendrimers.
Areas of Activity
Offer: Valorisation of Matriochka chemical library
Diverchim have developed a new concept in drug discovery and try to vaorlize its chemical libraries by adding biological activities
Page 144 of 487
Norway
DNV GL
Organisation Name
Country
Norway
City
Høvik
Street
Veritasveien 1
Website
Phone
Organisation Type
Large Company
Person
Name
Lars-Martin Berglund
Email
[email protected]
Job Position
Resarcher
Driven by its purpose of safeguarding life, property and the environment, DNV GL enables organizations to advance
the safety and sustainability of their business. We provide classification and technical assurance along with software
and independent expert advisory services to the maritime, oil & gas and energy industries. We also provide certification services to customers across a wide range of industries, for instance healthcare. Operating in more than 100
countries, our 15,000 professionals are dedicated to helping our customers make the world safer, smarter and greener.
Areas of Activity
(PCP)
Methods and data
policies
records (PPI)
Request: Alarm management
Looking for initatives regarding alarm management
New solutions to overcome present challenges
Technology partners and partners in general interested in driving change and increasing patient safety and the wellbeing of healthcare personnel.
Request: Safety and efficiency at lower cost when developing and finalising medical devices
New tehcnologies calls for new ways of assuring device safety. We wish to investigate the possibility for improving the
existing approach to implementing new technologies, for both care providers, patients and device developers.
Companies and institutions developing medical devices
Page 145 of 487
Norway
Request: Big data: Pharma, medical devices and patient safety
Our company business revolve around safety and risk management. We wish to join projects where we can use and
develop our experience within data management, data custodian, data risk management, product assurance, sensors, integrated care, co creating healthcare.
Most actors interested in the titled subjects.
Offer: Safety, quality and risk management increasing patient safety
We provide knowledge about safety and quality in an assurance framework. As a company we continously have to develop new ways to help ensure the safety of: hospitals, products the population consume, devices used by patients
and physicians, data utilised to promote health.
Any partner who would like to discuss the themes above
Page 146 of 487
Turkey
Dokuz Eylul University Faculty of Medicine Department of
Family Medicine
Organisation Name
Country
Turkey
City
Izmir
Street
Mithatpasa Cad
Website
http://www.deu.edu.tr/akademik/index.php?cat=3&akod=20020185
Phone
+902324124951
Organisation Type
University
Person
Name
Tolga Günvar
Email
[email protected]
Job Position
Professor
Dokuz Eylul University is one of the biggest university in Turkey. Almost 60 000 students and 7500 staff all over the
university. Dokuz Eylul University has 20 faculty and vocational high school. In the university there is an Research Instutute in the campus of Medical Faculty which is unique all over the Turkey. The are two Tecnopark one of them is
medical the other is technical. Faculty of Medicine is one of the faculty of Dokuz Eylul University which has 1200 medical students in undergratuate education. Also Dokuz Eylul University has university hospital with the capacity of 1000
bed. In medical faculty therea are almost 500 academician. Department of Family Medicine (DFM) has an 7 academician and 60 residency. DFM are working in the area of undergraduate and postgraduate edical education, researces
and projects about primary care, taking care of patients.
We are studing e-health for chronical disease such as hipertension, diabetes, osteoporosis, COPD, astma, health promotion, life style changing, smoking cessation, obesity, depression in primary care. Also do researches about adolesent health especially in reproductive health and mental health.
Areas of Activity
Preventing disease
young
(PCP)
(PPI)
population
Request: E-health for screening, diagnosing, therapy and monitoring of hypertension and
type 2 diabetes in primary care based on clinical decision support system for physicians
and patients.
The proposal objective is to design mobile and web based program for screening, diagnosing, therapy and monitoring
of hypertension and type 2 diabetes in primary care based on clinical decision support system for physicians and patients. International guidelines of hypertension and diabetes for screening, diagnosing, therapy and monitoring will be
used for preparing algorithms of clinical decision support system by the academician of family medicine, cardiology,
endocrinology. With using the algorithms the mobile and web based program will be done. The system will be used by
Page 147 of 487
Turkey
the physicians and the patient in collaboration. The physician in primary care will use clinical support system about
the illness for managing hypertension and diabetes. The patient also will use the web and mobile based system for
self monitoring. With wearable devices blood pressure, blood glucose, pulse ext. will be collected. These data will be
evaluated by the clinical decision support system and the advice or the medical condition will be informed to doctor
and patient. The system also will be used for therapy of life style changes of patients.
We need a partner who is expert in life style changes therapy. We need also a partner who is expert in sensor technology in medicine.
We want to study with experts in physical activities and nutritional therapy. We also sought for an organization which
producing about wearable sensors that collect the data of pulse, blood pressure, blood glucose etc.
Offer: Clinical expert in Ehealth of chronical disease, active aging in primary health care
E-health for screening, diagnosing, therapy and monitoring of hypertension and type 2 diabetes in primary care based
on clinical decision support system for physicians and patients.
Offer: Clinical expert and researcher in adolescent health in primary care
Page 148 of 487
France
E-Seniors Association
Organisation Name
Country
France
City
Paris
Street
11, cité de Phalsbourg
Website
http://www.eseniors.eu/
Phone
0646694055
Organisation Type
SME
Person
Name
Daria Kyslitska
Email
[email protected]
Job Position
European project manager
E-Seniors is a non-profit non-governmental organization, founded in 2005 in Paris. E-Seniors aims at fighting e-exclusion by providing access to and training in ICT to seniors and/or disabled people. Its main objectives are:
• Bridging the digital gap between generations,
• Encouraging seniors’ participation and involvement,
• Opening new horizons for efficient use of free time.
E-Seniors also proposes interactive gaming activities in residences for elders, retirement homes and day-care centres.
E-Seniors is aware of the challenges that healthy or dependant elders face and then invests resources in the development of new applications and services to enable independent living and help maintain physical and mental health.
E-Seniors has experience in different European projects related to ICT-tools designed for seniors and for active and
healthy ageing (Horizons2020, FP7, AAL, ICT-PSP, Erasmus+).
Areas of Activity
(PPI)
population
Offer: End-user expertise and deep implication in the users' studies and pilot testing of
the final product during the whole project
In the first stages of the project - advice and assistance for: • Identifying target user groups • Analyzing user needs,
acceptance and requirements: usability and accessibility problems • Advice and guidance about characteristics of
tests in regard to users and project objectives Practical field tests and user feedback/validation: • Setting up user
groups: interview/filtering • Carrying out tests • Gathering conclusions from users feedback in order to make recommendations improving product design
• Designing: scenarios and usage definitions • Thanks to our wide network of seniors end-users, we are capable to be
in the direct contact with the seniors • Validating pilot application and prototype interfaces and issuing recommendations with regards to specific approaches more adapted to a senior public
MARKET APPLICATION
- Health - ICT - Seniors - Robotics • Rehabilitation • Cognitive impairments
Page 149 of 487
France
- Research Institution or SME that will be able to coordinate the H2020 project in the are of Personal medicine or ICT
solutions for healthy & active ageing
Request: Project partners for Horizons2020
We are looking for the partners and in particular for the coordinators for the H2020 projects in the domain of healthy
and active ageing
Coordinators, research and industrial partners, SMEs, Universities from all countries and Europe and also from Japan
(for Japan-EU call)
Page 150 of 487
Belarus
Educational Institution "Gomel State Medical University"
Organisation Name
Country
Belarus
City
Gomel
Street
Lange str. 5
Website
www.gsmu.by
Phone
+375232756254
Organisation Type
University
Person
Name
Barys Paulau
Email
[email protected]
Job Position
International Project Coordinator
The Educational Institution "Gomel State Medical University" was founded only in 1990, but now it is one of the leading universities among the educational institutions of the Republic of Belarus.
The development of effective and mutually beneficial partnership with university centers is based on international
agreements on mutual cooperation in educational and scientific fields. The Educational Institution "Gomel State Medical University" successfully cooperates with such foreign educational and scientific institutions as the University of
Florence (Italy), University of Nagasaki (Japan), etc.
In April 2014 our University started a National Contact Point for the Health, demographic change and wellbeing on
new EU Framework Programme for Research and Innovation "Horizon 2020" (2014-2020).
Currently we are looking for partners in several directions of cooperative researches as part of Twinning Grants: IncoNet EaP supports "Clustering of Scientific Projects and Institutions" and EU "Horizon 2020" (Health, demographic
change and wellbeing).
Areas of Activity
EU level
population
Preventing disease
young
Methods and data
policies
Offer: Project "Gender Sensitive e-Health Promotion and Prevention"
Creation of preventive resources (websites, programs, etc.) for men's health promotion
We find project partners for a participation in the Horizon 2020 program
Electronics / e-Health / University, Research Institute, SME, Company / EU
Page 151 of 487
France
Embassy of Hungary
Organisation Name
Country
France
City
Paris
Street
5 bis square de l'avenue Foch
Website
Phone
Organisation Type
Person
Name
Szilvia Szanto
Email
[email protected]
Job Position
scientific and technological
attache
Representation of the Hungarian helth related reaserch, innovation and technology development sector in France. Interested in H2020 and/or bilateral cooperations.
Areas of Activity
the immune system
diseases
EU level
Preventing disease
Initiative
young
(PCP)
(PPI)
Methods and data
policies
records (PPI)
Health ICT SMEs
Page 152 of 487
France
population
Offer: Big data supporting public health policies
Hungary Semmelweis University's Health Services Management Training Centre (HSMTC) wish to join the project
(H2020 2016-2017. Personalised Medicine SC1-PM18-2016). Http://semmelweis.hu/emk/
Page 153 of 487
Turkey
Erciyes University
Organisation Name
Country
Turkey
City
Kayseri
Street
Talasyolu
Website
www.erciyes.edu.tr
Phone
+903524375279
Organisation Type
University
Person
Name
Umut Ozdemir
Email
[email protected]
Job Position
assistant director
Erciyes University was established under the name of Kayseri University in 1978. Gevher Nesibe Faculty of Medicine
was established as an affiliate of Hacettepe University in 1969, and Kayseri Faculty of Business was established in
1977; these two academic units formed the core of the Kayseri University. In 1982 Kayseri University incorporated
with two higher education institutions: Kayseri High Islamic Institute which was established in 1967, and Kayseri
State Academy of Architecture and Engineering which was established in 1977. The additions to Kayseri University
served as the Faculty of Theology and the Faculty of Engineering and the name of the university was changed to Erciyes University. The name of the university was inspired by Mt Erciyes (3916 m), which lies 15 kilometers to the
south-west of the city. Mt Erciyes is one of Turkey's most influential winter sports centers. Today, Erciyes University
consists of 18 faculties, 4 colleges, 9 vocational schools, 7 institutes, 6 departments and more than 37 research centers. The highly developed research hospital consisted of more that 1,500 beds with a general hospital (Gevher Nesibe Hospital) as well as Heart and Vascular Diseases Hospital, Organ Transplant and Dialysis Hospital, Oncology Hospital, Children's Hospital and Bone Marrow Transplantation and Stem Cell Therapy Center are among the most influential health facilities in the region.
Upon the endowment of Erciyes University, the Faculty of Medicine, Faculty of Economics and Administrative Sciences, Faculty of Theology, Faculty of Engineering and Faculty of Literature and Sciences were already providing education. As the university grew the following faculties were formulated into the educational structure: Faculty of Architecture and Fine Arts in 1992, Yozgat Faculty of Engineering and Architecture in 1995, Faculty of Veterinary Sciences,
Yozgat Faculty of Economics and Administrative Sciences and Yozgat Faculty of Science in 1995, Nevsehir Faculty of
Economics and Administrative Sciences, Faculty of Dentistry and Faculty of Communication in 1997, Faculty of Education in 2002, Faculty of Law and Faculty of Pharmacy in 2003 and Develi Seyrani Faculty of Agriculture in 2005.
The colleges that provide a four year education are as follows: College of Physical Education and Sports, Kayseri
Atatürk College of Health Sciences, College of Civil Aviation, School of Foreign Languages, College of Tourism and Hotel Management, Nevşehir College of Tourism and Hotel Management, Nevsehir College of Health and Yozgat College
of Health Sciences. The vocational colleges that provide a 2-year education are: Kayseri Vocational College, Halil
Bayraktar Health Services Vocational College, Safiye Çıkrıkçıoğlu Vocational College, Kocasinan Vocational College, Social Sciences Vocational College, Nevşehir Vocational College, Yozgat Vocational College and Develi Vocational College. The faculties, colleges and vocational colleges of Erciyes University that were endowed on the Yozgat campus
joined Yozgat Bozok University which was established in 2006; the faculties, colleges and vocational colleges that
were endowed on the Nevşehir campus were joined to Nevşehir University which was established in 2007.
In 2006, Kocasinan Vocational College was renamed as Mustafa Çıkrıkçıoğlu Vocational School.
In 2010, Erciyes University Faculty of Science and Literature separated and became their own faculties. Also, Atatürk
Health College was converted into the Faculty of Health Sciences.
Vocational Schools were established on the main campus and branch campuses. In 2006 Bunyan Vocational College;
2010 Vocational College of Justice and in 2011 Tomarza Vocational College were established and began education and
Page 154 of 487
Turkey
training.
The Faculty of Civil Aviation and Space Sciences ; and College of Applied Sciences was established in 2012. The College of Tourism and Hotel Management was converted to the Faculty of Tourism in 2013.
During the 2014-2015 academic year there were more than 50,000 students in various levels of education (associate,
bachelors, masters and doctorate) with a rich academic staff consisting of more than 2,200 personnel.
Since 1984 graduate education at Erciyes University has become quite important. Currently there are 2095 MSc students and 451 PhD students that are receiving education at the Institutes of Natural Sciences, Health Sciences and
Social Sciences, Fine Arts, Educational Sciences, Atatürk's Principles and History of Turkish Revolution and Gevher Nesibe History of Medicine .
Erciyes University has been able to integrate education, research and health services all on one campus. An important part of the infrastructure at Erciyes University is that a large portion of the buildings were built and donated to
the university by the local benefactors . Some of our benfactors also furnished the buildings and provided equipment.
Such a convenance has created a fairly new model for our country. In recent years, Erciyes University has
shown great progress with the important developemnts and has the ability to be a center of excellence . Due to these
recent developments, our university has emerged the image "Our University" in our community by giving confidence and hope for future developments.
Areas of Activity
Preventing disease
Initiative
(PCP)
Methods and data
policies
records (PPI)
We have developed a portable blood pressure measurement and recording device for patients with hypertension.
With this device, * The patient's blood pressure information can be monitorized (online and from everywhere) on a 24
hour basis by the doctor/carer without interrupting the patient's daily activities. * Regional disease data mapping can
be created. * In terms of hospitals labor loss can be avoided.
MARKET APPLICATION
* Hospitals * Patients with hypertension * Medical corporations
* Medical corporations
Page 155 of 487
Turkey
Erciyes University
Organisation Name
Country
Turkey
City
Kayseri
Street
Talasyolu
Website
www.erciyes.edu.tr
Phone
+903524375279
Organisation Type
University
Person
Name
Demet Unalan
Email
[email protected]
Job Position
manager
The Erciyes University Vocational Health College was founded in 1989. The school moved to its new building built by
benefactor Hüseyin Bayraktar ,who is a local businesman from Kayseri, at the beginning of the 1995-1996 Academic
year and the name of the school was changed to Halil Bayraktar Vocational Health College. Our college serves
teaching-learning facilities to ten programs. The education period is two years (four semesters), and those who are
succesful at the end of this period are awarded a diploma with the title of ‘health technician’ in First and Emergency
Aid, Anesthesia, Oral and Dentistry Health, Radiotheraphy, Medical Imaging Systems, Audiometre, Electroneurophysiology, Operation Room Services and Medical Lab Techniques Programmes. Those who succeeded to finish Medical
Documentation and Secreterial programme are awarded with the title of ‘Member of Profession’. The number of students enrolled in the 2014-2015 academic year was 229. Our existing student population is 855 and the total number
of students , who have graduated from our 10 programme so far is 3,949.
Our College’s mission is to train qualified manpower who will contibute to our country’s welfare and help raising
healthy individuals for a better future. Our College’s vision is to train mediary medical staff who are active,hardworking,receptive,responsive and problem solving focused. By training such staff our aim is to catch up a
high stantard of services that are coherent with universal standarts.
Areas of Activity
Preventing disease
young
(PCP)
(PPI)
population
Methods and data
policies
records (PPI)
Page 156 of 487
Turkey
To develop a device that would measure the hypertension patients' tension .This product will measure and record the
patient's tension and will send the recorded data to main server online. Also patient's measured tension data would
be traced by the specialist online while patient is in sleep or do his/her daily routine.
- Without lowering the quality of patient's daily activities both patient and doctor can trace the patient's tension online instantly . -To prevent the loss of time manpower in the perspective of hospitals. -To be able to acces patient's
recorded data from a distant device. -By archiving the patients former recorded data , establishing a regional hyper
tension map. -To measure the instant tension and trace these instant measurements periodically online simultaneously.
MARKET APPLICATION
Health services, medical companies, hospitals.
We want to corporate for manufacturing and distrubiting the product throghout Europe.
Page 157 of 487
France
Eukarys
Organisation Name
Country
France
City
Evry
Street
4 rue Pierre Fontaine
Website
www.eukarys.com
Phone
+33 672 815 048
Organisation Type
SME
Person
Name
Philippe Jais
Email
[email protected]
Job Position
Président and CSO
Eukarÿs SAS is a privately-owned French biotechnology company which develops products and applications based on
its proprietary C3P3 expression technology.
The C3P3 technology is an artificial system, which relies on a chimeric enzyme generated by synthetic biology and
multiple iterative optimization steps, in combination with specifically designed DNA templates. When assembled, in
order produce autonomously fully mature messenger RNA (i.e. capping and polyadenylation), which are complex molecules that conveys genetic information from DNA to the ribosome, where they specify the amino acid sequence of
the protein products. Patent of the C3P3 technology has been granted in Europe, Japan, and the USA amongst others.
The C3P3 technology was be used in virtually any type eukaryotic cell type (including yeast, plants and mammals) for
gene expression and/or inhibition. The C3P3 expression system can be used in various applications including bioproduction, gene therapy and DNA vaccination, transgenics plants or animals.
Eukarÿs is currently developing non-viral gene therapy approach to treat severe acute disorder. In addition Eukarÿs is
interested to co-develop or license products or applications based on its C3P3 system, including bioproduction, cell
assay, transgenics and gene therapy.
Areas of Activity
Preventing disease
Offer: Non-viral gene therapy for human or non human disorders based on the C3P3 technology
C3P3 is an artificial potent expression systems, which has interesting properties for the treatment of acute human disorders. Eukarÿs is currently developing its expression system for the treatment of an human severe liver disorder.
The approach developed by Eukarÿs for transient non-viral gene therapy using its C3P3 technology is potent, safe and
well tolerated.
MARKET APPLICATION
Human and animal therapeutics for severe disorders.
Page 158 of 487
France
Pharma, Biotech or academic organizations. Scientific and marketing collaboration - worldwide.
Offer: C3P3 Technology for protein bioproduction
The C3P3 technology is an artificial system, which relies on a chimeric enzyme , in combination with specifically designed DNA templates. When assembled, in order produce autonomously fully mature messenger RNA (i.e. capping
and polyadenylation). This system can be used for protein bioproduction in mammalian cells.
High yields of native proteins
MARKET APPLICATION
Protein bioproduction
Pharma or biotech for internal programs.
Page 159 of 487
Portugal
Fac Medicine Univ Porto
Organisation Name
Country
Portugal
City
Porto
Street
Al. Prof. Hernâni Monteiro
Website
http://med.up.pt
Phone
Organisation Type
University
Person
Name
Pedro Augusto
Email
[email protected]
Job Position
Science Manager
The Faculty of Medicine of the University of Porto (FMUP) promotes teaching, scientific research and medical
support activities to the community, besides its inherent responsibilities for the administration of its internal organization and to relation with national and foreign entities. The predecessors of the FMUP were the Royal School of Surgery
(1825-1836) and the School of Medicine and Surgery of Porto (1836-1911). By the decree of February 22, 1911, the
School of Medicine and Surgery of Porto University received faculty status and a radical reform of the medical statutes
was done. The inauguration of Hospital S. João occurred on June 24, 1959 and as a result of the acquired status of
Teaching Hospital, the Faculty of Medicine was installed in the Hospital which until that date had the use of some
wards of Hospital Santo António, which actually belong to the Hospital of the Poor (Santa Casa da Misericórdia). The
FMUP is today a prestigious institution at national and international levels, the one that requires the highest marks for
entry to the course of the degree in Medicine.
The FMUP is a creation, transmission and diffusion centre of the culture and of the science in the areas of Medicine
and Human Biology.
The specific objectives of the Faculty of Medicine, as consigned in its statutes are:
1. Develop educational programs in the areas of Medicine, Human Biology and Public Health, through the undergraduate and postgraduate teaching activities, performance of scientific research enabling it to attribute the
degree of Doctor of Medicine (MD), Master and PhD and the title of full Professor in the same areas;
2. Perform scientific research activities and development in the areas of Medicine and Human Biology, separately or in cooperation with other organic units of the University of Porto or other national or foreign Universities;
3. Provide health care services to the community, directly or through other public or private entities;
4. Provide other services, for which the faculty has the scientific-technical capacity in a perspective of reciprocal
evaluation;
5. Accomplish activities with other public or private entities, national or foreign, with providers of primary, secondary or tertiary health care, having as with the objective of the development of teaching activities and or
investigation and scientific exchange;
6. Contribute, in the extent of Medicine and Human Biology, to cooperation and international solidarity and for
promoting relations among people of different cultures, in particular with Portuguese speaking countries and
European countries.
The FMUP is responsible for the attribution of the degree in Medicine; it collaborates in the courses of Dental Medicine
and of Nutritional Sciences, and it is responsible for 8 master degree courses, 7 postgraduate courses and specialization, as well as non-degree courses in different specialty areas. It still collaborates in PhD studies, in medical internships, with national and international entities in the meetings that it promotes, in the academic trials and in the educational development of its members.
The Directive Committee of the medical magazines Arquivos de Medicina, Arquivos Portugueses de Cirurgia and Edu-
Page 160 of 487
Portugal
cação Médica, owned by the Association of Medical Students of the FMUP, is committed to Professors of the FMUP and
Professors of the Medical School mainly constitute the Editorial Boards, as well.
Areas of Activity
the immune system
EU level
Methods and data
records (PPI)
Preventing disease
Initiative
young
population
Offer: Portuguese academic/research medical faculty 300-staff strong, 100 of which clinical (twenty IF>10 papers/year: ALLERGY, CARDIAC & CARDIOVASCULAR SYSTEMS, GASTROENTEROLOGY & HEPATOLOGY); 20 international patents
High-level research topics in 2011-14 (77 papers in IF>10 ISI journals: h-index=29; ~5500 citations): ALLERGY, CARDIAC & CARDIOVASCULAR SYSTEMS, GASTROENTEROLOGY & HEPATOLOGY [ISI areas of the 16 most cited papers];
keywords of high-level topics: myocardial revascularization, cardiovascular diseases, systolic blood pressure,
(pre)diabetes, body-mass index, cholesterol, rhinitis, asthma, helicobacter pylori, lupus nephritis, stem cells.
Keywords of international patents held: fluorescence imaging, laryngoscope, bone, skin, ear, intestin, lung, cancer,
hepatitis C, Aspergillus Fumigatus, Escherichia Coli, Helicobacter Pylori, Streptococcus Agalactiae, parasite, resistant
microorganisms, protozoa, urea, p53, Eslicarbazepine. Services that we provide: surgical treatments in animal models; biochemical lab: Inflammatory, Oxidative Stress, and Angiogenic Markers, Catecolamine and Hormone Dosages,
Environment pollutants quantification, Lipoprotein and Enzyme activity determination; Animal Models, microscopy
and imaging: Genomics / Gene Expression Analysis / DNA Sequencing / DNA Synthesis / Real-Time PCR / Genotyping /
Microarray; Advanced cell and tissue Microscopy and imagiology
MARKET APPLICATION
Markets: pharmaceutical, medical devices (including imaging systems), prosthesis, materials (e.g. bone substitute)
Type: SME or large company; Country: any EU; Tasks: coordination; market exploitation; Technology and Knowledge
Transfer; clinical trials
Page 161 of 487
Switzerland
FHNW - IMA
Organisation Name
Country
Switzerland
City
Muttenz
Street
Gruendenstrasse 40
Website
www.fhnw.ch/ima
Phone
+41 61 4674-693
Organisation Type
R&D Institution
Person
Name
Joris Pascal
Email
[email protected]
Job Position
Professor
The Institute for Medical and Analytical Technologies (FHNW – IMA) is active in the area of in-vivo systems for diagnostic and therapeutic applications. We operate at the innovative intersection of industry, medicine and academia. The
focus of our efforts is patient-specific solutions, as well as the processing, analysis and communication of medical data. In co-operation with our partners, we identify medical-technical problems and develop innovative solutions, starting from the idea all the way through to the prototype.
Areas of Activity
Preventing disease
Initiative
(PCP)
(PPI)
population
Methods and data
Offer: Bio-signals Sensors Systems
The FHNW Institute for Medical and Analytical Technologies (IMA) is offering its expertise in the field of Sensors Systems development. The specificity of the sensors systems that can be developed at IMA are listed below: - Sensors
Systems for bio-signals acquisition and embedded signal processing. - Wireless sensors networks - Application Specific Integrated sensor systems using microelectronic technologies (ASIC design)
Offer: Sensors Systems for assisted surgery, active implants and robotics
In the field of assisted surgery (e.g. minimally invasive surgery), active implants and robotics, the IMA can offer its expertise in the development and integration of miniaturized, possibly MRI compatible sensors for bio-signals measurement and localization systems for e.g.: - MRI imaging coupled with bio-signals recording - Minimally invasive surgery
with integrated positioning sensors within the surgical tool - Active implants (implants with embedded electronics for
continuous implant condition monitoring) - Integration of miniaturized sensors systems within catheter or endoscope
for localization
Page 162 of 487
Switzerland
Offer: Implant Development
IMA is offering its expertise in the field of patient specific implant development using Medical additive manufacturing.
The available infrastructures at IMA are listed below: - Implant manufacturing site / selective-laser-melting process
with QMS (according ISO13485) for industrial services - 3D printing systems for metallic materials, bio-ceramic materials, polymers, CAD, FEM, freeform modelling
Page 163 of 487
France
FHU SUPORT (SUrvival oPtimization in ORgan Transplantation
Organisation Name
Country
France
City
Poitiers
Street
CHU de Poitiers - 2 rue de la Milétrie
Website
www.fhu-suport.com
Phone
Organisation Type
University
Person
Name
Isabelle Cameleyre
Email
[email protected]
Job Position
Project coordinator
Officially created on June 20th, 2014, the Federation Hospitalo-Universitaire SUPORT aims to group for the first time,
in the field of the organ transplantation, talents and skills to stimulate the innovation and develop new protocols of
clinical and fundamental research.
In a context of shortage of the transplant, clinicians, researchers and academics combine their expertise around two
priority axes: the improvement of the graft survival by optimizing the conditioning of the donor, and the personalized
care of the transplanted patient in the short and long term.
The FHU SUPORT involves the University Hospitals and the University of Limoges, Poitiers, and Tours, as well as research members of AVIESAN (3 Inserm units: U1082 - Poitiers, U850 / U1092 - Limoges and the EA4245 - Tours).
In partnership with numerous institutional and industrial actors, the FHU SUPORT meets the challenge: optimize the
chances of success of the organ transplant by developing innovative solutions in transplantation and improve the
quality of life of the transplanted patient.
Areas of Activity
Methods and data
policies
Request: Partnership for translational projects
The FHU SUPORT intends to prepare proposal for the challenge in Horizon 2020. The FHU SUPORT leads a true translational research program (from basic research to clinical applications and medico-economic evaluation), within a complete disciplinary and functional field (from donor and recipient conditioning to long term graft survival, via the optimization of organ procurement), regarding kidney, liver and heart transplantation. The FHU is looking for partners
from Europe and beyond, industrials and / or academic, to build consortiums of different translational projects, with
scientific and clinical approach in two top priority research themes: - Personalized patient management in the short
and long term: the goal is to set up patient procedures, biomarkers and predictive tools of organ dysfunction in order
to treat and prevent it. - Optimization, evaluation and conditioning of the donor, organ and recipient: the goal is to
identify at the donor, organ and recipient levels the factors influencing the response and the individual tolerance to
IR, immune suppressors, their association, and the antiviral drugs.
Page 164 of 487
France
Request: Information on research funding
The FHU is looking for funding for several clinical and translational research projects involving partnership with industrials. For this reason, the FHU needs more information on the new Horizon 2020 “Health” call corresponding to these
translational projects, in organ transplantation. For more details, please contact us.
Offer: The platform network of the FHU SUPORT
The FHU offers support structures for experimental surgery and preclinical investigations in transplantation and other
medical research domains, as the IBiSA Platform of experimental surgery and transplantation (MOPICT) and the Limousin platform of NMR and mass spectrometry (SCRABL).
Offer: Research platforms for experimental surgery and preclinical investigations
The FHU SUPORT offers platforms to the research and clinical teams, private or public, for experimental surgery and
preclinical investigations in transplantation and other medical research domains, as the IBiSA Platform of experimental surgery and transplantation (MOPICT) and the Limousin platform of NMR and mass spectrometry (SCRABL). For
more details, go to our website.
Page 165 of 487
Germany
Fraunhofer IAIS
Organisation Name
Country
Germany
City
St. Augustin
Street
Schloss Birlinghoven
Website
Phone
Organisation Type
R&D Institution
Person
Name
Stefan Rueping
Email
[email protected]
Job Position
Leader Big Data Analytics
Fraunhofer IAIS is a leading research institute in the area of Big Data Analytics. A particular focus of Fraunhofer IAIS is
medicine and healthcare. See http://www.iais.fraunhofer.de/datascience.html for details.
Areas of Activity
Methods and data
policies
population
Offer: Big Data Analytics in Healthcare
Medical science and technology has made huge leaps in recent years in understanding causes, underlying mechanisms, behavior, and treatment options of diseases. However, this advances have not yet contributed similarly to a
widespread impact in daily clinical practice. Current medical IT solutions are incapable of turning the large volume of
available heterogeneous data into useful information for the physician. To address this problem using the tools of machine learning and big data analytics, the following approach promise a high practical impact 1. Mining structured and
unstructured data: a wealth of information is gathered in modern EHRs and other medical records. While a lot of information can be extracted from structured data – from laboratory data over ECG reading to imaging information – it
must be acknowledged that in the domain of medicine significant information only exists in the form of unstructured
text data. To implement more precise textmining models, approaches to jointly mine structured data and unstructured
patient data are of interest. Basic technologies encompass topic models and deep learning 2. Predictive models: from
the wealth of medical information, including what can be extracted from medical texts and predicted by novel simulation algorithms, machine learning technologies can be applied for predictive modeling. Multi-layer and multi-view recommendation models can be used to adequately integrate statistical models, text-based models and simulation models for clinical decision support from multiple information. Clinical decision support, but also novel solutions such as
apps profit from this data intelligence. 3. Patient Journey Mining: in order to optimize patient treatment as a whole,
improve risk stratification, and monitor the quality of care on a population level, the complete medical history of the
patient during, before, and after the treatment has to be taken into account. Multimorbidities and long time scales
make this problem challenging. Mining patient journeys in order to identify interesting and risk-relevant patient subgroups and temporal sequences of diagnoses and treatments can help to address this problem. 4. Graph Mining: Medical data is very often best represented in terms of relational structures, which can adequately reflect hierarchical data types and complex dependencies. Mining graphs and other relational structures developed into an active research
field of Data Mining and Knowledge Discovery. Kernel methods – with Support Vector Machines being the most promi-
Page 166 of 487
Germany
nent example - have been proven to be powerful technique for a wide variety of structured machine learning problems. Graph kernels allow to use these methods natively on graph data. They can for example be used directly for
case-based decision support, in that a set of relevant historical cases can be displayed to the clinician who is looking
into a patient case where no recommended treatment path exist. This is often helpful in complex cases with multimorbidities. 4. Medical Data Scientist: in the medicine of the future, research willl involve the role of a data scientist,
i.e. a professional who is an expert in both medical aspects and data analytics. Innovative analytics tools, e.g. 1-clickmining solutions or visual analytics will help him to efficiently identify new interesting knowledge. This is complemented by appropriate training and startup processes.
Innovative data analytics solutions help the medical and healthcare professional to profit from big data and big data
analytics technologies. The advantages come in three different dimensions: 1. deep dive: implementing groundbreaking new analytics solutions 2. new data sources: integration of data such as knowledge hidden in text, or new sensor
information, ranging from smartphone sensors to new medical devices 3. smart systems: interactive tools for data scientists, recommendation algorithms for patients, and clinical decision support
MARKET APPLICATION
Medical research Healthcare provides (hospitals, insurance) New healthcare players (e.g. apps) Public authorities
Our expertise is in Big Data Analytics, Visual & Interactive Analytics, Machine Learning and Data Mining in streaming
and complex data, Semantic Textmining, Big-Data Architectures, and Privacy-Preserving Data Mining. We are currently
interested in joining consortia with a strong focus on exploitation, who are aiming to face the upcoming challenges of
Big Data Analytics in Healthcare.
Page 167 of 487
Spain
Fundació Sant Joan de Déu
Organisation Name
Country
Spain
City
Barcelona
Street
Carrer Santa Rosa 39-57 Esplugues de Llobregat
Website
www.fsjd.org
Phone
0034936009751
Organisation Type
R&D Institution
Person
Name
Leonor Norton
Email
[email protected]
Job Position
Project Manager
Fundació Sant Joan de Déu (FSJD) is a Research Institution in charge of managing the research and innovation activities of two organisations: Barcelona Children's Hospital Sant Joan de Déu and Parc Sanitari Sant Joan de Déu.
Barcelona Children's Hospital Sant Joan de Déu (HSJD) is one of the leading medical centers in Europe for
childhood and adolescence and offers a comprehensive and multidisciplinary approach to health care from birth
through 18 years of age. HSJD combines basic general pediatrics with specialized care for all tertiary-level pediatric
pathologies, covering a pediatric population of 200,000 children. Annually, it attends more than 4,100 births,
25,110 in-patient admissions, 250,000 outpatient visits and 213,900 emergencies, with 360 beds, 137 outpatient
rooms and 13 operating rooms.
The hospital is accredited by the Spanish Ministry of Health as a reference center for all Spain in a wide range
of specialties and conditions (e.g., orthopedics, neurology and neurosurgery, reconstructive surgery, ophthalmology).
In 2010, HSJD initiated a project named “H2O – Liquid Hospital”, an initiative that seeks to radically transform
health care through an intensive use of technologies oriented towards the patient, and leading the health care
assistance to go beyond the physical building blocks of the hospital. Currently, HSJD is the most relevant example in
Europe of a hospital using online care, telemedicine, mobile apps and health 2.0 tools to place the patient in the center of care.
Parc Sanitari Sant Joan de Déu (PSSJD) is composed by several health care centers, including a Mental Health
Centre and an Adult General Hospital. Our Mental Health Centre is integrated by different services like Acute Inpatient Units, Severe Mental Health Inpatient Unit, Day Hospitals, Community Mental Health Services, and Rehabilitation Units providing comprehensive mental health and disability services, including neurodegenerative diseases to a service area that includes approximately 1.500.000 people. PSSJD focuses on bringing together basic research scientists and research clinicians in the areas of public health, mental disorders and disability. It includes geriatrics, long-term care institutions and has a brain bank specifically devoted to psychiatric disorders. The
institution also develops new health care services, as home care for persons with severe disability or tele-medicine. The General Adult Hospital Hospital has 120 beds organized in 23 medical specialties, including internal medicine, cardiology, nutrition and endocrinology.
HSJD and PSSJD count with a highly specialized Clinical Trials Unit, which offers expert advice to researchers on ethical standards, regulations and negotiation of contracts topics, technical guidance on clinical protocols and support on
the performance of non-commercial clinical trials (from recruitment of cohorts, assessment or sample and data collection). It centralizes all the information and is the contact point of: Investigators, Pharmacy service, CRO‐Monitor,
Sponsor, Patients. HSJD is the National leading center on the number of Paediatric Clinical Trails, currently,
80 Clinical Trials and 46 Observational Studies, 10 Clinical Research Projects and 8 Clinical Innovation Projects.
Page 168 of 487
Spain
Fundació Sant Joan de Déu (FSJD) has a solid experience both in presenting and managing European projects, being coordinators of one H2020 project and partners in several H2020 and FP7 projects.
Areas of Activity
the immune system
diseases
EU level
Preventing disease
young
(PCP)
population
Offer: Active ageing and Self-Management of Health
Parc Sanitari Sant Joan de Déu (PSSJD) is a leading institution providing mental health care and disability services, including neurodegenerative diseases to a population of 1.5 million inhabitants in Catalonia. PSSJD focuses on bringing
together basic research scientists and research clinicians in the areas of public health, mental disorders and disability.
It includes geriatrics, long-term care institutions and has a brain bank specifically devoted to psychiatric disorders.
The institution also develops new health care services, as home care for persons with severe disability or tele-medicine. Our institution has a history of health provision of more than 150 years, and is integrated by different services
like Acute Inpatient Units, Severe Mental Health Inpatient Unit, Day Hospitals, Community Mental Health Services, and
Rehabilitation Units. There is also a General Health Hospital with 120 beds organized in 23 medical specialities, including internal medicine, cardiology, nutrition and endocrinology. PSSJD is a member of the Spanish Primary Care research network (www.rediapp.org), which aims are study the prevention of cardiovascular and mental disorders and
to promote better life-style behaviours. We also are a leading research institution in Severe Mental Health Disorders
and in Health Care Services Research. Our main third party is the Fundació Sant Joan de Déu (www.fsjd.org) who provides administrative research work to PSSJD. We have research agreements with main Spanish universities like Universitat Autònoma de Barcelona, Universitat Politècnica de Catalunya, and also European universities like the King’s
College of London and the London School of Economics and Political Science. http://www.fsjd.org/en/consolidatedresearch-groups_398 PSSJD has a strong experience and knowhow on epidemiology, study of treatment effectiveness
and suitability, the determining factors of mental health and the financial effects of mental health on society. - Prevalence of mental disorders -Effectiveness of interventions in primary care: anti-depressive treatment, psychoeducation,
pharmaceutical intervention, etc. Assessment of which health determinants influence the presentation and/or evolution of mental disorders. -Assessment of the financially the impact of mental disorders on society. - Innovative interventions in Fibromyalgia - New technologies and mental health - Economic evaluation of health care service - Prevention of common mental disorder - Collaborative depression treatment Keywords: Mental Health, Ageing, Public Health,
Mental Disorders, Disability, Schizophrenia, Gender, Psychosis, Fibromyalgia, Primary Care, Frailty, Depression, Economic Evaluation, First Episodes, Ageing. Fundation Sant Joan de Déu and Parc Sanitari Sant Joan de Déu have a solid
experience in FP7 and H2020 projects, both is Coordinators (H2020) and as partners (H2020 and FP7). In the area of
Mental Health - Coordinator in ATHLOS - Ageing Trajectories of Health: Longitudinal Opportunities and Synergies
(H2020). http://cordis.europa.eu/project/rcn/193326_en.html -Partner in m-RESIST - Mobile Therapeutic Attention for
Patients with Treatment Resistant Schizophrenia (H2020). http://cordis.europa.eu/project/rcn/194075_en.html -Partner
in MARATONE - Mental Health Training through Research Network in Europe (FP7) http://cordis.europa.eu/project/rcn/
105598_en.html -Partner in COURAGE (FP7) -Partner in PATHWAYS (SANCO)
Page 169 of 487
Spain
Offer: Rare Diseases: Diagnostic Characterization of rare Diseases and New Therapies for
rare Diseases
HSJD is deeply interested in collaborating in proposals to be presented to topics PM3-2017- “Diagnostic characterization of rare diseases” and PM8-2017 “New therapies for Rare Diseases”. Our principal investigators are internationally
recognized experts in the areas of rare metabolic and neurologic disorders, Oncology, Ophthalmology, Cardiology,
among others. Barcelona Children’s Hospital Sant Joan de Déu (HSJD) has opened a new paediatric institute conceived
to advance knowledge and research in the field of rare diseases, offering integral treatment and care to the over
10,000 patients with low-prevalence disorders who are currently being attended to at our institution and a quicker diagnosis of other children and adolescents who may be suffering from such conditions. The organising process of the
Paediatric Institute for Rare Diseases (IPER) is being coordinated by Dr Francisco Palau. The new institute’s aims are
to: a) Facilitate the diagnosis of low-prevalence disorders: The purpose of HSJD, which is endowed with all of today’s
most advanced technological means and a vast clinical experience, is to offer families a quicker diagnosis, timely advice in the event that the disorder is of genetic origin and all essential accompaniment throughout the patient’s care
process; b) Focus care on the patient; c) Stimulate translational research on low-prevalence diseases in order to
achieve a better understanding of the biological bases of these disorders and to discover treatments that can be
transferred as soon as possible to clinical practice, to the direct benefit of patients. http://www.hsjdbcn.org/portal/en/
institut-pediatric/noticia/ctnt/dD98/_/_/znr64u/New-Paediatric-Institute-for-Rare-Diseases.html HSJD counts with a
highly specialized Clinical Trials Unit, which offers expert advice to researchers on ethical standards, regulations and
negotiation of contracts topics, technical guidance on clinical protocols and support on the performance of non-commercial clinical trials (from recruitment of cohorts, assessment or sample and data collection). It centralizes all the information and is the contact point of: Investigators, Pharmacy service, CRO‐Monitor, Sponsor, Patients. HSJD is the National leading center on the number of Paediatric Clinical Trails, currently, 80 Clinical Trials and 46 Observational Studies, 10 Clinical Research Projects and 8 Clinical Innovation Projects.
Offer: Impulsivity and Compulsivity and the Link with Nutrition, Lifestyle and the SocioEconomic Enviroment
We are interested in collaborating with European Partners in a project to be presented to SFS-38-2016: Impulsivity and
compulsivity and the link with nutrition, lifestyle and the socio-economic environment. We offer a strategic advantage
since our organizations tackle both Paediatric and Adult population. For this topic we offer expertise in Impulsivity and
Compulsivity-Related Disorders, Nutrition, Microbiome and Adult Mental Health. >In paediatrics: >>Impulsivity and
Compulsivity-Related Disorders Hospital Sant Joan de Déu (HSJD) attends annually 700 paediatric patients newly diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). HSJD also attends patients with Oppositional Defiant Disorder, Autism Spectrum Disorder, Learning disability and Disorders and Anxiety and Affective Disorders. The ADHD
Unit of HSJD is among the largest National Units on ADHD, both in clinical activity and number of professionals. Is the
only Spanish ADHD Unit with a 24h/365days Psychiatry Emergency Service. In 2010, the ADHD Unit of HSJD led and
coordinated the National Health Service Guidelines for clinical practice on ADHD. Currently, our practitioners are involved in the elaboration of the new version of these guidelines. HSJD has a specialized Unit (in Catalonia there is also
two of these Units) to attend children with Compulsivity Disorders, including Addictive Behavior and Consumption of
Addictive Substances. We also have a Consolidated Research Group on Mental Disorders in Childhood and Adolescents. >>Microbiome The Research Group on Paediatric Infectious Diseases of HSJD is dedicated to the clinical, molecular and epidemiological studies of the main paediatric infectious diseases. The group has solid experience in the
study of nasopharyngeal microbiome and is particularly interested in translating this knowledge to studies focused on
the role of microbiome in the gut-brain axis. >In Adults: We receive more than 170.000 visits per year, this represents
that our professionals attend annually around 40.000 adult patients with mental health disorders. Our patients cover
a wide range of disorders including Impulsivity and Compulsivity disorders. We are responsible of the Forensic Psychiatry Units in Catalonia. This also includes penitentiary facilities for juveniles and women.
Offer: Clinical Trials, Chronic Diseases
We are willing to participate as Clinical partners in projects for Clinical Trials, Validation studies, Obervational studies
both in Paediatric and Adult populations. The Clinical Research Unit (CRU) is a Sant Joan de Déu Research Foundation
initiative to integrate all the activities derived from clinical research at Sant Joan de Déu Hospital and Parc Sanitari
Sant Joan de Déu. The Clinical research unit is the National leading unit on the number of Pediatric Clinical Trials currently managing more than 75 clinical trials. The unit's missions are to consolidate itself as a leading entitity in clinical
research, favouring and promoting quality research and innovation, and reaching sponsorship agreements with public
and private organizations. The integration of all clinical research in a coordinated model designed as a "one-stop/full
service" allows our research groups to request for expert advice and technical guidance and support on the performance of non-commercial clinical trials, while favouring the centralisation of all activities through this single contact
point for external sponsor clinical trials sponsors.
Page 170 of 487
Turkey
Gazi University
Organisation Name
Country
Turkey
City
Ankara
Street
Taç street
Website
www.gazi.edu.tr
Phone
Organisation Type
University
Person
Name
Bensu Karahalil
Email
[email protected]
Job Position
Gazi University is one of the few universities whose history dates back to the 1920s. Right after the declaration of the
Turkish Republic, it was decided to establish an institute with Mustafa Kemal Ataturk and his friends’ initiative. This
decision resulted in the establishment of the 'Secondary Teacher Training School and Civility Institute' in 1926.
The institute started its educational activities in the building which is now used as the Rectorate Building. The architect of our building was Mimar Kemaleddin. In 1929, the name of the institute was changed to 'Gazi Secondary
Teacher Training School and Civility Institute' and it served under this name for many years.
In 1976, it took the name 'Gazi Institute of Education'. In 1982, with the act numbered 2809, this institution was
converted to Gazi University. As a matter of fact, this is the continuation of the tradition under a new name which has
started with the Republic. Ankara Academy of Economics and Commercial Sciences, Ankara College of Technical
Teachers, Ankara Girls' College of Technical Teachers also played an equal role in the formation of the tradition.
Ankara Academy of Economics and Commercial Sciences was already like a university when it was united with Gazi
University. In those days, today’s departments of Faculty of Economics and Administrative, Faculty of Medicine, College of Dentistry and College of Pharmacology which would later be the College of Journalism and Public Relations
whose name would later be changed to Faculty of Communication, carried out education depending upon the academy. Ankara Academy of State Engineering and Architecture was also a part of Gazi University. When it was first built,
it had 9 faculties, 12 colleges and 4 institutes. However, the number of the units increased rapidly. Today, Gazi University, with its 15 faculties, 4 colleges, 9 vocational college, 35 research centers and 6 institutes carrying out educational and research activities, maintains its claim to be a higher education befitting to Gazi Mustafa Kemal Ataturk, from
whom it got its name. Education is provided in the fields of Education, Medicine, Dentistry, Pharmacy, Engineering
and Architecture, Economics and Administrative Sciences, Commutations, Science and Letters, Law and Fine Arts
within the university. Being the national leader in terms of education faculties, Gazi University consists of Faculty of
Industrial Arts, Gazi Education Faculty, Faculty of Vocational Education, Faculty of Technical Education, Faculty of Commerce and Faculty of Tourism Education. In addition to the students coming from all around the country, Gazi is the
university that accepts the most students from abroad with over 1500 students from other nations including the Turkic states and their communities.
It not only meets the needs of its own academic staff but also trains academic staff for other universities with more
than 5 thousand students studying in masters and PhD programmes. Gazi University carries out its education at different campuses. Having three campuses-Besevler, Emek and Maltepe in Ankara- Gazi shows the degree of importance it gives to education. With more than 50,000 students and over 3.000 academic staff, Gazi University demonstrates the standards of the world average in terms of the number of students per instructor. Gazi is one of the largest
universities with its faculties from education to communication, fine arts to engineering, sports to forestry, medicine
to pharmacy, dentistry to science and economics.
Page 171 of 487
Turkey
Areas of Activity
the immune system
(PCP)
population
Request: Pharmacogenetic and pharmacogenomic studies on drug toxicity and efficacy;
personalised medicine I would like to be partner one of projects.
Pharmacogenetics and pharmacogenomics studies have been widely used in drug toxicity and efficacy. These studies
have been fundamental steps toward personalized medicine. Genetically determined variants provide knowledge on
how individuals respond to drugs. There is clinical need for novel approaches to improve drug therapy. Clinical problem is that patients exhibit significant differences in drug response with same dose and the same drug treatment.
While some patients recovered, some do not heal moreover, adverse drug reactions (ADRs) (such as headache, nausea, dizziness, sleep, obesity, nephrotoxicity and hepatotoxicity) are observed. ADRs are a major concern for patients
and also for pharmaceutical companies since they can lead to drug withdrawal after marketing, or during phase II or
III clinical trials. Thus, it is important to identifying biomarkers to detect some ADRs in early stage, investigate the
mechanisms and identify the factors that increase the ADRs. Furthermore it is important to develop or identify pharmacogenetics tests which are based on individuals’ genotype to check individuals’ response to therapy before drug
therapy. Before therapy to apply genetic testing to individuals provides to diagnose possible toxicities at early stage,
gives chance immediately switch to another drug therapy (alternative treatment), prevent from wasting time (without
delay treatment of diseases ) and protect from both the drug itself and the result of its secondary complications. Aim;
I would like to involve studies on personalised medicine. So far, I have been investigating the associations between
DNA repair and metabolising enzyme and receptor polymorphisms and cancer risk and toxicity risks.
Genomic profilling on drug toxicities
Gene polymorphisms, gene expressions on drug toxicity and efficacy
Page 172 of 487
United Kingdom
GeneFirst
Organisation Name
Country
United Kingdom
City
Oxford
Street
E5 Culham Science centre
Website
Phone
01865407400
Organisation Type
SME
Person
Name
Guoliang Fu
Email
[email protected]
Job Position
CEO
GeneFirst is a molecular diagnostics company, based in Oxford, UK. Working predominantly in the field of infectious
disease testing and cancer diagnostics, GeneFirst offers simple, sensitive and affordable molecular diagnostics technologies and products. It has a rich portfolio of patented technologies. Genefirst’s cancer mutation detection is very
sensitive and detects rare cancer mutations within very high background of wild type sequence. For infectious disease
testing, we have developed a product of single closed-tube quantitative detection and genotyping for all 14 high-risk
HPV strains.
Areas of Activity
diseases
Offer: Detecting ultra-rare, cancer gene mutations in circulating cell-free DNA in blood using a novel NGS technology
It is now established that detection of circulating tumour DNA in blood, so called liquid biopsy, is quickly becoming a
method for early diagnostics, select personalised therapy, . Next-generation DNA sequencing (NGS) has revolutionised genomic studies and is driving the implementation of precision diagnostics. Genefirst has developed an improved NGS technology for the detection of multiple mutations with greatly increased sensitivity; this makes it suitable for detecting ultra-rare, cancer gene mutations in circulating cell-free DNA in blood
high sensitivity reduce sequencing errors
MARKET APPLICATION
Cancer research Molecular diagnostics
Looking for partners to co-apply for Horizon 2020, collaboration
Offer: a novel multiplex realtime PCR for infectious disease detection
We develop a novel multiplex real-time PCR technology, Multiplex Probe Amplification (MPA). Traditional real-time PCR
is limited by the fluorescent dyes; up to 4-5 targets can be detected. MPA technology overcomes this limitation, with
many potential applications, allowing more than 20 targets to be detected and quantified in a single closed-tube reaction, significantly increasing throughput capabilities.
Page 173 of 487
United Kingdom
highly multiplex simple sensitive
MARKET APPLICATION
in vitro molecular diagnostics Research
Offer: a novel multiplex realtime PCR for cancer mutation detection
MMD-PCR(Multiplex Mutation Detection - PCR) Ideal for cancer gene mutation detection (Kras, EGFR, Braf, Jak2, Abl,
PIK3CA). MMD-PCR is very sensitive and can detect rare cancer mutations within very high background of wild type
sequence.
sensitive simple
MARKET APPLICATION
research diagnostics
Page 174 of 487
France
GENOPOLE
Organisation Name
Country
France
City
EVRY
Street
5 rue Henri Desbruères
Website
http://www.genopole.fr/?lang=en#.VmhWSdA6G3c
Phone
Organisation Type
Other
Person
Name
Patricia Rigou
Email
[email protected]
Job Position
Project Manager
Genopole is a leading biocluster in France with 80 biotech companies, mostly in health care sector and biomedical
field such as vaccin, therapeutics, medical devices, scientific instrumentation, diagnostic and e-health, but also in environmental technologies, agro-industries and synthetic biology field. Genopole provide business development to
campus companies and help the companies to find good partners and expertise for european calls.
Genopole is looking for partners in the field of personalised therapies, patient stratification, biomarkers and personalised therapeutics interventions, rare diseases, vaccin, malaria, Chronic diseases, ICT and management of "omics"
data for public organism and industrial.
Areas of Activity
the immune system
diseases
Methods and data
policies
Preventing disease
Request: GENOPOLE, leading biocluster of biotech companies in Health, is looking for
partners in the field of personalized therapeutic interventions, malaria, biomarkers, rare
and chronic diseases, ICT and management of "omics" data
Genopole host 80 biotech companies and 20 academic laboratories with 20 shared-access technology platforms.
Campus biotech companies are mostly in health and biomedical sector, such as therapeutics and vaccin, scientific instrumentation, R&D services and products, industrial biotech, medical devices, diagnostics and e-health. A list of companies and services can be found here : http://www.genopole.fr/Consult-your-latest-directory-9364.html#.Vmhdb9A6G3c Genopole helps campus companies to identify the good european partner and expertise.
Genopole is looking for partners in the field of personalised therapies, patient stratification, biomarkers and personalised therapeutics interventions, rare diseases, vaccin, malaria, Chronic diseases, ICT and management of "omics"
data for public organism and industrial.
Page 175 of 487
France
In brief, Genopole is looking for partners wishing to answer SC1-PM-01-2016, SC1-PM-02-2016, SC1-PM-03-2016,
SC1-PM-06-2016, SC1-PM-08-2016, SC1-PM-09-2016, SC1-PM-18-2016 in order to make the good match with our
companies.
Page 176 of 487
Spain
GIRONA BIOMEDICAL RESEARCH INSTITUTE (IDIBGI)
Organisation Name
Country
Spain
City
Salt
Street
Parc Hospitalari Martí i Julià de Salt.
Website
http://www.idibgi.org
Phone
+34 872 987 087
Organisation Type
R&D Institution
Person
Name
Lluis Ramió-Torrentà
Email
[email protected]
Job Position
Neurologist, Researcher and
Associated Professor
The Biomedical Research Institute of Girona (IdIBGi) is a research network SEARCH centers of the Generalitat of Catalonia which aims to articulate and develop quality research in biomedical sciences and public health and community
and promotes his transfer to practice. All with the aim of responding to the health problems of the population.
Areas of Activity
the immune system
EU level
Preventing disease
Initiative
Methods and data
policies
(PCP)
Request: Managing population Big Data and Active and healthy ageing
I am interested in ways and tools to manage and analyse big data from population and research in active and healthy
ageing.
Page 177 of 487
France
Greenpharma S.A.S.
Organisation Name
Country
France
City
Orléans
Street
3 allée du Titane
Website
www.greenpharma.com
Phone
Organisation Type
SME
Person
Name
Quoc Tuan Do
Email
[email protected]
Job Position
Who we are
Greenpharma (http://www.greenpharma.com) is a CRO SME of 12 people, specialised in natural compound studies for
cosmetic, food and pharmaceutical industries. Built around an innovative technological platform, Greenpharma succeeded to gather expertise in wide and complementary fields such as chemoinformatic, pharmacognosy, medicinal &
analytical chemistry, pilot scale extraction and formulation. This has led to a unique know-how in natural compound &
extract selection, extract purification, metabolite measurement, homology modelling, virtual screening (e.g. Selnergy™), lead optimisation, ADMET prediction and database building. Greenpharma approach has led to several patents
on bioactive (natural or synthetic) molecules and extracts.
What we do
Greenpharma provides natural or synthetic compounds for high throughput screening. It utilises in silico tools to select the most relevant molecules (we have access to a database of 20 millions commercial compounds).
We provide the industries of pharmacy, cosmetics and agro-food with innovative bio-active molecules through R&D
projects.
Our services include:
• Phytochemistry: development of methods for extraction, purification (until pilot scale) and characterisation of
metabolites in complex matrices, activity-guided fractionations;
• Molecular modelling: ligand and structure-based virtual screening, QSAR, in silico activity identification (eg
drug repositioning, identification of activities for natural compounds...) with our proprietary tool Selnergy;
• Knowledge management: database design and building.
• Medicinal chemistry: synthesis on demand, lead optimisation, natural compound mimics (eg. Pyrazolotriazine...), library design...
• Pilot extraction: development of pre-industrial method to produce cosmetic/food ingredients
• Formulation: development of formulation for cosmetic and dermocosmetic products
Areas of Activity
Preventing disease
young
Methods and data
Page 178 of 487
France
Offer: Clinical evaluation of a new patented composition against addiction to drugs and
alcohol
The composition consists of an association of 2 drugs from the public domain that taken separately have no anti-addiction effect, but together (at a specific ratio) have a synergistic effect on dependency. Extensive in vivo studies
have proven its beneficial effects in stopping and avoiding relapse and recurrence of addiction.
As two marketed drugs are associated, the composition can enter phase II studies directly. The product was discovered by a drug reposition strategy that used old marketed drugs. Therefore, failure probability due to toxicity is reduced. The targeted biological pathway is original and allows to avoid relapse or recurrence.
MARKET APPLICATION
Addiction to alcohol or drugs but possibly other addictions (tobacco, gaming) and Posttraumatic Stress Disorder
(PTSD)
drug manufacturer clinical trial institutions product development galenic formulation
Offer: Drug discovery -- hit-to-lead optimisation
Greenpharma is a SME providing services and products in drug discovery. Its services ranges from phytochemistry
analysis, molecular modelling (virtual screening, QSAR,...), drug repositionning, medicinal chemistry. Greenpharma
supplies plant extract and natural compound libraries for HTS (GPEL, GPNCL, Ligendo libraries) and Human endogenous ligand library for receptor deorphanisation or chemogenomic studies. Furthermore Greenpharma is the owner of
the database hosted at www.ambinter.com that includes 20 millions of exisitng compounds (at least synthesised
once), which is a crucial tool for virtual screening.
Our platform gathers multidisciplinary tools to accelerate drug discovery such as chemoinformatics, virtual screening
and QSAR. The in silico tools allow to rationally select potential hits and reduce the number of real compounds to test
experimentally. Moreover, drug design assisted by computer can better guide the optimisation of hits. Our library of
natural products are good sources for HTS campaigns: molecules or plants are selected respectively by chemical diversity and biodiversity to ensure the probability to get hits in any assays.
MARKET APPLICATION
Our products and services are suitable for pharmaceutical, cosmetic, functional food and vetenary researches.
Experts in biological assays: protein binding, in vitro, in vivo Expert in ADMET Expert in protein crystallography
Offer: Valorisation of natural products, side-products and wastes for cosmetic, functional
food, veterinary industries and crop protection
Greenpharma is a SME providing services and products in drug discovery. Its services ranges from phytochemistry
analysis, molecular modelling (virtual screening, QSAR,...), drug repositionning, medicinal chemistry. Our company
has a database GPDB of 150,000 natural molecules, 160,000 organisms (plants, bacteria,...), biological data and traditional uses. We have developed an in silico biological profiling tool called Selnergy to predict possible interactions of
small molecules with proteins (10,000 structures), hence to unveil possible activities and applications for existing
compounds, extracts, raw materials. Furthermore, we have a pilot extraction platform (including SFE techniques) and
formulation to develop active ingredients.
GPDB is a unique database for data mining generate research hypothesis. The prediction software Selnergy allows to
reduce the number of tests to perform and accelerate the identification of new applications for existing products thus
increasing their value. Our approach can be used to valorise products, side-products or wastes.
MARKET APPLICATION
cosmetic, functional food, veterinary industries and crop protection
Experts in biological assays: binding, in vitro, ex vivo Experts in plant assays for crop protection Manufacturer
Page 179 of 487
Turkey
Hacettepe University
Organisation Name
Country
Turkey
City
Ankara
Street
meksika cad., Almina apt., 57/24, Umitkoy, Ankara
Website
https://www.hacettepe.edu.tr/
Phone
+905325221520
Organisation Type
University
Person
Name
Ahmet Tulga Ulus
Email
[email protected]
Job Position
senior surgeon
Hacettepe University, as one of the leading universities in Turkey, continues its activities with 14 Faculties, 14 Graduate Schools and Institutes, 2 Applied Schools, 1 Conservatory, 6 Vocational Schools, and 90 Research and Application
Centers located in 5 campuses in Ankara. The health care services offered by Hacettepe University Hospitals, which
holds the leading position in medicine education as well as being among the highly esteemed Turkish institutions on
the international platform, proudly serve as a major training centre for HUSM students and provide health care services at a total of 4 hospitals.
Areas of Activity
population
Offer: regenerative medicine, A multicentre, phaSe 1/2 clinical trial compAring bone marrow mononuclear and umbilical cord-deriVed multipotent stromal cElls in critical LIMB ischemia
The purpose of this project (SAVE LIMB TRIAL) is to evaluate the safety and therapeutic efficacy of human umbilical
cord-stroma derived multipotent (mesenchymal) stem cells (HUC-MSCs) and autologous bone marrow-derived
mononuclear cells (BMC) in patients with critical limb ischemia (CLI) in a phase 1/2 multicentre, placebo controlled
clinical trial. The effect of combined intra-arterial and intramuscular cell transplantation with No Option Critical Limb
Ischemia (NO-CLI) will be examined.
Regenerative medicine using progenitor cells has shown promising improvements in NO-CLI. Therapeutic search for
progenitor cells that can readily engraft to damaged tissue and differentiate into functioning cells still continues. BMCs and more recently mesenchymal stem cells (MSCs) have shown considerable promise in pre-clinical and clinical
studies albeit in a small number of patients (6-9). More specifically, HUC-MSCs have proven to be therapeutically very
successful in regulating the immune system, and exerting anti-inflammatory effects in a series of autoimmune and inflammatory diseases (10-15). Therefore, those cells can be considered as ready-to-use for clinical (in-patient) research in NO-CLI patients. The proposed project will assess the safety and efficiency of HUC-MSCs in NO-CLI patient
for the first time in the literature.
MARKET APPLICATION
As an ultimate outcome, the proposed field of therapy would contribute to the growth of medical and biotechnological
industry by generating new employment and stimulating economic growth.
Page 180 of 487
Turkey
Centers who are seeking of efficient therapeutic regimens for CLI; regenerative medicine. Clinical applications for the
CLI.
Request: cardiovascular surgery
We are working as a cardiovascular surgeon.
We can take a role on clinical or experimental part of the cardiac and vascular diseaes.
Diseases related with the cardiac and vascular pathologies.
Page 181 of 487
Netherlands
Hanze University of Apllied Sciences
Organisation Name
Country
Netherlands
City
Groningen
Street
Zernikeplein 11
Website
www.hanze.nl
Phone
Organisation Type
University
Person
Name
Hugo Velthuijsen
Email
[email protected]
Job Position
Professor of Applied Sciences
Univeristy of Applied Sciences. Part of the Healthy Ageing Network Northern Netherlands (hannn.eu). EIP AHA partner.
Solid experience in all aspects of healthy ageing, including the application and adoption of information technology in
healthcare and wellbeing. Partner of the 5G Fieldlab supporting ubiquitous connectivity in the City of Groningen and
the rural areas of the Northern Netherlands and thus providing a unique pilot environment for large scale development and validation of ICT supported innovations in healthcare.
Areas of Activity
(PCP)
(PPI)
population
Health ICT SMEs
Methods and data
policies
Offer: 5G Fieldlab
The next generation mobile communication standard of 5G offers ubiquitous connectivity and support of e.g. sensors
(personaloised digital health) and telemonitoring and telecare applications. The 5G Fieldlab in the Northern Netherlands will offer a unique test bed for piloting large scale eheath solutions in a rural environment. The close knit
healthy ageing network in the Northern Netherlands (organised via HANNN: Healthy Ageing Network Northern Netherlands) offers a community of all relevant types of health care professionals and organisations allowing for realistic,
large scale pilots in the area of Healthcare and wellbeing.
large scale, ubiquitous high-bandwidth connectivity, well-organised Healthcare and wellbeing ommunity, real-life testing,
MARKET APPLICATION
Independent Living, personalised (digital) health
Page 182 of 487
Netherlands
Parties , including SMEs ready for solution development in TRL levels 7-9.
Offer: Independent Living Business & Information Modelling & Solutions
The healthcare and wellbeing domain can be characterised as a complex business ecosystem in transition. Although
many (technical) solutions have been developed for independent living, the uptake of new solutions in real life is low.
Technology adoption is slow due to several factors, such as insufficient attention to organisational fit, healthcare as an
ecosystem, a sustainable business model for both the constituting parts and the whole, and users' digital literacy.
Business & information modelling for business ecosystems in energy transition have helped to understand and support the transition to renewable energy systems. These experiences and insights will be translated to large scale independent living trials to help facilitate the successful deployment and adoption of new solutions by citizens, informal
care, and formal care.
Business & Information modelling techniques to help design comprehensive technological, organisational, and usercentered solutions for independent living. The transition to more independent living implies change on at least 3 levels: individual, organsational, and systemic. Only when this transition is understood on all levels, a successful transition can be managed and achieved.
MARKET APPLICATION
Independent living
Partners, including SMEs, whith working prototypes of solutions for independent living.
Page 183 of 487
Turkey
Hayriya Teknoloji Ltd
Organisation Name
Country
Turkey
City
Istanbul
Street
Boğaziçi University Technology Development Center
Website
www.hayriya.com
Phone
+902122762772
Organisation Type
SME
Person
Name
Abdulkadir KAYIKLI
Email
[email protected]
Job Position
CEO
Hayriya Teknoloji provides innovative technology and services that are shaping a new age of medical devices and
healthcare information services.
We focus on wearable technologies with a proven approach to long-term continuous monitoring that enables diagnosis earlier to improve patient outcomes and reduce clinical costs. Hayriya Teknoloji was supported by Techno-Entrepreneurship Fund from Ministry of Technology Industry and Science in 2012, and has been taking over 1million Euro
funds until now from national resources. We have good knowledge on project management and business plan. Our
professionals are located at the corporate headquarters in Bogazici University Technology Development Center, Istanbul/Turkey. Our expertise in medical imaging and instrumentation, medical diagnostics, patient monitoring systems
help our customers to deliver better care to more people at around the world at a lower cost.
Areas of Activity
(PCP)
(PPI)
Health ICT SMEs
Offer: IoT HealthCare Information Systems
Hayriya provides qualified R&D colloboration and service as a design house. There are multi disciplinary engineers in
our team has experience on hardware design and software development. We accomplished a few projects being a
part of international working group as well as turnkey solution service. Our deep expertise in electronic design as well
as the experience in taking products to production enjoys an upper hand in the industry. We have a network of partners for ID (Industrial Design) as well as prototype production which enables us to provide a one-stop shop to our customers' product development needs. Expertise Overview • Hardware Design • System Architecture • Hardware Design and Schematic Capture • BOM Optimisation • Multi-Layer High Speed PCB Design • Design Simulation/Analysis –
SI, Thermal, MTBF etc • Proto Development • Bring-up and Integration Testing, Hardware DVT • Compliance Testing –
FCC, CE others as per regulatory norms • Production and Support • Software Design • Embedded Software • Android,
Linux, Windows • RTOS • BSP / Drivers • Testing and Validation • Bring up and Integration Testing • Hardware DVT •
Compliance Testing – FCC, CE others as per regulatory norms • Production Testing HW/SW and Support
Page 184 of 487
Turkey
We have good knowledge on making a business plan, budget management and project development.
MARKET APPLICATION
Medical Security
Hayriya offers R&D collaboration/cooperation partnership for all European companies and universities have projects
includes electronic design.
Request: A Self-Management Health Care Project
This proposal requires research health care technologies, mobile and/or portable and other new tools, new diagnostics, sensors and devices (including software) for monitoring and personalized services and interventions which promote a healthy lifestyle, prevention and self-care, improved citizen/healthcare professional interaction and personalized programs for disease management. This proposal aims to develop a self management personalized diagnostic
device for patients who have heart disease. This device includes wearable sensors, a mobile application based on artificial intelligence and cloud integration.
Empowering citizens and patients to manage their own health and disease can result in more cost-effective healthcare systems by enabling the management of chronic diseases outside institutions, improving health outcomes, and
by encouraging healthy citizens to remain so. This Proposal involves health procurers and support them in their efforts to lower costs, and reduce difficulties associated with limited numbers of health professionals by utilising the capacity and potential of the patient as a co-producer of health. Proposal aims to empower patients to manage their
pre-existing conditions. Health management is being addressed holistically, including healthy lifestyle interlinked with
disease management, placing the patient in the centre and putting increased emphasis on health education, secondary prevention and self-management of individual conditions, including co-morbidities.
Medical Devices HealthCare Information Systems
Page 185 of 487
United Kingdom
High Force Research
Organisation Name
Country
United Kingdom
City
Durham
Street
Bowburn North Industrial Estate
Website
www.highforceresearch.com
Phone
Organisation Type
SME
Person
Name
Stella James
Email
[email protected]
Job Position
Head of Business Development
For over 25 years, High Force Research (HFR) have specialised in chemical synthesis and R&D collaborating with companies at proof of concept stage of their product or technology life-cycle. We are experts in developing and scaling up
complex syntheses of molecules used by researchers in the pharmaceutical; biotechnology; imaging; diagnostics; fine
chemicals and printable electronics sectors including multinationals; SME’s; universities; research institutions; startups and virtual enterprises. HFR is the only independently-owned UK business working to GMP on small scale production and have been audited by the MHRA for early stage clinical trials. We pride ourselves on a flexible and adaptable
approach to synthesis. We work collaboratively achieving high quality compounds, from grammes to kilos, with products delivered to specification, safely and on-time.
Offer: Chemical Synthesis Services
High Force Research specialise in chemical synthesis and R&D with wide experience of multistep organic synthesis,
particularly of heterocyclic chemistry, catalytic hydrogenation, nucleoside and amino acid chemistry, fluorination and
chiral chemistry. HFR provides a confidential, high quality, chemical synthesis and research & development service including: chemical research and development; process development; contract synthesis; scale up; traceable manufacture, GMP manufacture and analysis.
High Force Research offer chemistry built on over twenty five years of experience in developing and scaling up of
complex syntheses of molecules for application in a wide range of end uses. Our 1,100sqm building at Durham operates 30 fume hoods as well as dedicated walk in facilities for cGMP manufacture and high pressure reactions. Other
specialised facilities include laboratories for electrochemistry and a segregated laboratory for handling corrosive materials including aqueous HF. We boast several custom made high pressure reactors, up to 7.5 litre, and operate up to
10 bar. We operate at scales of up to 30L in jacketed glassware at temperatures -40 – 180oC. Separation and purification techniques include semi preparative and preparative chromatography and Tangential Flow Filtration techniques.
MARKET APPLICATION
pharmaceutical, biotechnology, diagnostics, imaging, printed electronics, fine chemicals, agrochemical, performance
materials, polymers, coatings, paints
Offer: Novel Fluorescent Retinoids with applications in stem cell chemistries
Durham University and High Force Research have developed a range of stable retinoid derivatives with intrinsic fluorescence. These molecules can function as both a biologically active retinoid and at the same time act as a visual
probe. Imaging applications for the use of these novel compounds in cell biology range from visualisation and localisation to monitoring real-time concentration and local environments.
Stable to photoisomerisation and oxidation ? Molecules are intrinsically fluorescent, without bulky tags ? Retain biological activity of natural retinoids, and can enter cells and use retinal shuttling systems ? Range of analogues with
Page 186 of 487
United Kingdom
different bioactivities ? Fluorescence varies with polarity, for investigation of local environmental conditions ? Can also act as Raman probes, which allows concentration levels to be measured ? Manufacturing route and scale up complete
MARKET APPLICATION
Applications: ? Investigations in cell biology, including: ○ developmental biology ○ stem cell proliferation and differentiation ○ apoptosis ? Imaging of retinoid localisation ? Measurement of real-time concentration ? Investigation of local environment ? Active in cell culture, developing embryos, cultured tissues and bioengineered tissues Tissue Slicing
Cancer screening in single cells New retinoid drug development
Collaboration - partner to try our small molecules in their applications in order to determine which application is the
most promising.
Page 187 of 487
Spain
Hospital Consorci Sanitari de Terrassa
Organisation Name
Country
Spain
City
terrassa
Street
ctra torrebonica s/n
Website
www.cst.cat
Phone
+347310007
Organisation Type
Other
Person
Name
Ramon Roca
Email
[email protected]
Job Position
Project Coordinator
Consorci Sanitari de Terrassa (CST) is a public health consortium founded in 1989, comprised of sixteen healthcare
centres. CST provides integrated healthcare services to its patients who have all types of acute and chronic diseases
and to follow up at the primary health centers and social healthcare centers. Located in Terrassa, (Barcelona), CST
covers a population of around 200,000 people. CST has a reference clinical laboratory, excellent clinical diagnostic
imaging facilities, as well as, medical and technological equipment for surgical and diagnostic purposes. Research
programmes at CST are aimed at Geriatrics, Cardiology, Gastrointestinal, Molecular Genetics, Oncology, Neuropsychology and Cognitive Rehabilitation.
Consorci Sanitari de Terrassa (CST) comprises of: Hospital de Terrassa 450 acute care hospital beds, with, two social healthcare centres (Hospital de Sant LLàtzer and Hospital de Sant Jordi), seven Primary Healthcare centres,
three Mental Health centres and a Healthcare Unit at the High Performance Centre specialized in sports medicine,
(CAR Sant Cugat).
One of CST primary objectives is to Empower elderly people and their carers to support a continuum of care across a
range of services by using ICT solutions for active and healthy ageing
CST provides care to chronic patients and their families/carers in a transvers manner, from the time of the patients’
admission to the hospital until their discharge (and back again) because of its integrated healthcare characteristics.
Primary Healthcare Centres (PHC): PHC Anton de Borja, PHC Castellbisbal, PHC Matadepera, PHC Sant Genís, PHC
Sant Llàtzer, PHC Terrassa Nord, PHC Est.
Our institutional experience, as well as, that of our professionals in the care and follow-up of patients and their carers
is wide, due to the social-demographic characteristics of the population to whom we serve. One of the important characteristics is that we serve an ageing population, and a considerable increase in this community is expected during
the incoming years.
In view of this, our institution is very interested in participating in the PPI for deployment and scaling up of ICT solutions for active and healthy ageing with the aim of promoting the maximum independent living in their day to day activities. In addition, support strategies favouring quality of life of the patient and carers in their own home. This is why
we are interested in supporting the implementation of new ICT strategies due to the high reference population and
because it is crucial to favour active ageing.
Currently we count with both professionals and devices oriented to continuity of care, treatment adherence, and patient empowerment. Trained by multidisciplinary teams: nurses, internists, primary healthcare professionals and social
workers.
Thanks to the Home Visiting Services, we can carry out interventions at the patients’ homes that favour the detection
of possible risks, promote autonomy and improve the quality of life of the patient.
Page 188 of 487
Spain
Areas of Activity
Preventing disease
young
Health ICT SMEs
(PCP)
(PPI)
population
Offer: Health organization offers big capabilities of recruitment for e-health devices deployment at homes for healthy aging solutions
Our institution is very interested in participating in the PPI for deployment and scaling up of ICT solutions for active
and healthy ageing with the aim of promoting the maximum independent living in their day to day activities. In addition, support strategies favouring quality of life of the patient and carers in their own home. This is why we are interested in supporting the implementation of new ICT strategies due to the high reference population and because it is
crucial to favour active ageing. Currently we count with both professionals and devices oriented to continuity of care,
treatment adherence, and patient empowerment. Trained by multidisciplinary teams: nurses, internists, primary
healthcare professionals and social workers. Thanks to the Home Visiting Services, we can carry out interventions at
the patients’ homes that favour the detection of possible risks, promote autonomy and improve the quality of life of
the patient. Our experience in European Projects is listed below: • 2014 European Project Coordinator – PhysioDom
PhysioDom-HDIM is an innovative solution that improves living conditions for the elderly, as well as, integration and
efficiency for healthcare and social care systems. It consists of a lifestyle coaching system that will suggest diet and
physical exercise levels in accordance with the individual situation of each end user, and monitor the compliance of
these recommendations. In this way, the project will contribute to higher quality and more sustainable health and social care systems in Europe, as well as, improving health and wellbeing among Europe’s elderly. • 2015 European Project Miami: An Innovative patient support tool to develop mHealth application targeted to patients with mild dementia. The tool will help patients to adhere to their treatment and share data with their careers and dotorcs; carers will
use the same application to monitor patients more easily and share their own well-being with doctors. This will slow
the patient’s cognitive and functional decline, avoid carers getting exhausted and reduce the costs of emergencies. •
2015 Innovage INNOVAGE is a project dedicated to social innovations which support active and healthy ageing. The
project will develop and test, as well as, survey and catalogue, social innovation that will have solid impact on improving the quality of life and well-being of the elderly
Consorci Sanitari de Terrassa (CST) comprises of: Hospital de Terrassa 450 acute care hospital beds, with, two social
healthcare centres (Hospital de Sant LLàtzer and Hospital de Sant Jordi), seven Primary Healthcare centres, three
Mental Health centres and a Healthcare Unit at the High Performance Centre specialized in sports medicine, (CAR
Sant Cugat). We have a considerable recruiting capabilities of participants to deploy devices at home of elderly people that can be monitored directly from the primary health centers in an urban area of 200.000 people.
Offer: SFS-38-2016 Impulsivity and compulsivity and the link with nutrition, lifestyle and
the socio-economic environment
One of CST primary objectives in our organization is focused in Neuropsychology and Cognitive Rehabilitation. At CST
our Mental Health unit is composed of different areas including the Center for Adults Mental Health (CSMA), Mental
Health Centre for Children and teenagers (CSMIJ), the day hospital, the Community Rehabilitation Service, the Care
Center to Track and care drug addiction, and the Unit for Pathological Gambling and other nontoxic additions
Page 189 of 487
Spain
Offer: Empowering patients
One of CST primary objectives is to Empower the hospitalized patients, outpatients and their families/carers to support a continuum of care across a range of services. CST provides care to chronic patients and their families/carers in
a transvers manner, from the time of the patients’ admission to the hospital until their discharge (and back again) because of its integrated healthcare characteristics. CST provides services to people needing hospitalization through the
“Hospital de Terrassa”, once the patient has been discharged; his continued care is carried out by the professionals at
one of the 7 “Primary Healthcare Centre” as well as, mental healthcare centres addressing the mental health needs of
the community. Currently we provide service to an area of 200.000 people with a wide population with chronic
pathologies older than 16 years old, and the most prevalent illnesses of our referenced population are: diabetes,
heart diseases, kidney failure, dementia, chronic obstructive pulmonary disease and mental health problems. Additionally,in the population with ages ranging from 16 years or younger, we have a number of people suffer some type
of chronic illness, of which we find: Type I Diabetes, Mental Health (Autism, Behavioural Disorders), Asthma, Cerebral
Paralysis and Obesity.
Page 190 of 487
Spain
Hospital Vall d'Hebron - Institute of Research
Organisation Name
Country
Spain
City
Barcelona
Street
Passeig Vall d'Hebron
Website
Phone
+34934894013
Organisation Type
R&D Institution
Person
Name
Anne-Laure Aslanian
Email
[email protected]
Job Position
International Project Advisor
Fundació Hospital Universitari Vall d’ Hebron – Institut de Recerca (VHIR) is a public sector institution that promotes
and develops innovative biomedical research and was created in 1994 to serve and support the research of University
Hospital Vall d’Hebron (HUVH). HUVH, the leading hospital complex in Catalonia, is one of the largest in Spain with
more than 1400 beds and a team of around 7,000 professional. It is structured into three main healthcare areas (General, Mother and Child, and Orthopaedics and Rehabilitation) and encompasses practically all medical and surgical
specialities and the necessary forms of healthcare to cover them, including clinical services and clinical support units,
university, educational centres, public health service companies, research centres, laboratories and other installations
to round out its activities in healthcare.
VHIR is oriented towards undertaking high quality and competitive research at international level in the field of health
and life sciences, more particularly in the areas of basic, clinical, epidemiological, economic and health care services
in order to favor the transfer of knowledge allowing a better diagnosis, treatment and prevention of the health problems of our society.
More than 1,300 people work at VHIR, out of which over 1,200 do research and around 100 persons provide support in
research and its transfer to the society, whether achieved by projects, technology transfer and innovation, communication or fundraising.
VHIR is currently managing more than 80 International and European FP7 and H2020 funded projects as partner and
as coordinator mainly in the following areas: Oncology, Endocrinology, Neurosciences, Infectious disease, Digestive,
Paediatrics diseases, Rare diseases and Nanomedicine.
VHIR has also a significant participation in national and international clinical trials. Besides, HUVH is a world-class
leader in Clinical Research with one of the largest portfolios of studies, so our patients have access to some of the
most cutting edge treatments. In addition, VHIR performs legal, financial and administrative tasks to support the Hospital in the proper management of the on-going projects.
Areas of Activity
the immune system
diseases
EU level
Methods and data
policies
records (PPI)
Page 191 of 487
Spain
Preventing disease
young
(PCP)
(PPI)
population
Health ICT SMEs
Offer: As a partner PM-06-2016 - Vaccine for malaria/neglected infectious diseases
Research in the Department of Infectious Diseases aims to try to give answers or try to improve strategies of the clinical problems observed in clinical practice, therefore, we work in clinical research. The research is mainly developed
within the Network program of the Institute of Health Carlos III (in Spain), specifically as part of the Network for Infectious Diseases (REIPI), HIV Network (RIS) and the International Health Network (RICET).
Research lines are focused on the problems associated with international health, particularly tuberculosis and Chagas
disease; on the infectious pathology observed in the cancer population, especially bacterial and fungal infection; on
HIV infection, especially antiretroviral medication, pharmacokinetic interactions and opportunistic infections but also
on the nosocomial infection, especially bacterial infection.
We are willing to collaborate as Research Institute but also as Hospital providing patients data in any collaborative
projects related to infectious diseases.
Page 192 of 487
Switzerland
Huperion Pharmaceuticals
Organisation Name
Country
Switzerland
City
Geneva
Street
c/o Pomery Capital, 1 Rue de la Tour-de-l'île
Website
www.huperion.com
Phone
+41792447070
Organisation Type
SME
Person
Name
Patrick Page
Email
[email protected]
Job Position
CEO
Huperion is developing personalized cancer medicine targeting epigenetic dysregulation. We focus on the discovery
and development of small molecule inhibitors of Histone Methyl Transferases (HMTs). Our main focus is on cancer but
we consider any age-related diseases were HMTs are being involved.
Areas of Activity
the immune system
diseases
Offer: Drug discovery and development company willing to participate in project involving
drug therapy and with relevance for epigenetic processes and Histone Methyl Transferases
(HMTs)
- We can participate to project on our current center of interest (Hepatocellular Carcinoma, Acute Myeloid Leukemia,
Colon cancer, Breast cancer) or on any other cancers or non-related cancer therapeutic indications (inflammation,
cardiovascular, metabolic, neurodegenerative, pulmonary diseases, etc.). - Dysregulation of Epigenetic processes and
Histone methyl Transferases should be potentially involved or suspected to be involved in the treatment of such diseases - We are also interested in project involving companion diagnostic related to our target of interest
We are one of the few SME company world-wide working on the discovery and development of epigenetic drugs and
the only European-based SME/biotech specialized in the discovery and development of Histone Methyl Transferase Inhibitors for cancer and age-related diseases.
MARKET APPLICATION
- All age-related diseases asscociated with epigenetic dysregulation - Cancer - Neurodegenerative diseases - Cardiometabolic diseases - Pulmonary diseases - Inflammation
We can provide and take care of the following tasks: - Hit finding for specific Histone Methyl Transferase including
High Throughput Screening (HTS), Structure-Based Drug Design (SBBD) and Fragment Based-Drug Design (FBDD) Approaches - Hit to lead and Lead Optimisation, allowing to demonstrate in vitro and in vivo activities of HMTs inhibitors,
particularly our expertise is related to development of Structure Activity Relationship, improvement of ADME and
Page 193 of 487
Switzerland
Pharmacokinetic properties - Market analysis and Compound positioning, development and implementation of preclinical and clinical development plans
Page 194 of 487
France
Hôpital Saint Louis, APHP ,Hla &Medecine
Organisation Name
Country
France
City
Paris
Street
1 av C Vellefaux
Website
Phone
Organisation Type
Other
Person
Name
Dominique Charron
Email
[email protected]
Job Position
Medical Advisor,President
APHP is the largest university hospital organisation in europe
HLA@MEDECINE is a Research association devoted to the development of Immunogenetics in science and medicine
in the fields of transplantation,auto-immunity and regenerative medicine
Areas of Activity
the immune system
Preventing disease
Initiative
Offer: Personalized immunology and immunogenetics in transplantation and regenerative
medicine
We have international scientific and medical expertise in immunobiology and immunogenetics of
transplantation;auto-immunity and regenerative medicine
Page 195 of 487
France
i Sonic Medical
Organisation Name
Country
France
City
Paris
Street
6 rue de Jarente
Website
www.isonic-medical.com
Phone
+33 1 42 77 74 37
Organisation Type
SME
Person
Name
PIERRE BITOUN
Email
[email protected]
Job Position
PRESIDENT
i Sonic Medical developped a technology plateform of Intelligent Contactless tonometers for the operator-independent
precise measurement of eye pressure for screening, diagnosis and monitoring of glaucoma including for thin corneas
or after Lasik surgery.
Glaucoma is the second leading cause of blindness worldwide with 50% of subjects unaware and undignosed in
wealthy countries because of lack of screening in doctor's office or for homecare digital health self-monitoring personnalized medicine via smartphone. The technology is validated with 1st prototype in large clinical trial on 300 participants: TLR 6+. We are ready to radically change the quality of eye care to prevent blindness. We are meeting with
several global industry leaders who have shown interest in our technology in a $1B+ market with 10% CAGR.
Areas of Activity
(PCP)
(PPI)
Request: MINIATURISATION OF TONOMETER DEVICE
We have developped a Vibration Tonometry platform to measure eye pressure for screening, diagnosis and home
monitoring of eye pressure for patients affected or at risk of Glaucoma , the second cause of blindness worldwide for
76 millions people with 10% blind . We need to find a partner who is ISO 13485 certified and able to manufacture a
portable homecare self monitoring device for patients . It is a small handheld, smartphone-enabled device communicating with our server to calculate eye pressure from the induced response of the cornea measured . Capacity in
miniaturization of medical devices is sought.
Technological cooperation: Capacity in miniaturization of medical devices is sought and must be ISO 13485
Manufacturing of portable medical device, smartphone application and 3 server portals . Company must have all ISO
Certification for medical devices and medical software.
Request: FINANCING
We have developped a Vibration Tonometry platform to measure eye pressure for screening, diagnosis and home
monitoring of eye pressure for patients affected or at risk of Glaucoma , the second cause of blindness worldwide for
Page 196 of 487
France
76 millions people with 10% blind . We are currently seeking a partner who is ISO 13485 certified and able to manufacture device for patients . It is a small handheld, smartphone-enabled device communicating with our server to calculate eye pressure from the induced response of the cornea measured, with Capacity in miniaturization of medical
devices
TARGET PARTNER SOUGHT FOR FINANCING MARKET PENETRATION OVER NEXT 3 YEARS MEDICAL DEVICE PROTOTYPE
STAGE FINANCING TLR6 +
INVESTOR OR INDUSTRIAL PARTNER WOULD BE ADEQUATE
Page 197 of 487
Luxembourg
IBBL (Integrated Biobank of Luxembourg)
Organisation Name
Country
Luxembourg
City
Luxembourg
Street
6 rue Nicolas Ernest Barblé
Website
www.ibbl.lu
Phone
Organisation Type
R&D Institution
Person
Name
Catherine Larue
Email
[email protected]
Job Position
Chief Executive Officer
The IBBL (Integrated BioBank of Luxembourg) Institute is a biobank dedicated to supporting biomedical research for
the benefit of patients. The mission of IBBL is to provide high-quality biospecimens and associated data, foster scientific excellence, catalyse partnerships and support research that translates scientific discoveries into new healthcare
solutions.
IBBL is an integrated research infrastructure, compliant with international quality standards, offering biobanking services, including the collection, processing, analysis and storage of biological samples and associated data. In addition,
IBBL carries out research to optimise biospecimen processing and certify biospecimen quality. IBBL is an autonomous
institute, organised within the Luxembourg Institute of Health (LIH). For more information, please visit our corporate
website (www.ibbl.lu).
IBBL is committed to participating in European Research Programmes and is open to collaborations with large multinational and EU research consortia. IBBL is the ideal biobanking and biomarker validation partner for consortium research projects from the European Research Programmes such as the 7th Framework Programme (FP7), the new Horizon 2020 programme and the Innovative Medicines Initiative (IMI). Read more >
Areas of Activity
the immune system
diseases
EU level
Preventing disease
Offer: Biobanking and biomarker validation partner for consortium research projects
IBBL is the ideal biobanking and biomarker validation partner for consortium research projects from the European Research Programmes such as the 7th Framework Programme (FP7), the new Horizon 2020 programme and the Innovative Medicines Initiative (IMI).
Page 198 of 487
Luxembourg
Why team up with the IBBL biobank? IBBL can bring its biobanking and biomarker validation expertise, and provide a
comprehensive range of services, including: Biospecimen collection, sample processing and storage Biorepository logistics and IT infrastructure Sample testing and assay validation, biospecimen testing and validation Biospecimen
quality control Well-annotated (clinical, pre-analytical, pathological, molecular annotations) retrospective and
prospective samples Tools to standardise pre-analytical parameters (sample collection and validation) Production of
reference materials according to ISO Guide 34 standards Proficiency testing services on sample processing, sample
analysis, according to ISO17043 standards Validation of biomarkers and establishment of corresponding analytical
procedures according to ISO17025 standards Standard operating procedures (SOPs)
MARKET APPLICATION
Existing collaborations with European consortia and projects CANCER-ID, a public-private partnership supported by
Europe’s Innovative Medicines Initiative (IMI). European Union-supported MINDACT study (Microarray In Node negative
Disease may Avoid ChemoTherapy). BIOMARKAPD project of the European Union Joint Programme for Neurodegenerative Disease (JPND) Research. European Commission FP7 Framework Programme: STORE (for Sustaining access to Tissue and data frOm Radiobiological Experiments). Read more : http://www.ibbl.lu/about-ibbl/our-partners-clients/
european-research-partnerships/
IBBL is committed to participating in European Research Programmes and is open to collaborations with large multinational and EU research consortia.
Page 199 of 487
Luxembourg
IBBL (Integrated Biobank of Luxembourg)
Organisation Name
Country
Luxembourg
City
Luxembourg
Street
rue Nicolas Ernest Barblé
Website
www.ibbl.lu
Phone
Organisation Type
R&D Institution
Person
Name
Sarah Weiler
Email
[email protected]
Job Position
Science Communication Officer
The IBBL (Integrated BioBank of Luxembourg) Institute is an autonomous institute dedicated to supporting biomedical
research for the benefit of patients. The mission of IBBL is to provide high-quality biospecimens and associated data,
foster scientific excellence, catalyse partnerships and support research that translates scientific discoveries into new
healthcare solutions.
IBBL is an integrated research infrastructure, compliant with international quality standards, offering biobanking services, including the collection, processing, analysis and storage of biological samples and associated data. In addition,
IBBL carries out research to optimise biospecimen processing and certify biospecimen quality. IBBL is an autonomous
institute, organised within the Luxembourg Institute of Health (LIH). For more information, please visit our corporate
website (www.ibbl.lu).
IBBL is committed to participating in European Research Programmes and is open to collaborations with large multinational and EU research consortia. IBBL is the ideal biobanking and biomarker validation partner for consortium research projects from the European Research Programmes such as the 7th Framework Programme (FP7), the new Horizon 2020 programme and the Innovative Medicines Initiative (IMI). Read more >
Areas of Activity
the immune system
diseases
EU level
Preventing disease
Offer: Biobanking, sample processing & analysis, biomarker validation, biospecimen research
IBBL provides a comprehensive range of services, including: Biospecimen collection, sample processing and storage
Biorepository logistics and IT infrastructure Sample testing and assay validation, biospecimen testing and validation
Biospecimen quality control Well-annotated (clinical, pre-analytical, pathological, molecular annotations) retrospective
Page 200 of 487
Luxembourg
and prospective samples Tools to standardise pre-analytical parameters (sample collection and validation) Production
of reference materials according to ISO Guide 34 standards Proficiency testing services on sample processing, sample
analysis, according to ISO17043 standards Validation of biomarkers and establishment of corresponding analytical
procedures according to ISO17025 standards Standard operating procedures (SOPs)
Page 201 of 487
France
ID2Santé
Organisation Name
Country
France
City
Rennes
Street
avenue du Pr Léon Bernard 2
Website
www.id2sante.fr
Phone
+ 33 2 23 23 45 81
Organisation Type
Other
Person
Name
Jocelyne Le Seyec
Email
[email protected]
Job Position
Innovation Officer
ID2Santé is a technology innovation centre operating in Bretagne (Western France).
It is in close contact with researchers and companies from the health sector and helps forge partnerships to develop
innovative health projects.
It is able to connect you with regional key players and experts in areas such as:
• Medical technologies with diagnostic and therapeutic purposes (medical devices, computer assisted surgery,
imaging); living labs in ambient assisted living
• E-health, telemedicine, personal medical e-file, big data processing
• New therapeutic solutions with biotech/pharmaceuticals (new molecules, biomarkers, genetics, preclinical and
clinical research, biological resource centres, marine compounds sourcing…)
• Prevention and nutrition (development of ingredients, food for medical purposes, clinical research in nutrition
and metabolism, expertise in toxicology and ecotoxicology)
You find below some profiles, among many others we can connect you with. Explain your project and we’ll search for a
possible partner in our territory.
Areas of Activity
the immune system
diseases
(PCP)
(PPI)
population
Preventing disease
young
Methods and data
policies
records (PPI)
Page 202 of 487
France
Request: European network for oncology research in blood biomarkers
A research unit specialised in oncology (lymphoma, melanoma, breast, prostate, lung cancers…) is looking forward to
build or to participate in a European network involved in the research of blood biomarkers – Multicenter data with a
large task force – Cross comparison for candidate biomarkers – Use common highthroughput platforms: sequencing,
bioinformatic, algorithms, etc. – development of news tools, devices – Collaboration with pharma companies or companies involved in diagnosis
Offer: mHealth Diagnostics and therapy monitoring
A French biotech SME develops mHealth solutions for in vitro diagnosis, prognosis and therapy monitoring in human
and veterinary fields. Vision of the company is to enable accurate rapid testing anytime anywhere along with mobility,
connectivity and smart data. The patented platform allows to analyse a finger prick blood sample in 5 minutes and to
communicate the results from any smartphone. The company develops mHealth diagnostics in drug monitoring, drug
resistance monitoring, efficacy monitoring, stratification, post treatment follow up. It already sells a range of CE
marked rapid tests worldwide. The company is ISO 9001 and 13485 certified.
Offer: Organic compounds analysis by infrared optical fiber
A French SME develops single use biosensors that allow detecting changes in metabolic compositions of the tissues
and biological fluids. Those sensors are made with chalcogenide fiberglass, which is biocompatible, hydrophobic and a
very good light transmission in the mid infrared. Mid-infrared spectroscopy, which was previously limited to research
due to its implementation and interpretation complexity, now becomes an accessible tool in clinical practice, providing a result in less than 10 mn.
Offer: Non-clinical and clinical studies
A French CRO performs non-clinical and clinical early development studies for the pharmaceutical industries. It is a
leading provider of Non-Clinical Pharmacology services. In addition to GLP safety pharmacology in vivo studies, it provides specialized efficacy models in the Oncology, CNS, Respiratory and Cardiovascular areas. It also offers complete
clinical research services (phase I clinics, phases II-IV trial management). A wide range of bioanalytical services and
core lab services for drug development are also available (imaging, cardiac safety, CNS equipment).
Offer: Healthcare data management
A grouping of hospitals created a dedicated organization for healthcare information management systems. It is ISO
9001:2008 certified. Services include: - Design of information management systems for hospitals and care institutions, - Development of software programmes for medical and administrative data management and decision support
systems - Personal data hosting (accredited by the French Ministry for Health) - Consultancy and training
Page 203 of 487
Spain
IESE Business School
Organisation Name
Country
Spain
City
Barcelona
Street
Avda Pearson
Website
www.iese.edu
Phone
+34 932534200
Organisation Type
University
Person
Name
Magdalene Rosenmoller
Email
[email protected]
Job Position
Profesora Asociada
IESE, the International Business School based in Barcelona (www.iese.edu) set up the Center for Research in Healthcare Innovation Management (CRHIM) in 2012, responding to the need of better understanding the role of management in Health care. Main objective is research on innovation management in healthcare: managing innovation and
innovating management!
The IESE CRHIM brings together faculty and experts in the field of innovation in healthcare, building on IESE’s insights
in health management and a wide‐ranging experience working with providers, other academic institutions and the industry. The centre undertakes research and develops tools to facilitate the uptake of innovation in technologies and
managerial practices across the entire health care value chain.
By increasing managerial knowledge and capacity, CRHIM enables health sector actors to address challenges and realize opportunities to deliver better, more effective and affordable healthcare.
The research, analysis, and debate CRHIM generates contribute to shaping real practice and policy throughout its
large network of institutions, public and private actors from developed and developing countries
Areas of Activity
(PCP)
(PPI)
population
Methods and data
policies
Page 204 of 487
Spain
Offer: Support to Business Concept Development / Market Deployment for Innvoative
Technologies
We are interested in supporting innovative products / services for health care (ICT or others), with Business Concept
development, Market Deployment, but also the way they impact on health care provided. - While we build on much
past experience, we are very enthousiastic about learning to apply this in the broad fields of health and social care, as
that will inform all our activities, resarch and managerial (business executive ) capacity development, also in the context of EIT Health.
veyr innotvative ways of going about market deployment, See the impact in terms of Disruptive Innvoation, etc.
MARKET APPLICATION
Any market. we support the getting out in the
Industries, SME, technology innovator. Any country.
Page 205 of 487
Belgium
Ile-de-France Europe
Organisation Name
Country
Belgium
City
Brussels
Street
rue Montoyer 10
Website
Phone
Organisation Type
Person
Name
Cédric Daumas
Email
[email protected]
Job Position
EU Policy adviser
Ile-de-France Europe is the association representing the Ile-de-France Region in Brussels. Its missions:
•
•
•
•
Informing and raising the awareness on EU policies and programmes
Increasing the value and promoting the interests of its members to the European institutions
Advising and supporting Ile-de-France local authorities and players in their European initiatives
Representing the Ile-de-France regional and local authorities to the European institutions
In the field of research and innovation, Ile-de-France Europe publishes regular alerts on the calls publication (H2020,
COSME, etc) and help regional players identify the right EU and national interlocutors, find partners and integrate projects.
Areas of Activity
(PCP)
(PPI)
population
Health ICT SMEs
Page 206 of 487
France
IMAGENE
Organisation Name
Country
France
City
Evry
Street
5 rue henri desbruères, Genopole campus 1,
Website
www.imagene.eu
Phone
+33160778300
Organisation Type
SME
Person
Name
Anne-Lise Fabre
Email
[email protected]
Job Position
RD department manager
Imagene is a biotechnology company specialized in room temperature preservation of biospecimens. Its unique in the
world disruptive technology is based on the encapsulation of biospecimens in "minicapsules" containing an inert atmosphere. Once encapsulated, biospecimen can be stored and shipped with no need for freezers or dryice. The encapsulation process can be applied to many biospecimens such as DNA, RNA, bacteria, virus...
Completely anhydrous, anoxic and perfectly airtight, the minicapsules possess the expected decisive advantages
when compared to freezing by providing enhanced stability, safety, and transport and distribution of biospecimens as
well as lower operation and maintenance costs.
The technology is being used in diagnostic kits to provide reference material standards and clinical controls that asses
the performance of the diagnostic method for instance.
We are looking for new opportunities to develope novel reference material and controls used for in vitro clinical diagnostic applied to either clinically validated biomarkers or to-be-developped ones.
We are looking for opportunities to participate in cohort or biobanking projects. Our preseration technology will ease
logistics related to shipping and storage of biospecimens (DNE, RNA, blood, buffy coat, white blood cells, ...).
Areas of Activity
the immune system
diseases
EU level
Preventing disease
Methods and data
Page 207 of 487
France
Offer: Clinical reference material and standards - offer for technical and/or commercial
collaboration
In addition to its biobanking-related activity, Imagene aims at developing new standards and controls used in in vitro
clinical diagnostics. Its unique in the world technology allows stand alone room temperature preservation of standards
and controls, even for fragile biomolecules such as RNA. The minicapsules are economically competitive and technologically disruptive while being sustainable (no energy required). For instance, the technology has been used to develop novel CE-IVD internal quality controls for the performance control of Leukemia monitoring methods.
- room temperature preservation: no need for freezers or cold chain - stand alone preservation: no maintenance, no
freezer alarm - qualitative and quantitative recovery: standardized materials and quality controls needed for ISO
15189 for instance - full traceability (unique laser-engraved 2D code): product compatible with international standards related to traceability and archiving
MARKET APPLICATION
We are looking for partners who are interested in devoloping new standards and controls for in vitro clinical diagnostics. Projects could be related to either clinically-validated biomarkers or to-be-developped biomarkers (lncRNA, miRNA).
We are looking for an expertise in in vitro clinical diagnostic and novel biomarker developments.
Offer: Innovative Biobanking at room temperature
Imagene has developped a unique in the world technology to allow room temperature storgae of biospecimens. It has
been adopted by many infrastructures and domains (forensics, biobanking, national museum, diagnostics...). Through
collaborations, Imagene develops innovative products for room temperature biospecimens archiving such as for
blood, buffy cotat, DNA, RNA, microroganisms, phages...
the innovation: a combination of biostabilization solutions and innovative banking format (endless hermetic inert atmopshere). main advantages: - shipping and storing are cold-free - space saving up to 10 X - no maintenance, no relative humidity or AC control
MARKET APPLICATION
markets: biobanking but also diagnostics, forensics, agro
any infrastuctures that works with biospecimens biobanking (ie cohort).
Page 208 of 487
France
IMSTAR S.A.
Organisation Name
Country
France
City
PARIS
Street
60 RUE NOTRE DAME DES CHAMPS
Website
Phone
0142349370
Organisation Type
SME
Person
Name
Françoise SOUSSALINE
Email
[email protected]
Job Position
President & CEO
Corporate Profile in brief
• Founded and managed by Francoise Soussaline PhD-DSc, a world expert in advanced digital
biomedical imaging.
• Invested around $13M in R&D over the past 15 years.
• Strong international Intellectual Property portfolio of 13 patents, 105 copyrights and 15 trademarks.
• Multidisciplinary staff combining over 100 years of expertise in various fields such as instrument automation, high performance image processing and analysis algorithms, biophysics
and bio modeling, experimental cell biology and cytopathology and oncology.
• Over the past ten years, involved as the pilot or partner in 6 European and 3 French R&D consortia collaborative R&D projects in the fields of automated in vitro/in vivo genetic toxicology
testing, large scale multiplex phenotype screening for tumour biomarkers(Proof-of-Concept)
and High-Performance Image Processing for Medical Use.
• Sustained relationships with Blue Chip industrial partners and high profile research customers
and consultants around the world.
• More than 800 IMSTAR Pathfinder™ systems are installed all over the world, with a significant
imprint in China.
Corporate Mission
IMSTAR is a 20-year old, privately owned, Paris-based company, founded as a spin-off of the Atomic Energy Commission’ Life Sciences Direction. Since its inception, the enterprise specialized in the design, development and international marketing of a range of innovative digital bio imaging cytometry systems for Life Sciences preclinical research
and assisted in vitro diagnostic.
IMSTAR’s mission is to combine advanced medical research, innovative mechanisms-based biology concepts and
leading edge imaging and ICT technologies into world-class products, i.e. microscope-based instruments integrating
specific proprietary software, to address the medical needs for a personalized ultra-early, more sensitive and overall
more specific diagnostic. The IMSTAR’s cytometry systems allow cell or tissue samples imaging for quantitative phenotype and morphology fine characterization necessary to pharmaceutical industry, Biotechs, academic research and
assisted in-vitro diagnostic preclinical markets.
IMSTAR mature and innovative company
• Developed and market world-wide the Pathfinder™ Image Cytometer Systems: a High
Content Analysis (HCA) smart instrument, covered by a strong IP
Page 209 of 487
France
• Being involved in key collaborative R&D projects over the past ten years (6 EU consortia, and
2 French R&D consortia in the fields of automated in vitro/in vivo genetic toxicology testing
and large scale multiplex phenotype screening for tumour markers’ Proof-of-Concept.
• Has sustained relationships with high profile industrial and research customers around the
world.
• The company innovates continuously, in particular in the field of oncology biomarkers’ identification and validation for personalized therapy through digital quantitative cytopathology and
characterization of diagnostic, predictive tumour biomarkers, notably Circulating Tumour Cells
(CTC).
• More than 800 IMSTAR Pathfinder™ ICS and stand-alone software are installed all over the
world.
Markets & Applications
• Life Sciences research for Pharmaceutical, Biotechnology, and cosmetics industries applications or fundamental research aiming personalised treatment.
• Cytopathology quantitative biomarker assays and oncology companion tests for preclinical research, including
CTC.
• Genetic toxicology automated testing in Bio monitoring (Centres of Disease Control, environmental, chemical
compounds mutagens) and Pharmaceutical, Cosmetics, Nutrition and Tobacco industries.
• Digital Cytogenetic for cell therapy research use.
• Digital pathology for remote control of frozen section, distributed Tele-expertise, Biomarkers oriented Patient
Data Base management and Bio banking.
Areas of Activity
diseases
Preventing disease
Initiative
(PPI)
Methods and data
policies
Health ICT SMEs
Offer: Innovative High-Content Cellular Imaging proprietary solutions for cost effective
biomarkers’ quantification in Oncology preclinical research, assisted Cyto-Pathology and
large scale DNA damage assessment
What we offer: IMSTAR develops and markets a technology platform: Pathfinder™ Image Cytometry System (ICS), an
automated multimodality imaging, high-content & throughput reader/analyser for detection of rare or tumour cells in
cytology/histology samples, increasing sensitivity and specificity, while reducing dramatically expert’s time. These
modular solutions are currently used in hospitals, public or private cytopathology, cytogenetics laboratories, Pharmaceutical, Biotechs, Nutrition, Tobacco and Cosmetic companies, and Life Sciences academic laboratories. IMSTAR offers also related services to these domain with customized developments based on the Pathfinder™ proprietary technology platform.
IMSTAR mature and innovative company Pathfinder™ ICS is a powerful quantitative tumour markers’ reader-analyser
for cyto-pathology (companion) tests for: • Quantitative Digital imaging, assisted Histo-Cyto-Pathology & Cytogenet-
Page 210 of 487
France
ics. • DNA damage in human cells, related to cancer environment, nutrition or treatment for predictive medicine, genetic toxicology, mutation research, radiation biology. • A large range of cellular tumour markers assessed by IHC, IF
and I-FISH. • Circulating Tumour Cell (CTC) as a predictive marker in major cancers. • Multiplex high content cellular
analysis in Life Sciences research • The Pathfinder™ Image Cytometer Systems: Automated High Content Analysis
'Smart' instrument are covered by a strong IP. • All products were validated through collaborative R&D projects with
key KOL's academic institutions, over the past ten years (6 EU consortia, and 2 French R&D consortia in the fields of
automated in vitro/in vivo genetic toxicology testing and large scale multiplex phenotype screening for tumour markers’ Proof-of-Concept. • Sustained relationships with high profile industrial and research customers around the world.
• Continues to innovate and has a strong pipeline of new products in cytopathology. • More than 800 IMSTAR Pathfinder™ ICS and strand alone software are installed all over the world.
MARKET APPLICATION
IMSTAR’s target markets are: • Life Sciences research for Pharmaceutical, Biotechnology, and cosmetics industries applications or fundamental research aiming personalised treatment. • Cytopathology quantitative biomarker assays
and oncology companion tests for preclinical research, including CTC. • Genetic toxicology automated testing in Bio
monitoring (Centres of Disease Control, environmental, chemical compounds mutagens) and Pharmaceutical, Cosmetics, Nutrition and Tobacco industries. • Digital Cytogenetic for cell therapy research use. • Digital pathology for remote control of frozen section, distributed Tele-expertise, Biomarkers oriented Patient Data Base management and
Bio banking.
In all European countries: IMSTAR seeks R&D partners in H2020 programs who would benefit from our expertise and
innovative comprehensive solutions for automated cells detection, multiplex fine characterization (phenotype, morphology) and large scale screening in assisted in vitro/ex vivo Diagnostic tests (breast, lung, prostate, bladder, colon
cancers and onco-haematology). We also offer our applied Pathfinder™ software modules enabling early detection of
tumour cells as well as automated quantification of DNA damage Genetic toxicology or predictive biomarkers in preclinical research and development. Other Partnering objectives • Technical agreements for co-development of biomarkers’ assessment and companion tests • Alliance for comprehensive solutions; diagnostic kit “test-drug”. • Joint
Venture, out/cross-licensing agreements, co-marketing for specific application/territory. • Pathfinder™ Products Distribution
Page 211 of 487
France
Inato
Organisation Name
Country
France
City
Paris
Street
113 rue Saint Maur
Website
Phone
+33682993224
Organisation Type
SME
Person
Name
Kourosh Davarpanah
Email
[email protected]
Job Position
CEO
Inato is a technology and clinical trials organization based in Paris.
We are focused on the automation and digitization of the clinical trial process to maximize efficiency and offer an unmatched user experience to sponsors, investigators and patients.
Background and approach
The clinical research industry is crippled by three major problems:
• The current staff-intensive model wastes financial and human resources
• Digital technologies are both underused and misused
• User experience with CROs is poor
Our company was founded and designed to provide the best solution to these issues.
All clinical trials can be divided into three steps, each of which is tailored to the study:
1. The design of the protocol. After collecting the client’s track-record and expectations, we design a refined protocol to demonstrate the product’s performance. Having designed hundreds of clinical studies, our CSO has a
huge body of experience in this field.
2. The operational phase. Unlike conventional CROs who rely primarily on clinical research associates, we automate data capture and data monitoring. This allows us to produce highly reliable clinical information while reducing costs.
3. Data analysis and interpretation. Once the study is achieved, data are then analyzed and interpretation is
done through collegial working of the scientific team. This is a critical step since wrong analyses can lead to
miss favorable outcomes and have proved counterproductive for many companies in the past.
Our approach allows us to deliver very high quality clinical studies at a significantly lower price than traditional players.
Team
We are 5 cofounders with an extensive clinical, scientific and technological background:
• Kourosh Davarpanah and William Pambrun, respectively CEO and CTO, both graduated from France’s leading
engineering schools and have previously cofounded startups
• Prof. Philippe Ravaud, Chief Science Officer, MD, PhD, director of the INSERM research center and the epidemiology department at Hotel Dieu. He has published more than 300 scientific articles, among which more than
30 in the “Big 6” journals.
Page 212 of 487
France
• Dr. Jean-David Zeitoun, MD, MHPM. He is specialized in Gastroenterology and has a five year experience in
consulting for health industries. He is an advisor at The Family, an investment company, where he is responsible for healthcare startups.
• Prof. Gabriel Thabut, MD, PhD. He is specialized in respiratory diseases and holds a PhD in biostatistics and
data analysis. He has published landmark papers in the most prestigious medical journals. He is a recognized
data analysis expert.
Areas of Activity
EU level
Preventing disease
Initiative
(PCP)
Methods and data
policies
records (PPI)
Health ICT SMEs
Offer: Disruptive clinical trials
We fully take care of your clinical trial needs from the design of the protocol to the analysis of the results Our disruptive digital approach along with our the extensive scientific, clinical and technological expertise of our founders allow
us to conduct better trials for ~30% less than traditional CROs.
- Unlike conventional CROs who rely primarily on clinical research associates, we automate data capture and data
monitoring. This approach allows us to produce highly reliable clinical information while reducing costs. - We carefully
tailor the study protocol to our clients' needs. Our Chief Science Officer has designed hundreds of clinical studies both
for academic and commercial purposes. Our broad scientific and academic network allows us to involve leading experts when necessary to fully understand the specificities of our clients' products.
MARKET APPLICATION
Our approach is especially relevant for device manufacturers, small to midcap pharma companies and biotechs, digital medicine companies and actors from non-traditional industries such as food and cosmetics.
Companies with clinical trial needs
Page 213 of 487
France
Inato
Organisation Name
Country
France
City
Paris
Street
113 rue Saint Maur
Website
Phone
Organisation Type
SME
Person
Name
Jean-David Zeitoun
Email
[email protected]
Job Position
Board Member
Inato is a technology and clinical trials organization based in Paris.
We are focused on the automation and digitization of the clinical trial process to maximize efficiency and offer an unmatched user experience to sponsors, investigators and patients.
Background and approach
The clinical research industry is crippled by three major problems:
• The current staff-intensive model wastes financial and human resources
• Digital technologies are both underused and misused
• User experience with CROs is poor
Our company was founded and designed to provide the best solution to these issues.
All clinical trials can be divided into three steps, each of which is tailored to the study:
1. The design of the protocol. After collecting the client’s track-record and expectations, we design a refined protocol to demonstrate the product’s performance. Having designed hundreds of clinical studies, our CSO has a
huge body of experience in this field.
2. The operational phase. Unlike conventional CROs who rely primarily on clinical research associates, we automate data capture and data monitoring. This allows us to produce highly reliable clinical information while reducing costs.
3. Data analysis and interpretation. Once the study is achieved, data are then analyzed and interpretation is
done through collegial working of the scientific team. This is a critical step since wrong analyses can lead to
miss favorable outcomes and have proved counterproductive for many companies in the past.
Our approach allows us to deliver very high quality clinical studies at a significantly lower price than traditional players.
Team
We are 5 cofounders with an extensive clinical, scientific and technological background:
• Kourosh Davarpanah and William Pambrun, respectively CEO and CTO, both graduated from France’s leading
engineering schools and have previously cofounded startups
• Prof. Philippe Ravaud, Chief Science Officer, MD, PhD, director of the INSERM research center and the epidemiology department at Hotel Dieu. He has published more than 300 scientific articles, among which more than
30 in the “Big 6” journals.
Page 214 of 487
France
• Dr. Jean-David Zeitoun, MD, MHPM. He is specialized in Gastroenterology and has a five year experience in
consulting for health industries. He is an advisor at The Family, an investment company, where he is responsible for healthcare startups.
• Prof. Gabriel Thabut, MD, PhD. He is specialized in respiratory diseases and holds a PhD in biostatistics and
data analysis. He has published landmark papers in the most prestigious medical journals. He is a recognized
data analysis expert.
Areas of Activity
EU level
Preventing disease
Initiative
(PCP)
Methods and data
policies
records (PPI)
Health ICT SMEs
Page 215 of 487
Portugal
INEB - Instituto de Engenharia Biomédica/i3S - Instituto de
Investigação e Inovação em Saúde
Organisation Name
Country
Portugal
City
Porto
Street
Rua Alfredo Allen, 208
Website
www.ineb.up.pt
Phone
Organisation Type
R&D Institution
Person
Name
João Cortez
Email
[email protected]
Job Position
INEB (www.ineb.up.pt) is a private non-profit association with the statute of public interest, founded in June 1989.
The Mission of INEB is to generate knowledge, by promoting research, advanced training and technology transfer in
Biomedical Engineering.
Transdisciplinarity is a distinctive feature of INEB. Integrative research, involving specialists in biomaterials, tissue regeneration, nanomedicine, bioimaging, medical signals, geoepidemiology, biology and medicine has brought international recognition to the institute.
In the past decade, over 30 prototypes, 6 products and 3 spin-offs were generated from the research work of INEB researchers. INEB has also established fruitful collaborations with research institutions, hospitals and companies worldwide.
INEB hosts several research groups (see cooperation profiles) with activity in several distinct fields of biomedical engineering, namely biomaterials, tissue regeneration, nanomedicine, bioimaging, biomedical signals and geoepidemiology.
The clinical applications of work in progress are in orthopedics and dentistry, neurology, obstetrics, oncology, and cardiology.
INEB also has two clinical research groups based at Hospital São João (Porto), in nephrology and obstricts.
i3S - Institute for Research and Innovation in Health (www.i3s.up.pt)
i3S, headed by the University of Porto (UPorto), brings together four institutions and researchers from several schools
of UPorto. i3S results from the long-term collaboration between Instituto de Biologia Molecular e Celular (IBMC), Instituto de Engenharia Biomédica (INEB), Instituto de Patologia e Imunologia Molecular da UPorto (IPATIMUP) and some
research groups from Faculdade de Medicina da UPorto (FMUP), encompassing joint projects, co-supervision of PhD
students, sharing of large equipment and employment of research staff under coordinated policies.
In the 2014 international peer-review evaluation organized by Fundação para a Ciência e a Tecnologia (FCT), i3S obtained the maximum score (25/25) being classified as among the 11 national Research Units rated as exceptional.
i3S is a transdisciplinary institution whose mission lies on the promotion of research and innovation in the Health Sciences at the highest international level, while carrying out graduate training and contributing to solve current major
societal challenges. Around a thousand collaborators work at i3S, which is organized into three thematic units: Cancer, Host Interaction and Response, and Neurobiology and Neurologic Disorders, encompassing 50 research groups
and over 400 researchers with a PhD running more than 192 nationally or internationally funded projects. Our researchers are funded by different sources and around 120 of them are lecturers in schools of the University of Porto.
Currently, i3S is running five PhD programs but it hosts students from several other programs, reaching over 220 PhD
Page 216 of 487
Portugal
and more than 180 MSc Students. Being a major infrastructure in the region, i3S endorses a policy of sharing regarding core scientific platforms, including Genomics, Biomolecular Analysis, Cell Analysis, Imaging, and Animal Experimentation.
At i3S we capitalize the institute’s scientific know-how via a Technology Transfer & Programmes Unit that engages in
all required steps for the valorization and exploitation of intellectual property, including industry research contracts.
Our commitment to research translation into valuable assets for society goes even further thanks to three clinical and
diagnostic services and to a well-defined responsible research and innovation agenda, which includes effective policies and programs in research ethics, interdisciplinary research, integrative initiatives with and for society, and advanced training for the scientific community.
i3S is the place where brilliant minds explore innovative thinking to solve health challenges, playing a crucial role in
the development of a sustainable and solid regional strategy.
Areas of Activity
the immune system
diseases
EU level
Methods and data
policies
Health ICT SMEs
(PCP)
(PPI)
Offer: Competences available
Biomedical applications; biomaterials for bone/ skin/ nervous system; nanomedicine; regenerative medicine
Page 217 of 487
Spain
INNAXIS Foundation
Organisation Name
Country
Spain
City
Madrid
Street
Jose Ortega y Gasset 20
Website
www.innaxis.org
Phone
Organisation Type
R&D Institution
Person
Name
Carlos Alvarez-Pereira
Email
[email protected]
Job Position
President
Innaxis is a non-profit organization promoting applied interdisciplinary research in complex systems and data science
since 2006.
We have a strong experience in EU-funded research projects, and we are willing to extend the domain of applicability
of our techniques to challenges in health and life sciences.
Areas of Activity
the immune system
diseases
Methods and data
policies
Offer: Modelling complex biomedical challenges through networks and data analysis
Our expertise is in complex system modelling by means of complex networks (a theory drawn from statistical physics,
and that has gained much momentum in the last decade) and data science. Beside pure theoretical works, we have
recently moved to biomedical applications, including the analysis of human brain EEG and MEG activity under normal
and pathological (AD and MCI) conditions; and the detection of biomarkers from -omics data. We are looking for projects that need a different and innovative perspective to biological systems modelling.
Use of the perspective of complex nextworks to frame the analysis and modelling of challenging biomedical problems.
MARKET APPLICATION
Among others, areas related with the human brain and its pathologies.
Experts in biomedical research looking for new techniques to interpret data and perform data analytics, deep learning, etc.
Page 218 of 487
France
INRA
Organisation Name
Country
France
City
Clermont-Ferrand
Street
5 Chemin de Beaulieu
Website
Phone
Organisation Type
R&D Institution
Person
Name
Blandine Comte
Email
[email protected]
Job Position
Research Director
INRA is a public French research organization employing some 12,000 people and has among its strategic interests
the impact of food on human health and well-being. It is ranked 2nd in the world and 1st in Europe for publications in
agricultural sciences, and plant and animal sciences. It takes part in the project through the Department of Human
Food. INRA has significantly contributed to the development of high-throughput approaches in nutrition particularly
for metabolomics as an approach for investigating and understanding the effects of nutrition on health. The Unit of
Human Nutrition (UHN), located in Clermont-Ferrand gathers 150 persons, including a permanent staff of over 50 scientists, all sharing as a common goal the elucidation of key mechanisms involved in the prevention of ageing-associated diseases by nutrients and foods. Increasing our understanding of the needs is crucial for establishing nutritional
recommendations and preventing metabolic alterations. To address this issue, the UHN is developing an innovative
approach integrating the human complexity at the physiological, metabolic and nutritional levels. The main objective
is to determine the functionality of food in different pathophysiological conditions associated with ageing in order to
prevent the decline of physiological functions, but also to prevent the development of ageing-related diseases (cardiovascular diseases, obesity, etc.).
Areas of Activity
Offer: Metabolic Phenotype, Nutrition & Modeling
Our research group has expertise/interest in/on: - the identification of early and/or predictive (bio)markers of chronic
metabolic diseases development and effects of nutrition using integrative approaches, - the mechanisms by which nutrition (macro- and micronutrients) contributes to the development or the prevention of chronic diseases such as type
2 diabetes and associated risk of cardiovascular diseases using nutrigenomics approaches, - development of new
tools and approaches to integrate multidimensional data (food intake, phenotypic and biochemical data, socio-economic parameters and metabolomics) in order to get a comprehensive view of health determinants and diet-diseases
links. Within the Human Nutrition Unit, our team is focusing on the identification of early and/or predictive
(bio)markers of chronic metabolic disease (ie type 2 diabetes). The team is currently coordinating and involved in several programs (national and EU) involving integrated and multifactorial studies, combining phenotypic parameters
(metabolic, multi-omics…), socio-economic and nutritional parameters for the identification of metabolic dysfunctions:
case-cohort studies (French Gazel and Haguenau cohorts) regarding metabolic chronic diseases (metabolic syndrome
and type 2 diabetes) and/or intervention study (FP7 Nu-AGE). The team works in very close collaboration with the
platform PFEM led by E Pujos-Guillot, an infrastructure which aims at proposing to the scientific community the concepts, methods and tools dedicated to metabolism studies. PFEM is member of MetaboHUB (infrastructure Investissements d’Avenir for metabolomics and fluxomics). PFEM is a national and international leader in mass spectrometry
Page 219 of 487
France
(MS) metabolomics applied to nutrition, particularly in the development of analytical strategies for biomarker discovery using ultra high resolution MS, statistics and bioinformatics.
Research groups willing to participate or coordinate a project within the call PM-02-2017: New concepts in patient
stratification.
Request: Integrative approaches/systems biology
stratification
Request: Clinician/Physician with expertise in obesity and type 2 diabetes
stratification.
Page 220 of 487
France
INRA
Organisation Name
Country
France
City
Clermont-Ferrand
Street
5 Chemin de Beaulieu
Website
www.inra.fr
Phone
Organisation Type
R&D Institution
Person
Name
Estelle PUJOS-GUILLOT
Email
[email protected]
Job Position
Researcher
INRA is a public French research organisation employing some 12,000 people and has among its strategic interests
the impact of food on human health and well-being. It is ranked 2nd in the world and 1st in Europe for publications in
agricultural sciences, and plant and animal sciences. It takes part in the project through the Department of Human
Food. INRA has significantly contributed to the development of high-throughput approaches in nutrition particularly
for metabolomics as an approach for investigating and understanding the effects of nutrition on health. The Unit of
Human Nutrition (UHN), located in Clermont-Ferrand gathers 150 persons, including a permanent staff of over 50 scientists, all sharing as a common goal the elucidation of key mechanisms involved in the prevention of ageing-associated diseases by nutrients and foods. Increasing our understanding of the needs is crucial for establishing nutritional
recommendations and preventing metabolic alterations. To address this issue, the UHN is developing an innovative
approach integrating the human complexity at the physiological, metabolic and nutritional levels. The main objective
is to determine the functionality of food in different pathophysiological conditions associated with ageing in order to
prevent the decline of physiological functions, but also to prevent the development of ageing-related diseases (cardiovascular diseases, obesity, etc.).
Areas of Activity
Offer: Metabolic phenotype, nutrition and modeling
Our research group has expertise/interest in/on: - the identification of early and/or predictive (bio)markers of chronic
metabolic diseases development and effects of nutrition using integrative approaches, - the mechanisms by which nutrition (macro- and micronutrients) contributes to the development or the prevention of chronic diseases such as type
2 diabetes and associated risk of cardiovascular diseases using nutrigenomics approaches, - development of new
tools and approaches to integrate multidimensional data (food intake, phenotypic and biochemical data, socio-economic parameters and metabolomics) in order to get a comprehensive view of health determinants and diet-diseases
links. Within the Human Nutrition Unit, our team is focusing on the identification of early and/or predictive
(bio)markers of chronic metabolic disease (ie type 2 diabetes). The team is currently coordinating and involved in several programs (national and EU) involving integrated and multifactorial studies, combining phenotypic parameters
(metabolic, multi-omics…), socio-economic and nutritional parameters for the identification of metabolic dysfunctions:
case-cohort studies (French Gazel and Haguenau cohorts) regarding metabolic chronic diseases (metabolic syndrome
and type 2 diabetes) and/or intervention study (FP7 Nu-AGE). The team works in very close collaboration with the
platform PFEM led by E Pujos-Guillot, an infrastructure which aims at proposing to the scientific community the concepts, methods and tools dedicated to metabolism studies. PFEM is member of MetaboHUB (infrastructure Investissements d’Avenir for metabolomics and fluxomics). PFEM is a national and international leader in mass spectrometry
Page 221 of 487
France
(MS) metabolomics applied to nutrition, particularly in the development of analytical strategies for biomarker discovery using ultra high resolution MS, statistics and bioinformatics.
Research group willing to participate or coordinate a project within the call PM-02-2017: New concepts in patient
stratification
Request: Integrated approaches / Systems biology
Research group willing to participate or coordinate a project within the call PM-02-2017 : New concepts in patient
stratification
Request: Physician with expertise in obesity and type 2 diabetes
Research group willing to participate or coordinate a project within the call PM-02-2017 : New concepts in patient
stratification
Page 222 of 487
France
Inria
Organisation Name
Country
France
City
75013
Street
23 Avenue d'Italie
Website
http://www.inria.fr
Phone
Organisation Type
R&D Institution
Person
Name
Philippe GESNOUIN
Email
[email protected]
Job Position
Tech Transfer Associate
Inria, the French National Institute for computer science and applied mathematics, promotes “scientific excellence for
technology transfer and society”. Graduates from the world’s top universities, Inria's 2,700 employees rise to the
challenges of digital sciences. With its open, agile model, Inria is able to explore original approaches with its partners
in industry and academia and provide an efficient response to the multidisciplinary and application challenges of the
digital transformation. Committed to assisting innovators, Inria provides the ideal conditions for fruitful relations between public research, private R&D and industry. Inria transfers its expertise and research results to startups, SMEs
and major groups in fields as diverse as healthcare, transport, energy, communications, security and privacy protection, smart cities and the factory of the future. Inria has also fostered an entrepreneurial culture that has led to the
creation of 120 startups.
Areas of Activity
diseases
(PCP)
(PPI)
population
Methods and data
policies
records (PPI)
Health ICT SMEs
Offer: ORPHAMINE (Data mining platform for Orphan diseases)
http://webloria.loria.fr/~mosmuk/orphamine/
Offer: Shanoir (Sharing NeurOImaging Resources)
http://shanoir.org/ Shanoir (Sharing NeurOImaging Resources) is an open source neuroinformatics platform designed
to share, archive, search and visualize neuroimaging data. It provides a user-friendly secure web access and offers an
intuitive workflow to facilitate the collecting and retrieving of neuroimaging data from multiple sources and a wizzard
to make the completion of metadata easy. Shanoir comes along many features such as anonymization of data, support for multi-centres clinical studies on subjects or group of subjects.
Page 223 of 487
France
Offer: Shanoir (Sharing NeurOImaging Resources)
SOFA is an open-source framework primarily targeted at real-time simulation, with an emphasis on medical simulation. Today, SOFA has a long story, but remains a very active platform and proposes many functionalities.
https://www.sofa-framework.org/
Offer: Examples videos.
There are indeed many available technologies, knw-how and software. To give an overview here is a link to a few
videso, some are in English : ( I might post an updated profile with more information in English) • Paylist : Dispositif
médical, objets connectés, systèmes d'information • Playlist : Smart City & mobility • Playlist : Technologies du Web :
ce réseau de ressources numériques mondial • Playlist : Télécoms du futur • Playlist : Data Analytics : Des données
aux connaissances et à la création de valeur • Playlist : Bio-informatique et outils numériques pour les produits de
santé • Playlist : Modélisation, simulation et calcul intensif • Playlist : Simulation numérique pour la santé, de la cellule à l'humain virtuel
Page 224 of 487
France
Inserm
Organisation Name
Country
France
City
PARIS
Street
101 RUE DE TOLBIAC
Website
Phone
Organisation Type
Person
Name
Gilles Chiocchia
Email
[email protected]
Job Position
Inserm Unit Director
Inserm
http://english.inserm.fr/
Founded in 1964, the French National Institute of Health and Medical Research (Inserm) is a public scientific and
technological institute which operates under the joint authority of the French Ministry of Health and French Ministry
of Research.
As the only French public research institute to focus entirely on human health, in 2008 Inserm took on the
responsibility for the strategic, scientific and operational coordination of biomedical research. This key role as coordinator comes naturally to Inserm thanks to the scientific quality of its teams and its ability to conduct translational research, from the laboratory to the patient’s bed.
The decree adopted in March 2009 will enable Inserm to perform its research missions in the face of the new scientific, health and economic challenges of the 21st century. Scientific monitoring and expertise are now part of the Institute’s official missions.
In early 2008, 9 thematic institutes were created in the light of this new coordination role, in association with Inserm. The aforementioned decree secures a long-term future for them and clearly defines their remit, an inventory of
French research in their field, how this research is to be managed and their objectives.
From the outset, Institute has forged close partnerships with the other public and private research establishments as
well as hospitals to fulfil its missions. 80% of Inserm’s 318 research units are currently set up in university hospitals or cancer research centers. The research campuses of the French National Center for Scientific Research (CNRS),
along with the Pasteur and Curie Institutes, also house Inserm research divisions. With the law on the independence
of universities placing them at the heart of the research policy, they will also be a key partner of Inserm.
In April 2009, national coordination was strengthened by the Alliance nationale pour les sciences de la vie et de la
santé (French National Alliance for Life and Health Sciences), which Inserm co-founded with other research institutes
and the Conférence des présidents d’université (Association of University Presidents). To extend the strategic and programmatic coordination of research to all life and health sciences, the Alliance relies on 10 multi-body thematic institutes jointly overseen by two research institutes (Inserm, CNRS, French Atomatic Energy Commission/CEA or French
National Institute for Agricultural Research/Inra), depending on the research field.
Lastly, Inserm plays a leading role in creating the European Research Area and boosts its standing abroad through
close partnerships (teams and partner laboratories abroad).
Areas of Activity
Page 225 of 487
France
the immune system
EU level
Request: Infection and Inflammation
Our projects are dedicated to be a research Unit focused on fundamental and applied aspects of inflammation (infection, arthritis, sepsis), from induction to resolution. We developped project in strong associationwith several hospitals
of the Groupe Hospitalier “Paris-Ile de France Ouest”; and already connected to numerous Paris-Saclay research
groups. Our actibities include: 1) Molecular understanding of apoptosis and cell stress involved in inflammatory
processes from drosophila to human; 2) Analysis of Phenotypic and Functional differentiation of macrophages, dendritic cells and T cells; 3) Preclinical research and target validation on rats and mice models; 4) Developing a translationnal interface between fundamental and clinical research; 5) Leadership or Participation in patients' cohorts management; 6/ Discovery and development of new biomarkers : genetics, molecular signatures, antibodies, proteins,...
Page 226 of 487
France
INSERM
Organisation Name
Country
France
City
Bagnolet
Street
40 rue Jean Jaurès
Website
Phone
Organisation Type
R&D Institution
Person
Name
Héloïse Verweyen
Email
[email protected]
Job Position
Founded in 1964, the French National Institute of Health and Medical Research (Inserm) is a public scientific and
technological institute which operates under the joint authority of the French Ministry of Health and French Ministry
of Research.
As the only French public research institute to focus entirely on human health, in 2008 Inserm took on the
responsibility for the strategic, scientific and operational coordination of biomedical research. This key role as coordinator comes naturally to Inserm thanks to the scientific quality of its teams and its ability to conduct translational research, from the laboratory to the patient’s bed.
I am responsible for the shared management platform of the UMR of INSERM and Paris Diderot University at the Paris
7 regional delegation
Page 227 of 487
France
INSERM U1034
Organisation Name
Country
France
City
Pessac
Street
Avenue Magellan
Website
http://u1034.bordeaux.inserm.fr
Phone
+33 557891979
Organisation Type
University
Person
Name
Boiron Jean-Michel
Email
[email protected]
Job Position
Responsible Valorisation-Impacts INSERM U1034
The INSERM U1034 laboratory is devoted to understand the molecular mechanisms that control blood vessel development and function. Our strategy is to develop a highly integrative research applying molecular, biochemical and metabolism approaches to ask questions that are both fundamental and applied. Vessel diseases are involved in major
public health relevant chronic disease (AD, Diabetes, Stroke, CV diseases) and are involved in the Aging processes.
We, and others, have lauched two research consortiums focused on vessel diseases, one mainly biological (VIVA-Vascular aging, Pr T Couffinhal) and one with a larger scope (GWAS studies, imagery, clinical studies, in addition to biological studies) : SMART (for SMall ARTeries, Pr S Debette, Inserm Center U897).
We are searching for partners in our domains of interest and participation to H2020 programs.
Areas of Activity
(PCP)
Offer: A complete panel of experts on a bright health challenge
Two consortiums build on various and complementary skills to enhance knowledge and care of vascular diseases
(stroke, CV disease, diabetes, retinopathy, AD, dementia).
From community and patient large cohorts to patient's bedside through bio-informatics, genotyping, cutting-edge
imaging tools, animal models to improve diagnosis, stratification, and management of Small Artery Diseases.
Page 228 of 487
France
Inserm U1163 - Human lymphohematopoiesis Laboratory
Organisation Name
Country
France
City
Paris
Street
24 Boulevard du Montparnasse
Website
Phone
Organisation Type
Other
Person
Name
Isabelle André-Schmutz
Email
[email protected]
Job Position
DR2
The laboratory’s projects focus on studying human lymphohematopoiesis in physiological and pathological context, as
known as hereditary immunodeficiencies, and on the development of innovative strategies for gene and cell therapy.
Regarding the gene transfer strategy, the laboratory has set up 5 phase I/II clinical trials for primary immunodeficiencies. For most ofthese projects, both translational researchand the monitoring ofthe patientare performedwithin the
laboratory or in collaboration with European partners implicated in networks supported by FP7 and H2020 grants).
Beyond the pioneer expertise of Marina Cavazzana’s and Isabelle André-Schmutz team in the field of cell and gene
therapy, they have dedicated their research to the characterization of the early steps of human T and B cell differentiation in the bone marrow and in the thymus.
Thanks to the development of new and complex in vitro and in vivo tools set up in the lab, this work has led to the
identification of a human lymphoid progenitor capable of colonising the thymus after birth and the creation of an artificial thymic niche integrating Notch signalling, able to mimic the very first step of T-cell commitment. This last discovery is being translated toward a clinical trial for the treatment of T-cell immune deficiency following hematopoietic
stem cell transplantation.
Isabelle André-Schmutz and Marina Cavazzana laboratory benefits from numerous national and international collaborations in the field. They have participated as partner, WP leader or PI to several EU-funded networks under FP7, including ERC Regenerative Therapy (PI : MCC), Cell-PID, Genegraft, EUROFANCOLEN, Net4CGD and under H2020 (SCIDNet).
Areas of Activity
diseases
Request: Optimization of conditioning regimen before transplantation of hematopoietic
stem cells or T-cell progenitors in order to favor engraftment in the bone marrow and in
the thymus.
The aim of this project is to find a non-toxic way through antibodies, peptides or proteins to specifically target the
hematopoietic stem cells niche in the bone marrow and the early T cell precursors in the thymic niche. We would like
to conduct these investigations in murine models and to develop in the future a clinical trial in humans.
Page 229 of 487
France
The main activity of the laboratory is focused on hematopoiesis and thympoiesis in mice and humans. The laboratory
have developed a huge expertise in: • Access to human samples such as cord blood, peripheral blood, bone marrow
and mobilized or bone marrow derived hematopoietic stem cells. • T cells progenitors from thymus and derived from
hematopoietic stem cells in culture. • Hematopoietic stem cells differentiation in all lineages both in vitro and in vivo.
• Gene transfer for clinical trials in humans. • NSG humanized mice model and specifically immune differentiation and
reconstitution in vivo.
We are extremely interested in developing a partnership with biologists involved in lymphohematopoiesis projects as
well as chemists or biochemists in academic field or in a private company with the aim of developing new tools for
this specific study.
Page 230 of 487
France
INSERM, US14 - Orphanet
Organisation Name
Country
France
City
Paris
Street
96 rue Didot
Website
www.orpha.net
Phone
0156538150
Organisation Type
R&D Institution
Person
Name
Charlotte Rodwell
Email
[email protected]
Job Position
Partnerships, business development and strategic
communications officer
Orphanet is the reference portal for information on rare diseases and orphan drugs, for all audiences. Orphanet’s aim
is to help improve the diagnosis, care and treatment of patients with rare diseases. Orphanet is highly involved in political and scientific initiatives in the field of rare diseases as coordinator of the EU Joint Action RD-Action on rare diseases (www.rd-action.eu).
Orphanet offers a range of freely accessible services:
• An inventory of rare diseases and a classification of diseases elaborated using existing published expert classifications.
• An encyclopaedia of rare diseases in English and French, progressively translated into the other languages of
the website.
• An inventory of orphan drugs at all stages of development.
• A directory of expert resources, providing information on expert clinics, medical laboratories, ongoing research projects, clinical trials, registries, networks, technological platforms and patient organisations, in the
field of rare diseases, in each of the countries in Orphanet’s consortium.
• An assistance-to-diagnosis tool allowing users to search by signs and symptoms.
• An encyclopaedia of recommendations and guidelines for emergency medical care and anaesthesia.
• A fortnightly newsletter, OrphaNews, which gives an overview of scientific and political current affairs in the
field of rare diseases and orphan drugs, in English and French.
• A collection of thematic reports, the Orphanet Reports Series, focusing on overarching themes, directly downloadable from the website.
Orphanet also makes its datasets available in XML files for research via www.orphadata.org
Areas of Activity
diseases
Methods and data
policies
Offer: Orphanet: providing data and an ontology for rare disease research
Orphanet (www.orpha.net) is the reference portal for information on rare diseases and orphan drugs, for all audiences. Orphanet’s aim is to help improve the diagnosis, care and treatment of patients with rare diseases. Orphanet
Page 231 of 487
France
offers a range of freely accessible services: An inventory of rare diseases and a classification of diseases elaborated
using existing published expert classifications. An encyclopaedia of rare diseases in English and French, progressively
translated into the other languages of the website. An inventory of orphan drugs at all stages of development. A directory of expert resources, providing information on expert clinics, medical laboratories, ongoing research projects,
clinical trials, registries, networks, technological platforms and patient organisations, in the field of rare diseases, in
each of the countries in Orphanet’s consortium. An assistance-to-diagnosis tool allowing users to search by signs and
symptoms. An encyclopaedia of recommendations and guidelines for emergency medical care and anaesthesia. A
fortnightly newsletter, OrphaNews, which gives an overview of scientific and political current affairs in the field of rare
diseases and orphan drugs, in English and French. A collection of thematic reports, the Orphanet Reports Series, focusing on overarching themes, directly downloadable from the website. Orphanet also makes its data available for research purposes, freely for academia, via the platform www.orphadata.org in XML format. It also makes available, ORDO the Orphanet Rare Diseases Ontology (via Orphadata, the EBI Ontologies Look-up Service and Bioportal) which
provides a structured vocabulary for rare diseases capturing relationships between diseases, genes and other relevant features which will form a useful resource for the computational analysis of rare diseases. It integrates a nosology (classification of rare diseases), relationships (gene-disease relations, epiemological data) and connections with
other terminologies (MeSH, UMLS, MedDRA),databases (OMIM, UniProtKB, HGNC, ensembl, Reactome, IUPHAR, Geantlas) or classifications (ICD10). Orphanet is part of the ELIXIR ERIC French node via its affiliation with the Institut
français de bioinformatique.
Orphanet is the most exhaustive information resource on rare diseases, based on a nomenclature of rare diseases
constructed from the clinical point of view. Each disease is annotated with genetic, epidemiological and phenotypic information and is cross-referenced with other resources and nomenclatures. Orphanet also makes this data available
for research purposes, freely for academia, via the platform www.orphadata.org in XML format. It also makes available, ORDO the Orphanet Rare Diseases Ontology (via Orphadata, the EBI Ontologies Look-up Service and Bioportal)
which provides a structured vocabulary for rare diseases capturing relationships between diseases, genes and other
relevant features which will form a useful resource for the computational analysis of rare diseases. It integrates a
nosology (classification of rare diseases), relationships (gene-disease relations, epiemological data) and connections
with other terminologies (MeSH, UMLS, MedDRA),databases (OMIM, UniProtKB, HGNC, ensembl, Reactome, IUPHAR,
Geantlas) or classifications (ICD10).
MARKET APPLICATION
Data from Orphanet can be used to identify therapeutic hypotheses for R&D into therapies for rare diseases.
Academic partnership to improve integration of ontologies, interoperability of databases to improve research on rare
diseases and advance towards IRDIRC goals for rare diseases diagnostics and therapeutics.
Page 232 of 487
Spain
Inspiralia Tecnologia Avanzada SL
Organisation Name
Country
Spain
City
MADRID
Street
Calle La Estrada 10B
Website
www.inspiralia.com
Phone
+34 91 417 04 57
Organisation Type
SME
Person
Name
Francesco Di Martino
Email
[email protected]
Job Position
Innovation process Manager
Inspiralia is a New Product Development company based in Madrid and founded in 2005. It is a successful NPD
company which offers a 360º service that covers concept generation, innovation strategy, technology and product development, finishing with Market launch.
Areas of Activity
the immune system
EU level
Preventing disease
Initiative
Methods and data
policies
Health ICT SMEs
(PCP)
(PPI)
Offer: H2020 collaboration
If you are you looking for public funding sources to accelerate your new product development, Inspiralia can be of
help. In line with our commitment to accompany our clients throughout the whole new product development cycle, we
have developed excellent skills in acquiring the necessary funding for our customers in order to keep their development works on track. Our funding specialists wisely select the relevant publicly available funding source to match
your individual funding requirements and our skilled grant funding authors prepare professional proposals that are
submitted in competitive calls to compete for funding. Throughout the whole application process as well as the project execution we carefully monitor the financial and administrative project flow assuring all requirements of the funding body are satisfied. And if you wish our product developers and engineers to accompany your team throughout the
Page 233 of 487
Spain
technical execution of the project or you need commercial guidance or new partners and clients we can provide you
with the necessary support just when needed. Our long experience in proposal writing based on a solid writing
methodology, our pan-European contacts network combined with multiple know-how in different technological areas,
business intelligence as well as a mixture of professionalism and energy enable us to work each year with some 100
satisfied customers that successfully profit from public funding. The H2020 SME Instrument is particularly attractive
for small and medium sized enterprises in order to bridge the gap from their research and development efforts to the
market. Whether your product is at an early development stage and needs to go through a feasibility assessment or
you need financial support for the scale-up of your product we point you in the right direction. Our teams work closely
with you in order to maximise your success chances by selecting the right calls, designing the right commercial strategy, sharing ideas on how to improve the features of your current prototype, identifying the best partners and of
course putting together a professional business plan to help you visualise your new product development and attract
the necessary funding. At Inspiralia we do not only prepare proposals, we do our best to make sure new products happen.
Page 234 of 487
France
Institut Carnot CALYM
Organisation Name
Country
France
City
Pierre-Benite
Street
Secteur St Eugénie, Pavillon 6E
Website
www.calym.org
Phone
Organisation Type
R&D Institution
Person
Name
Stefanie Wojciech
Email
[email protected]
Job Position
Manager Development Europe
The CALYM Carnot institute aims to accelerate innovation and its transfer in the field of lymphoma, 6th cancer worldwide and the first blood cancer. The institute, with no international equivalent, has a unique R&D offering, from new
target identification to large international phase 3 clinical trials.
The “Carnot institute” is a label of excellence awarded by the French Ministry of Research to public/parapublic research consortia with a strong track record of partnering research. They receive state funding to improve their scientific and technological competences and conduct a proactive policy on partnership research for the benefit of the
socio-economic world.
CALYM brings together 11 research teams specialized in the lymphoma field, and hospitals for clinical and translational research, federated around LYSA (The Lymphoma Study Association) cooperative group, as well as their operational
structure to carry clinical studies, LYSARC.
CALYM research activities are structured into 4 R&D pillars:
1-Research and validation of biological targets and in vitro/in vivo lymphoma models
2-Identification of blood and tissue biomarkers
3-Characterization of early pharmacodynamic signs of activity
4-Optimisation and exploitation of tools, process and platforms in collaboration with clinical research
Our multidisciplinary expertise in the lymphoma field requires a tight interface between researchers and clinicians.
LYSA’s expertise in clinical research ranges from early phase studies of drug development to leading large international phase 3 collaborations. LYSA gathers a network of 750 lymphoma specialists, hematologists, oncologists, pathologists, biologists, nuclear medicine specialists, radiologists in 150 hospitals. LYSA is also conducting numerous studies
and trials aimed to evaluate the role of new imaging tools, in particular PET, in facilitating treatment adaptation based
on the efficacy observed in a given individual and also anatomical-pathological or biological studies.
LYSARC implements clinical, biological and epidemiological studies approved by the LYSA Scientific Advisory Committee. LYSARC covers the clinical research of phase 1 to 3 trials both in France and internationally with a team of clinical
project management, data management, biostatistics, regulatory affairs, pharmacovigilance, quality assurance, platforms of pathology, imaging and biological sample collections.
CALYM research teams have expertise in the physiology of normal and pathological lymphoid tissue. They are specialized in the study of signaling pathway such as pathways involving protein kinases, apoptosis and oncogenetic pathways (transcription, epigenetics, non-coding RNAs). They search for the genetic alterations associated with lymphoid
malignancies, they investigate the host and tumor crosstalk within the tumor niche through molecular and functional
Page 235 of 487
France
approaches, they study the alterations of innate immunity associated with cancer and the ways to circumvent them
using biotherapies. CALYM research relies on imaging platforms, large-scale flow cytometry platform, qualified omics
platforms such as large scale sequencing and transcriptomics.
Areas of Activity
diseases
Methods and data
Offer: Lymphoma expertise, from non-clinical to phase III clinical studies
CALYM is focused on partnership research. The institute is certified ISO 9001:2008 for the management and monitoring of its partnering research activities. We are looking forward to developing collaborations with the aim of answering
unmet medical needs in the field of lymphoma: - Understanding of lymphomas - Tests of drug candidates - Preclinical
research - Clinical development, from phase 1 to 3 - …
Clinical trials that evaluate new active treatments in lymphoma, alone or in combination. Evaluating the role of imaging tools, in particular PET. Identification and validation of tissue and blood biomarkers for diagnostics, orientation of
the therapeutic decision or prediction of tumor response. Clinical, biological, anatomical-pathological, and imaging
databases. Unique cryopreserved viable cell collection. Large T cell lymphoma frozen tumor collection.
Page 236 of 487
France
Institut du Cerveau et de la Moelle Epinière
Organisation Name
Country
France
City
Paris
Street
47 bd de l'Hopital
Website
http://icm-institute.org
Phone
+33157274745
Organisation Type
R&D Institution
Person
Name
Michel Thiebaut de Schotten
Email
[email protected]
Job Position
Associate Professor CNRS
The Institut du Cerveau et de la Moelle épinière – ICM (Brain & Spine Institute) – is an international brain and spinal
cord research center whose innovative concept and structure make it the only institute of its kind in the world. The
ICM brings patients, doctors and researchers together with the aim of rapidly develop treatments for disorders of the
nervous system and enable patients to benefit from them as quickly as possible.
Areas of Activity
diseases
Offer: Research program on population stratification and rewiring of the brain
We're offering a new cutting edge research program on population stratification and rewiring of the brain. We're looking for (mainly pharmaceutical) company who will support us financially, and advise us professionally on setting up a
start up build upon our results. I am head of a group entitled Brain Connectivity and Behaviour
(http://www.brainconnectivitybehaviour.eu). Our actual project is to identify brain connectivity phenotype related to
different functioning of the brain (stratification of the population) and study their impact on brain recovery after a
stroke or surgery. (you can read some of our work on that matter in Thiebaut de Schotten et al. Nature Neuroscience
2011, Cerebral Cortex 2014, Forkel et al Brain 2015). We recently extended our research on rewiring the brain (grant
under submission) combining the exploration of the mechanisms of axonal regeneration in other species and its interaction with gene specific inhibitor drugs (e.g. : nutlin3). We will be delighted collaborating with the industry on that
matter to boost our research effort by supporting us financially and speeding up the diffusion of the results and clinical translation.
Page 237 of 487
France
Institut du Cerveau et de la Moelle épinière (ICM)
Organisation Name
Country
France
City
Paris
Street
47 boulevard de l'Hôpital
Website
Phone
Organisation Type
R&D Institution
Person
Name
Iwona Jablonska
Email
[email protected]
Job Position
Head of European affairs
The Institut du Cerveau et de la Moelle épinière – ICM (Brain & Spine Institute) – is an international brain and spinal
cord research center whose innovative concept and structure make it the only institute of its kind in the world. The
ICM brings patients, doctors and researchers together with the aim of rapidly develop treatments for disorders of the
nervous system and enable patients to benefit from them as quickly as possible.
The best scientists from all backgrounds and countries come together at the Institute to perform leading-edge research in this area. To help researchers advance in their work and give patients tangible reasons for hope, we must all
play a role: government agencies, corporate actors and individuals.
The research teams are independent, but allied in Transversal Research Programs that favour the mutualisation of
competencies.
Basic research
Basic or pure research focuses on the foundations of a given discipline. It includes scientific research undertaken without an established economic purpose. Basic research is, however, essential because it helps us identify and understand how the body’s various systems function.
Clinical research
People are the central focus of this approach, still too rarely undertaken. Subjects with or without a health condition
participate in research protocols to advance knowledge of a disease or therapy.
Translational research
This research provides a crucial link between basic and clinical research. The translational approach helps patients
benefit more quickly from innovations in diagnosis and treatment. It constitutes the basis of the research undertaken
at the ICM.
By bringing all three activities into the organization, driven by a shared purpose, we accelerate the discovery of new
treatments.
4 Scientific Domains:
•
•
•
•
Molecular and Cellular Neuroscience
Integrated Neurophysiology
Cognitive Neuroscience
Clinical and Translational Neuroscience
Transversal Scientific thematics:
Page 238 of 487
France
•
•
•
•
•
•
•
•
Neurogenetics
Neuroimmunology
Stem Cell and Repair
Motor Neuron: from the cell body to the synapse
Investigating subcellular organelles in NDG
Propagation in brain proteinopathies
Analysis of multimodal data
Methodologies to treat rare neurological diseases
Areas of Activity
diseases
EU level
Preventing disease
young
population
Methods and data
policies
Page 239 of 487
France
Institut Pasteur
Organisation Name
Country
France
City
Paris
Street
25-28 Rue du Dr Roux
Website
Phone
Organisation Type
R&D Institution
Person
Name
Darragh Duffy
Email
[email protected]
Job Position
The Institut Pasteur is an international research institute of excellence with a mission to advance science, medicine
and public health. The Institut Pasteur is a private, non-profit foundation with recognized charitable status entrusted
with four core missions of public interest – Research, Education, public health, and Valorisation of scientific research
via technology transfer and industrial partnerships. Institut Pasteur scientists address many vital questions such as:
What are the basic properties of living organisms? How do hosts, vectors and pathogens interact with each other?
What are the physiological and pathological mechanisms associated with infectious and non-infectious diseases? How
do we devise novel anti-microbial strategies? These issues are addressed by around 2,400 people working side by
side on the Paris campus. This includes 1,500 scientists (researchers, engineers, students), within 11 departments
and 130 research units. This major hub of activity facilitates collaboration between colleagues in the different laboratories and fosters interdisciplinary approaches and transversal research programs.
Areas of Activity
the immune system
EU level
Methods and data
policies
Preventing disease
Offer: Milieu Intérieur: multi-disciplinary consortium dissecting the interplay between genetics, environment and impact on a healthy immune response
The Milieu Intérieur project is an ambitious population-based study coordinated by the Institut Pasteur, Paris. The objective is to dissecte the interplay between genetics and environment and their impact on the immune system. This
project is named after the French physiologist Claude Bernard’s concept of milieu intérieur and aims to establish the
determinants of a healthy immune response by identifying genetic and environmental factors that contribute to the
Page 240 of 487
France
observed heterogeneity of immune responses. Restoring the ‘personal’ in medical care is a major challenge for medicine, and the driving vision of the project.
A 1000 healthy donor cohort stratified by age and gender with - full lifestyle, medical history & dietary information genetically characterised - standardized whole blood immune response to bacteria, viruses, and fungi - enterotype
sampling - extensive sample warehouse & cellular biobank collection - parrallel disease based studies
MARKET APPLICATION
- Therapeutic and prophylactic vaccines (especially with respect to adjuvant choice for an aging population); - Drug
Treatment optimization while minimizing side effects - Drug adverse effect prediction - Development and implementation of pro- and pre-biotics.
Industrial, SME, or clinical partners to advance our findings into clinical markets Clinical/Experimental investigators interested in healthy cohorts for disease based studies Other human population cohorts for harmonization and integration of large studies
Page 241 of 487
France
Institut Pasteur
Organisation Name
Country
France
City
Paris
Street
25 rue du Dr Roux
Website
Phone
Organisation Type
R&D Institution
Person
Name
Myriam LY- LE MOAL
Email
[email protected]
Job Position
The Institut Pasteur is an international research institute of excellence with a mission to advance science, medicine
and public health. The Institut Pasteur is a private, non-profit foundation with recognized charitable status entrusted
with four core missions of public interest – Research, Education, public health, and Valorisation of scientific research
via technology transfer and industrial partnerships. Institut Pasteur scientists address many vital questions such as:
What are the basic properties of living organisms? How do hosts, vectors and pathogens interact with each other?
What are the physiological and pathological mechanisms associated with infectious and non-infectious diseases? How
do we devise novel anti-microbial strategies? These issues are addressed by around 2,400 people working side by
side on the Paris campus. This includes 1,500 scientists (researchers, engineers, students), within 11 departments
and 130 research units. This major hub of activity facilitates collaboration between colleagues in the different laboratories and fosters interdisciplinary approaches and transversal research programs.
More information: http://www.pasteur.fr/fr/institut-pasteur/qui-sommes-nous#sthash.nMB8T35A.dpuf
Areas of Activity
the immune system
Page 242 of 487
United Kingdom
Organisation Name
Country
United Kingdom
City
Bristol
Street
Coldharbour Lane
Website
http://www.biosensingtech.co.uk/
Phone
+44 117 3282472
Organisation Type
University
Person
Name
Janice Kiely
Email
[email protected]
Job Position
Director of the Institute of
Bio-Sensing Technology
The Institute of Bio-Sensing Technology (IBST), based at the University of the West of England, Bristol, UK, has an international reputation in research and development relating to bio-sensing technology, particularly focussing on
point-of-care diagnostics. IBST has expertise across the relevant disciplines of biomarker discovery, sensor development, instrumentation and signal processing, data analysis and sensor evaluation with clinicians and industry-based
end-users.
Areas of Activity
(PCP)
(PPI)
Request: New concepts in patient stratification – biosensors for identifying patient groups
We have biosensor technologies that can be developed for home/personalised testing and monitoring which could be
used to identify particular treatments specific for an individual. Examples of biosensor tests that could be developed
include rapid drug testing or detection of specific biomarkers. We have experience in non-invasive measurements
such as biomarker testing in saliva and urine testing. The technologies allow rapid (less than 5 minute) measurements and can detect sub nanogram concentrations of target.
We have biosensor technologies that can be developed for home/personalised testing which can be used for monitoring particular biomarkers related to chronic disease which would be used to assess the effectiveness of therapeutic interventions. We have experience in non-invasive measurements such as saliva for monitoring biomarkers associated
with COPD. The technologies allow rapid (less than 5 minute) measurements and can detect sub nanogram concentrations of target.
Page 243 of 487
United Kingdom
We have biosensor technologies that can be developed for home/personalised testing which can be used to monitor
particular biomarkers that could be used to assess the effectiveness of a healthcare intervention. We have experience
in non-invasive measurements of biomarkers in saliva or urine for the monitoring the health of patients with COPD or
chronic infections. The technologies allow rapid (less than 5 minute) measurements and can detect sub nanogram
concentrations of target.
We have developed a novel technology of monitoring changes in cells based on impedance spectroscopy. Using a
sensing system that is external to the cell growth vessel we have produce characteristic finger print patterns that
show cell changes due to toxicological or physiological challenges that result in cell death of cell differention. This
“non-invasive” approach to cell monitoring could be valuable in assessing the quality of cells be produced for regenerative medicine applications.
We have biosensor technologies that can be developed for home/personalised testing. These could be used as part of
developing an eHealth platform for patients. We have experience in non-invasive measurements of biomarkers in saliva or urine for the monitoring the health of patients with COPD or chronic infections. The technologies allow rapid
(less than 5 minute) measurements and can detect sub nanogram concentrations of target. The biosensor system can
be used as a model to evaluate connectivity of self-testing devices.
Offer: Standardisation of procedures for in-vitro diagnostics
We have experience in developing biosensor technology of in-vitro diagnostics, especially point of care testing. Standardisation of protocols is important to us in terms of developing connected devices that will form part of the Internet
of Things. We would like to be part of a consortium developing these standards and help with developing standards
for “stand alone” devices that could be developed by small companies or research centres across Europe. In the UK
we are connected with Academic Health Science Networks and Medilnk South West
Page 244 of 487
United Kingdom
Organisation Name
Country
United Kingdom
City
Bristol
Street
Coldharbour Lane
Website
http://www.biosensingtech.co.uk/
Phone
+44 117 3282472
Organisation Type
University
Person
Name
Richard Luxton
Email
[email protected]
Job Position
The Institute of Bio-Sensing Technology (IBST), the first of its type in the UK, aims to develop academic/industrial partnerships to address the technological challenges posed by each of these sectors - from the development of novel
technology for detection and measurement of biological systems to the integration of biological systems into novel
sensing technology.
Areas of Activity
(PCP)
Offer: New concepts in patient stratification – biosensors for identifying patient groups
We have biosensor technologies that can be developed for home/personalised testing and monitoring which could be
used to identify particular treatments specific for an individual. Examples of biosensor tests that could be developed
include rapid drug testing or detection of specific biomarkers. We have experience in non-invasive measurements
such as biomarker testing in saliva and urine testing. The technologies allow rapid (less than 5 minute) measurements and can detect sub nanogram concentrations of target.
We have biosensor technologies that can be developed for home/personalised testing which can be used for monitoring particular biomarkers related to chronic disease which would be used to assess the effectiveness of therapeutic interventions. We have experience in non-invasive measurements such as saliva for monitoring biomarkers associated
with COPD. The technologies allow rapid (less than 5 minute) measurements and can detect sub nanogram concentrations of target.
We have biosensor technologies that can be developed for home/personalised testing which can be used to monitor
particular biomarkers that could be used to assess the effectiveness of a healthcare intervention. We have experience
in non-invasive measurements of biomarkers in saliva or urine for the monitoring the health of patients with COPD or
Page 245 of 487
United Kingdom
chronic infections. The technologies allow rapid (less than 5 minute) measurements and can detect sub nanogram
concentrations of target.
We have developed a novel technology of monitoring changes in cells based on impedance spectroscopy. Using a
sensing system that is external to the cell growth vessel we have produce characteristic finger print patterns that
show cell changes due to toxicological or physiological challenges that result in cell death of cell differention. This
“non-invasive” approach to cell monitoring could be valuable in assessing the quality of cells be produced for regenerative medicine applications.
We have biosensor technologies that can be developed for home/personalised testing. These could be used as part of
developing an eHealth platform for patients. We have experience in non-invasive measurements of biomarkers in saliva or urine for the monitoring the health of patients with COPD or chronic infections. The technologies allow rapid
(less than 5 minute) measurements and can detect sub nanogram concentrations of target. The biosensor system can
be used as a model to evaluate connectivity of self-testing devices.
Request: Standardisation of procedures for in-vitro diagnostics
We have experience in developing biosensor technology of in-vitro diagnostics, especially point of care testing. Standardisation of protocols is important to us in terms of developing connected devices that will form part of the Internet
of Things. We would like to be part of a consortium developing these standards and help with developing standards
for “stand alone” devices that could be developed by small companies or research centres across Europe. In the UK
we are connected with Academic Health Science Networks and Medilnk South West
Page 246 of 487
France
Institute of Cardiometabolism and Nutrition (ICAN)
Organisation Name
Country
France
City
PARIS
Street
47-83 Boulevard de l'Hôpital
Website
http://www.ican-institute.org/
Phone
+33673908142
Organisation Type
R&D Institution
Person
Name
Stephane COMMANS
Email
[email protected]
Job Position
Projects & Partnerships Portfolio Manager
The Institute of Cardiometabolism and Nutrition (ICAN) is an excellence research centre created in 2011 to accelerate
basic research findings directly to care of patients suffering from cardiovascular and metabolic pathologies. ICAN was
created in response to a French government call for projects to bridge together university basic research with hospital
clinical research. The founding members of ICAN are Assistance Publique des Hôpitaux de Paris (AP-HP), University
Pierre and Marie Curie (UMPC) and INSERM.
The overall objective of the ICAN is to prevent, predict, innovate and develop personalized medicine for the diagnostic, care and treatment of patients affected with cardiometabolic diseases (CMD).
The research performed at ICAN benefits from the complementary expertise of internationally recognized research
centres (14 basic research teams, >120 researchers), 5 clinical units in Cardiology, Endocrinology, Metabolism & Nutrition – gathered under the umbrella of the “Heart-Metabolism Division” (> 100 MDs and 650 paramedics) who have
built a common vision and unique identity by promoting interdisciplinary as the main scientific drive.
ICAN has put together a fully integrated state-of-the-art clinical dataset and biobank to study CMDs progression and
decompensation with over 2000 individual cardiometabolic phenotypes (using the integrated personal omics profiling
or iPOP including biomedical Imaging), ranging from healthy individuals to terminally ill-patients with organ failure
(heart, pancreas and/or liver), with over several thousand of clinical variables. This constitutes a unique phenotype
and data repository in Europe for data mining and research to understand CMDs progression and test novel biomarkers (mainly metabolites and imaging biomarkers), not only for internal use but also for both public and private partnerships.
To solve the technical challenges of analysing these huge amount of data, ICAN has developed novel research and analytical tools through its 5 clinical & technology platforms (i.e. Core facilities) in order to translate this scientific findings into Innovative Therapy and Care Management.
ICAN is focussing on the major unmet medical needs in chronic CMDs by addressing Metabolic diseases progression &
complications, Vulnerable patients and Heart Diseases/Failure challenges. In order to synergize across these focussed
diseases areas and provide opportunities for disease stratification and personalized medicine, 4 common molecular &
research denominators have been put forward (Tissue Damage & Tissue Repair – Personalised “Omics” – Personalized
Care & Epidemiology – Behavior / environment & Host Biology).
Inside the 4 common molecular & research denominators previously described, ICAN has identified in 2014 fast-track
programs which should deliver novel scientific paradigms and their resulting societal impact in the short / mid-term (2
to 4 years) using the available scientific strengths and platforms within the ICAN scientific community, available for
co-operation:
Page 247 of 487
France
- Tissue Damage & Tissue Repair: Role of fibrotic micro-environment in CMD stage of progression – from biomarkers to
innovative therapy
- Personalized “Omics”: Genetic cardiomyopathies – “disease in a dish” a translational research paradigm
- Personalized care & epidemiology: Novel Patient pathways in CMDs breaking medical compartmentalization
- Behavior / Environment & Host Biology: Gut microbiota impact on CMDs – a therapeutic paradigm shift ?
Areas of Activity
Methods and data
population
Offer: Translational research towards innovative personalized medicine for cardiometabolic diseases
The overall objective of the ICAN is to prevent, predict, innovate and develop personalized medicine for the diagnostic, care and treatment of patients affected with cardiometabolic diseases (CMD). The research performed at ICAN
benefits from the complementary expertise of internationally recognized research centres (14 basic research teams,
>120 researchers), 5 clinical units in Cardiology, Endocrinology, Metabolism & Nutrition – gathered under the umbrella of the “Heart-Metabolism Division” (> 100 MDs and 650 paramedics) who have built a common vision and unique
identity by promoting interdisciplinary as the main scientific drive.
ICAN has put together a fully integrated state-of-the-art clinical dataset and biobank to study CMDs progression and
decompensation with over 2000 individual common cardiometabolic phenotypes (using the integrated personal omics
profiling or iPOP including biomedical Imaging) ranging from healthy individuals to terminally ill-patients with organ
failure (heart, pancreas and/or liver), with over several thousand of clinical variables. This includes clinical cohorts on
bariatric surgery (BAR-ICAN), liver diseases (FIFA-EpoS), vulnerable plaques (APPROACH-ACS) and heart failure
(MYOCARD-ICAN) as well as the METACARDIS cohort (http://www.metacardis.net). To solve the technical challenges of
analysing these huge amount of data, ICAN has developed novel research and analytical tools through its 6 clinical &
technology platforms (i.e. Core facilities) in order to translate this scientific findings into Innovative Therapy and Care
Management: - ICAN-Investigation, a clinical platform dedicated to patient recruitment and phenotyping - BIO-ICAN, a
platform collecting, processing and storing bioresources - ICANalytic, an analytical platform focussing on biomarker
identification (specialized in lipidomics, metabolomics, flow cytometry and metagenomics in link with INRA) - ICANIMAGING, a core lab dedicated to novel imaging technologies as an alternative to surgical biopsy - PreclinICAN, a platform dedicated to cardiometabolic preclinical model systems including rodent models and iPS cellular models using
genomic editing - IntegrOMICs, a bioinformatics platform dedicated to high-dimensional biomedical data integration
and data mining to provide novel predictors, signatures and patients stratification In order to provide opportunities for
disease stratification and personalized medicine, 4 common molecular & research denominators have been put forward (Tissue Damage & Tissue Repair – Personalised “Omics” – Personalized Care & Epidemiology – Behavior / environment & Host Biology). Inside these 4 common molecular & research denominators, ICAN has identified in 2014
fast-track programs which should deliver novel scientific paradigms and their resulting societal impact in the short /
mid-term (2 to 4 years) using the available scientific strengths and platforms within the ICAN scientific community,
available for co-operation: - Tissue Damage & Tissue Repair: Role of fibrotic micro-environment in CMD stage of progression – from biomarkers to innovative therapy - Personalized “Omics”: Genetic cardiomyopathies – “disease in a
dish” a translational research paradigm - Personalized care & epidemiology: Novel Patient pathways in CMDs breaking
Page 248 of 487
France
medical compartmentalization - Behavior / Environment & Host Biology: Gut microbiota impact on CMDs – a therapeutic paradigm shift ?
MARKET APPLICATION
- Wellbeing and healthy ageing - metabolic diseases (diabetes, obesity, NASH) - cardiovascular diseases (atrial fibrillation, acute coronary syndrome and heart failure)
- Complementary Expertise in clinical research and integrated personal omics profiling and phenotyping - Novel tools/
methods for development of personalised medecine in cardiometabolic diseases (including eHealth and IoT)
Page 249 of 487
Czech Republic
Institute of Experimental Medicine - Academy of Sciences
Czech Republic
Organisation Name
Country
Czech Republic
City
Prague
Street
Videnska 1083
Website
www.iem.cas.cz
Phone
+420 296 443 633
Organisation Type
R&D Institution
Person
Name
George Sakellaris
Email
[email protected]
Job Position
International Cooperation
The Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, is the leading institution in the Czech Republic for biomedical research, particularly in cell biology and pathology, neurobiology, neurophysiology, neuropathology, developmental toxicology and teratology, molecular epidemiology, molecular pharmacology, immunopharmacology, cancer research, molecular embryology, stem cells and nervous tissue regeneration. The
Institute is an internationally recognized center in these fields, and as such it was selected as an EU Center of Excellence (MEDIPRA).
www.iem.cas.cz
Areas of Activity
Methods and data
policies
records (PPI)
Page 250 of 487
Croatia
Institute of Public Health for the Osijek-Baranya County
Organisation Name
Country
Croatia
City
Osijek
Street
Drinska 8
Website
www.zzjzosijek.hr
Phone
+38531225724
Organisation Type
Person
Name
Dario Brdaric
Email
[email protected]
Job Position
Environmental Public Health
Professional
Institute of Public Health for the Osijek-Baranya County is the biggest public health research institution in eastern
Croatia. It has a wide spectrum of expertise in epidemiology, environmental health, pest control, clinical microbiology,
school medicine, general public health and addiction prevention. Institute was established in 1925. The institute collaborates with national Ministries, Universities, NGOs and international organizations.
Our experts were involved in some international projects with EU and WHO, focused on implementation of Regional
Priority Goals of WHO Parma Declaration commitments and in cancer and regenerative medical research by integration of cross-border resources between Croatia and Hungary.
Currently there are 160 employees (epidemiologists, microbiologists, public health specialists, school medicine specialists, environmental public health professionals, biologists, molecular biologists, toxicologists, food technology engineers etc.). Most of the scientists with PhD degrees are involved at the medical universities as lecturers.
Areas of Activity
EU level
Preventing disease
Initiative
Methods and data
policies
records (PPI)
Offer: Institute’s expertise
• Preventive health protection of children and young people, especially in primary and secondary schools and colleges, monitors, examines, evaluates and reports on the health needs and functional disability of the elderly and provide
health measures • Collects and analyzes statistical reports • Evaluates the health status of the population • Provides
hygienic and epidemiological protection with epidemiological analysis of the situation and supervises the implementa-
Page 251 of 487
Croatia
tion of mandatory vaccination • Implements the measures and activities for prevention, early detection and drug
abuse • Monitors the implementation of pest control measures and implements preventive epidemic procedures •
Performs microbiological activities • Monitors drinking water, bathing water, surface and waste water, water supply
systems and food hygiene • Performs environmental health analysis and programs in emergency situations • Performs environmental protection measures • Evaluates the effects of the environment on the health status of the population • Participates in planning, proposals and implementation of preventive measures in early detection and suppression of mass chronic diseases • Organizes mandatory vaccination at the primary level of health activities • Takes
part in theoretical and practical training of health professionals • Carries out scientific researches • Provides implementation of international health policies
Request: Managing of bacterial resistance to antibiotics in real time
Determining the cause of the infectious disease in different samples is a standard practice in microbiological labs. The
aim is to identify causes and apply the most effective antibiotics as soon as possible. Processing of a sample takes
time, depending on the technology. In the meantime, if so required by circumstances, physicians administer antibiotics according to their experience. The consequence is often failure of first-hand antibiotic therapy, development of
resistance to antibiotics, further deterioration of health (not only elderly people, however mostly them) and financial
loss for the community. Currently, there is no specialized IT solution (software) capable to provide real-time information to physicians about what the most probable cause of the bacterial infection was during some period in samples
(urine, throat etc.). Sensitivity to antibiotics, its trend and the relationship of bacteria - virus as the cause is also unknown. Such software has not yet been developed. Microbiological analysis and data are already performed in microbiological labs, data are stored in an IT format and there are needs to further customize the hardware and software
for real-time data analysis. The processed data would be available at all times to all interested health professionals,
free of charge on the web site and secure protected. The project duration would be 36 months. The project partners
should commit to maintain and further build on this software for at least 5 years after the completion of the project.
The developed software would be free to use for other health care institutions, and also for anyone who met the criteria of professional and IT connectivity. Target groups would be physicians, the health care institutions, the ministries,
health insurance agencies, manufacturers and distributors of antibiotics, the general population, and the mass media.
Providing real-time information about pathogens and their antibiotic resistance would change and further improve the
use of antibiotics. Antibiotics would no longer be given to patients based on experience only, but based on current information as well. It would reduce unnecessary and improper use of antibiotics which would then have an impact on
the development of resistance to antibiotics. Also, it would directly reduce not only the price and length of treatment,
but also reduce the indirect costs associated with illness (length of labour absenteeism,...). So such presentation and
processing of microbiological data is of great importance for the quality of education for the medical staff and other
professionals who directly or indirectly work in health care.
Page 252 of 487
Belarus
Institute of Radiobiology of the National Academy of Sciences of Belarus
Organisation Name
Country
Belarus
City
Gomel
Street
Fedyuninskogo 4
Website
www.irb.basnet.by
Phone
+375232570706
Organisation Type
R&D Institution
Person
Name
Ihar Cheshyk
Email
[email protected]
Job Position
Director
Radiobiology Institute carries out scientific and scientific-organizational activities in accordance with the following areas of research:
- Assess and forecast long-term medical and biological effects of ionizing radiation;
- The study of the combined effect on the body of radiation and non-radiation factors, including electromagnetic radiation, the development of protective measures;
- Assessment of the impact of radioactive contamination on the environment, plants and animals, the development of
safe environmental management, radio-ecological monitoring;
- Study of the processes of radionuclides into the food chain in a contamination including transuranic elements, receipts and their accumulation in the body and forming doses to provide methods to influence these processes in order
to reduce adverse effects.
Areas of Activity
EU level
Methods and data
policies
population
Offer: Comparing the effectiveness of existing healthcare interventions in the adult population
Effective health care and prevention may be improved by additional evidence as to the most effective health interventions.
Randomised controlled trials, pragmatic trials, observational studies, large scale databases and meta-analyses may
be considered for this topic. Where relevant the study population should address gender as well as socio-economic
differentials in health and/or any other factors that affect health equity.
MARKET APPLICATION
According to the chosen theme, we can get the funding under STI International Cooperation Network for Eastern Partnership Countries (IncoNet EaP) "Twinning Grants: IncoNet EaP supports Clustering of Scientific Projects and Institu-
Page 253 of 487
Belarus
tions" for joint work on the preparation of applications for participation in the program "Horizon 2020" (Health, demographic change and wellbeing)
University, Research Institute, SME, Company / EU
Page 254 of 487
Portugal
Instituto Pedro Nunes (Las) and Ageing@Coimbra
Organisation Name
Country
Portugal
City
Coimbra
Street
Rua Pedro Nunes
Website
http://www.ipn.pt/laboratorio/LAS
Phone
239 700 933
Organisation Type
R&D Institution
Person
Name
António Cunha
Email
[email protected]
Job Position
Executive Director
Founded in 1991 as an initiative by the University of Coimbra, Instituto Pedro Nunes (IPN) – Association for Innovation
and Development in Science and Technology – is a non-profit private institution for public benefit. “It promotes innovation and the transfer of technology, establishing the interface between the scientific and technological system and
the production sector.”
Instituto Pedro Nunes (IPN) automation lab has a long experience in the areas of: unobtrusive monitoring using wireless sensor networks and vision-based systems; electrophysiological sensor integration in smart devices; activity
recognition and behavior analysis; and development of ICT based platforms for Health & Quality of Life. Therefore, we
are open to take over development tasks, and/or provide some technological tools/ frameworks if appropriated.
IPN is one of the founders of the Ageing@Coimbra (http://www.ageingcoimbra.pt) reference site of the European Innovation Partnership on Active and Healthy Ageing (EIP-AHA). As an EIP-AHA reference site it aims to develop a program
of activities contributing to improve the functional independence of old people and to increase, by 2020, two years of
active healthy life of the European citizens.
IPN is member of InnoStars region from EIT Health (http://www.eithealth.eu), a consortium of more than 50 core partners (and in addition 90 associate organisations) of leading businesses, research centres and universities from 9 EU
countries.
Furthermore, IPN team has vast experience in technology transfer processes, transforming research technologies in
market products, and also in coordinate multidisciplinary teams. Also, IPN has been responsible for several initiatives
in Portugal and EU related with Ambient Assisted Living and ICT for Health and Quality of Life, and has participated in
projects dealing with aspects of system design and architectures and the development large scale ICT based platforms for Health & Quality of Life. For a detailed overview of project’s portfolio and team involved please refer to
(http://las.ipn.pt/).
We have a solid track record in European and National projects, with results already marketed by the firms we work
with. Our “secret sauce” is a solid university/enterprise relationship, professional management teams and combining
R&D competences with business skills.
Areas of Activity
(PCP)
(PPI)
Page 255 of 487
Portugal
Offer: eVida – Digital Social Innovation Platform
The aim of the project is provide the infrastructure to stimulate the development of Digital Social Innovation vectors
focused in the challenges imposed by ageing population - societal challenge – with particular focus on social care
providers needs and associated community, which face trials in a daily basis. We propose to integrate available technologies to improve an ecosystem of products and services, promoting digital social innovation (e.g. holistic community involvement). We aim to bring together collection, intelligence and visualization of data of a person and its community. The person may have access to information gathered from software applications, wearable devices or intelligent environments. Data gathered will provide health and wellbeing indicators, which will be relevant for social care
providers (e.g. to provide personalized services), and when anonymous will allow municipalities analyzing information
and propose health-promoting actions.
The concept contributes significantly to promote interoperability and integration between formal and informal care
ecosystems. In fact, opportunity and market need are identified to introduce solutions that promote self-management
of health, and health prevention actions. Prevention requires a pro-active ecosystem, but this is many times difficult,
due to numerous reasons (e.g. inconvenient access to information, complex log of personal health data). This imposes
barriers to adhere to trending solutions. The platform provides the infrastructure and tools to quickly develop new applications by the developers community (students, SME’s, entrepreneurs, among others) leveraging the creation of
new businesses, thus it is aligned with the EIT Health objective to support and grow the number of new products/services and the to create new start-ups until 2018. This project proposes to stimulate a large caregivers network to collect and publish the organization needs (challenges) in the platform (in return they will receive the licence to use the
APPs). Simultaneous the project will involve the developers community to implement the APPS. To assure their commitment the project will integrate the cascade funding methodology, collecting, evaluating and supporting the best
business ideas that follow the “challenges” proposed by the caregivers. Furthermore the project intends to involve
other financial instruments to support the development (e.g. other cascade funding initiatives like FIWARE accelerators, Business Angels associations, among others).
MARKET APPLICATION
Which market is most relevant for your product/service Promote Healthy living. • Self-management of health. •
Lifestyle interventions. Support Active Ageing. • Overcoming functional loss.
Developers communities (Universitities, SME’s, Entrepeneurs), End-user organizations (Caregivers organizations),
Business partners (Business Angels associations, Communication providers, Banks).
Page 256 of 487
Spain
Intelligent Pharma, S.L.
Organisation Name
Country
Spain
City
Barcelona
Street
Baldiri i Reixac 4
Website
www.intelligentpharma.com
Phone
0034 934034551
Organisation Type
SME
Person
Name
Oscar Villacañas
Email
[email protected]
Job Position
Head of Computational Chemistry
Department
Intelligent Pharma is a biotechnology company dedicated to developing, commercializing and using new computational technologies for drug discovery. According to our clients' needs, we carry out customized computational
chemistry projects using cutting-edge technologies.
Business Lines
Molecular Modeling Services
Intelligent Pharma’s goal is to be your computational chemistry & bioinformatics team, working with you to developcomputational chemistry tasks relevant to your drug discovery project. We can also act as a support team
for your computational department on the development processes you already have in place. Click here to visit Molecular Modeling Services!
3rd Party Data Management Solutions
Intelligent Pharma provides you with software solutions to manage the acquired information and knowledge of your
organization. Click here to visit 3rd Party Data Management Solutions!
Scientific Software Development Services
Intelligent Pharma offers advanced software development solutions for companies and institutions working in
life sciences including the pharmaceutical, biotechnological, cosmetic and nutritional fields. Click here to visit Scientific Software Development Services!
Areas of Activity
the immune system
diseases
(PCP)
population
Methods and data
policies
Page 257 of 487
Spain
Offer: Molecular modeling
Our goal is to develop new computational tools and apply them in H2020 projects: Computational drug design, protein
modelling, docking, pharmacophore, QSAR/prediction models, molecular dynamics, hit identification and optimization,
target identification, chemogenomics, ... We have special interest in data analysis for the target prediction of small
molecules and drug-drug interactions.
We have our own developed tools which can be adapted to the project and/or available experimental information. We
have carried out 150 molecular modeling projects and have potent teams in both chemistry/biology and computer engineering.
Page 258 of 487
Italy
Intelsint srl
Organisation Name
Country
Italy
City
Villarbasse
Street
Via Rivoli 122
Website
www.intelsint.it
Phone
+390119528015
Organisation Type
SME
Person
Name
Sergio Cometto
Email
[email protected]
Job Position
CEO
Intelsint is a company totally focused on the development, manufacturing and marketing of capital equipment and
consumables for Histology laboratories.
Our products rank among the most important tools for labs in the preparation of human tissue specimens for the
diagnosis of cancer and other diseases. We design them with a view to provide users with high-quality automation
and
consistent results.
Intelsint is operating successfully in most of the major countries of the world: United States, Italy, Germany, France,
Spain and more. Recently it has celebrated the 1000th unit sold.
Areas of Activity
Request: Full automation for sample prep in Histolabs
Our project aims to the TOTAL automation (no human intervention) for the costly and currently not standardized histology sample preparation. The most important targets of the project are: 1) costs reduction 2) elimination of human
errors 3) standardization 4) elimination of any possible DNA sample cross contamination We are looking for industrial
partnership and funding for the development of parts of this project (approx 50% of the project is already funded and
under development)
Mecatronics for fast handling of small objects Automatic storage/retrieval of small objects Automatic transfer/handling
of small objects Image recognition and AI applied to it.
We are looking for companies available to partecipate in the project as industrial partner. Country: any.
Page 259 of 487
Portugal
IPMA
Organisation Name
Country
Portugal
City
Lisboa
Street
Av Brasília
Website
Ipma.pt
Phone
00351213027000
Organisation Type
R&D Institution
Person
Name
Narcisa Bandarra
Email
[email protected]
Job Position
Head Division
IPMA, I.P. is a public research institute devoted to carry out research, technological development, innovation, services
and dissemination activities on sea and atmosphere. In what regards activities on sea, sustainable exploitation of marine resources as well as on production, upgrading and processing of high quality seafood products are included. IPMA
acts as counselor to the national authorities on aquaculture, fisheries, fishing industry and fishery organizations, and
member of a high number of national and international commissions. The team belongs to the Aquaculture and Upgrading Division (DivAV), which deals with pre competitive research and experimental development on seafood and
aquaculture products utilization, quality monitoring and assurance and support to fishermen and the fish industry, by
way of technical advice, technological tests and technology transfer. The team group has expertise in nutritional, toxicology and in the benefit-risk assessment as well as in the evaluation of bioaccessibility/bioavailability of essential nutrients and contaminants elements from food, marine products including microalgae matrix and this impact on health
and well-being of the consumers. Moreover, DivAv team has also a deep expertise in making use of biotechnological
processes and innovative technologies to obtain new nutritional marine products and biomolecules with several applications.
Areas of Activity
the immune system
Methods and data
policies
Offer: Bioprospection of marine bioative compounds with health benefits
Dr Narcisa Bandarra, head of Aquaculture and Upgrading Division (DivAV), has a consolidated experience concerning
the influence of omega3-enriched diets in terms of incorporation of omega 3 fatty acids in the phospholipid fraction of
animal tissues (kidney, liver, muscle and aorta) and human plasma and erythrocytes in normal and haemodialysis patients. She has participated in several clinical studies related to the prevention of cardiovascular disease and has
been responsible for the determination of fatty acid profile and lipid classes of plasma and erythrocytes phospholipids. Facilities of IPMA Product development - Making use of biotechnological processes and innovative technologies
to obtain new products and biomolecules with various applications in omega 3 fatty acids, selenium, carotenoids, tocopherols, squalene, antioxidants. AS well as these compounds were used in the preparation of innovative nutritional
products as microalgae pasta, cakes, gels and others). Blood measurements – omega 3 index, total Cholesterol (HDL,
LDL, TG), Prostaglandins PGF2a, ICAM, VCAM, Reactive C protein, ROS, 4-HHE, 4-HNE, Total antioxidant status, GSH re-
Page 260 of 487
Portugal
dutase, Malondialdehide (LPO), Cortisol, Leptin, Adiponectin, Ghrelin, serotonin among others. Participation in intervention studies –with normal, hem dialysis, young obese and pre-obese as a collaborator. Role of nutrients (including
those from marine sources where relevant) in the human organism (their bioavailability and interactions)-Experience
in applicability of an in vitro digestion model, which simulates the human digestion (in the mouth, stomach and small
intestine), in assessing the bioaccessibility of nutrients (such lipids, and macro and microelements) and contaminants
from foodstuffs. As well as, in vitro evaluation of the bioavailability of several compounds by using cell lines. This tool
is important for understanding and predicted the mechanisms of synergism, antagonism and potentiating between
compounds present in the foodstuffs or in the new healthy products in order to prevent and treat the malnutrition in
the elderly. Benefits and risks assessment associated to marine products consumption -The statistical tools used are
enable to a more accurate assessment of the binomial risk-benefit for different case scenarios. In particular, extreme
value theory, proven in hydrology and other scientific areas, is be applied. The probabilities of exceeding critical
thresholds, such as, the maximum values of contaminants intake (eg, 'Tolerable Weekly Intake' for methylmercury,
MeHg TWI or the recommended minima for achieving a health benefit (eg, 'Recommended Daily Intake' for n-3 fatty
acids, n-3 Fatty Acids RDI) can be calculated. These probabilities can be processed through dose-response functions
for attaining measurable health effects, with reference to the published literature and the correlation factors between
dosages and effects proposed. Finally, these effects can be quantified with 'Quality-Adjusted Life Years' (QALYs) or
'Disability-Adjusted Life Years' (DALYs), thereby enabling the calculation of a net effect. Comparison with a baseline
scenario (for instance, the consumption of meals containing only meat and without fish) will make possible the assessment of the benefits or risks for health (measured in QALYs or DALYs) of any given diet. Additionally, an index that
will translate into a more accessible and immediate outcome the existence of a global benefit or risk (and their size)
can be developed). In this context were developed food questionnaires including, validation and data treatment. This
information is essential to give advices and guidelines to consumers and stakeholders Literature review Microalgae in
novel food products, Developing functional seafood products, Health Benefits Associated with Seafood Consumption,
Fatty Acids: Types, Roles and Health Effects, Fish Oil: Production, Consumption and Health Benefits Selenium: Sources,
functions and health effects, Tocopherols in Seafood and Aquaculture Products, Marine products Bioaccesibility, etc.
Data bases Lipid and Mineral composition of fish products Mercury, cadmium and lead in fish products. Dissemination
Organization of workshops in the frame of seafood health benefits, targeting seafood processors, health authorities,
consumers and consumers’ associations among others. c Research Institute. Marine Research Institute.
Role of nutrients (including those from marine sources where relevant) in the human organism (their bioavailability
and interactions)-Experience in applicability of an in vitro digestion model, which simulates the human digestion (in
the mouth, stomach and small intestine), in assessing the bioaccessibility of nutrients (such lipids, and macro and microelements) and contaminants from foodstuffs. As well as, in vitro evaluation of the bioavailability of several compounds by using cell lines. This tool is important for understanding and predicted the mechanisms of synergism, antagonism and potentiating between compounds present in the foodstuffs or in the new healthy products in order to
prevent and treat the malnutrition in the elderly.
Page 261 of 487
France
ISoft
Organisation Name
Country
France
City
Saint-Aubin
Street
route de l'Orme
Website
Phone
+33169353737
Organisation Type
SME
Person
Name
Jean-Philippe MEYNIEL
Email
[email protected]
Job Position
Research & Computational
Biologist
ISoft is a SME, founded in 1990, that offers an innovative technology, based on the most powerful calculation engine of the market, coming from Business Intelligence, which facilitates the processing of massive and heterogeneous biological data. This technology, dedicated to production environments, can meet the regulatory requirements and ensures a high level of quality of the obtained results.
With your current tools, you can analyse 10 genomes ! We offer you the ability to analyse 1000 genomes, even
10000, on several dimensions, simply using a desktop computer !
Areas of Activity
the immune system
EU level
Methods and data
policies
Offer: Innovative technology dedicated to the management and the processing of massive and heterogeneous biological data
Our bioinformatics environment represents a real technological breakthrough. The calculation engine, named Data
Morphing engine, provides a high level of performance and can process data "on the fly". Our proprietary technology
provides the required flexibility and reactivity to: - connect to the data, whatever their type and their format - quickly
adapt to new data flow, whatever its nature We developed this tool according to our vision of Bioinformatics : a processing of biological data has to be conducted by biologists and not by programers. We therefore propose a BIOinformatics tool that is primarily intended for those who know how to interpret the data content rather than for those able
to interpret their format. Moreover, in our approach, we prefer not to run after the implementation of tools dedicated
to already outdated problematic but allow creating, on the fly, the necessary tools responding to today’s and tomorrow’s problems. Our bioinformatics environment has already been used and validated in many practical cases, among
which are followings: - clinical data : ISIMS project - omics data : HKIS project - NGS data : GB3G project, QCheck tool
which assess the quality of raw data, ... We offer 2 kinds of tools : - A development environment : users of this environment can grasp a new bioinformatics approach in their development. Our environment is a graphical assembling of
function bricks. It requires no particular knowledge of programming languages. This developmental specificity confers
to the user the ability to have access to all the intermediate results, at the output of each of the functional bricks, at
any time and effortlessly. This feature allows an exploratory and iterative approach, required in research, that will allow to quickly converge to the optimal solution. The user can thus adopt an Agile development methodology. With our
tools, a researcher in biology will quickly find himself in a familiar research environment. He will thereby be able to
create computer tools in the same manner he creates biological experiments, but backed by the strength of IT to
Page 262 of 487
France
replicate, automate and industrialize analysis process. - Turnkey tools : based on the same technology as the development environment, implemented in close collaboration with end users, in order to fit to the laboratories' concrete
problems. Regardless of the chosen formula, we offer our customers a premium support, so that they never slow
down their work. Also, our tools include all the functionalities for a strict monitoring of the generated data and of the
performed analyzes. Thus, they are perfectly suited for environments with strong regulatory constraints, requiring
traceability, security and confidentiality. They are well prepared to meet the audit trails.
Functional advantages of our technology : - Better control of development time: compared to a conventional programming solution, we certify development time divided by 10. The individual productivity is thus greatly increased. - Scalable hardware resources ("cloud computing free" solution): the power of our technology is its ability of performing advanced processing on a basic desktop computer. This power is consequently multiplied (tenfold) when working on a
server or a in distributed environment. - An optimal compression rate of working data: it is possible to work with a
large amount of data in environments, especially convenient currently regarding the constant running out of disk
space. This specificity allows, for example, to host up to fifteen biological databases on a single laptop. - Very short
execution times: the same processing performed by the R language takes two days while it takes only 6 minutes with
our technology. Similarly, some tests have shown that our environment is thousand times faster than the Galaxy environment to process NGS data. - A strong interaction with the data: Our tools make it easy to manipulate the data in
order to comprehend them completely and excerpt the deep biological meaning.
Research teams or Pharmas that face troubles to manage and process their massive and heterogeneous biological/
non-biological data.
Page 263 of 487
Turkey
Organisation Name
Country
Turkey
City
Istanbul
Street
Kusbakisi Cad. No:22
Website
http://www.sehir.edu.tr
Phone
+902165599000
Organisation Type
University
Person
Name
Ali Cakmak
Email
[email protected]
Job Position
Faculty Member
SEHIR, which was established in 2008, has a solid foundation of knowledge in the areas of Social Sciences and Humanities, Engineering, and Natural Sciences. Research activities are carried out in the College of Humanities & Social
Sciences, School of Law, School of Islamic Studies, College of Communications, School of Management and Administrative Sciences, College of Engineering and Natural Sciences as well as in research centers, Center of Urban Studies
and Center for Modern Turkish Studies.
Currently 5 EU 7thFP Marie Curie IRG/CIG projects (4 of which are being implemented in College of Engineering and
Natural Sciences while 1 project in Sociology Department) and 1 EU H2020 MSC-IF project implemented in College of
Engineering and Natural Sciences and 31 nationally funded projects are being implemented with an overall budget of
~2,9 M Euro..
In terms of international collaborations, SEHIR has agreements with George Mason University (USA), University of
Wisconsin-Madison (USA), Georgia State University (USA), Wilfrid Laurier University (CDA) , China University of Political Science and Law (China), Somali City University (SOM) and INCEIF in Malaysia providing SEHIR’s students and faculty members with exchange and collaboration possibilities. Moreover SEHIR has ERASMUS agreements with 46 European Universities.
Areas of Activity
the immune system
diseases
(PPI)
Methods and data
policies
records (PPI)
Request: Research collaboration is sought in personalized medicine
We do research along the following directions: Bioinformatics: We develop computational models and automated
analysis methods for biological data. In particular, we focus on biochemical interactions (enzyme-enzyme and
enzyme-metabolite) and metabolomics. Data mining, data management, databases: We develop data mining and
management algorithms to automatically predict variety of data pieces in diverse applications that range from predicting high impact scientific papers to mining graph and text patterns in biomedical databases. For more information,
please see: http://ww.sehir.edu.tr/alicakmak http://biodb.sehir.edu.tr
Page 264 of 487
Turkey
We are particularly interested in the following calls, but we are also open to other ideas/projects as well.
SC1-PM-01-2016: Multi omics for personalised therapies SC1-PM-03–2017: Diagnostic characterisation of rare diseases
Medical doctors with active research agenda, medical biologists, computational omics-data analysis researchers
Page 265 of 487
Turkey
Organisation Name
Country
Turkey
City
Istanbul
Street
Kuşbakışı Caddesi No: 27 Altunizade – Üsküdar
Website
http://cs.sehir.edu.tr/people/mehmetbaysan/
Phone
+90 216 559 90 00 (ext. 9736)
Organisation Type
University
Person
Name
mehmet baysan
Email
[email protected]
Job Position
Assistant Professor
SEHIR is a recently established private university in Istanbul; the city that connects Europe with Asia with more than
fourteen million people and a major hub for technology and innovation. By combining its prominent location, strong
support from governmental and industrial organizations, and the global vision of the university’s founders; SEHIR has
attracted highly qualified faculty members who completed their education in globally renowned institutions. SEHIR
focuses on combining faculty members who work in strategically critical fields which will play important roles in shaping the future. These faculty members are expected to be the pioneers on establishing centers of excellence that will
function as reference points that guide the national research strategy in their respected areas.
Areas of Activity
the immune system
diseases
Offer: I am an expert on Translational Cancer Research Using Computational Techniques
and I seek Biologists and MDs for collaborations
I have obtained my MS and PhD degrees in Computer Science in United States (US) in 2003 and 2008 from University
of Texas at Dallas. I have studied cancer genomics between 2010-2015 in premier US research institutions such as
National Institutes of Health, NYU Medical College and Cornell Medical School. I have extensive experience on analyses and integration of different genomic data types such as microarrays and sequencing, identification of the role of
intratumor heterogeneity in tumor development and maintenance and evaluation of experimental cancer models. I
have moved to Istanbul Sehir University in September, 2015 and seeking European collaborators for Horizon2020
Calls.
Page 266 of 487
Turkey
Organisation Name
Country
Turkey
City
Istanbul
Street
Ayazaga Campus
Website
www.itu.edu.tr
Phone
+90 212 285 7194
Organisation Type
University
Person
Name
Lütfiye Durak Ata
Email
[email protected]
Job Position
Faculty Member
ITU Informatics Institute is a unit of Istanbul Technical University (ITU) that specializes in graduate education and research on the application of information technologies in all aspects of human development. ITU was established in
1773 and since then continued and developed its higher education in various forms. In 1946, ITU became an autonomous university, including the Faculties of Civil Engineering, Architecture, Mechanical Engineering, and Electrical Engineering. ITU is a state university which defines and continues to update methods of engineering and architecture in Turkey. With its educational facilities and strong institutional contacts, ITU has been preferred by Turkey’s most
distinguished students since its foundation and has achieved justified respect. Graduate studies in ITU have been carried out in 6 Institutes, including the Informatics Institute, by more than 140 programs. The Informatics Institute aims
to form an interdisciplinary platform to encourage research and education on all application fields of information technologies, including bioinformatics, biomedical signal and image processing, and networking. Informatics Institute
hosts the National Center for High Performance Computing (UHeM) with various hardware, software, and high data
storage resources, and visualization facilities.
Areas of Activity
(PCP)
(PPI)
population
Health ICT SMEs
Methods and data
policies
records (PPI)
Request: Research and Development on personalised coaching for well-being and big data supporting public health policies
Dr. Durak-Ata managed projects including signal detection and parameter extraction, multi-sensor landmine detection, dissimilarity measures and data retrieval on time-frequency distributions as two-dimensional signals. Recently,
Page 267 of 487
Turkey
she has completed a project as a PI on developing a device for indoor warning sound detection, and classification for
hearing-impaired persons. In this project cheap microphones are used as sensors for warning signals, they are integrated to microcontrollers, and the communication of sensors are realized using the Zigbee protocol, which can be extended to any other alternative. The results are displayed visually on a TV for the hearing-impaired. Dr. Durak-Ata's
research group is currently a part of The Informatics Institute of Istanbul Technical University. Research groups at the
institute, including Durak-Ata's group, are interested in participating at project proposals for the following calls:
PM-15-2017 - Personalised coaching for well-being and care of people as they age and PM-18-2016 - Big Data supporting Public Health policies as partners conducting research in signal processing and data analysis. For PM-15-2017,
Durak-Ata's group is willing to take part in developing novel techniques and algorithms that are able to adapt users'
personal needs, emotional and behavioral patterns, conditions and preferences as well as the users' living environment and their social connections. Regarding PM-18-2016, Durak-Ata's group may collaborate on development of
methods and algorithms on turning large amounts of data into actionable information to authorities for planning public health activities.
Any partner candidate who thinks may complement Durak-Ata's capabilities presented in the description section are
all welcome to meet Dr. Durak-Ata during the event.
Dr. Durak-Ata is seeking research partners especially aiming at calls PM-15-2017 and PM-18-2016 who may possibly
complement her group's research.
Page 268 of 487
Turkey
Organisation Name
Country
Turkey
City
Istanbul
Street
Macka
Website
http://www.econ.itu.edu.tr/about.php?lang=EN
Phone
Organisation Type
University
Person
Name
Sencer Ecer
Email
[email protected]
Job Position
Assoc. Prof.
The Department of Economics of Istanbul Technical University (see below for a general description of ITU), located at
Maçka, a vibrant and central location of Istanbul, offers unique programs in economics that excel both in the theory
and the practice of economics with the goal of producing world class and globally competitive economics majors at
the undergraduate, master’s, or Ph.D. levels.
The Department of Economics at ITU plays a central role in channeling ITU’s vast technical expertise of 240 years to
micro- and macroeconomic policy-making. To achieve this goal, the Department employs in its teaching and research
activities a multidisciplinary approach including joint workshops, seminars, guest lecturers and projects with ITU’s basic science and engineering departments. Field expertise of departmental faculty parallels this mission and includes
Development Economics, Education Economics, Energy Economics, Health Economics, Industrial Organization, and International Trade.
The faculty is heavily involved in both research and private and public sector consulting, and they reflect their practical experience in their teaching in addition to providing students with sound theoretical background. Successful students are integrated into departmental research and consulting projects in their areas of developing expertise to help
them gain experience under the direct supervision of their professors. Thus, our graduates have a unique advantage
in placement and success in corresponding fields of study.
ISTANBUL TECHNICAL UNIVERSITY:
Founded in 1773 as the Imperial School of Naval Engineering during Ottoman Empire, Istanbul Technical University
(ITU) is now one of the leading state universities in Turkey with approximately 20,000 students. The University offers
76 undergraduate and 140 graduate degree programs. ITU comprises 13 Faculties, 43 Departments, and 6 Graduate
Institutes.
Research:
Being Turkey’s first technical university, ITU aims to create a new generation of technology and innovation to drive
economic growth by conducting value-added and industrially applicable research. ITU’s researchers carry out research
in the fields of engineering, core sciences, earth/planetary sciences, arts and social sciences. Particular research areas, in which the ITU researchers pursue discoveries and implement projects, are materials science, nanotechnology,
aeronautics, mechatronics, biotechnology, renewable energy, sustainable building systems and design.
Regarding EU funded research, ITU currently has 22 projects from 6th Framework Programme, 47 projects from 7th
Framework Programme, 4 projects from MEDA Programme, 2 projects from MINERVA Programme, 1 project from
Page 269 of 487
Turkey
Leonardo Da Vinci Programme, 1 project from MATRA Programme, 1 project from Grundtvig Programme, 1 Project
from Youth in Action Programme and 1 project from Black Sea Cross Border Cooperation Programme, 1 project from
Erasmus Intensive Programme, 4 projects from Horizon 2020 Programme. Besides, ITU is actively involved in wide
range of national projects. In this respect, ITU has around 6400 projects funded by different national research programmes since 2003.
ITU faculty holds significant positions in a number of international institutions of academy. For instance, one of the
three Turkish members of American Academy of Sciences, two of the three Turkish members of Russian Academy of
Sciences and two of the three Turkish members of European Academy of Sciences are from ITU. Furthermore, the University has more than 130 international partnership agreements and is a member of various international networks
such as European Association for International Education (EAIE), European University Association (EUA), International
Association of Universities (IAU), Advanced Technology Higher Education Network (ATHENS), Black Sea University Network (BSUN), International Association of Universities (IAU), Community of Mediterranean Universities (CMU), and Top
Industrial Managers for Europe (TIME).
Istanbul Technical University has an office called European Union Centre Research Office that gives information about
EU Framework Programs and other EU Programs to the academic staff either by giving seminars, workshops ITU EU
Centre Research Office works as a help desk office and gives technical guidance, information to the academic staff of
ITU. ITU EU Centre Research Office has experts who have expertise in drafting and monitoring EU Programmes. ITU
European Union Centre Research Office is one of the EURAXESS Service Centers in Europe. EURAXESS Service Centers
were established to support foreign researchers in Turkey and to encourage Turkish researchers in the participation of
the mobility programs of the European Union (EU), works in accordance with more than 200 other mobility centres
currently established in the other member and associate countries of the EU. ITU adopts the principles set out in the
European Charter for Researchers and in the Code of Conduct for the Recruitment of Researchers.
Lastly, ITU Libraries hold more than 1 million items including books, periodicals, electronic resources, digital media
collections, and musical recordings while the Mustafa Inan Library of Maslak Campus, provides 7 days 24 hours access
to the ITU community. The Digital Library has digitized significant amounts of local material to enable online access to
these resources. Currently, all ITU theses and dissertations until 2010 are online for the ITU Community. Additionally,
the Special Collections department houses a collection of rare books pertaining to the history of engineering education and a wide range of archival documents on history of engineering in Turkey.
Areas of Activity
Preventing disease
young
Methods and data
policies
Offer: Health Economist
With several years of teaching, research, and consulting experience in health economics and policy, I can participate
in a range of projects and provide economic and econometric/data analysis. Examples include • Developing health
policy solutions such as analysis and development of innovative reimbursement policies and innovative co-payment
schemes based on data analysis and econometric estimations to address inequalities in accessing healthcare for various demographic groups in Europe, including elderly, unemployed, young, poor, and immigrants. • Innovating and implementing drug abuse reduction policies in Europe based on economic theories of analyzing addiction demand and
Page 270 of 487
Turkey
econometric methods of analyzing related data. Providing empirical analysis based on theories of rational addiction
and habit formation to help identify key variables in reducing drug demand in Europe.
Using state-of-the art econometric techniques to analyze economics of health and health policies. Main advantage is
theoretical soundness and accuracy of econometric results that policies or business strategies are going to be based
on.
MARKET APPLICATION
Health Insurance, pharmaceutical companies, nursing homes.
Research Institutes who are interested in teaming with a health economist who can analyze data using econometric
techniques, experienced in health policy and economics of pharmaceutical markets.
Page 271 of 487
Turkey
Organisation Name
Country
Turkey
City
İstanbul
Street
İTÜ Bilgisayar Mühendisliği
Website
Phone
+905323758642
Organisation Type
University
Person
Name
Ömer Sinan Saraç
Email
[email protected]
Job Position
Assistant Professor
Founded in 1773 as the Imperial School of Naval Engineering during Ottoman Empire, Istanbul Technical University
(ITU) is now one of the leading state universities in Turkey with approximately 32,000 students. The University offers
76 undergraduate and 140 graduate degree programs. ITU comprises 13 Faculties, 43 Departments, and 6 Graduate
Institutes and Turkish Music Conservatory.
ITU is one of the leading research-intensive technical universities in Turkey. Regarding EU funded research; ITU currently has 22 projects from 6th Framework Programme, 47 projects from 7th Framework Programme, 4 projects from
MEDA Programme, 2 projects from MINERVA Programme, 1 project from Leonardo Da Vinci Programme, 1 project from
MATRA Programme, 1 project from Grundtvig Programme, 1 Project from Youth in Action Programme and 1 project
from Black Sea Cross Border Cooperation Programme, 1 project from Erasmus Intensive Programme, 6 projects from
Horizon 2020 Programme. Besides, ITU is actively involved in wide range of national projects. In this respect, ITU has
around 7600 projects funded by different national research programmes since 2003.
Areas of Activity
the immune system
diseases
Methods and data
Offer: Understanding the mechanisms of complex diseases for prevention and treatment
ITU have strong ties between its computer engineering and molecular biology departments for both experimental and
bioinformatics research. Working with university hospitals in Istanbul, we are pursuing projects for understanding the
mechanisms of complex diseases like Multiple Sclerosis and producing diagnostic support decision systems.
We are interested in finding research project partners: 1- Who can provide patient/control cohorts or data for complex
diseases and seek bioinformatics analysis 2- Who would like to get involved in research of complex diseases in experimental and computational level
MARKET APPLICATION
We are open for any type of collaboration with industry or academia
Page 272 of 487
Turkey
Organisation Name
Country
Turkey
City
Istanbul
Street
Ayazaga Yerleskesi - Maslak
Website
http://www.itu.edu.tr/en/homepage
Phone
+902122857194
Organisation Type
University
Person
Name
Behcet Ugur Toreyin
Email
[email protected]
Job Position
Faculty Member
ITU Informatics Institute is a unit of Istanbul Technical University (ITU) that specializes in graduate education and research on the application of information technologies in all aspects of human development. ITU was established in
1773 and since then continued and developed its higher education in various forms. In 1946, ITU became an autonomous university, including the Faculties of Civil Engineering, Architecture, Mechanical Engineering, and Electrical Engineering. ITU is a state university which defines and continues to update methods of engineering and architecture in Turkey. With its educational facilities and strong institutional contacts, ITU has been preferred by Turkey’s most
distinguished students since its foundation and has achieved justified respect. Graduate studies in ITU have been carried out in 6 Institutes, including the Informatics Institute, by more than 140 programs. The Informatics Institute aims
to form an interdisciplinary platform to encourage research and education on all application fields of information technologies, including bio-informatics, biomedical signal and image processing and networking.
Areas of Activity
(PCP)
(PPI)
population
Health ICT SMEs
Methods and data
policies
records (PPI)
Request: Research and Development on personalised coaching for well-being and big data supporting public health policies
Dr. Töreyin's research group's activities span over the broad fields of signal processing and pattern recognition with
applications to image/video analysis, communication and biomedical systems. Research is focused on developing
novel algorithms to analyze and compress the content of signals from multitude of sensors such as visible/infra-red/
Page 273 of 487
Turkey
hyperspectral cameras, microphones, passive infra-red sensors, vibration sensors and spectrum sensors for wireless
communications. The group is a member of European Research in Consortium Informatics and Mathematics (ERCIM)
working group MUSCLE. Currently, the group's research activities are funded through the following projects: Online
Learning Based Compression of Hyperspectral Images Acquired for Remote Sensing - funded by Research Council of
Turkey (TÜBİTAK) National Young Researchers Career Development Programme [01/10/2014 - 01/10/2016] Machine Vision Based Bearing Inspection - funded by ORS Inc. [01/01/2014 - ] and by TÜBİTAK - TEYDEB 1501 R&D Funding Programme [12/2014 - 12/2016] Evaluation of Forest Fire and Impact using Imagery (EFFRII) - funded by Research Council of Turkey (TÜBİTAK) and Tunisian Science Foundation (MHESR) [01/01/2015 - 01/01/2017] Detection of People and
Fire Using a Low-cost Multi-Sensor System - funded by Research Council of Turkey (TÜBİTAK) The group is currently a
part of The Informatics Institute of Istanbul Technical University. Research groups at the institute, including Töreyin's
group, are interested in participating at project proposals for the following calls: PM-15-2017 - Personalised coaching
for well-being and care of people as they age and PM-18-2016 - Big Data supporting Public Health policies as partners
conducting research in signal processing and data analysis. For PM-15-2017, our groups in the institute are willing to
take part in developing novel techniques and algorithms that are able to adapt users' personal needs, emotional and
behavioral patterns, conditions and preferences as well as the users' living environment and their social connections.
Regarding PM-18-2016, our groups may collaborate on development of methods and algorithms on turning large
amounts of data into actionable information to authorities for planning public health activities.
Any partner candidate who thinks may complement our capabilities presented in the description section are all welcome to meet us during the event.
We are seeking research partners especially aiming at calls PM-15-2017 and PM-18-2016 who may possibly complement our capabilities.
Page 274 of 487
Italy
ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA
CURA DEI TUMORI (IRST)
Organisation Name
Country
Italy
City
Meldola (FC)
Street
via P. Maroncelli n 40
Website
www.irst.emr.it
Phone
0039 0543 739100
Organisation Type
R&D Institution
Person
Name
Luca Battistelli
Email
[email protected]
Job Position
Grant office Manager
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS is a public-private oncological hospital, a
partnership between public Regional Health authorities, a non-profit private organization, and local banking foundations. IRST is formed by a network of operationally and functionally interconnected centres that contribute to its being
a recognized cutting-edge reference centre for cancer treatment and research in Italy. The centre, located in Meldola
(FC), has a strong technological and scientific potential and is the main hub of the network being the only centre
where research activities and innovative treatments are carried out. Moreover, such activities are extremely complex
from a technological and assistance viewpoint. The centre is also a reference for clinical research in the local area and
aims at promoting the integration of assistance services offered by cancer treatment centres in said area;
The focal point of IRST’s role in coordinating research and development projects is oncological researches, especially
translational applications i.e. the integration between laboratory and clinical activity. IRST’s research is oriented on
three areas/research lines, in which programs and projects are developed:
LINE 1: Development of management and health care organizational models in the field of Romagna’s Oncology Network (Comprehensive Cancer Network) which are functional for the continuity and quality of the pathways of prevention, diagnosis and treatment.
LINE 2: Elaboration and study of clinical and biological models & concepts (at the cellular and molecular level) for the
development of innovative multi-centric clinical trials, and for the development of new drugs.
LINE 3: Experimental models for the study of biomolecular processes and mechanisms of carcinogenesis, tumor invasion and metastatic spreading.
Research activities are supported by the Bioscience Laboratory of IRST. The Bioscience Lab has two macro areas,
namely "Genetic Counselling and Clinical Molecular Diagnostics" and "Basic and Preclinical Experimental Research".
The aim of the "Basic and Preclinical Experimental Research" area is to carry out research based on the identification
of tissue and circulating biomarkers as a diagnostic, prognostic and predictive tool for clinical response as well as
deepen our knowledge of bone metastasis, preclinical pharmacology & radiobiology, stem cells and of isolation and
study of rare tumour cells that circulate in the bloodstream known as Circulating Tumour Cells (CTCs).
Also, in IRST is present a Biological Resource Center (CRB). This is responsible for collecting human biological materials (tissues, blood, DNA, isolated cells or other), freely donated by patients suffering from cancer. This, in compliance
with all the ethical criteria and regulations requested by the EC, is a real asset for researchers of AUSL-Romagna and
IRST, as well as of the whole world. Every project involving specimens from the CRB can be performed after evalua-
Page 275 of 487
Italy
tion of the scientific nature of the proposed research projects, guaranteed by the Medical and Scientific Committee of
IRST (CMS) and the National Ethics Committee.
Areas of Activity
Offer: Cytometry and CTCs Lab
Circulating tumor cells (CTCs) are cells that spread from the tumor mass into the peripheral blood and as such constitute the main vehicles for disease diffusion, making them of unquestionable importance. IRST's Bioscience laboratory
has a research area, called "Cytometry and CTC Lab", especially devoted to Circulating tumor cell (CTCs) studies. In
particular, the "Cytometry and CTC Lab" carries out: 1- Detection and isolation of CTCs using the most advanced techniques and tools currently available (such as OncoQuick, RosetteSep, DEPArray, ISET), to define them as prognostic
and predictive for treatment response. 2- Study of CTCs, up to single cell analysis methodologies, in order to determine cellular heterogeneity of primary and metastatic tumours as potential therapeutic targets and/or containing targets for biological treatment aimed at identifying which therapeutic regimen is best suited for each patient (treatment
personalization). 3- Identification, validation and setting up new tools and/or applications, to be used together with
the aforementioned techniques and tools, as well as new methods for the detection and capture of vital and proliferating CTCs.
Offer: : A new method for CTC-based patient stratification and personalized medicine
To date, there is evidence that CTCs can play a prognostic role in metastatic cancer patient and are somewhat capable of predicting response to therapy. CTCs could be used as a marker of invasion and of tumor aggressiveness. If
their clinical utility will be demonstrated, in the future, they could provide important information about the presence
and nature of minimal residual disease and could facilitate the selection of the best therapeutic personalized regimen.
Thus, CTCs could become key elements for monitoring disease, even after the primary tumor has been removed,
helping patient stratification and treatment personalization. With these assumptions in mind, our aim is to develop a
new device to improve CTC capture, detection and study, in order to demonstrate their clinical utility and utilize them
as theranostic markers. Hence, to test and validate such a device we need to cooperate with research institutes interested in testing and validating a new technology when it will be available and research institutes and/or SMEs involved in the production, functionalization and testing of the materials needed to make the device.
Research institute with core biology facility and/or SMEs specialized on: - software modeling and in silico tests to generate and study fluid dynamic information and to simulate the medical device operation; - antibody production; - high
throughput genomics, transcriptomics and proteomics analysis; - in-vivo studies on test animals.
Research institutes interested in testing and validating a new technology when it will be available. Hospital and clinical researchers should help in finding samples of metastatic cancer patients.
Page 276 of 487
Italy
ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA
CURA DEI TUMORI, IRST SRL (IRST)
Organisation Name
Country
Italy
City
Meldola (FC)
Street
via P. Maroncelli n 40
Website
www.irst.emr.it
Phone
0039 0543 739100
Organisation Type
R&D Institution
Person
Name
Pietro Fici
Email
[email protected]
Job Position
Researcher
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS is a public-private oncological hospital, a
partnership between public Regional Health authorities, a non-profit private organization, and local banking foundations. IRST is formed by a network of operationally and functionally interconnected centres that contribute to its being
a recognized cutting-edge reference centre for cancer treatment and research in Italy. The centre, located in Meldola
(FC), has a strong technological and scientific potential and is the main hub of the network being the only centre
where research activities and innovative treatments are carried out. Moreover, such activities are extremely complex
from a technological and assistance viewpoint. The centre is also a reference for clinical research in the local area and
aims at promoting the integration of assistance services offered by cancer treatment centres in said area;
The focal point of IRST’s role in coordinating research and development projects is oncological researches, especially
translational applications i.e. the integration between laboratory and clinical activity. IRST’s research is oriented on
three areas/research lines, in which programs and projects are developed:
LINE 1: Development of management and health care organizational models in the field of Romagna’s Oncology Network (Comprehensive Cancer Network) which are functional for the continuity and quality of the pathways of prevention, diagnosis and treatment.
LINE 2: Elaboration and study of clinical and biological models & concepts (at the cellular and molecular level) for the
development of innovative multi-centric clinical trials, and for the development of new drugs.
LINE 3: Experimental models for the study of biomolecular processes and mechanisms of carcinogenesis, tumor invasion and metastatic spreading.
Research activities are supported by the Bioscience Laboratory of IRST. The Bioscience Lab has two macro areas,
namely "Genetic Counselling and Clinical Molecular Diagnostics" and "Basic and Preclinical Experimental Research".
The aim of the "Basic and Preclinical Experimental Research" area is to carry out research based on the identification
of tissue and circulating biomarkers as a diagnostic, prognostic and predictive tool for clinical response as well as
deepen our knowledge of bone metastasis, preclinical pharmacology & radiobiology, stem cells and of isolation and
study of rare tumour cells that circulate in the bloodstream known as Circulating Tumour Cells (CTCs).
Also, in IRST is present a Biological Resource Center (CRB). This is responsible for collecting human biological materials (tissues, blood, DNA, isolated cells or other), freely donated by patients suffering from cancer. This, in compliance
with all the ethical criteria and regulations requested by the EC, is a real asset for researchers of AUSL-Romagna and
IRST, as well as of the whole world. Every project involving specimens from the CRB can be performed after evalua-
Page 277 of 487
Italy
tion of the scientific nature of the proposed research projects, guaranteed by the Medical and Scientific Committee of
IRST (CMS) and the National Ethics Committee.
Areas of Activity
Offer: Oncology Research institute-Cytometry and CTC Lab
Circulating tumor cells (CTCs) are cells that spread from the tumor mass into the peripheral blood and as such constitute the main vehicles for disease diffusion, making them of unquestionable importance. IRST's Bioscience laboratory
has a research area, called "Cytometry and CTC Lab", especially devoted to Circulating tumor cell (CTCs) studies. In
particular, the "Cytometry and CTC Lab" carries out: 1- Detection and isolation of CTCs using the most advanced techniques and tools currently available (such as OncoQuick, RosetteSep, DEPArray, ISET), to define them as prognostic
and predictive for treatment response. 2- Study of CTCs, up to single cell analysis methodologies, in order to determine cellular heterogeneity of primary and metastatic tumours as potential therapeutic targets and/or containing targets for biological treatment aimed at identifying which therapeutic regimen is best suited for each patient (treatment
personalization). 3- Identification, validation and setting up new tools and/or applications, to be used together with
the aforementioned techniques and tools, as well as new methods for the detection and capture of vital and proliferating CTCs.
Identification, conceiving, validation and setting up new tools and/or applications and methods for the detection,
study and capture of CTCs.
MARKET APPLICATION
Innovative treatment strategies and patient management in oncology Oncology related medical devices
Research institute with core biology facility and/or SMEs specialized in: - software modeling and in silico tests to generate and study fluid dynamic information and to simulate the medical device operation; - antibody production; - high
throughput genomics, transcriptomics and proteomics analysis; - in-vivo studies on test animal Research institutes interested in testing and validating a new technology when it will be available. Hospital and clinical researchers should
help in finding samples of metastatic cancer patients.
Offer: A new method for CTC-based patient stratification and personalized medicine
To date, there is evidence that CTCs can play a prognostic role in metastatic cancer patient and are somewhat capable of predicting response to therapy. CTCs could be used as a marker of invasion and of tumor aggressiveness. If
their clinical utility will be demonstrated, in the future, they could provide important information about the presence
and nature of minimal residual disease and could facilitate the selection of the best therapeutic personalized regimen.
Thus, CTCs could become key elements for monitoring disease, even after the primary tumor has been removed,
helping patient stratification and treatment personalization. With these assumptions in mind, our aim is to develop a
new device to improve CTC capture, detection and study, in order to demonstrate their clinical utility and utilize them
as theranostic markers. Hence, to test and validate such a device we need to cooperate with research institutes interested in testing and validating a new technology when it will be available and research institutes and/or SMEs involved in the production, functionalization and testing of the materials needed to make the device.
Research institute with core biology facility and/or SMEs specialized on: - software modeling and in silico tests to generate and study fluid dynamic information and to simulate the medical device operation; - antibody production; - high
throughput genomics, transcriptomics and proteomics analysis; - in-vivo studies on test animals
Research institutes interested in testing and validating a new technology when it will be available. Hospital and clinical researchers should help in finding samples of metastatic cancer patients.
Page 278 of 487
Poland
ITTI
Organisation Name
Country
Poland
City
Poznań
Street
UL. RUBIEZ 46, C5
Website
www.medstar.co
Phone
0048616226985
Organisation Type
SME
Person
Name
Wojciech Dymowski
Email
[email protected]
Job Position
Managing Consultant
ITTI Sp. z o.o. (Ltd.) is a private company, fully owned by its partners, initially focused on consulting and applied research in IT and telecommunications. It is located in Poznan, Poland. The activities of ITTI can be grouped into three
categories: consulting for the telecommunications sector, IT and telecom consulting for the end-users and development of innovative IT solutions. Since 2013 ITTI is developing it's won telemedical platform - http://medstar.co. MedStar is a mobile health service to provide the patients with better medicare and the doctors with more free time. It allows gathering of health related data on the mobile phone and providing access to it to doctors via web based interface.
Areas of Activity
Health ICT SMEs
Offer: Distant health monitoring platform - MedStar.co
MedStar is a mobile health service to provide the patients with better medicare and the doctors with more free time.
It allows gathering of health related data on the mobile phone and providing access to it to medical personnel via web
based interface. More information at www.medstar.co and https://www.facebook.com/MedStar-for-pregnancy-452726078251293/
REMOTE PATIENT TREATMENT Equip your patients with a measuring set. Remotely monitor and analyse their health.
Track trends, add information to their calendar, and supervise their rehabilitation. READY TO USE. You can just take
the set and give it to your patients. The system is ready to use from day one. You do not need to set anything up. We
will do it all for you providing you with easy online access to all features. SENSORS. MedStar offers the most essential
sensors for typical chronic diseases: thermometer, blood pressure monitor, pulse-oximeter, peak flow meter. We are
continuously working on additional sensors. In the meantime, all additional result can be entered into the application
manually. Telemedicine has proven saving of time and money and increasing care effectiveness.
Page 279 of 487
Poland
MARKET APPLICATION
Currently we are serving the following medical scenarios: pregnancy monitoring, heart failure, elderly health care, pulmonary diseases, preoperative rehabilitation, chemotherapy.
Robotic solution provider from Japan for "EU-Japan cooperation on Novel ICT Robotics based solutions for active and
healthy ageing at home or in care facilities" https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/2433-sc1-pm-14-2016.html. Care providers and other end-users for "New therapies for chronic diseases" https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/
3060-sc1-pm-09-2016.html. Any care providers interested in distant monitoring oh health.
Page 280 of 487
France
JDRF
Organisation Name
Country
France
City
Paris
Street
68 rue du Faubourg Saint Honoré
Website
www.jdrf.org
Phone
+33681480271
Organisation Type
Person
Name
Olivier ARNAUD
Email
[email protected]
Job Position
Senior Director, European
Research
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. JDRF is now the largest charitable
supporter of T1D research ($116M of direct support in 2011). JDRF funds Research projects (islets / cells encapsulation, artificial pancreas, sensors, CGM, antigen specific, vaccines, biomarkers, insulin, glucagon, complications, clinical
trials, microbiome ...) with the goal to improve the lives of all people affected by T1D by accelerating progress on the
most promising opportunities for curing, better treating, and preventing T1D.
JDRF collaborates with a wide spectrum of partners who share this goal. Driven by passionate, grassroots volunteers
connected to children, adolescents, and adults with this disease, since its founding in 1970, JDRF has awarded more
than $1.6 billion to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with
this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. More than 80 percent of JDRF's expenditures directly support research and research-related education. For
more information, please visit www.jdrf.org.
JDRF particularly encourages partnerships: (a) to translate early-stage academic and industry research discoveries
with the goal of identifying more advanced therapeutic candidates, (b) to conduct testing of therapeutic candidates in
relevant animal models or in people, and (c) to work closely with private and public capital allocators to leverage
funds and source opportunities in our strategic areas. Partnerships are focused on creating opportunities for JDRF to
foster long-term collaborative relationships with industry, taking promising research through discovery and development, and toward commercialization.
Areas of Activity
the immune system
EU level
Methods and data
policies
(PCP)
Page 281 of 487
France
Request: Diabetes type 1 in Microbiome - Autoimmunity - Vaccine areas
JDRF Research Foundation leader in Type 1 diabetes fields - Already founding partner in FP7 and IMI2 calls. JDRF particularly encourages partnerships: (a) to translate early-stage academic and industry research discoveries with the
goal of identifying more advanced therapeutic candidates, (b) to conduct testing of therapeutic candidates in relevant
animal models or in people, and (c) to work closely with private and public capital allocators to leverage funds and
source opportunities in our strategic areas. Partnerships are focused on creating opportunities for JDRF to foster longterm collaborative relationships with industry, taking promising research through discovery and development, and toward commercialization.
In the context of new H2020 2016-17 calls in the fields : Microbiome - Autoimmunity - Vaccines
Looking for Companies - Foundations - Associations - Academics interested in the topics above, on a worldwide basis
Page 282 of 487
Belgium
Johanniter International
Organisation Name
Country
Belgium
City
Brussels
Street
Rue Joseph II
Website
johanniter.org
Phone
+322821046
Organisation Type
Person
Name
Lubumbe Van de Velde
Email
[email protected]
Job Position
Project Assistant
Johanniter International incorporates 16 Associations under the umbrella of Johanniter/St.John. Our members are active in various fields, such as patient and elderly care. In essence, we bring together CARE-and End-User organisations in Europe.
We are the contact and network office for our members. We are a cooperation platform for dissemination activities,
we coordinate field trials across Europe and we support scientific evaluation in order to increase the broader European impact.
Areas of Activity
EU level
Health ICT SMEs
(PCP)
(PPI)
population
Offer: Experienced Proposalwriters and End User Connection
_
Offer: Europeanwide Test facilities and network
_
Page 283 of 487
Belgium
Offer: European Policy Making and large scale trials
_
Page 284 of 487
Turkey
Kadir Has University
Organisation Name
Country
Turkey
City
Istanbul
Street
Cibali, Fatih
Website
www.khas.edu.tr
Phone
Organisation Type
University
Person
Name
ARIF SELCUK OGRENCI
Email
[email protected]
Job Position
Assistant Professor
Founded in 1997 as a private non-profit institution, Kadir Has University (KHAS) is one of the leading mid-size universities in Turkey. The university, which has six faculties and three vocational schools, is dedicated to becoming a leader
in university education in Turkey and neighbouring areas. More than 5000 undergraduate students were enrolled in
2015 at twenty-nine different departments in the faculties of Engineering and Natural Sciences, Economics, Administrative and Social Sciences, Communications, Law, Art and Design, and Applied Sciences. The university also strives
to link research with graduate education through its twenty Master’s and eight Doctoral degree programs in the graduate schools of social sciences as well as science and engineering. As an outcome of the concrete steps taken since
the strategic decision to shift its orientation from education to research was made in 2006, the university’s current research portfolio boasts 151 projects of which 90 are funded by sources other than KHAS. For the last three years, the
university has ranked in the top 50 universities in the University Entrepreneurship and Innovation Index List, prepared
by the Turkish Ministry of Science, Industry and Technology. The university’s Innovation and Technology Transfer Research and Application Center (INEO) has been awarded funding by TÜBİTAK in 2014 for capacity building.
Expertise of 6 FT faculty members in data science, big data, computational intelligence, machine learning, parallel
computing at Faculty of Engineering and Natural Sciences brings huge research oppurtunities in these fields directly
related with the calls of interest.
Areas of Activity
(PCP)
(PPI)
population
Methods and data
policies
Offer: Smart position and movement monitoring using iBeacons
A software to be used for elderly, mentally handicapped, patients, staff, or children to monitor their movements in a
certain area (indoor or outdoor) equipped with electronic beacons. The system (SW in mobile device and the server)
will monitor the position and the changes in position so that alerts and guidance signals (voice, e-mail, SMS, etc.) can
be created in case of policy violations (moving out of the allowed area) and emergency situations (unusual rest). Collected data will be processed using computational intelligence techniques for anomaly detection. The SW is supported
Page 285 of 487
Turkey
by web browsers and mobile devices (Android, IOS, Windows ?). KEYWORDS: e-Beacons, mobile app, web app, database, computational intelligence, monitoring movements
Mobile and local solution for indoor and limited range outdoor monitoring of movement. Computational intelligence
used for anomaly detection.
MARKET APPLICATION
Elderly people living alone who go out of their home for short range walk in the vicinity of their home (park, market,
etc.) Hospitals where patient may experience health problems like fainting
Hospitals for specifications, integration, prototyping Company to develop mobile app, event detection algorithms
Company to design, implement iBeacon placements Municipalities to place such iBeacons to form a platform/testbed
Offer: Interest to participate in a consortium: Smart data processing for Big Health Data
Extensive experience in data science, computational intelligence, machine learning and paralel computing techniques
to be applied at Big Health Data. Experience in modeling, design and development of database systems, enterprise
web and mobile applications along with project management capability.
Combination of theoretical and practical capabilities in big data related issues.
MARKET APPLICATION
Health management, public sector, ...
Hospitals/Health organizations that wish to analyze data and synthesize solutions (with available data or that want to
collect data) Research institutions with expertise in similar topics for collaboration
Page 286 of 487
France
Keyrus Biopharma
Organisation Name
Country
France
City
Levallois-Perret
Street
18-20, rue Clément Bayard
Website
www.keyrusbiopharma.com
Phone
Organisation Type
SME
Person
Name
Nicolas Leroy
Email
[email protected]
Job Position
International Business Developer
Keyrus Biopharma, a french clinical research organization belonging to Keyrus group (Consulting and Integration for
Corporate Information Systems), provides a complete set of services for clinical research and development in the
pharmaceutical industry since 1998 with roughly 250 consultants in Europe/MENA region and Canada:
• Feasibility studies, study set-up and management (including monitoring, regulatory submissions and pharmacovigilance),
• Data management, biostatistics and medical writing,
• Regulatory affairs,
• Development and programming of SAS® applications for data management activities, statistical analysis of
clinical data and reporting.
• IWRS & Drug Supply Management tool
Areas of Activity
Preventing disease
Initiative
young
Methods and data
policies
Offer: CRO Partnering for your projects
Keyrus Biopharma can be the CRO in charge of the management of the clinical trials part of your projects and has acquired the experience of European projects as a member of consortiums or subcontractor for years with projects funded within the framework of FP5, FP7 and Horizon 2020 programs. We can be involved as a French, Belgian, Spanish or
German companies, which have all their own PIC number.
Page 287 of 487
France
MARKET APPLICATION
European and US markets and MENA region
other CRO and/or academic Partner in Europe
Page 288 of 487
France
Organisation Name
Country
France
City
Paris
Street
3-5 impasse Reille
Website
Phone
Organisation Type
SME
Person
Name
Emmanuelle Jordi
Email
[email protected]
Job Position
Project manager
LEADS TO DEVELOPMENT (L2D) specialises in the early-stage development of therapeutic products. We offer consultancy, regulatory and operational management services to our clients in order to help them bridge the gap between
therapeutic lead identification and clinical development. Our clients benefit from our development expertise without
having to build additional internal headcount, whilst we ensure that their products are advanced rapidly and cost effectively to clinical proof of concept. We offer a personal service carefully tailored to our customers' needs that maintains the transparency, flexibility and availability associated with an internal team.
Our thorough understanding of the biotechnology sector also allows us to offer a range of business and strategic advice and services (including due diligence) to investors, academic groups, technology transfer offices, biotechnology
and pharmaceutical companies. We provide the expertise required to assess project potential, design development
strategies and deliver effective project advancement in a manner that minimises risk and increase project value.
L2D is currently participating in a number of international collaboration projects including the CDVAX consortium
which has secured almost 6 million Euros of European FP7 financing to develop an effective oral vaccine against
Clostridium difficile, a hospital acquired bacterial infection, which is a major public health threat.
Areas of Activity
Preventing disease
Page 289 of 487
France
Organisation Name
Country
France
City
Paris
Street
166 Bld Montparnasse
Website
http://leadstodevelopment.com/
Phone
Organisation Type
SME
Person
Name
Jonathan Kearsey
Email
[email protected]
Job Position
Director
having to build additional internal headcount, whilst we ensure that their products are advanced rapidly and cost effectively to clinical proof of concept. We offer a personal service carefully tailored to our customers' needs that maintains the transparency, flexibility and availability associated with an internal team.
Our thorough understanding of the biotechnology sector also allows us to offer a range of business and strategic advice and services (including due diligence) to investors, academic groups, technology transfer offices, biotechnology
and pharmaceutical companies. We provide the expertise required to assess project potential, design development
strategies and deliver effective project advancement in a manner that minimises risk and increase project value.
L2D is currently participating in a number of international collaboration projects including the CDVAX consortium
which has secured almost 6 million Euros of European FP7 financing to develop an effective oral vaccine against
Clostridium difficile, a hospital acquired bacterial infection, which is a major public health threat.
Areas of Activity
Preventing disease
Offer: Preclinical and non-clinical development support
having to build additional internal headcount, whilst we ensure that their products are advanced rapidly and cost effectively to clinical proof of concept. We offer a personal service carefully tailored to our customers' needs that maintains the transparency, flexibility and availability associated with an internal team. Our thorough understanding of the
biotechnology sector also allows us to offer a range of business and strategic advice and services (including due diligence) to investors, academic groups, technology transfer offices, biotechnology and pharmaceutical companies. We
provide the expertise required to assess project potential, design development strategies and deliver effective project
advancement in a manner that minimises risk and increase project value. L2D is currently participating in a number of
international collaboration projects including the CDVAX consortium which has secured almost 6 million Euros of Euro-
Page 290 of 487
France
pean FP7 financing to develop an effective oral vaccine against Clostridium difficile, a hospital acquired bacterial infection, which is a major public health threat.
Optimized and accelerated project advancement in a regulatory compliant manner.
MARKET APPLICATION
Therapeutic, diagnostic, medical devices
Offer: Preclinical and non-clinical development support (regulatory, production, toxicology
and quality)
therapeutic lead identification and clinical development.
Page 291 of 487
Spain
LEITAT Technological Center
Organisation Name
Country
Spain
City
Barcelona
Street
C/ Pallars 179
Website
Phone
Organisation Type
R&D Institution
Person
Name
Izabel Alfany
Email
[email protected]
Job Position
International Project Manager
LEITAT is a Spanish Technological Center specialized in production technologies. LEITAT develops R&D activities in the
areas of biomedicine, biotechnologies, environment, surface treatments, material science, nanotechnology and renewable energies with deep knowledge and experience in technological transfers to several industrial sectors. Furthermore, LEITAT can provide a full range of services the different industrial sectors going from material design, testing and processing, to the development of prototypes. In particular, the several testing departments at LEITAT offer
services for the determination of more than 800 physical and chemical parameters (including ISO Certification and
Normalization). Additionally, LEITAT takes part each year in many projects financed by the regional and national governments, participates in projects co-funded by the European Commission, and develops private R&D projects funded
by industrial partners.
EU-Projects background: IPO LEITAT
Areas of Activity
the immune system
diseases
Preventing disease
population
Methods and data
Offer: BIOMED Division
The Biomed Division of LEITAT’s R&D Department has its origins in the Bioinvestigation laboratory that Merck had in
Barcelona, now Merck-Serono. The previous experience of the group accounts with more than fifteen years of preclinical investigation in oncology in a multinational pharmaceutical concern. Their main tasks have been to identify therapeutic targets, the validation of these targets, the generation of therapeutic agents (monoclonal antibodies, MAb, and
chemically synthesised compounds), the study of their mechanisms of action and their functional characterization in
Page 292 of 487
Spain
in vitro and in vivo models (preclinical proof-of-principle). Also, some members of this team have participated in the
pharmacological security of some of the mentioned compounds and in preclinical studies associated to Phase I and II
trials.
Cancer therapy: targets, drug generation & characterization, targeting and drug delivery. Analysis of the therapeutic
efficacy of new compounds. Other indications: inflammation, autoimmune diseases. Diagnosis, prognosis and monitorization: biomarkers, reagents, tools, devices (monoclonal antibodies, LFD, biosensors…). Industrial sectors: Pharma
& Veterinary (diseases, infections, vaccines) Food (contaminants, allergies, intolerances, quality) Environment, etc
Drug reprofiling: identification of new indications for well-known and phase-III drugs. Generation of monoclonal antibodies (mAb) for basic research, diagnosis and therapy. mAb engineering: chimerization, humanization & biosimilars
Biogenomics In vitro cell models In vivo animal models
MARKET APPLICATION
Biotechnology and Healthcare
Offer: Safety & Sustainability Division
R&D activities of Nanohealth and Safety division are focused in human health, environmental risk assessment and environmental impact (Life Cycle Assessment analysis) of nanotechnology-based products, to offer technological solutions for the recycling of nanomaterials. The division also has expertise in personal protective equipment for nanotechnology workers, working on the hazard evaluation to offer solutions to reduce their exposure. In addition, in the
area of nanomedicine, the team synthesise and functionalise nanoparticles for drug delivery (therapy) and diagnostics, participating as well in the design and development of nanoparticle-based platforms for the detection of biomolecules. In the areas described, this division has been involved and is currently contributing with its expertise in many
national and European projects, as coordinator and as a partner.
Nanotoxicology: in vitro/in vivo toxicology. Nanomedicine: Synthesis and functionalization of organic, inorganic
nanoparticles and quantum dots with photo- and electroluminescent properties; Diagnostics: electrochemical and colorimetric bionanosensors platforms: ? Therapy: Synthesis of biofunctionalized nanoparticles for drug delivery purposes or as phototherapeutic agents; ? Detection: Synthesis of bioconjugated nanoparticles as optical markers (QDs,
AuNP) ? Biocompatibility and viability studies for nanoparticles used in biological applications;
MARKET APPLICATION
Biotechnology and Healthcare
Offer: Devices & Design & Engineering (D2E) Division
The objective of D2E Division is the innovation in products and processes meeting the needs of different sectors such
as textile, telecommunications, health, energy, transport or environment, and focused on: • Technology research. •
Industrial design and development. Thanks to a multidisciplinary team grouped by physicists, chemists, mathematicians, electrochemists and engineers, D2E can develop innovative projects from different perspectives.
Smart Systems: Sensors and actuators integration Wireless communications (Low-Power Wireless Communications
Networks: ZigBee, Bluetooth 2.1, Bluetooth 4.0, NFC Identification, BTLE...) Firmware development Custom made
portable devices New production and processes: 3D scanning; Reverse Engineering; 3D Measurement. Prototype development; Simulation FEA; Advanced Manufacturing; Smart Robotics: Human-robot collaboration. Bio-parameter
monitoring devices Bio-sensors
MARKET APPLICATION
Healthcare, ICT, engineering.
Offer: Advanced Materials Division
Advanced Material Division is focused on global and optimized projects for the development of new materials aimed
at the main industrial sectors as health, transport, building, energy, packaging, consumer goods, aeronautics and textile, and focused on 4 great pillars: • Nanotechnology. • Polymers and polymeric composites. • Surface technology. •
Inorganic materials of the building sector. We perform integral projects in the sector of the science of materials covering the whole scale of values and different phases of the productive processes: synthesis phases, formulation of raw
materials with pilot tests and realization of technology demonstrators applied to the new materials developed, as well
as studies on recyclability and useful life of new materials. By doing so, we try to help the industry to develop their
projects from any stage of the value chain of the materials with the aim of providing knowledge and innovation and
creating an industrial network in the field of materials and industries to apply the new products and processes developed.
Page 293 of 487
Spain
New Polymers synthesis: New Biopolymers with high degrees of biocompatibility for tissue regeneration and sutures.
Formulation of new adhesives for after-surgery applications with bio mimetical effects on human organs. Micro and
nanoencapsulation: Encapsulation of drugs for controlled release Encapsulation of drugs for controlled release: Hollow
nanofibers with drugs for medical applications (sutures, bandages, etc.) Nanofibers for tissue regeneration Core Shell
nanofibers for controlled release.
MARKET APPLICATION
Healthcare & Biotechnology
Page 294 of 487
France
LIVANOVA SORIN CRM
Organisation Name
Country
France
City
Clamart
Street
Sorin crm 4 avenue reaumur
Website
Www.livanova.com
Phone
0146013333
Organisation Type
Large Company
Person
Name
Renzo Dal Molin
Email
[email protected]
Job Position
Research development and manufacturing of medical devices wearable or implantable for apnea, cardiovascular and
neurological diseases
Areas of Activity
Methods and data
records (PPI)
Health ICT SMEs
Offer: Active implantable medical devices
Expertise in research and development of AIMD for cardiac and neuro applications
MARKET APPLICATION
Cardio and neuro
Page 295 of 487
Luxembourg
Luxembourg Institute of Health
Organisation Name
Country
Luxembourg
City
Strassen
Street
1A-B rue Edison
Website
www.lih.lu
Phone
Organisation Type
R&D Institution
Person
Name
Yvan Devaux
Email
[email protected]
Job Position
Associate Head of Laboratory
Mission statement
LIH’s mission is to deliver scientific, economic and societal value for Luxembourg by performing research, studies and
developments in the fields of clinically-oriented biomedical research and public health.
LIH’s activities lead to the generation of new knowledge in disease mechanisms, epidemiology, diagnostics and treatments of human diseases, and they improve the understanding of health determinants and of the financial structures
of health care.
Vision statement & Goals
At the forefront of biomedical research, LIH aims at translating knowledge into clinical applications impacting on
health care while shaping personalised medicine.
To reach that vision, LIH has set the following goals for 2017:
• To be recognized by the international scientific community for the excellence of biomedical and translational
research, while at the same time creating value for our local society
• To remain the national leader in biomedical and clinical research, implementing personalised medicine in our
country in close collaboration with the health care providers and other stakeholders
• To remain the first supplier of public health information in Luxembourg, enabling public authorities to make
decisions based on scientific data and to communicate validated data to international institutions
• To strengthen our position as reliable and active partner for training and higher education in close collaboration with national and international universities
Areas of Activity
the immune system
EU level
Methods and data
Page 296 of 487
Luxembourg
Request: Research and developpment of a RNA-based diagnostic tool to predict outcome
of acute cardiovascular disease
PROJECT DESCRIPTION The objective of the project is the development of a diagnostic assay to predict the outcome of
patients having suffered an acute cardiovascular event such as myocardial infarction, cardiac arrest, aortic dissection,
or acute decompensated heart failure. The assay will be based on the measurement of circulating levels of RNAs.
Even though all types of RNAs will be considered, both coding and non-coding RNAs, the focus will be on long noncoding RNAs. The project will be a joint effort of members of the Cardiolinc network (www.cardiolinc.org). INNOVATIVE ASPECTS/MAIN ADVANTAGES/BENEFITS Being able to predict the outcome of patients suffering an acute cardiovascular
event will allow tailoring healthcare to the individual patient. The use of transcriptomic profiles measured in the blood
to predict patient outcome is innovative. The main advantage is the use of a readily available single blood sample for
prognostication. Benefits are for the patient and will allow minimizing healthcare costs. TECHNICAL SPECIFICATION An
automatable diagnostic assay based on the measurement of several RNAs in the blood. The assay has to be applicable to the clinic, accurate and cost-effective. CURRENT STAGE OF DEVELOPMENT Several RNAs are already identified
for their association with patient outcome in different disease conditions. INTELLECTUAL PROPERTY RIGHTS To be discussed. EXPERIENCE Details at https://www.lih.lu/page/departments/cvru-cardiovascular-research-unit-786 TYPE AND
QUALIFICATION OF CO-OPERATION PARTNERS SMEs and public research institutes skilled in research & development
of RNA-based diagnostic assays. Hospitals with large cohorts of patients with acute cardiovascular conditions.
Expertise in RNA sequencing, bioinformatics, systems biology, RNA measurement, multiplex assays, development and
certification of diagnostic assays. Access to large cohorts of patients with acute cardiovascular conditions is needed.
Public and private institutions. Academic centers and SMEs. International.
Request: Research and developpment of a molecular diagnostic tool based on RNA detection in blood cells
PROJECT DESCRIPTION The objective of the project is the development of a molecular diagnostic assay to collect
blood samples, stabilize RNA and measure gene expression in whole blood cells. Several studies have shown that
gene expression profiles of blood cells can be used as biomarker to predict the occurrence of an acute disease, diagnose an underlying disease, or predict the outcome of patients having suffered an acute disease. Although the tool
will be first tested in the context of cardiovascular disease such as myocardial infarction, cardiac arrest, aortic dissection, or acute decompensated heart failure, it can be applied to any type of disease having a biosignature in the
blood. The assay will be based on the measurement of circulating levels of RNAs. Even though all types of RNAs will
be considered, both coding and non-coding RNAs, the focus will be on long noncoding RNAs. The project will be a joint
effort of members of the Cardiolinc network (www.cardiolinc.org). INNOVATIVE ASPECTS/MAIN ADVANTAGES/BENEFITS
Being able to detect an underlying disease, predict the occurrence of an acute disease, and predict the outcome of
patients having suffered an acute event represents a step forward towards personalized medicine. It will allow tailoring healthcare to the individual patient. The use of transcriptomic profiles using both coding and non-coding RNAs
measured in the blood is innovative. The main advantage is the use of a readily available single blood sample. Benefits are for the patient and will allow minimizing healthcare costs. The tool will be innovative and independent of the
existing PAXgene Blood RNA system. The advantage of the tool over this existing system will be on its simplicity and
rapidity to use. TECHNICAL SPECIFICATION An automatable diagnostic tool based on the collection of a blood sample,
RNA stabilization and measurement of RNA expression profiles in the blood. The tool has to be applicable to the clinic,
accurate, simple to use and cost-effective. CURRENT STAGE OF DEVELOPMENT Several RNA profiles are already identified for their association with disease states. Several disease conditions are concerned, including cardiovascular diseases. INTELLECTUAL PROPERTY RIGHTS To be discussed. EXPERIENCE Details at https://www.lih.lu/page/departments/
cvru-cardiovascular-research-unit-786 TYPE AND QUALIFICATION OF CO-OPERATION PARTNERS SMEs and public research institutes skilled in research and development of blood-based molecular diagnostic tools are required for technological aspects. Hospitals with large cohorts of patients, notably acute cardiovascular conditions, are required for
testing purposes.
Expertise in the development of blood collection solutions, RNA stabilization, RNA expression profiles, multiplex assays, development and certification of molecular diagnostic assays. Access to large cohorts of patients with acute diseases, including but not limited to cardiovascular diseases, is needed.
Public and private institutions. Academic centers and SMEs. International.
Page 297 of 487
Portugal
MD Tour - Medical Tourism and Medical Innovation
Organisation Name
Country
Portugal
City
Viseu
Street
Rua Miguel Bombarda
Website
www.mdtour.pt
Phone
+ 351 968334457
Organisation Type
SME
Person
Name
António Ramalho
Email
[email protected]
Job Position
Director
Information about MD Tour
We develop strategies and projects envolving a multidisciplinay team in the area of medical innovation, WellBeing,
Preventive Health and Active Ageing…. associated with Thermal Treatment, Hidrotherapy, ….also envolving the
Medical Tourism ( with our Partners from Europe, USA and Canada)
My multidisciplinary team includes very interesting international Expertises .
Our strategies aimed at strengthening an international multidisciplinary team in partnership with key organizations
worldwide.
Active Ageing – Preventive Health
Youth - Preventive Health
Assistance and medical procedure - medical treatment, Thermal Waters, hydrotherapy( we have in our region the
largest Thermal waters Treatment in Iberian Península – envolving Portugal and Spain
Build a network for development in Health Tourism
on a global scale , based on collaborative platform
that articulates and strategically orient the internal and external market
Preventive Health; WellBeing; Natural Therapies; Rehabilitation
thermal waters
. Hydrotherapy
. welness
Areas of Activity
(PCP)
(PPI)
population
Health ICT SMEs
Page 298 of 487
Portugal
Offer: MD tour Medical Tourism , Medical innovation
We develop strategies and projects envolving a multidisciplinay team in the area of Medical Innovation, Wellbeing and
Active Ageing…. and associated with Hydrotherapy, …. Thermal Treatment, envolving the Medical Tourism ( with our
Partners from USA and Canada) My multidisciplinary team includes very interesting international Expertises .
http://issuu.com/termasspsul/docs/brochura?e=2522370/2640872 Our strategies aimed at strengthening an international multidisciplinary team in partnership with key organizations worldwide. Active Ageing – Preventive Health Youth
- Preventive Health Assistance and medical procedure - Preventive Medicine, medical treatment, Thermal Waters, hydrotherapy( we have in our region the largest Thermal waters Treatment in Iberian Península – envolving Portugal and
Spain Build a network for development in Health Tourism on a global scale , based on collaborative platform that articulates and strategically orient the internal and external market. Preventive Health; Wellness and Well Being; Natural
Therapies; Rehabilitation
Active Ageing – Preventive Health Youth -Preventive Health Medical Tourism, Thermal Treatment Medical Congresses
Investigation Training
MARKET APPLICATION
Preventive Health Medical treatment, Thermal Waters, Hydrotherapy Medical Tourism Medical Congresses Medical
Congresses Active Ageing Thermal Treatment Transnational Network - ( Europe- USA- Canada - Australia)
Entities and Expertises in Preventive Health Thermal Waters Medical Tourism Medical Congress
Request: MD tour Medical Tourism , Medical innovation
Our strategies aimed at strengthening an international multidisciplinary team in partnership with key organizations
worldwide. Active Ageing – Preventive Health Youth - Preventive Health Assistance and medical procedure - Preventive
Medicine, medical treatment, Thermal Waters, hydrotherapy( we have in our region the largest Thermal waters Treatment in Iberian Península – envolving Portugal and Spain Build a network for development in Health Tourism on a
global scale , based on collaborative platform
Preventive Health Active Ageing Medical Tourism Medical Congresses Thermal Treatment
Entities and Expertises in Preventive Health Thermal Waters Medical Tourism Medical Congress
Page 299 of 487
France
Medclinik
Organisation Name
Country
France
City
Paris
Street
38 rue de Berri
Website
Phone
0762465060
Organisation Type
SME
Person
Name
Claire Kamoun
Email
[email protected]
Job Position
Dir Patient Initiatives
MedClinik is a 360Medlink subsidiary focused on addressing unmet medical needs with clinically validated eHealth/
mHealth solutions targeting an improvement in patient health behavior, with a particular focus on treatment adherence.
MedClinik is introducing TAVIERX the first clinically validated VirtualNurseTM platform to improve patient therapeutic adherence in chronic and acute diseases
Areas of Activity
Health ICT SMEs
(PCP)
population
Offer: Clincally validated Virtual Nurse for Treatment adherence
TAVIE is the world’s first clinically validated virtual nurse platform, with personalized and interactive patient support
to optimize treatment adherence. TAVIE was developed to provide tailored realtime support to patients living with a
chronic disease who must manage the challenges inherent to their health conditions. The TAVIE online behavioral intervention uses the most recent clinical, medical and research- based evidence to address the critical barriers to patient adherence to medication. The platform is developed and tested in each medical indication of the portfolio including chronic and acute conditions. Existing solutions in: HIV, Cardio, Transplant, Lifestyle, Diabetes, Poste Operative
pain
- Clinical validation in acute and chronic disease for qualitative patient experience and quantitative efficacy - Supporting algorithm to tailor the intervention to patient profile - Patient and PRO collection to monitor behavioral progress Connected device integration to monitor behavior - Web and mobile app - Awarded: Helping Hands award, Doctors 2.0
And you award; Presented at the SIDIIEF conference, Health 2.0 conference and Patient summit
MARKET APPLICATION
Our client segments are - Pharmaceutical companies - HMO and Health Insurances - Hospitals
Page 300 of 487
France
- Deployement partners to integrate or newly pilot TAVIE portfolio solutions - R&D Partners with expertise in Mental
Health, Oncologie, HCV, Diabetes Type II - Commercial partners
Request: Clinical and techno partner for H2020 project on patient self management in
cardio / transplant care
Partner to build a research protocol validating an approach to patient self management after transplantation or acute
cardiac syndrome based on the VirtualNurse (and other relevant monitoring technologies) to evaluate the impact on
patient outcomes. the Virtual Nurse is clinically validated in Canada and this prohject aims to validate here in europe
(RCT) as well as establishing best practices for patient care after hospital discharge
Clinical sites Monitoring patient centeed technologies (device, captor)
Page 301 of 487
Turkey
Organisation Name
Country
Turkey
City
Ankara
Street
İSTASYON MAH. 2314. SOK. 1A No:12
Website
www.medlabenerji.com
Phone
+90 312 244 61 63
Organisation Type
SME
Person
Name
Emrah Akkoyun
Email
[email protected]
Job Position
Researcher
MedLab Software is a new company which is financially supported by government as a result of a proposed Research
& Development project having high potential on the economical impact. We are a group of young people working on
medical informatics system and trying to provide innovative solutions especially by following trends in the health.
Software development on an integrated circuit using various sensors as well as on mobile platform are the main focus
area that we are trying to be specialized. Furthermore, cloud computing using open source is another field that we
want our company to be addressed in order to utilize different kinds of solution provided by the platform for personalized medicine.
Areas of Activity
Preventing disease
Initiative
young
Methods and data
policies
Health ICT SMEs
(PCP)
(PPI)
population
Page 302 of 487
Turkey
Organisation Name
Country
Turkey
City
Ankara
Street
İSTASYON MAH. 2314. SOK. 1A No:12
Website
www.medlabenerji.com
Phone
+905057827119
Organisation Type
SME
Person
Name
Nuran Akkoyun
Email
[email protected]
Job Position
Founder
MedLab Software is a new company which is financially supported by government as a result of a proposed Research
& Development project having high potential on the economical impact. We are a group of young people working on
medical informatics system and trying to provide innovative solutions especially by following trends in the health.
Software development on an integrated circuit using various sensors as well as on mobile platform are the main focus
area that we are trying to be specialized. Furthermore, cloud computing using open source is another field that we
want our company to be addressed in order to utilize different kinds of solution provided by the platform for personalized medicine.
Areas of Activity
Preventing disease
Initiative
(PCP)
(PPI)
population
Methods and data
policies
Health ICT SMEs
Request: MedLab Solutions for Monitoring Patient
The company mostly focused on the project which aims to monitor babies fever using mobile phone and share the results with clinicians using the cloud technology. We would like to establish a platform where we can extend the solutions for ageing population as well as patients having chronicle diseases. Therefore, we are open the collaboration
with other partners. Furthermore, we are interested in analyse bio-signals and providing specific solution for disability
people. At the same time, our company has PhD candidates who are studying on the personalized medicine such as
biomechanical analysis collaboration with the university hospitals.
Page 303 of 487
Turkey
Mobile software development as well as circuit design and development using sensor are the main needs for our company. We are also interested in software development on the cloud where health professionals and patients can meet
on the collected medical information.
We would like to collaborate with a number of companies, universities or SMEs which are interested in the field of
monitoring patient and the personilized medicine
Page 304 of 487
France
MedTrucks
Organisation Name
Country
France
City
Aigues-Mortes
Street
5 place du18 juin
Website
Phone
+613915268
Organisation Type
Large Company
Person
Name
Anass El Hilal
Email
[email protected]
Job Position
CEO
MEDTRUCKS, MOBILE HEALTHCARE SOLUTIONS
MedTrucks designs and develops innovates mobiles healthcare solutions to facilitate the access in remote area.
What if mobile healthcare units could provide access to life-saving treatment in a way not previously possible.
By deploying health systems positioned close to the patient, we facilitate their daily life all over the world.
Areas of Activity
(PCP)
Methods and data
policies
Request: Partnership for deploying Mobile Dialysis Unit in remote area.
The burden of end-stage renal disease (ESRD) is increasing across the world, propelled by the rising prevalence of two
major risk factors: diabetes and hypertension. Kidney failure is a chronic disease which affects 250M people in the
world. 1.9M people are undergoing dialysis, and 1.2M premature deaths each year due to lack of access to dialysis.
MedTrucks provides access to rural patients who would otherwise have to travel great distances to receive this lifesaving treatment; to avoid transportation costs and risk of flight for correctional care facilities; and even disaster response needs. Our solutions include a range of MedSystems®: -MedMapping : a real-time patient map based on
crowdsourcing geolocation method. -MedTracking: a smart location tool intended to pin servicing station and draw optimum itinerary. -MedTrucks : enables patients to receive a dialysis procedure while seating in a fully equipped medical truck. -MedEducation: a telemedicine platform to remote control dialysis sessions. By deploying health systems
close to the patients, we facilitate their daily life.
Mapping : E-health data, security, bigdata Tracking : medical logostic, medical facilities Truck : compact medical device (generator) Education : dialysis knowledge
Page 305 of 487
France
MethodCO
Organisation Name
Country
France
City
Puteaux
Street
ESSEC VENTURES - CNIT Paris la Défense
Website
Phone
Organisation Type
SME
Person
Name
Guillaume Costil
Email
[email protected]
Job Position
MethodCO offers a weight loss program that revolutionize patient care with a multidisciplinary and innovative approach.
Our program is designed by renowned physicians and experts involved in weight loss and is supported by the last scientific studies, is shaped by an holistic approach : nutrition et cooking workshop, physical activity, psychology and uses technological devices for a continuous monitoring 24/7
Areas of Activity
(PCP)
Methods and data
Request: Weight Management and weight loss program
MethodCO offers weight management program to companies and customers. Its leading experts, helped by technologies, promote and educate people in order to bring them sustainable health benefits. Our operations takes place in
Paris and its region - our goal is to operates broader.
> We are looking for distribution channels. And we are always eager to meet people that are interested in this field
and confident of its future and wealth in its in Europe and Asia.
- Business Developer - Connected devices companies - Clinics - Public or private institutions, looking for studies results - Investors to finance the development based in EMEA
Page 306 of 487
Turkey
Organisation Name
Country
Turkey
City
Ankara
Street
Mithatpasa Cd. 3 B Blok Kat 1 Sihhiye
Website
www.saglik.gov.tr
Phone
Organisation Type
Person
Name
Ozan Beyhan
Email
[email protected]
Job Position
Consultant
The Ministry of Health Turkey (MOH), which was established in 1920, is the main government body responsible for
health sector policy making, implementation of national health strategies through programs and direct provision of
health services. MOH is the major provider of primary, secondary and tertiary health care services. It is essentially the
only provider of preventive health services through an extensive network of health facilities (Public Health Centers).
As of January 2015, MOH has more than 900 hospitals and more than 7,000 health centers – about twice as many as a
decade ago. MOH currently comprises nine general directorates:
(i) Health for Border and Coastal Areas
(ii) Health Services
(iii) Emergency Health Services
(iv) Administrative Services
(v) Health Promotion
(vi) Health Information Systems
(vii) Health Researches
(viii) Health Investments
(ix) EU and Foreign Affairs
The organization is essentially structured along vertical lines of responsibility reflected in the topic-based, functional
divisions within each directorate, also at provincial level and, to a certain extent, in hospitals and health centers. At
the provincial level, provincial health directorates (for 81 provinces) are responsible for administering health services
provided by MOH.
The General Directorate of Health Information Systems (GDHIS) is responsible for country-wide policies, strategies
and standards for information systems and communication technologies in healthcare services, information systems
and projects for personal health records. It is the host to NHIS (national health information system) of Turkey.
GDHIS has been a part of 3 EU projects so far: epSOS, EMPOWER, and PALANTE. GDHIS is also implementing the Digital Hospital Project with HIMSS Europe. The GDHIS developed the National Health Data Dictionary (NHDD) in which
the commonly used healthcare data elements and data sets are defined. The GDHIS operates the National Health Information System (NHIS) of Turkey since 2008, which is the nation-wide infrastructure for collecting the EHRs from all
over the country.
The Ministry of Health is a highly-esteemed and authoritative organization in Turkey, whose policies and missions will
be welcomed by formal and informal caregivers, which will greatly contribute to the dissemination and exploitation
activities of any project.
Areas of Activity
Page 307 of 487
Turkey
• PM-12-2016
(PCP)
• PM-13-2016
(PPI)
• PM-14-2016
• PM-15-2017
population
- eHealth innovations for the patient
- ICT solutions for ageing population
- EU-Japan cooperation in ICT Robotics
- Personalised coaching for ageing
Request: General Directorate of Health Information Systems
Among the targets which are stated in Strategic Plan 2013 – 2017 of Ministry of Health of Turkey are: • To develop an
Electronic Health Record system and a portal to collect, monitor and provide safe access to and sharing of personal
health records • To establish systems that enable people to reach all their health data and share them with others by
using mobile devices In order to reach these targets, Ministry of Health of Turkey launched its electronic/personal
health record for the use of Turkey’s citizens in Turkey in April 2015: E-Nabız. E-Nabız is a highly advanced electronic/
personal health record system where you can reach your health-related information including but not limited to
healthcare facility visits, prescriptions, medical reports, diagnoses, laboratory results and medical images, allergy information, blood and organ donations, emergency notes and documents. E-Nabız allows integration of medical devices with the system for wireless data communication. You can also schedule and manage appointments with physicians from primary, secondary and tertiary levels of care. You may share your information (such as previous lab results or medical images) with your doctor(s) for better medical decisions and treatments, and with your family for better assisted living. (Default is no share.) You may reach the health information of your children under 16, monitor their
health statuses and manage their vaccine schedules. E-Nabız also allows messaging between you and your doctor on
a safe platform, where you may share with your doctor any files and images regarding your health. Despite having a
high number of features, E-Nabız is operated with a user-friendly interface and has a rapidly growing number of users
in Turkey. All services of E-Nabız are given free of charge, and it is possible to use the system on both desktop and
mobile devices. Mobile versions may easily be downloaded from most common platforms such as Google Play and
App Store. Besides being an electronic health record (health data coming from healthcare facilities), E-Nabız is also a
personal health record (data fed into the system by the user himself/herself). Among the data which may be entered
to the system by the patients is blood sugar value. The patients may choose to enter and save the data for their future reference or they may choose to share the data with healthcare professionals. Entries do not have to be done
manually. Bluetooth and wireless devices may easily be integrated with one’s E-Nabız account.
Page 308 of 487
Turkey
Organisation Name
Country
Turkey
City
Ankara
Street
Mithatpasa Cad.
Website
www.saglik.gov.tr
Phone
Organisation Type
Person
Name
Muhammet Ilkay KAYNAK
Email
[email protected]
Job Position
Consultant
The Ministry of Health Turkey (MOH), which was established in 1920, is the main government body responsible for
health sector policy making, implementation of national health strategies through programs and direct provision of
health services. MOH is the major provider of primary, secondary and tertiary health care services. It is essentially the
only provider of preventive health services through an extensive network of health facilities (Public Health Centers).
As of January 2015, MOH has more than 900 hospitals and more than 7,000 health centers – about twice as many as a
decade ago.
MOH currently comprises nine general directorates:
i. Health for Border and Coastal Areas
ii. Health Services
iii. Emergency Health Services
iv. Administrative Services
v. Health Promotion
vi. Health Information Systems
vii. Health Researches
viii. Health Investments
ix. EU and Foreign Affaris
The organization is essentially structured along vertical lines of responsibility reflected in the topic-based, functional
divisions within each directorate, also at provincial level and, to a certain extent, in hospitals and health centers. At
the provincial level, provincial health directorates (for 81 provinces) are responsible for administering health services
provided by MOH. General Directorate of Health Information Systems (GDHIS) is responsible for country-wide policies,
strategies and standards for information systems and communication technologies in healthcare services, information
systems and projects for personal health records. It is the host to NHIS (national health information system) of Turkey.
GD of Health Information Systems has been a part of 3 EU projects so far: epSOS (completed), EMPOWER (completed), PALANTE (completed). GD of Health Information Systems is also implementing the Digital Hospital Project with
HIMSS Europe. GDHIS developed the National Health Data Dictionary (NHDD) in which the commonly used healthcare
data elements and data sets are defined. GDHIS operates the National Health Information System (NHIS) of Turkey
since 2008, which is the nation-wide infrastructure for collecting the EHRs from all over the country. NHIS is based on
HL7 CDA R2, and HL7 v3 Web Services Profile is being used as the communication protocol. Every day, hundreds of
thousands of Minimum Health Data Set (MHDS) instances such as Prescription, Medical Examination and Diabetes
Monitoring are collected with these Web Services.
GDHIS operates the Health Coding Reference Server (HCRS) which serves all the code systems in use in Turkey from a
single point. GDHIS operates Doctor Data Bank (DDB) which serves as a Healthcare Professional Registry. GDHIS is developing Geographical Information System (GIS), which is a decision support system with multiple modules driven by
a geographical interface and which enables to monitor specific diseases on an epidemiological level, and monitor
healthcare services and statuses on provincial and regional level. GIS gives the ability to do evidence-based early risk
detection, using decision support systems.
Page 309 of 487
Turkey
Areas of Activity
Methods and data
policies
(PCP)
(PPI)
population
Offer: Turkish Ministry of Health, General Directorate of Health Information Systems
Turkish MOH, GDHIS is responsible for country-wide policies, strategies and standards for information systems and
communication technologies in healthcare services, information systems and projects for personal health records. It is
the host to NHIS (national health information system) of Turkey.
Among the targets which are stated in Strategic Plan 2013 – 2017 of Ministry of Health of Turkey are: • To develop an
Electronic Health Record system and a portal to collect, monitor and provide safe access to and sharing of personal
health records • To establish systems that enable people to reach all their health data and share them with others by
using mobile devices In order to reach these targets, Ministry of Health of Turkey launched its electronic/personal
health record for the use of Turkey’s citizens in Turkey in April 2015: E-Nabız. E-Nabız is a highly advanced electronic/
personal health record system where you can reach your health-related information including but not limited to
healthcare facility visits, prescriptions, medical reports, diagnoses, laboratory results and medical images, allergy information, blood and organ donations, emergency notes and documents. E-Nabız allows integration of medical devices with the system for wireless data communication. You can also schedule and manage appointments with physicians from primary, secondary and tertiary levels of care. You may share your information (such as previous lab results or medical images) with your doctor(s) for better medical decisions and treatments, and with your family for better assisted living. (Default is no share.) You may reach the health information of your children under 16, monitor their
health statuses and manage their vaccine schedules. E-Nabız also allows messaging between you and your doctor on
a safe platform, where you may share with your doctor any files and images regarding your health. Despite having a
high number of features, E-Nabız is operated with a user-friendly interface and has a rapidly growing number of users
in Turkey. All services of E-Nabız are given free of charge, and it is possible to use the system on both desktop and
mobile devices. Mobile versions may easily be downloaded from most common platforms such as Google Play and
App Store. Besides being an electronic health record (health data coming from healthcare facilities), E-Nabız is also a
personal health record (data fed into the system by the user himself/herself). Among the data which may be entered
to the system by the patients is blood sugar value. The patients may choose to enter and save the data for their future reference or they may choose to share the data with healthcare professionals. Entries do not have to be done
manually. Bluetooth and wireless devices may easily be integrated with one’s E-Nabız account.
MARKET APPLICATION
ICT, healthy aging, ICT-based solutions for non communicable diseases, decision support systems, personalised medicine, health informatics
As being the central authority on health in Turkey, MOH can perform various tasks including dissemination & exploitation, pilot application, use case composition, software development and so forth with its dedicated staff.
Page 310 of 487
France
MITOLOGICS
Organisation Name
Country
France
City
Romainville
Street
102, Av Gaston Roussel
Website
www.mitologics.com
Phone
0981487530
Organisation Type
SME
Person
Name
Annie Borgne-Sanchez
Email
[email protected]
Job Position
CEO/CSO
MITOLOGICS S.A.S. is an innovative biotechnology company specialized in detection of mitochondrial alterations. Mitologics owns 3 technological platforms dedicated to compounds screening on a large range of mitochondrial models:
MiToxView®: toxicity assays on healthy mitochondria and cell lines allowing detection of acute and long-term mitochondrial toxicity as source of drug-induced organotoxicity risks (PoC for DILI prediction),
MitoPathway®: efficacy assays on healthy and tumor mitochondria allowing the identification of tumor specific-compounds and their mechanism of action,
MitoXpert®: targeting assays (mitochondrial targeting and protection against particular stress).
Both mitochondrial integrity and functionality are measured in Mitologics’ technology, reflecting the global mitochondrial behaviour. The company has already managed 100 research contract studies for pharmaceutical, biotechs and
cosmetic companies in Europe and USA.
Areas of Activity
Offer: Mitochondrial dysfunction
Mitologics is looking for partners interested by innovative assays to detect mitochondrial dysfunctions. Through such
collaboration the company wishes to validate and integrate new biological models and tools.
Compounds screening on mitochondria from various origins Identification of mitochondrial damages in particular diseases
MARKET APPLICATION
Drug discovery Toxicology Rare and chronic diseases
R&D partners, worldwide
Offer: Mitochondrial targeting in oncology
Mitologics is looking for partners interested by innovative assays and therapeutic solutions to induce apoptosis in cancer cells by targeting the mitochondrion.
Unexplored mitochondrial target Tumor cell specificity Identified Hits
Page 311 of 487
France
MARKET APPLICATION
Drug discovery Oncology
R&D partners, worldwide
Page 312 of 487
Poland
Mossakowski Medical Research Centre of the Polish Academy of Sciences - MMRC
Organisation Name
Country
Poland
City
Warsaw
Street
Pawinskiego 5
Website
http://www.imdik.pan.pl
Phone
0048226685250
Organisation Type
R&D Institution
Person
Name
Agnieszka Czupryniak
Email
[email protected]
Job Position
Project and Development
Manager
Mossakowski Medical Research Centre is a well known, internationally reputable Institute of Medical Sciences Faculty
and the only institute of the Polish Academy of Sciences conducting research in the fields of both medical biology and
clinical medicine. It has also received the status of Leading National Research Centre (KNOW) for the period
2012-2017.
Established in 1967, MMRC consists of 20 departments including seven clinical research units directly collaborating
with hospitals and seven core facilities laboratories.
Main subjects of interest are: basic and clinical neurophysiology; neurochemistry; neuropathology; clinical pathophysiology; neurosurgery; applied physiology; renal physiology; transplantation; immunology; experimental pharmacology;
and biotechnology and bioinformatics.
Principal areas of study:
• Rare diseases;
• Regenerative medicine, including stem cells;
• Civilisational diseases, especially: metabolic, neoplastic, neurological and vascular, as well as ageing and age-related diseases;
• Brain diseases and disorders, including brain ischaemia, degenerative disorders of the central nervous system
(Alzheimer’s disease in particular), hepatic encephalopathy, neuromuscular diseases, and trauma of the central nervous system;
• New diagnostic methods for tumors, the synthesis of new biologically active compounds, and umbilical cord stem
cells that can be converted into brain cells; and biotechnology and bioinformatics.
MMRC has a range of well-equipped laboratories for cell cultures and organotypic slice cultures, an operating theatre
with six operating rooms and a number of laboratories for molecular biology. An integral part of the centre is the (NIHcertified) Animal House, where many species of small rodent are bred under specific pathogen free conditions.
MMRC has extensive experience in the realisation of national and international research and R&D projects. Currently
MMRC is involved in the following programmes: e.g. ERA-NET NEURON 2011 programme “European Research Projects
on Cerebrovascular Diseases” –“MRI Navigated Enhancement of Mesenchymal Stem Cell (MSC) Homing Toward Stroke
Lesion – Evaluating an Impact on Animal Recovery with Behavioral Testing and Imaging”; EEA and Norway Grants
“Contribution of glutamine transport to brain edema and dysfunction of the glutamatergic synapse associated with
hepatic encephalopathy (Hepentrans)”; EU Joint Programme - Neurodegenerative Disease (JPND) “Biomarkers for
Alzheimer’s and Parkinson’s diseases”.
MMRC is a member of the Centre for Preclinical Research and Technology Consortium (CePT). It is also running a
Translational Platform for Regenerative Medicine dedicated to basic research, developmental projects (within the pre-
Page 313 of 487
Poland
clinical ones) and clinical trials concerning the application of adipose derived regenerative cells in regenerative medicine.
MMRC co-ordinates co-operative connections that increase the chances of commercialisation research such as Mazovian Peptide Cluster, Alice Med (Advanced Laboratories in Centre of Excellence) and Pain Relief Scientific Cluster, and
the centre has its own spin-off company focused on technology transfer to business.
MMRC publishes about 140 annual indexes by JRC articles. In 2014, MMRC had a Hirsch Index of 62, with 3,016 citations.
MMRC offers its experience and looks for new ideas and scientific and business partnerships for co-operation.
Areas of Activity
the immune system
diseases
Offer: partner in rare diseases - chronic diseases - regenerative medecine projects
MMRC offers its experience in its principal areas of study as: • Rare diseases; • Regenerative medicine, including stem
cells; • Civilisational diseases, especially: metabolic, neoplastic, neurological and vascular, as well as ageing and agerelated diseases; • Brain diseases and disorders, including brain ischaemia, degenerative disorders of the central nervous system (Alzheimer’s disease in particular), hepatic encephalopathy, neuromuscular diseases, and trauma of the
central nervous system; • New diagnostic methods for tumours, the synthesis of new biologically active compounds,
and umbilical cord stem cells that can be converted into brain cells; and biotechnology and bioinformatics.
MARKET APPLICATION
We are interested in preparation as a partner in consortia preparing project proposals in the following topics:
PM-08-2017 - Rare diseases therapies PM-09-2016 - Chronic diseases therapies PM-11-2016-2017 - Regenerative
medicine PM-01-2016 - Multi-omics addressing diseases of the immune system PM-03-2017 - Diagnostic characterization of rare diseases
Research organizations, clinics, industry.
Page 314 of 487
Belgium
MULTITEL
Organisation Name
Country
Belgium
City
Mons
Street
2 rue Pierre et Marie Curie
Website
Phone
Organisation Type
R&D Institution
Person
Name
Fabian Dortu
Email
[email protected]
Job Position
Group Leader Biophotonics
Multitel is private non profit organisation in the field of Information and communication Technologies. Among various
activities like Image analysis, Signal processing or Wireless networks, Multitel is also active in Applied Photonics.
This activity includes various research topics like laser sources for imaging and spectroscopy, lab-on-chip and fibre
optic sensors, terahertz technology...
Areas of Activity
(PCP)
(PPI)
Offer: Development of multi-modal optical imaging from visible to THz.
In multi-modal imaging, different imaging modalities, like visible, infrared, fluorescence intensity or lifetimes, Raman,
two and third-harmonic generation, nanoscopy, can be combined for improved diagnostic of biological samples. Multitel's know how on state-of-art fiber lasers (ultrashort, IR and visible) development, microscopy, and advanced image
processing can be combined for the next generation diagnostic tools.
• Combined information in one shot (structural and chemical) • Non invasive biopsy
MARKET APPLICATION
• in vivo / ex-vivo diagnostic
• In-vivo / ex-vivo diagnostic: testing on relevant samples • chemometrics: extracting information from spectra (Raman, IR, fluorescence lifetimes) • endoscopy: embedding optical probe into endoscopes • Manufacturing: design and
manufacturing of instrument
Request: Applications of novel biomolecular sensors
We are looking for applications of our biomolecular sensors: from multiplexed reading of colorimetric/fluorescent assays, to label-free sensing on lab-on-a-chips and novel imaging technologies such as THz, fluorescent lifetime and Raman imaging)
Development of bioassays Surface functionalisation Validation on real samples Integration / commercialisation of
technologies
Page 315 of 487
Belgium
SMEs, Hospitals
Offer: Optical sensors and instruments for labeled or label-free assays
Page 316 of 487
France
mydoctool
Organisation Name
Country
France
City
75012
Street
76 rue de bercy
Website
www.mydoctool.com
Phone
+33 670019048
Organisation Type
SME
Person
Name
Sophie Davidas
Email
[email protected]
Job Position
ceo
Mydoctool is a French startup developing a digital platform for care-givers (doctors, surgeons, nurses ...) to manage
distant communication and interactions with their « patients».
Two of the founders have more than 20 years experience in innovation, startup developpement and technology sales.
The third one has more than 10 years experience as a private clinic director.
The objective of Mydoctool is to offer a flexible platform to program health and wellness follow up protocol. The first
users are private clinics, but long term diseases center, as well as insurances and big companies are interested by the
solution both for prevention and cure. Mydoctool aims is to provide a solution easy to use by caregivers as well as by
patients to engage short or long term communication and control.
Areas of Activity
(PCP)
(PPI)
population
Request: Health care follow up protocol design and test
We are looking for partners and early adopters willing to work with us on health follow up protocol. We are looking for
doctors (surgeons or long term diseases specialists) as well as potential content partners (data, information, devices)
to work on protocol.
We are looking for doctors, surgeons, or health organisations willing to design with us and test health follow up protocol. As some of the parameters might be health data, or data coming from health connected devices, we will be happy to discuss with companies providing health data.
Page 317 of 487
France
We are looking for doctors, surgeons, or health organisations willing to design with us and test health follow up protocol.
Page 318 of 487
Netherlands
MyLife Technologies BV
Organisation Name
Country
Netherlands
City
Enschede
Street
Hallenweg 23, CR1347
Website
www.mylifetechnologies.nl
Phone
+31-20-6893753
Organisation Type
SME
Person
Name
PieterJan Vos
Email
[email protected]
Job Position
CEO
We are offering a platform technology for ceramic nano-porous microneedle arrays (npMNA's) for dermal drug delivery. The npMNA's are integrated into a skin patch and allow for minimally invasive and pain-free administration of
pharmaceuticals. The technology is particularly suitable for intradermal delivery of vaccines or immunotherapeutics
and transdermal delivery of specific small molecules. In the case of (prophylactic or therapeutic) vaccines, the dermal
delivery should lead to better immunoreponses and implies a considerable drug dose-sparing potential compared to
intramuscular delivery.
We are a spin-off from University of Twente, MESA+, Institute for Nanotechnology (NL). Our labs are based at the Leiden BioScience Park (NL).
Patents were granted to our technology in the US, Japan, China and in Europe. The production of our npMNA's is done
in an ISO certified plant for high-tech ceramics in The Netherlands. We are currently at the phase of proof-of-concept
for various drug delivery applications (vaccines, immunotherapeutics, small molecules) in animal models (mice, pigs).
We collaborate with pharmaceutical and biotech companies (co-development) and we develop products in-house. We
are open to collaborations with companies working in the field of vaccines, immunotherapy, ... In our labs in Leiden,
we can test the feasability of our delivery solution for your specific compounds.
Areas of Activity
Preventing disease
Request: Smart microneedle patches for dermal drug delivery
We offer a patented technology based on nanoporous microneedle arrays (npMNA's) for dermal drug delivery. The
npMNA's are integrated into a skin patch and allow for minimally invasive and pain-free administration of pharmaceuticals via the skin. Our focus areas are prophylactic vaccines, therapeutic vaccines (immunotherapy) and specific
small molecules. In the case of vaccines and immunotherapeutics the intradermal delivery (targeting dendritic cells),
better immuneresponses and a considerable dose sparing potential are expected. The delivery is easy and pain-free
and allows for self-administration by the patient.
We are looking for partners working in the field of vaccines (infectious diseases) or immunotherapy. We wish to combine your drug compound with our drug delivery technology with the aim to develop the best possible solution for the
patient. Also companies working in the field of transdermal delivery of small molecules could be of interest.
Page 319 of 487
Netherlands
We are open for discussions with big pharma, small biotech companies, research institutes, etc. with expertise in the
fields described above, We are open for discussions with people from any of the EU or EU-associated countries. Also
CRO's working in any of the relevant fields could be of interest.
Page 320 of 487
Switzerland
NANOGALENIX Sàrl
Organisation Name
Country
Switzerland
City
Porrentruy
Street
7, rue d'Airmont
Website
www.nanogalenix.com
Phone
+33750608797
Organisation Type
SME
Person
Name
Raphaël DUVAL
Email
[email protected]
Job Position
CSO
NANOGALENIX is developing Drug Delivery Systems for all administration routes. The company is also involved in the
design and commercialization of nutraceuticals and Home & Personal Care products.
Areas of Activity
Preventing disease
young
Offer: Mesoporous silica nanoparticles fot theranostics
Mesoporous silica nanoparticles ("MSNPs") have the ability to carry at the same time multiple therapeutic agents as
for example, constrat molecules for MRI medical diagnosis and anticancer drugs loaded together in the MSNP. Additional functionality can also be added, as antibodies or antibody fragment to target a specific receptor. Imaging and
treatment of solid tumors would be a challenge but taking advantage of the EPR effect (enhanced permeation and retention effect) this difficulty could be overcome on the principle. The company offers an broad experience in silica
modification with suitable silanes for anchoring peptides, proteins, antibodies, sugars ...
theranostic principle : imaging and treating at the same time No toxicity associated with MSNPs I.V. administration
(shunt of the firts hepatic path) targeting one organ or a specific type of cells (cancer cells)
MARKET APPLICATION
Pharmaceuticals Nanomedicine
Pharmaceutical companies, start-up. Academic partners
Offer: Nano/micro drug delivery systems for the enteral administration route with enhanced bioavailability
A Swiss start-up Company is offering original solutions for the administration of pharmaceutical or nutraceutical actives via the enteral route using Nano-Drug Delivery Systems “nano-DDSs” in the form of emulsions or gels. Nanoand micro-DDSs have been produced in the form of emulsions or gelified emulsions (aqueous) with omega-3 as a
Page 321 of 487
Switzerland
model drug. The Nano/micro-DDSs emulsions can be then further dried leaving Nano- and micro-DDSs powders.
These powders are self-emulsifying when rehydrated giving back the target size of the starting emulsion. By choosing
the adequate emulsifiers and stabilizers, facilitated diffusion from the gastrointestinal tract (through the Peyer’s
plaques) to the blood plasma can be envisioned. Enhanced plasma delivery of DHA (docosahexaenoic acid) or
carotenoids (lutein) or omega-3 acids are proposed as a starting project.
Advantages and innovations: - low cost process - no toxicity issues - enhanced bioavailability
MARKET APPLICATION
pharmaceuticals, nutraceuticals, food nutriments
Industrial partners from the pharmaceuticals, nutraceuticals or food sectors are sought for co-development and production Academic institutions with expertise in pharmacology, pharmacokinetics Academic Institutions having expertise with mini-pigs models
Offer: OENE: oxygen entrapped nano-emulsions for local delivery of oxygen to cells, tisssues and organs
Oxygen delivery to cells, tissues and organs is a very important issue and necrosis if often associated with hypoxia. In
addition oxygen seems to have the property to enhance antimicrobial effects of drugs. Local delivery of oxygen to its
target using nano-emulsions as carrier is a new approach that could open new horizon in the field of combined therapeutics or regenerative medicine.
Company offers several strategies to synthesize the OENE. Proof of concept has been validated at the lab scale. OENE
can be further modified at its surface for targeting. OENE has also been gelified for further incorporation into tissues
for example. The company is looking to cooperate with partners active is the fields of tissue/organ injuries, wound
healing, microbial infections, and regenerative medicine
MARKET APPLICATION
Pharmaceuticals, nanomedicine, regenerative medicine
Universities, Research Centers having interest on new tools for oxygen use/delivery Companies/start-up working on
regenerative medicine and antimicrobials.
Offer: Antibiotics from the natural pool active on multiresistant bacterial strains
Essential oils "EOs" have been recognized as beneficial to mammal health for centuries. One major limitation to the
medical use of EOs up to now has been their insolubility in aqueous media (plasma). NANOGALENIX has designed
nano-emulsions of EOs (NEEOs) leading to an inceased efficiency through a better biovailibilty with less associated
toxicity.
NEEOS can be tailored for specific use. The Nanogalenix formulation gives superior stability with enfanced biovailibility. All administration routes can be envisionned. Selection of EOs extracts have demonstrated high efficiency on multiresistant bacterial strains (MDR)
MARKET APPLICATION
Pharmaceutics: antimicrobial polymers for hospital use (medical Device), mucosa delivery: dual combination with registered antimicrobials to overcome resistance on MDR strains. Animal pharmaceutics, nutraceuticals, cosmetics.
Academic partners involved in antimicrobial research. Pharmaceutical companies interested by co-delivery of NEEOs
with other actives Companies developin Medical Devices
Page 322 of 487
Hungary
National Healthcare Service Center
Organisation Name
Country
Hungary
City
Budapest
Street
Diós árok 3.
Website
Phone
Organisation Type
Person
Name
Balázs Babarczy
Email
[email protected]
Job Position
analyst
Our institution is the manager of most (ca. 100) public hospitals in Hungary, but it also has national competences of
strategic alanysis and policy advice. An ongoing project aims at the coordination of R&D activities in our hospitals. We
are members of the Central European Health Policy Cooperation, a recently established network of government background institutions in healthcare which would like to participate in Horizon projects.
Areas of Activity
EU level
Preventing disease
young
(PCP)
(PPI)
population
Methods and data
policies
Offer: Data analysis and policy concept making
The National Healthcare Service Center of Hungary is a middle-level government organisation, responsible for the organisation of inpatient and related outpatient care. We manage the bulk of the country's hospitals, define care guidelines, help ensure high quality care, and prepare concepts for the development of the health care system.
We have recently mapped the R&D activities ongoing in some of the most important research hospitals in the country,
and defined a strategy to better exploit the know-how and potential of these institutions. We are also preparing policy
recommendations a regular basis, aiming at the implementation of international best practice in Hungary.
MARKET APPLICATION
We can offer system wide knowledge of health care performance assessment, quality management and provider system planning. We also exploit a large database on health care interventions across the country.
Page 323 of 487
Hungary
We are looking for consortia with system wide projects related to health system design/implementation. Mental health
care is a field of particular interest for us.
Request: SC1-PM-21 Implementation research
We are looking for patners with analytical and/or organisational competences regarding the SC1-PM-21 call on implementation research.
Page 324 of 487
Hungary
National Healthcare Service Center (NHSC)
Organisation Name
Country
Hungary
City
Budapest
Street
Diós árok 3
Website
Phone
Organisation Type
Person
Name
István Csizmadia
Email
[email protected]
Job Position
Head of International Programmes and Projects
NHSC is a central government organisation responsible for overseeing more than 100 public hospitals across Hungary,
which make up more than 80% of total hospital beds. It controls hospital management and administers centralised
procurement. In its strategic roles, it is involved in capacity planning, patient safety measures, development of care
pathway guidelines and for health system performance assessment and supporting RDI activities of hospitals too.
NHSC has substantial experience in the preparation and execution of EU Health programme joint actions and EFSI projects (e.g. development of RDI at national level and in the convergence regions). We led Subgroup’2 (“SG2” on sharing and analysing experiences, best practices, to build up success factors for the effective use of Structural Funds for
health investments, 2011-2013) within the Reflection Process on Health Systems (Council (EPSCO) Conclusions on
Health Systems “Towards modern, responsive and sustainable health systems”).NHSC is a central government organisation responsible for overseeing more than 100 public hospitals across the country, which make up more than 80%
of total hospital beds. It controls hospital management and administers centralised procurement. In its strategic roles,
it is involved in capacity planning, patient safety measures, development of care pathway guidelines and for health
system performance assessment and supporting RDI activities of hospitals too. NHSC has substantial experience in
the preparation and execution of EU joint actions and EFSI projects (e.g. development of RDI at national level in the
convergence regions). We led Subgroup’2 (“SG2” on sharing and analysing experiences, best practices, to build up
success factors for the effective use of Structural Funds for health investments, 2011-2013) within the Reflection
Process on Health Systems (Council (EPSCO) Conclusions on Health Systems “Towards modern, responsive and sustainable health systems”).
Areas of Activity
EU level
Methods and data
policies
Preventing disease
young
Page 325 of 487
Hungary
(PCP)
(PPI)
Offer: Unmet needs and validation
Description: NHSC is an end user of RDI results, therefore, we offer our capacities for partnerships looking for partner
in defining RDI needs and/or validation RDI results.
Offer: National Healthcare Service Center (NHSC) colleagues and NHSC hospitals are interested in joining consortium looking for end-user of research
National Healthcare Service Center (NHSC) colleagues and NHSC hospitals are interested in joining consortium looking
for end-user of research
Request: Looking to partner with National Healthcare Service Center (NHSC) and NHSC
hospitals
Looking to partner with National Healthcare Service Center (NHSC) and NHSC hospitals
Page 326 of 487
Belgium
NCP-Wallonie
Organisation Name
Country
Belgium
City
Wavre
Street
Chemin du Stocquoy 3
Website
http://www.ncpwallonie.be/fr/
Phone
003210485033
Organisation Type
Other
Person
Name
Francois Louesse
Email
[email protected]
Job Position
NCP
National Contact Point for Horizon-2020 in Wallonia / BELGIUM
NCP-Wallonie provides you with advice and guidance, as well as customised support to boost your chances of securing funding from the European Commission and Wallonia. Our services are aimed at businesses (small, medium or
large), universities, research centres, associations and other organisations based in Wallonia (BELGIUM) with
ambitious R&D and innovation projects.
NCP-Wallonie is in contact with organisations looking for partners and/or consortium for different topics.
Areas of Activity
the immune system
diseases
EU level
Methods and data
Preventing disease
Initiative
young
Page 327 of 487
Belgium
Offer: NCP in Belgium / Identifying and selecting the best Belgian partners for your project.
NCP-Wallonie is in contact with organisations looking for partners and/or consortium for different topics.
Page 328 of 487
Turkey
Nesne Elektronik Danışmanlık Ltd. Şti
Organisation Name
Country
Turkey
City
Izmir
Street
Ege Sanayi Sitesi
Website
www.nesne.com
Phone
Organisation Type
SME
Person
Name
Hilal Tolasa Gündoğdu
Email
[email protected]
Job Position
NESNE Electronic Design and Consultancy is a high-tech, private R&D Company based in Izmir Institute of Technology
(Turkey), the mission of which is to carry out research and development work on behalf of industry, mainly SMEs, in
order to contribute in their competitiveness, productivity and sustainability.
Nesne’s activities are mainly divided into the following business areas; Project / Product Design, Development and
Production Technology; has generally concentrated its efforts on designs and development of; industrial electronics,
sensor technologies, hardware and software development for embedded systems, military products & systems, underwater technologies (robotics), wireless communication systems, underwater communication systems, home appliances, manufacturer and supplier of technical equipment for aquaculture industry, agricultural machinery, testing
equipment, production control automation and related electronic – electro mechanic products and related products In
addition to product design, Nesne is considered a key partner in projects' development due to their vast experience in
product design and validation of prototypes at industrial scale.
Nesne team is built upon a platform of knowledge and expertise pertaining to its founders in carrying out research
and development initiatives for industry under the National TUBİTAK (The Scientific and Technological Research Council of Turkey) Programmes and EU projects;
• ARROWS FP7-308724 (Archaeological Robot systems for the World’s Seas)
• eFISHent -FP7- 262155 (Improvement of Feeds and Feeding Efficiency for Sea Bass in Cage Farms in the
Mediterranean)
• FISH-FP6-508547 (Facilitating Innovation for Sustainable Fisheries and marine resources
• FP6 SUSTAINAQ FOOD-CT-043150 (Sustainable Aquaculture production through the use of Recirculation systems)
Areas of Activity
(PCP)
(PPI)
Offer: Interested in development of Exo-skeleton systems
As Nesne Elektronik, R&D company, experienced in electronics and mechanics, our main interest is working on development of exoskeleton systems. However, we're open to discuss for possible collaborations that we can support and
contribute to the proposals within our expertise.
Page 329 of 487
United Kingdom
Northumbria University
Organisation Name
Country
United Kingdom
City
Newcastle upon Tyne
Street
Camden Street
Website
Phone
00441912437611
Organisation Type
University
Person
Name
Maia Angelova
Email
[email protected]
Job Position
Professor of Mathematical Physics
Research rich and teaching excellence with high student satisfaction;
Research is orientated towards applications;
Large portfolio of teaching undergraduate and post-graduate programmes;
large portfolio of research and enterprise activities.
Areas of Activity
Preventing disease
Initiative
(PCP)
(PPI)
Methods and data
Offer: Integrated approach to modelling of health and disease with links to ageing
Mathematical and computer models for physiological networks including regulation and control and dynamical systems approach and connectivity between network nodes. Investigation of early warning signals for health and disease
and predictive models of ageing.
Innovative integrative mathematical models with predictive aspects; Holistic approach to health; Development of
tools for personalised medicine.
MARKET APPLICATION
Health and preventive medicine; Ageing and chronic disease management; Telecare and telemedicine.
Medical; data generation; testing of models; Engineering - prototype of tool
Page 330 of 487
Norway
Organisation Name
Country
Norway
City
Trondheim
Street
Høgskoleringen 1
Website
Phone
Organisation Type
University
Person
Name
Steinar Krokstad
Email
[email protected]
Job Position
The Norwegian University of Science and Technology (NTNU) is the primary Norwegian university in engineering and
technology, and with more than 21000 students. As a full range university, NTNU encompasses 7 faculties and 53 departments. More than 300 PhD-degrees are awarded yearly, within the fields of technology, science, arts and humanities, social sciences and medicine. From 1st January 2016, NTNU is merged with three regional colleges and will be
Norway’s largest university, with about 38000 students.
NTNU has a broad range of contacts with industry. The annual budget of NTNU is around € 600 million, 25% of which
is externally funded. NTNU is an active participant in the EU Framework Programmes for Research and Innovation,
and participate in more than 130 FP7 projects and 26 H2020 projects, so far.
Areas of Activity
Methods and data
policies
The Department of Public Health and General Practice at NTNU is responsible for the Nord Trøndelag Health Study
(HUNT), one of the largest health studies ever performed. It is a unique database of personal and family medical histories collected during three intensive studies. Every citizen of Nord-Trøndelag County in Norway 20 years or older,
was invited to participate. The fundamental strategy is to earn and maintain the confidence of the population we work
in and with as is necessary for any successful population study. This strategy has resulted in extraordinarily high participation rates. There is enthusiastic public and political support for HUNT and of the HUNT Research Centre. This has
created a good basis for further health surveys in the county and an excellent research environment.
HUNT Study includes data from questionnaires, interviews, clinical measurements and biological samples (blood and
urine). In the latest survey a state of the art bio-bank was established, with availability of biomaterial for decades
ahead. About 80% of the population lives in typically Norwegian small urban environments/towns. Moreover, the Trønderlag Health Study has collected the health data in conjunction with data that allow characterising living-, working-,
environmental conditions as well as lifestyle habits; self reported health and behavioural patterns. The data allow to
build cohort-profiles characteristic for specific groups of a population; and to relate these profiles to data that describe the status of health and wellbeing.
We wish to join a consortium for that will apply for the SC1-PM-18-2016 call "Big data supporting public health policies". In addition, we are also interested to discuss with potential applicants for SC1-PM-10-2017, "comparing the effectiveness of existing healthcare interventions in the adult population". We believe that our HUNT database is a valu-
Page 331 of 487
Norway
able resource that can be exploited in either of these calls to identify the determinants of health and disease and best
practices in medicine.
Offer: One of the largest total population based helath
Offer: One of the largest total population based longitudinal health surveys, The HUNT
Study, Norway
Adult (20+ yrs) cohorts from the 1980ies that can be followed over decades in hight quality Norwegian registers. Data
from questionnaires, clinical measurements and biological samples. Adolescent (13-19 yrs) cohorts from the 1990ies.
A new large survey under planning in 2017. The individual data can be linked to big data and wearable technology.
MARKET APPLICATION
Publicly funded research, innovation.
Partners with competance in Big Data handling and other health studies.
Page 332 of 487
Norway
Organisation Name
Country
Norway
City
Trondheim
Street
Høgskoleringen 1
Website
Phone
Organisation Type
University
Person
Name
Emma Walton
Email
[email protected]
Job Position
EU Advisor
The Norwegian University of Science and Technology (NTNU) is the primary Norwegian university in engineering and
technology, and with more than 21000 students. As a full range university, NTNU encompasses 7 faculties and 53 departments. More than 300 PhD-degrees are awarded yearly, within the fields of technology, science, arts and humanities, social sciences and medicine. From 1st January 2016, NTNU is merged with three regional colleges and will be
Norway’s largest university, with about 38000 students.
NTNU has a broad range of contacts with industry. The annual budget of NTNU is around € 600 million, 25% of which
is externally funded. NTNU is an active participant in the EU Framework Programmes for Research and Innovation,
and participate in more than 130 FP7 projects and 26 H2020 projects, so far.
Areas of Activity
EU level
Preventing disease
young
Methods and data
policies
created a good basis for further health surveys in the county and an excellent research environment.
Page 333 of 487
Norway
build cohort-profiles characteristic for specific groups of a population; and to relate these profiles to data that describe the status of health and wellbeing.
We wish to join a consortium for that will apply for the SC1-PM-18-2016 call "Big data supporting public health policies". In addition, we are also interested to discuss with potential applicants for SC1-PM-10-2017, "comparing the effectiveness of existing healthcare interventions in the adult population". We believe that our HUNT database is a valuable resource that can be exploited in either of these calls to identify the determinants of health and disease and best
practices in medicine.
Page 334 of 487
Norway
Organisation Name
Country
Norway
City
Levanger
Street
Forskningvegen 2
Website
http://www.ntnu.no/hunt
Phone
Organisation Type
University
Person
Name
Andreas Weser
Email
[email protected]
Job Position
Scientific Project Developer
The Norwegian University of Science and Technology (NTNU) is a centre for science and technology education in Norway. It is Norway’s second largest university with more than 21000 students and 4800 employees. NTNU encompasses 7 faculties and 53 departments. Between 250 and 350 PhD-degrees are awarded yearly, within the fields of technology, science, medicine, arts and humanities and social sciences. NTNU has a broad range of contacts with industry.
NTNU is an active participant in the EU R&D Framework Programmes and participated in 98 FP7 projects.
The Faculty of Medicine has 1200 employees, with 200 students entering studies in clinical medicine, masters in neuroscience, health science or exercise physiology annually. The Department of Public Health and General Practice is
one its five departments, and is involved in research within disease comprehension and prevalence, general practice
and primary healthcare, forming and evaluating health services, preventive medicine and medical ethics. The Department is involved in education in community medicine, general practice, epidemiology, doctor- patient communication,
health politics and health economics, medical ethics and women's health.
The Department is responsible for the Nord Trøndelag Health Study (HUNT), which is is one of the largest health studies ever performed. It is a unique database of personal and family medical histories collected during three intensive
studies. The fundamental strategy is to earn and maintain the confidence of the population we work in and with as is
necessary for any successful population study. This strategy has been successful and has resulted in extraordinarily
high participation rates. There is enthusiastic public and political support for HUNT and of the HUNT Research Centre.
This has created a good basis for further health surveys in the county and an excellent research environment.
Areas of Activity
EU level
Preventing disease
young
Methods and data
policies
Offer: Exploitation of a unique population data repository for public health policy development, forecasting of health trends, impacts and comparing effectiveness of interventions.
Challenge: PM-18-2016 - Big Data supporting Public Health policies
The Nord Trøndelag Health Study (HUNT) covers longitudinal population data, which include health, social, occupational, behavioral and environmental data. It is one of the largest health studies ever performed. The cohort was es-
Page 335 of 487
Norway
tablished in the 1980-ies, HUNT4 is planned in 2017. The resulting HUNT databank is a structured relational database
that includes data from the HUNT Study. The Data Bank Web application provides an excellent overview of the material for researchers. http://www.ntnu.edu/hunt / and http://www.ntnu.edu/hunt/databank
build cohort-profiles characteristic for specific groups of a population; and to relate these profiles to data that describe the status of health and wellbeing. Base on HUNT data we developed - in cooperation with national and regional health authorities in Scandinavia - innovative , pragmatic approaches for forecasting health impacts of clinical and
public health interventions in a qualitative but also quantitative manner. Furthermore, results from our "policy-labs"
initiative enables us to define and extract those determinants and variables that need to be tackled in order enhance
patient's compliance with guidelines and to have a chance influence health political decision making.
MARKET APPLICATION
Developers and implementors of health interventions, prevention programs, e.g. for lowering obesity rates, prevalence of cardio-vascular diseases etc. - both clinical and public health. Public health sector health institutes. Health
policy developers, health administrations and politicians.
practices in medicine. Apart from that we are open to discuss any other reasonable project initiative.
Request: Treating and managing diseases PM-10-2017 - Effectiveness of healthcare interventions for adult population
created a good basis for further health surveys in the county and an excellent research environment. Innovative aspects and main advantages: HUNT Study includes data from questionnaires, interviews, clinical measurements and biological samples (blood and urine). In the latest survey a state of the art bio-bank was established, with availability of
biomaterial for decades ahead. About 80% of the population lives in typically Norwegian small urban environments/
towns. Moreover, the Trønderlag Health Study has collected the health data in conjunction with data that allow characterising living-, working-, environmental conditions as well as lifestyle habits; self reported health and behavioural
patterns. The data allow to build cohort-profiles characteristic for specific groups of a population; and to relate these
profiles to data that describe the status of health and wellbeing. Market application: (I left this blank) Type of partner
sought: We wish to join a consortium for that will apply for the SC1-PM-18-2016 call "Big data supporting public health
policies". In addition, we are also interested to discuss with potential applicants for SC1-PM-10-2017, "comparing the
effectiveness of existing healthcare interventions in the adult population". We believe that our HUNT database is a
valuable resource that can be exploited in either of these calls to identify the determinants of health and disease and
best practices in medicine.
created a good basis for further health surveys in the county and an excellent research environment. Innovative aspects and main advantages: HUNT Study includes data from questionnaires, interviews, clinical measurements and biological samples (blood and urine). In the latest survey a state of the art bio-bank was established, with availability of
Page 336 of 487
Norway
biomaterial for decades ahead. About 80% of the population lives in typically Norwegian small urban environments/
towns. Moreover, the Trønderlag Health Study has collected the health data in conjunction with data that allow characterising living-, working-, environmental conditions as well as lifestyle habits; self reported health and behavioural
patterns. The data allow to build cohort-profiles characteristic for specific groups of a population; and to relate these
profiles to data that describe the status of health and wellbeing. Market application: (I left this blank) Type of partner
sought: We wish to join a consortium for that will apply for the SC1-PM-18-2016 call "Big data supporting public health
policies". In addition, we are also interested to discuss with potential applicants for SC1-PM-10-2017, "comparing the
effectiveness of existing healthcare interventions in the adult population". We believe that our HUNT database is a
valuable resource that can be exploited in either of these calls to identify the determinants of health and disease and
best practices in medicine.
build cohort-profiles characteristic for specific groups of a population; and to relate these profiles to data that describe the status of health and wellbeing. Base on HUNT data we developed - in cooperation with national and regional health authorities in Scandinavia - innovative , pragmatic approaches for forecasting health impacts of clinical and
public health interventions in a qualitative but also quantitative manner. Furthermore, results from our "policy-labs"
initiative enables us to define and extract those determinants and variables that need to be tackled in order enhance
patient's compliance with guidelines and to have a chance influence health political decision making.
MARKET APPLICATION
Developers and implementors of health interventions, prevention programs, e.g. for lowering obesity rates, prevalence of cardio-vascular diseases etc. - both clinical and public health. Public health sector health institutes. Health
policy developers, health administrations and politicians.
practices in medicine. Apart from that we are open to discuss any other reasonable project initiative.
Page 337 of 487
Belgium
Novadip
Organisation Name
Country
Belgium
City
LLN
Street
chemin du cyclotron 6
Website
Phone
Organisation Type
SME
Person
Name
JF Pollet
Email
[email protected]
Job Position
CEO
Established in 2013, Novadip Biosciences is a biopharmaceutical company founded to design, develop and bring to
the market innovative stem cell-based therapies for regenerative medicine. The first proprietary cellular therapy of
Novadip Biosciences is a totally differentiated and 3D osteogenic scaffold-free structure which provide innovative
treatments for severe bone healing disorders.
Their lead product CREOST® introduces new principles of guided tissue regeneration based on stem cells from fatty
tissue, associated to osteoinductive, osteoconductive and osteogenic properties to manufacture 3D natural bone implants with the right shape, mineralization and all mechanical properties for replacement and repair of large bone defects.
Areas of Activity
diseases
Methods and data
Offer: Clinical development of Novadip Biosciences (Regenerative Medicine)
Established in 2013, Novadip Biosciences is a biopharmaceutical company founded to design, develop and bring to
the market innovative stem cell-based therapies for regenerative medicine. The first proprietary cellular therapy of
Novadip Biosciences is a totally differentiated and 3D osteogenic scaffold-free structure which provide innovative
treatments for severe bone healing disorders. Their lead product CREOST® introduces new principles of guided tissue
regeneration based on stem cells from fatty tissue, associated to osteoinductive, osteoconductive and osteogenic
properties to manufacture 3D natural bone implants with the right shape, mineralization and all mechanical properties for replacement and repair of large bone defects.
Creost® is a proprietary cellular therapy to provide innovative treatments for bone healing disorders and bone defects. The product is made of adipose-derived stem cells obtained after their isolation from a minimally invasive subcutaneous procedure, and their differentiation with a proprietary quality controlled demineralised bone matrix (DBM)
into 3-dimensional bone implant. Creost® is an easy-to-use 3D osteogenic structure from autologous stem cells which
reconstructs critical size bone defects without the use of any scaffold. The product is easily and directly implantable
Page 338 of 487
Belgium
by the surgeon on the bone defect for a perfect engraftment. The 3D implant can be sutured, glued or naturally fixed
in small or large bone defects. Creost® is a totally differentiated osteogenic structure and fully characterized in view
to obtain the same properties as a real bone, non-immunogenic, with a desirable handling and mechanical characteristics required for perfect engraftment in cases of severe bone healing disorders and bone defects. Main advantages/
technical specifications/current stage of development: minimally invasive procedure (stem cells from fat tissue), high
capacity of differentiation, same properties as a real bone, easy-to-use without any scaffold / autologous and allogenic
approachs / phase II in preparation Areas of activity: Europe and US markets
MARKET APPLICATION
Areas of activity: Europe and US markets
Cooperation profile with Partners in preclinical and clinical developments for orthopedic surgeries (spine) ; Orthopedic
centers interested to participate to our clinical studies ; CRO ; CDMO (manufacturing and/or QC activities) ; partnership with suppliers of devices for spine surgeries
Page 339 of 487
Germany
Nurogames GmbH
Organisation Name
Country
Germany
City
Köln
Street
Schaafenstr. 25
Website
www.nurogames.com
Phone
Organisation Type
SME
Person
Name
Andrew Pomazanskyi
Email
[email protected]
Job Position
Project Manager
Nurogames GmbH, Cologne/Germany is an independent games development company, founded in early 2006 by
experts of the game and media industry. Next to our head office in Cologne we maintain representative offices in
Barcelona and Berlin. By participating in multiple research projects on a national and international level,
Nurogames ensures long-term orientation and knowledge of state-of-the-art technologies. The Team of Nurogames
has got many years of experience in research projects of the BMBF and the European Union.
Nurogames’ primary activity is the development and publishing of mobile, cross-platform and Smart TV
games. Another focus of the company is placed on the development of games for Xbox 360 (Kinect), Playstation 3,
Playstation Vita, Nintendo 3DS, Nintendo DS and Nintendo Wii.
Further activities include the development of web-based e-learning games and game-based e-learning solutionsas well as the production of online and browser games for an international market. Recently Nurogames started
developing games for Smart TV as well as location-based and augmented-reality games.
Areas of Activity
Preventing disease
young
(PCP)
(PPI)
population
Methods and data
policies
records (PPI)
Health ICT SMEs
Page 340 of 487
Germany
Offer: Nurogames GmbH Research and Innovation Profile
Nurogames GmbH is an independent software development company, founded in early 2006 by experts of media industry. Nurogames develops, produces and markets quality products, services and trend-setting media solutions for
mobile applications and interactive rich-media content, focusing on user interfaces and human-machine interaction
with offices in Cologne (Germany, head office), Berlin (Germany) and Barcelona (Spain). Nurogames covers the entire
chain of game development – from the initial idea to final production – and has a wealth of experience in developing
mobile and cross-platform games, especially for iOS (iPhone & iPad), Android (Smartphones & Tablets), Windows
Phone, PC (Windows & MacOS) and consoles (Nintendo 3DS, DS & Wii, XBox, PlayStation etc.). Other fields of expertise include the development of e-learning games, game-based e-learning solutions and the integration of social networking services (Facebook, Google+, etc.). Nurogames develops high quality gamification solutions for Leisure-, Serious- and e-health markets. With many B2B and B2C products it has an extensive experience in cross-platform design
and software development. By participating in research & development projects within national and international research consortia, Nurogames ensures that its projects will always utilize the most advanced state-of-the-art technology.
By participating in multiple research projects on a national and international level, Nurogames ensures long-term orientation and knowledge of state-of-the-art technologies. The Team of Nurogames has got many years of experience in
research projects of the BMBF and the European Union (FP6,FP7 and H2020). Further activities include the development of e-health software application and m-health software solutions which can bee seeing in a number of health-related research projects (http://en.nurogames.com/index.php/f-e)
Cooperation partners, Coordinators
Page 341 of 487
Germany
Nuromedia GmbH
Organisation Name
Country
Germany
City
Köln
Street
Schaafenstr. 25
Website
http://www.nuromedia.com
Phone
+4922139880800
Organisation Type
SME
Person
Name
Jens Piesk
Email
[email protected]
Job Position
CEO / Managing Director
Nuromedia GmbH, Cologne/Germany, was founded in 2006 by Jens Piesk and Dr. Holger Sprengel, experienced entrepreneurs in the media and mobile sector. The team of Nuromedia/Nurogames has 15 years of experience of european
and national funded research, development & innovation projects. The company consists of the following departments: Nuromobile, Nurogames, Nuromedia online and Nurostudios.
Nuromedia develops, produces and markets quality products, services and trend-setting media solutions for mobile
applications and interactive rich-media content, focusing on user interfaces and human-machine interaction. Nuromedia bundles high design and software competence as well as know-‐how related to the market and communication. All
the project teams reflect this interdisciplinary idea. Since the beginning the technology focus lied in the mobile and
internet sector for interactive and mobile applications. In order to give the customers a lasting competitive edge in
communication, Nuromedia is continuously developing new application- and performance-possibilities in the fields of
communication and cross-media applications in close cooperation with well-known research- and technology-partners.
The mobile division is specializing in the development, production and marketing of mobile applications and contents,
covering innovative applications like games, e-learning, active screens, instant messaging etc. Current developments
in the area and the proliferation of mobile platforms (e.g. iOS, Android, Windows Phone) require a universal development approach. Most recently, Nuromedia developed several cross-platform applications and games with the cross-platform open source technology Cocos2d-x.
Customers of Nuromedia include Brainpool, Kiddinx, Hahn Film, Tivola, Nickelodeon, KIKA, Disney, Bertelsmann, Vodafone, T-mobile, Ströer AG, Mabber.com, PKW.de, scoyo.com, Jamba, Mindmatics, Sky, and a number of media and advertising agencies.
Nuromedia participated / participates in 9 national and international research projects. Their overview can be found
below and on the website www.nuromedia.com/en/research.
Areas of Activity
EU level
(PCP)
(PPI)
Health ICT SMEs
Page 342 of 487
Germany
population
Methods and data
policies
records (PPI)
Offer: ICT: development of cross-platform ehealth & mhealth applications and games
Most recently, Nuromedia developed several cross-‐platform applications and games with the cross-platform open
source technology Cocos2d‐x and Unity. Nuromedia participated / participates in a number of national and international research projects. Their overview can be found below and on the website www.nuromedia.com/en/research. The
Core-Expertise for Nuromedia/Nurogames and tasks & roles that Nuromedia/Nurogames can fulfill in a consortium are
- Requirements Analysis - Software & System Design & Integration, Software Architecture - Software / Server Development for Massively Multi-User Online Games & Applications - Software / Client Development for 2D Applications in
Cocos2D-x for Mobile ( iOS, Android, etc.), PC ( Windows, MacOS, etc.), etc. - Software / Client Development for 3D Applications in Unity3D for Mobile (iOS, Android, etc.), Web Applications (Browser), PC (Windows, MacOS, etc.), Console
(esp. Nintendo DS & Wii), etc. - iOS/Android App & Game Development - GUI Design, Application Design, Game Design
- 2D Graphics Design, Illustration - 3D Graphics Design, Modelling & Animation, Motion Capturing - 2D / 3D Character
Design - Web Development & Web Design - Mobile Development & Mobile Application Design - Cross-Platform-Development & Design
PATHway: Technology enabled behavioral change as a pathway towards better self-management of CVD
http://pathway2health.eu Technology enabled behavioral change as a pathway towards better self management of
CVD. Nurogames creates an exergaming platform as well as an autonomous graphical avatar. Call/Topic: Horizon 2020
PHC 26-2014, Self management of health and disease: citizen engagement and mHealth RehaInterAct: 3D motion
therapy for the home environment In the project “RehaInteract - 3D motion therapy for the home environment” a
sensor-based interaction and communication platform for the therapeutic monitoring of rehabilitation exercises in the
home environment was developed. The goal is to support individual exercise scenarios related directly to the particular handicap of the patient by using pressure, motion and optical sensors (both local and integrated into therapeutical
objects) Smart Senior: Intelligent solutions for senior citizens’ home environments http://www.smart-senior.de SmartSenior is one of the flagship projects of BMBF within the high-tech strategy for Germany. Intelligent assistance systems (AAL – Ambient Assisted Living) are developed to contribute to the prevention of accidents and diseases and to
facilitate everyday household work. Thanks to them, it will be possible for older people to live a long, happy and independent life in the Runsafer - Development of a Sensor-enhanced Running Shoe with Real-Time Biomechanical Feedback http://www.runsafer.eu The research project RunSafer focuses on developing a new running shoe with integrated
electronics, which should reduce the risk of injury of the athlete by providing biomechanical feedback in real time. In
parallel, a mobile application and a web portal as a tool for training program management will be developed. The project is implemented by a European consortium of research institutes, research companies and development companies including Nuromedia.
MARKET APPLICATION
- cardio-vascular deseases - physio-therapy - fitness etc.
Coordinator / Consortium Leader Hospitals etc.
Page 343 of 487
France
OpenHealth Company
Organisation Name
Country
France
City
Paris
Street
141 rue de Rennes
Website
Phone
0645576745
Organisation Type
SME
Person
Name
Nicolas GRELAUD
Email
[email protected]
Job Position
International Development
Director
OpenHealth Company provides healthcare data analysis applied to marketing and clinical research for the healthcare product industry and will also focus on public health, epidemiological research and medico-economic issues for
the entire healthcare world.
Areas of Activity
Methods and data
policies
records (PPI)
Offer: Meet H2020 Healthcare data challenge through value creating EU partnerships
Open analysis through new technologies represent one of the major challenges for the health sector. At EU level,
joined initiatives to preserve healthcare systems sustainability are particularly valuable.
Leverage on open healthdata analysis to drive marketing or clinical projects in the pharma industry thanks to the implementation of advanced algorithms Cooperate with Public Healthcare decision makers setting up innovative epidemiology tracking tools or medico-economic models
MARKET APPLICATION
Pharma industry - Medicines
Healthcare data provider, multi-country dimensional projects
Page 344 of 487
Spain
OPESVAL European Health Projects Office- Valencia Region
Organisation Name
Country
Spain
City
Valencia
Street
Avenida Menéndez Pelayo 4 accesorio
Website
Phone
Organisation Type
Other
Person
Name
Ana M. Levin
Email
[email protected]
Job Position
Coordinator
The European Health Projects Office- Valencia Region was created in March 2015. It connects researchers, regional
government and other relevant stakeholders (i.e. biomedical/biotech companies, health providers, patient associations…) creating an open space for collaboration. The office acts as a catalyst for health research coordination in Valencia Region having an impact on innovation processes and effective knowledge translation. Our mission is to dynamize international initiatives in health research institutes and clinical foundations in order to create an environment
that supports the internationalization of our research influencing the translation of technology and knowledge to the
society.
In 2014 our researchers participated in:
- 38 international projects
- 300 national projects
- More than 2000 clinical trials
- More than 2000 papers
- 22 patents
- 7 spin offs
Areas of Activity
the immune system
diseases
EU level
(PCP)
Preventing disease
Initiative
Page 345 of 487
Spain
Offer: The European Health Projects Office- Valencia Region
The European Health Projects Office- Valencia Region connects researchers, regional government and other relevant
stakeholders (i.e. biomedical/biotech companies, health providers, patient associations…) creating an open space for
collaboration. The office acts as a catalyst for health research coordination in Valencia Region having an impact on innovation processes and effective knowledge translation. We represent six Valencian Health research institutes and
Clinical Foundations: Fundación Hospital Clínico de Valencia-INCLIVA, Instituto de Investigación Sanitaria La Fe, Fundación para el fomento de la investigación biomédica de la Comunidad Valenciana-FISABIO, Centro de Investigación
Principe Felipe, Fundación para la investigación del Hospital General Universitario de Valencia and Fundación del Hospital Provincial de Castellón.
We have access to over 2000 researchers from the Valencian health system and over 800 researchers from partner
institutions. If you need a specific partner, contact us and we will look for the best clinical researcher that matchs
your project.
Page 346 of 487
Czech Republic
OR-CZ
Organisation Name
Country
Czech Republic
City
Moravska Trebova
Street
Brnenska 19/20
Website
www.orcz.cz
Phone
+420461361111
Organisation Type
SME
Person
Name
Eva Chmelova
Email
[email protected]
Job Position
Key Account Manager
The OR group employs nowadays approx. 100 employees, and it takes care over more than 200 important customers
in Czech Republic and Slovak Republic through the above mentioned companies and other co-operators. The OR-CZ
parent company is a stable company that keeps on searching for new possibilities for its further expansion. We stand
among the leading players of the Central European region who offer integrated software and web solutions. We continue to develop our portfolio of products, services, and solutions towards the widest possible range in the information
and communication technologies field. We offer services based on a wide spectrum of platforms and technologies, including custom made application development, and information protection and security projects. The traditional market segment, which base was formed with production and business company since the beginning, has spread gradually to the medical field. Main activities of the company are aimed to the Czech Republic and Slovakia, where branches
and affiliate companies are located. Company activities expand to Germany, Hungary, Bulgaria and other countries,
whereas these activities have been implemented in cooperation with chosen partners and above all with the members of OR CSI (OR-CZ ltd., OR-NEXT ltd., ORM ltd., ORTEX ltd., PULSATOR electronics (Bulgaria), Software SNAJDR (Germany)).
Areas of Activity
Preventing disease
Initiative
(PCP)
(PPI)
Health ICT SMEs
Methods and data
policies
records (PPI)
Page 347 of 487
Czech Republic
Offer: Developing information systems for healthcare
MARKET APPLICATION
Healthcare
Request: CS1-PM12-2016: PCP eHealth innovation in empowering the patient
Searching for partners for projects in H2020 calls with this thema.
Request: SC1-PM18-2016 Big data supporting public health policies
Request: SC1-PM19-2017 PPI for uptake of standards for the exchange of digitalised
healthcare records
Offer: We developed own information systems for archiving, viewing and sharing radiology data (imaging pictures) in DICOM format.
Offer: Secure and guarantee big data archiving.
Page 348 of 487
France
Orange Healthcare
Organisation Name
Country
France
City
PARIS
Street
21 rue Jasmin
Website
Phone
Organisation Type
Large Company
Person
Name
Alexandre FAESCH
Email
[email protected]
Job Position
Marketing & Partnerships
Orange helps modernize the healthcare infrastructure as well as healthcare systems as a whole, and equip healthcare
facilities with communications solutions.
The medicine of tomorrow is connected medicine in which the management of healthcare data and medical information play an essential role.
At Orange Healthcare, we are using our expertise in communications to enable healthcare professionals to increase
patient comfort and peace of mind.
Page 349 of 487
France
ORPHELIA Pharma
Organisation Name
Country
France
City
PARIS
Street
65 rue Rambuteau
Website
www.orphelia-pharma.eu
Phone
Organisation Type
SME
Person
Name
Hugues BIENAYME
Email
[email protected]
Job Position
CEO
ORPHELIA Pharma is a biopharmaceutical company dedicated to improving the health and well-being of severely disabled children. Orphelia focuses its efforts in bringing new medicinal products to the market in niche indications
where the medical need is the most salient: in neuro-pediatry (epilepsy, neuro-degenerative diseases) and in metabolic diseases. The current company set-up is focused on product development and commercialization.
Areas of Activity
Request: Looking for partners in the neuro-paediatric and metabolic diseases fields
ORPHELIA is seeking partners to initiate new projects in the neuro-paediatric and metabolic diseases fields. We will
consider any project targeting CNS paediatric conditions of high unmet medical need, where a small molecule therapeutic could be developed (repositionning, new formulations, etc...). Orphan indications are welcomed.
Ideally the partner would bring an idea and a proof of concept (e.g. in an animal model of the condition). Nonclinical /
clinical expertise is welcomed. ORPHELIA would bring its expertise of drug development (pharmaceutical, clinical) and
marketing abilities.
We would be eager to collaborate with European and north american academic and/or industrial partners to develop
new drugs in CNS orphan indications.
Page 350 of 487
Norway
Oslo and Akershus University College
Organisation Name
Country
Norway
City
Oslo
Street
Pilestredet 50
Website
www.hioa.no
Phone
Organisation Type
University
Person
Name
Anne Gerd Granas
Email
[email protected]
Job Position
Professor
Oslo and Akershus University College of Applied Sciences is a recognised environment for professionally oriented and
vocationally relevant education, research and development. It has 17000 students and ca 2000 employees. The research activities covers the different possibilities created in the international and multicultural metropolitan area of
Oslo, Norway.
Oslo and Akershus University College Faculty of Health offers:
–Norway’s most comprehensive portfolio of study programmes within health and social sciences
–An academic portfolio covering most of the health professions
–A strong and competent academic environment that develops knowledge on what is needed to strengthen and renew the welfare society.
–5300 students and 530 staff members
Areas of Activity
EU level
(PCP)
population
Request: Medicines and patients safety
Our Research Group "Medicines and patient safety" combines pharmacoepidemiological medicine information, therapeutic drug monitoring and patient focused research. We use quantitative and qualitative methods from the fields of
pharmacy practice, clinical pharmacy, clinical pharmacology, biopharmaceutical and medical biochemistry to study
how patient safety can protected with increasingly medicine use. We focus on Three main areas: 1. Inter-disciplinary
collaboration on prescribing and medicine use We study how increased collaboration between health professionals
can improve medicine prescribing and medicines reconciliation, for example in interdisciplinary medicine reviews.
Systematic tools (STOP, START, NORGEP etc) have become common to improve prescribing quality. We are researching the effect of interdisciplinary collaboration in hospitals, nursing homes and home care services. 2. Patients' understanding of medicines and disease Polypharmacy and increased medicalization increases the risk of improper use of
drugs and side effects. Why do patients use medicines "wrongly"? How do patients sense that their medicines work?
Page 351 of 487
Norway
Do they have side effects? Does patient self-monitoring of blood glucose and INR actually improve treatment? We use
qualitative methods to study how patients’ and relatives’ arguing that they must be listened to, in order to increase
safety, improve efficiency and potentially give fewer side effects. 3.2. Optimal medicine use and monitoring We conduct research on changes in prescribing patterns and use of drugs in vulnerable patients groups with chronic diseases
such as diabetes, epilepsy and mental illness, or complications related to age (children, elderly, pregnancy). For example, older patients commonly have extensive polypharmacy, and pharmacodynamic and pharmacokinetic factors
change with increasing age. For many medicine groups monitoring and/or information is vital for optimal treatment in
terms of the balance between efficacy and tolerability.
Our Research Group for Medicines and Patient safety is looking for Cooperation With other partners in Europe on Interdisciplinary collaboration on prescribing and medicine use in the elderly population. We have special interest in inappripriate prescribing in nursing homes and home care services, and on the use of systematic Tools in medication reviews. We seek Cooperation on the study of interventions to avoid extensive polypharmacy in elderly, and how medicine therapy has to be adjusted to accomodate that pharmacodynamic and pharmacokinetic factors change with increasing age. Fall-risk-increasing medicines and or/epilepsy is of special interest.
Pharmacists or other Health prfessionals working on medication and inappropriate prescribing in the elderly. We are
interested in a European Country with good overviews of national prescribing data and with an interest in interprofessional Collaboration on medication reviews in elderly. Comparative Research or RCTs on interprofessional prescribing
interventions.
Page 352 of 487
Norway
Oslo medtech
Organisation Name
Country
Norway
City
oslo
Street
Gaustadaleen 21
Website
Phone
Organisation Type
Other
Person
Name
Waqar Ahmed
Email
[email protected]
Job Position
Oslo Medtech is a health technology cluster, dedicated to accelerate and support the development of new medtech
and eHealth products, services, and innovative solutions for the Norwegian and global healthcare market.
Our mission is to industrialize world class health technology products and services that enable sustainable and high
quality treatment and care, and Norwegian medtech industry growth.
Our focus areas:
• Facilitate R&D&I collaboration between research, industry, and healthcare providers, nationally and internationally
• Stimulate and facilitate market-driven innovation and innovative procurement processes
• Facilitate clinical trials, testing and verifications
• Accelerate business development and international scaling
• Attract development and investment capital
• Provide co-working space in our Medtech Growth House
• Spread the word on the Norwegian health technology industry nationally and internationally
Key Figures:
• Non-profit organization founded in the fall of 2009
• 190 members -- including representatives from medtech, eHealth and assistive technology industry, hospitals,
R&D institutions, TTO & incubator, investors and finance institutions, service providers, design and manufacturing firms
• The full health value chain is represented in the cluster
• Awarded status as a Norwegian Centre of Expertise (NCE) in health technology in 2015
Areas of Activity
Preventing disease
young
Methods and data
policies
Page 353 of 487
Norway
(PCP)
population
Health ICT SMEs
Page 354 of 487
Norway
Oslo Medtech
Organisation Name
Country
Norway
City
Oslo
Street
Gaustadalleen 21
Website
www.oslomedtech.no
Phone
Organisation Type
Other
Person
Name
Ane Solesvik Oppedal
Email
[email protected]
Job Position
International Project Manager
Oslo Medtech is a health technology cluster, dedicated to accelerate and support the development of new medtech
and eHealth products, services, and innovative solutions for the Norwegian and global healthcare market.
Our mission is to industrialize world class health technology products and services that enable sustainable and high
quality treatment and care, and Norwegian medtech industry growth.
Our focus areas:
• Facilitate R&D&I collaboration between research, industry, and healthcare providers, nationally and internationally
• Stimulate and facilitate market-driven innovation and innovative procurement processes
• Facilitate clinical trials, testing and verifications
• Accelerate business development and international scaling
• Attract development and investment capital
• Provide co-working space in our Medtech Growth House
• Spread the word on the Norwegian health technology industry nationally and internationally
Key Figures:
• Non-profit organization founded in the fall of 2009
• 190 members -- including representatives from medtech, eHealth and assistive technology industry, hospitals,
R&D institutions, TTO & incubator, investors and finance institutions, service providers, design and manufacturing firms
• The full health value chain is represented in the cluster
• Awarded status as a Norwegian Centre of Expertise (NCE) in health technology in 2015
Areas of Activity
Preventing disease
young
(PCP)
(PPI)
Page 355 of 487
Norway
Health ICT SMEs
Request: Accelerating market introduction of ICT solutions for Health, Well-Being and
Ageing Well
Oslo Medtech is a cluster With roughly 140 industrial members (SMEs). Over the NeXT two years Oslo Medtech will facilitate a minimum of 10 proposals in the SME instrument Within the Scope of ICT solutions for Health, Well-Being and
Ageing Well.
We are searching for SME or other industrial partners With expertise in the following areas: -interoperable and secure
eHealth solutions or platforms -open software platforms
Countries: France, UK, Germany Type: SME/industrial Task: open platform Development, Fireware integration, Piloting
With end-users in local markets
Page 356 of 487
France
PARTNERS
Organisation Name
Country
France
City
Paris
Street
10 avenue de Verdun
Website
www.emibiotech.eu
Phone
Organisation Type
Other
Person
Name
Céline Feger
Email
[email protected]
Job Position
PARTNERS member
The PARTNERS (PArtners for inTernational cliNical rEsearcheS) platform, labeled F-CRIN, is an alliance of stakeholders
which provides professional support for clinical trials to investigators and sponsors, in compliance with the highest international standards. PARTNERS’ members bring together their scientific, operational, financial, and regulatory expertise for achieving the optimal design and operational conduct of your clinical trials.
PARTNERS is a full-service CRO (Clinical Research organization) in clinical trials, with the added value of
its academic credibility and the diversity of its members’ expertise. PARTNERS’ offer can be adapted to
sponsor’s needs, full-service or more adjusted.
PARTNERS’ value is in its global vision, its smooth and efficient coordination, and its transversal support including expertise in innovative methodology and proof-of-concept studies, in clinical treatment units preparation by AGEPS, in
bioinformatics and in imaging. PARTNERS platform is available nationwide, and in Europe through the E-CRIN network.
Areas of Activity
Preventing disease
young
Offer: Research cooperation / clinical development plan design and clinical research execution
Any clinical research project can be managed by PARTNERS, from early phase proof-of-concept studies to large scale
multinational clinical trials, sponsored by the pharmaceutical industry or by academic institutions and covering multiple therapeutic areas and research fields. PARTNERS’ high level trained staff is reactive and easy to mobilize up on
sponsor/investigator request. PARTNERS can help to design and optimize your clinical development plan, combining
your company's strategic vision of your project, the regulatory constraints, market access perspectives, etc. PARTNERS platform combines the expertise of its members to efficiently address the sponsor’s and investigator’s expectations and to carry out their research projects at a high quality standard and in a timely manner through all stages of
the clinical trial process.
The PARTNERS platform assembles numerous experts in the same structure through associated major institutions:
Public Assistance - Paris Hospitals (AP-HP), French National Institute for Health and Medical Research (INSERM) and
Paris Sorbonne Cité University (USPC). Corinne Alberti and Eric Vicaut, coordinators of the PARTNERS platform, lead
teams dedicated to clinical research, including experts in clinical trial design and methodology, as well as team members experienced in conducting high quality clinical trials on a timely manner. Operating for a long time within a network comprising most current members of PARTNERS, they demonstrated the efficiency of this network for clinical tri-
Page 357 of 487
France
als. PARTNERS can efficiently manage pharmaceutical aspects of clinical trial units processing, allocation and shipment through the Clinical Trial Department (CTD) of AGEPS.
Page 358 of 487
France
Pasteur Institute
Organisation Name
Country
France
City
Paris
Street
28 rue du Docteur Roux
Website
Phone
Organisation Type
Large Company
Person
Name
Sean Kennedy
Email
[email protected]
Job Position
Head of Biomics Unit
The Biomics Pole (BP) is the CITECH structure responsible for Next Generation Sequencing and High Throughput
Proteomicstechnologies. The BP is headed by Sean Kennedy, to whom inquiries and project requests can be made.
The BP handles bothservice and collaborative projects and works closely with the C3BI and DSI to provide data
analysis solutions and data storage for researchers. Please contact us for pricing and turnaround times, or for any
questions you might have.
• The BP is open to any type of project. Some examples of what we provide are:
• – De novo and targeted sequencing of viruses, prokaryotes and eukaryotes
• – Variant (SNP, indel, large rearrangements) detection
• – Human and Mouse SNP detection by array
• – Transcriptional analysis (RNA-Seq) for both prokaryotes and eukaryotes
• – 16S and deep-sequencing metagenomic studies (mouse, human, and other environments)
• – Bottom-up whole proteomic analysis and quantification
• – Analysis of a wide range of post-translational modifications
• – Determination of the dynamics of protein complexes.
• – Epigenetics (methylation studies)
• – Projects involving two or more techniques (i.e. proteogenomics, single-cell DNA/RNA analysis)
Areas of Activity
the immune system
Page 359 of 487
France
Offer: NGS and analysis research platform for genomic, metagenomics and proteomic
studies
The group's mission is to collaborate with the Pasteur Institute’s international network, with diverse research teams
and with private industry in order to provide a research service to the scientific community. The complementary technologies and synergistic expertise of the different teams facilitates the investigation of complex biological problems
from DNA sequence to gene expression and through to protein expression. Areas of metagenomics (16s and Deep-Sequencing) and the human microbiome in relation to human health and disease are the primary collaborations we
seek.
Integrated Sequencing and Data Analysis laboratory. Analysis of prokaryotic and eukaryotic systems. DNA, RNA and
protein analysis using Illumina sequencers and ThermoFisher LC-MS systems. Wide range of techniques: – De novo
and targeted sequencing of viruses, prokaryotes and eukaryotes – Variant (SNP, indel, large rearrangements) detection – Human and Mouse SNP detection by array – Transcriptional analysis (RNA-Seq) for both prokaryotes and eukaryotes – 16S and deep-sequencing metagenomic studies (mouse, human, and other environments) – Bottom-up whole
proteomic analysis and quantification – Analysis of a wide range of post-translational modifications – Determination of
the dynamics of protein complexes. – Epigenetics (methylation studies) – Projects involving two or more techniques
(i.e. proteogenomics, single-cell DNA/RNA analysis)
MARKET APPLICATION
Fundamental and applied research in to microbiota. Clinical studies and bio-marker discovery.
Clinical partners and hospitals for disease study in relation to the microbiota. PMEs and private industry in general for
bio-marker discovery and technology development. Immunology expertise for linking host response to microbiota.
Sample handling, DNA extraction and DNA QC, and Bio-banking services.
Page 360 of 487
United Kingdom
PCI Pharma Services
Organisation Name
Country
United Kingdom
City
Hereford
Street
Wye Valley Business PArk
Website
Phone
Organisation Type
Large Company
Person
Name
Clelia Chauvin
Email
[email protected]
Job Position
BD Manager
PCI is an integrated full service provider and a trusted partner to leading companies in the global healthcare industry;
we offer unparalleled expertise and experience in taking compounds from the earliest stages of development through
to commercial launch, delivering speed to market and commercial success for our customers. Core services include:
analytical services, formulation development, clinical trial supply, commercial manufacturing and packaging, QP services, supply chain management, storage and distribution.
Areas of Activity
Methods and data
Offer: Supply chain services
PCI Pharma Service is a Supply chain services provider for clinical trials and product commercialisation.
PCI is an integrated full service provider and a trusted partner to leading companies in the global healthcare industry;
we offer unparalleled expertise and experience in taking compounds from the earliest stages of development through
to commercial launch, delivering speed to market and commercial success for our customers. Core services include:
analytical services, formulation development, clinical trial supply, commercial manufacturing and packaging, QP services, supply chain management, storage and distribution.
Page 361 of 487
Switzerland
PKNM Solutions Sarl - CH
Organisation Name
Country
Switzerland
City
Cottens (VD)
Street
Chemin du Grand Pre 6
Website
http://pknmsolutions.ch/
Phone
+41 (0) 215 348 588
Organisation Type
SME
Person
Name
Petros Malitas
Email
[email protected]
Job Position
CEO PKNM Solutions Sarl CH
PKNM Solutions is an independent strategy consulting & advisory services private company for the Healthcare Systems & Organizations and Life Sciences industry, CROs, Biotechnology, Biomedical Informatics and Medical Devices
Industry.
It is the mission of PKNM Solutions to establish and manage international public-private partnerships in pursuit of innovative, multidisciplinary R&D for safe and socially treasured therapeutic solutions.
Areas of Activity
EU level
(PCP)
(PPI)
Methods and data
policies
Offer: Exploitation of the Major H2020 Calls of PKNM Solutions’ Interests (as described
above)
PKNM Solutions provides a synthesis of complementary services necessary for identifying, originating, preparation,
implementing and handling successful international research, development and innovation projects. Translating
knowledge into a product for the benefit of the end-user is the major expertise task of the team involving physicians,
basic scientist, (bio) engineers, informatics specialists, epidemiologists and economists. The Alliance Team consists of
a great pool of Professionals with an academic background in Translational Science, Health & Life Sciences, Medicine,
Biotechnology, Engineering and Bioengineering, Biomedical Engineering, Biomedical Informatics, Socio- economic Sciences, Epidemiology and Public Health Issues, Information Technology and specialists on Natural sciences. We cooperate closely with highly specialized partners from different areas and are part of an exclusive R&D network, throughout
in Europe. The Alliance has developed a wide range of collaborations throughout Asia, US, Australia and Africa for implementing European interests within the global region.
Page 362 of 487
Switzerland
Offer: Consulting Advisory Role, Design of a Project, Project Management, Exploitation,
Dissemination and Communication of the H2020 Calls
We are focusing on National and International Competitive Research and Development Grants/Projects. From 2015,
PKNM Solutions has created an exclusive Team of Experts focusing on the success in HORIZON – H2020 Funding
Scheme by EU. • Advocate the scientific coordinator in administrative issues in big consortiums• Associate role in
work packages• Principal role in work packages• Training contributor• Research and Development partner.
Regenerative Medicine
Novel Treatments for Chronic Diseases
Interesting for all the Calls that we are involved for the H2020
Development & Validation of Innovative Biomedical Technology in novel Therapeutic Areas
A Network of Excellence on Big Data Science
Page 363 of 487
United Kingdom
Plymouth Graduate School of Management
Organisation Name
Country
United Kingdom
City
Plymouth
Street
Mast House
Website
Phone
01752585728
Organisation Type
University
Person
Name
Irina Neaga
Email
[email protected]
Job Position
Lecturer
University of Plymouth is one of the UK's most prominent and dynamic universities with an educational history dating
back to 1862. Consistently ranked as one of the top modern universities, Plymouth has over 26,000 students, almost
3,000 staff, and an annual income of around £234 million. The University has a long record of high quality innovative
research as demonstrated by its achievements in the Research Excellence Framework (REF) 2014. The results show
that 63% of the research submitted by the university included world-leading research, achieving 3 and 4-stars. In the
Research Fortnight research power league table, the University retains its place in the top 50 universities in the UK.
Nearly two-thirds of Plymouth University’s research has been graded as world-leading or internationally excellent, according to the nationwide review of research standards across the higher education sector. From agriculture to art
and design, clinical medicine to mathematics, earth sciences to education, the University improved its scores across
the board in the Research Excellence Framework (REF).
Overall Plymouth had more than 63 per cent of its research graded at 3 and 4-stars – nearly double its score from
2008, when the previous assessment exercise was conducted. The results will be used by national funding bodies to
allocate block-grant research funding to universities from 2015-16. Additional details at: http://www1.plymouth.ac.uk/
research/ourresearch/assessment/REF/Pages/default.aspx
The Plymouth Graduate School of Management (PGSM) presented at https://www.plymouth.ac.uk/schools/pgsm
is oriented towards developing scientific and business knowledge alongside the managerial skills of the potential
leaders of the future through high quality, professionally accredited, postgraduate programmes and PhD or professional doctorate in international business, sustainability, marketing, finance and human resource management, as
well as in more specialist fields such as international shipping and logistics supply chain management and procurement considering the environmental aspects. The PGSM has solid research foundations led by the three research centres :
1. Centre for Sustainable Leadership, Governance and Policy provides research, consultancy and advice regarding a wide range of sustainable, leadership, governance and policy issues.
2. Service and Entrepreneurship Research Centre carries out world leading research in the fields of services and
enterprise, and their applications across a range of public, private, voluntary and community sectors
Our research portfolio including digital technology, (big) data analytics, knowledge driven economy, key aspects of
operations management and logistics in healthcare that have many exciting opportunities and challenges for high
level research and dissemination as well as engagement with the communities. The academic staff research with professional bodies and companies across the UK and overseas including European R&D organisations and Universities.
Page 364 of 487
United Kingdom
The Faculty of Health and Human Sciences includes schools of Health Professions, Nursing and Midwifery, and
Psychology combining world-leading research and practical expertise across a wide range of scientific and practical
disciplines.Working closely with local councils, the NHS, and health and social care providers, we are having a truly
transformational impact on the well-being and economy of the South West and beyond.
Areas of Activity
(PCP)
(PPI)
Health ICT SMEs
Methods and data
policies
records (PPI)
Offer: Developing an Innovative Big Data Approach and Dedicated Platform to support Future Healthcare Organisations
Big data is generating a lot of hype in every industry including healthcare. Big data analytics has the potential to
transform the way healthcare providers use sophisticated technologies to gain insight from their clinical and other
(big) data repositories and make informed decisions. In the near future it is expected a rapid, widespread implementation and application of big data analytics having the foundation in data mining and knowledge discovery in data
bases across the healthcare organization and the healthcare industry. Therefore several challenges must be addressed at conceptual, development and implementation level. As big data analytics has became more mainstream,
issues such as guaranteeing privacy, safeguarding security, establishing standards and governance, and continually
improving the tools and technologies will receive a lot of attention. Big data analytics and applications in healthcare
are at an early stage of development, but rapid advances in platforms and related business intelligence tools can accelerate their maturing process.
Big Data Driven Approach is innovative and has several advantages such as detecting diseases at earlier stages when
they can be treated more easily and effectively; managing specific individual and population health and detecting
healthcare fraud more quickly and efficiently. Several key open questions could be addressed applying big data analytics and related strategies. Certain developments or outcomes may be predicted and/or estimated based on vast
amounts of historical data, such as length of stay (LOS); patients who will choose elective surgery; patients who likely
will not benefit from surgery; complications; patients at risk for medical complication, hospital-acquired illness; illness/
disease progression; patients at risk for advancement in disease states; causal factors of illness/disease progression.
Healthcare R&D organisation including Universities end user such as hospitals, healthcare units
Page 365 of 487
Switzerland
Polygene AG
Organisation Name
Country
Switzerland
City
Rümlang
Street
Riedmattstrasse 9
Website
www.polygene.ch
Phone
0041 44 818 8803
Organisation Type
SME
Person
Name
Stefan Selbert
Email
[email protected]
Job Position
Executive Director Business
& Development
PolyGene is a privately held research institute, located in the area of Zurich, Switzerland, offering stateof-the-art transgenic animal model development services to a world-wide research clientele. Founded in
2002, PolyGene is run by an international team of scientists with academic and industrial backgrounds,
having notable track records as well in mouse transgenesis as in business management.
PolyGene has a fully functional production site for the establishment of transgenic and knockout mouse lines, and also
offers co-development opportunities in model building, including also rat and rabbit models. The entire site is owned
and used exclusively by PolyGene, and is maintained and further developed continuously with highest standards. It is
one of the most preferred, leading professional transgenic services in the world, with over 330 completed customer
projects and more than 750 individual mouse lines generated to date.
Areas of Activity
diseases
Offer: State-of-the-art technologies for the generation of animal models of human disease
Polygene is a Swiss based SME and would like to offer transgenic services within future Horizon2020 calls. As a partner and/or work package leader, Polygene can take over all work related to the generation of animal models for target
validation purposes. Beside that, Polygene is searching for partners who are willing to validate Polygene's proprietary
innovative inducible expression systems in vitro and in vivo.
Polygene has fully equipped molecular and cell biology laboratories and injection units. Polygene offers all state-ofthe-art technologies for genome engineering Projects, such as the generation of conditional or inducible gene knockouts/-ins or the Generation and breeding of inducible transgenic mice, rats and rabbits. State-of-the-art Technologies
include promoter-switch gene targeting, TALEN and CRISPR/Cas9 mediated genome engineering, BAC transgenic animals, multiple inducible Expression Systems, suitable to Switch on/off transgene expression at will.
MARKET APPLICATION
R&D, drug target validation
We are searching for researchers, groups or consortia within Europe, who are in need for the generation of animal
models, e.g. for molecular and/or functional target validation within future Horizon2020 calls, such as
SC1-PM-03-2017; Diagnostic characterisation of rare diseases. Polygene is very experienced in giving consultancy in
Page 366 of 487
Switzerland
setting up competitive consortia. Within the last round of FP7 Polygene successfully contributed to currently running
HEALTH consortia, such as CAM-PaC, TumADoR, VIA, SYBIL or CartarDis.
Request: Forming consortia and projects, which need customized animal models of human disease, e.g. within the call "Diagnostic characterisation of rare diseases"
PolyGene is a Swiss based SME with core expertise gene targeting and animal models of human disease. Within Horizon2020 call SC1-PM-03.2017 we are ideally set up to fullfill one of the tasks, which is "Molecular and/or functional
characterisation to confirm diagnosis of rare disease"
1.) Forming consortia, who are in need for customized animal models of human disease and, 2.) Research groups, who
would be willing to apply our innovative inducible expression systems within their cellular- or animal model studies.
These inducible expression systems will allow to reversibly switch on / off transgene expression at will, simply by
adding drugs, such as RU486, erythromcin, etc. to the System.
Any group who is willig to submit a proposal and is in need for animal models or inducible gene expression systems.
Page 367 of 487
France
Polytech Orleans
Organisation Name
Country
France
City
orleans
Street
8, rue leonard de vinci
Website
Phone
Organisation Type
University
Person
Name
Hambli Ridha
Email
[email protected]
Job Position
I am a member of a Laboratory (PRISME) in Orleans city in France which works in tfield of living organs modeling. This
includes:
1. The development of numerical models to personalize diagnostics against osteoporotic people.
2. Prediction of the risk of fracture of human bone organs under static to dynamic (impact) loading: from side fall
cases of elderly people to car crashes.
3. The development of 3D virtual models (finite element) allowing for the simulation of the effects of bone drugs
treatments against osteoporosis and cancers on the bone organs
4. Modeling the aging of human skin aging with a focus on the cosmetology aspects.
Areas of Activity
Methods and data
Request: Computer models for living organs: Diagnostic and Drug treatments
My research team is looking for opportunities of cooperation with academic and industrial partners to develop computer modeling tools to simulate and predict the responses of human organs in the field of biomedical, biomechanics
and mechanobiology.
Our expertise includes: 1. The development of numerical models to personalize diagnostics against osteoporotic people. 2. Prediction of the risk of fracture of human bone organs under static to dynamic (impact) loading: from side fall
cases of elderly people to car crashes. Such models may interest clinical applications in the field of osteoporosis diagnostic and the development of devices to protect against bone fractures in the context of car crashes. 3. The development of 3D virtual models (finite element) allowing for the simulation of the effects of bone drugs treatments against
Page 368 of 487
France
osteoporosis and cancers on the bone organs 4. Modeling the aging of human skin aging and the effect of cosmetic
products on the wrinkles with a focus on the cosmetology aspects.
My research team is looking for opportunities of cooperation with academic and industrial partners to develop works
in the fields described in the previous sections
Page 369 of 487
United Kingdom
Public Health England
Organisation Name
Country
United Kingdom
City
Porton Down
Street
Manor farm road
Website
Phone
007880052041
Organisation Type
Person
Name
Eva Barkauskaite
Email
[email protected]
Job Position
Business Development Manager
Public Health England (PHE) is an operationally autonomous executive agency of the UK Department of Health. PHE is
responsible for responsible for:
• making the public healthier by encouraging discussions, advising government and supporting action by local
government, the NHS and other people and organisations;
• supporting the public so they can protect and improve their own health;
• protecting the nation’s health through the national health protection service, and preparing for public health
emergencies;
• sharing our information and expertise with local authorities, industry and the NHS, to help them make improvements in the public’s health;
• researching, collecting and analysing data to improve our understanding of health and come up with answers
to public health problems;
• reporting on improvements in the public’s health so everyone can understand the challenge and the next
steps;
• helping local authorities and the NHS to develop the public health system and its specialist workforce;
Areas of Activity
diseases
Preventing disease
Initiative
young
Methods and data
policies
records (PPI)
Page 370 of 487
United Kingdom
(PCP)
(PPI)
population
Request: PM-07-2017 Mental Health and Wellbeing in the Young
One of the key priorities for Public Health England is the protection of mental health well-being in both adult and children populations and we are actively looking for partners for research in mental health. Therefore if a consortium is
being formed for the PM-07-2017 call, PHE would be very interested to be part of it. PHE is actively involved in mental
health research and is supporting local authorities in their work and providing national leadership on mental health for
the public health system. In spring 2014 we launched: a national framework for action for the new public health system; a new National Mental Health Intelligence Network, in partnership with NHS England; a series of evidence summaries on the best evidenced interventions for improving the public’s mental health; and a new health and wellbeing
strategy for PHE staff, which embeds action on mental health and reflects our ambition to become an exemplary employer. The National Mental Health Intelligence Network is for commissioners, providers and stakeholders to better understand health intelligence to improve services and achieve the best outcomes for local communities. In turn, better
access to data and information leads to better decisions. The Mental Health Intelligence Network (NMHIN) brings together data already collected around mental health and wellbeing. This network and leading national expertise is
something we could directly contribute to the consortium.
Request: Participating in active ageing and self-management of health programme calls
PHE would be interested in participating in the research projects promoting health ageing. In partnership with NHS
England, Age UK we published a Practical Health Ageing Guide in January 2015, which was further refined in October
2015 through discussions with focus groups and partnership organisations. We have recently started our participation
in a CHAFEA Joint Action for Prevention of Frailty and have national experts who work in the field and who may be interested in joining consortia addressing the aim of self-management in health programme calls.
Page 371 of 487
Portugal
Raríssimas - Associação Nacional de Deficiências Mentais e
Raras
Organisation Name
Country
Portugal
City
Moita
Street
Rua D. Manuel I, nº 6
Website
www.rarissimas.pt
Phone
+35121211165300
Organisation Type
Person
Name
Nuno BRANCO
Email
[email protected]
Job Position
Member of the Administration board
Raríssimas is a patients organization founded in 2002 by a group of mothers of rare disesases' patients.
We have been developing at a quick pace and today we have the fisrt Resource Centre for Rare Diseases in Portugal
(according to Eurordis classification), gathering health, social, information andtraininng services. Raríssimas has several delegations accross the country and 2 other rehabilitaiton centres (one in the NOrth delegation, near Oporto and
another in the Azores archipelago, Pico Island).
We have been developing several prohjects in partnership with other countries and are taking the first steps in the reserach are, in several scientific areas.
Areas of Activity
diseases
EU level
Methods and data
policies
records (PPI)
(PCP)
Health ICT SMEs
Similar to the profile of Maria João Freitas, form the same organization
Page 372 of 487
Portugal
Raríssimas - Portuguese National Association for Rare and
Mental Disorders
Organisation Name
Country
Portugal
City
MOITA
Street
Rua D. Manuel I, nº 75
Website
www.rarissimas.pt
Phone
+351211165300
Organisation Type
Person
Name
Maria João Freitas
Email
[email protected]
Job Position
Head of Unit - International
Affairs and Project Management
Raríssimas is a Portuguese umbrella rare and mental diseases' patients organization, founded in 2002.
Raríssimas has been quite active in oatient advocacy, but also in delivering services to patients, families and professionals.
Raríssimas has devolped and grew at a fast but solid pace. After developing several awareness raising campaigns,
partiicpating in the first National Program for Rare Diseases (2008), publishing several books, with patients life stories, but also technical books about diagnosis (both in Portugal and brazil), today the organizations is structuered as
follows:
Headquarters in Lisbon;
The first Portuguese Rare Diseases Resource Centre - Casa dos Marcos (in the regioan of Lisbon), offering both social,
health, informaiton an trainign services, with a total of 68 beds, functioning both in ambulatory and residential regimens, but also operned to the community; Linha Rar helpline and TRACE RD - our training centre are located at Casa
dos Marcos
North Delegation (Oporot region) with a very active rehabilitation centre;
Centre Delegation (in Viseu) with a rehabilitaiton centre to open in 2016;
South Delegation (in the Algarve) with a rehabilitaiton centre to open in 2016;
Azores Delegation (Pico Island) with a rehabilitation centre running for several years now;
Raríssimas has founded Raríssimas Brazil and has obtained the certification of NGO for Development and Cooperation, having already signed cooperation protocols with several Brazilian entities (Universities, Hospitals and governmental institutions) and will be signing new protocols with Angola (in early 2016) and negotiating the terms of cooperaiton with Mozambique.
Raríssimas is now structuring its Research Centre, establishing a cooperation network both at national and international levels,connecting with universities, hospitals, governmental authorities and other NGO's working on Rare and
Mental Dirsorders a well ad chorinic Diseases.
Please visit us at: www.rarissimas.pt and www.linharara.pt
Areas of Activity
Methods and data
Page 373 of 487
Portugal
diseases
EU level
policies
records (PPI)
(PCP)
Raríssimas - the Portuguese National Association for Rare and Mental Diseases is an umbrella patients' organization,
focused on rare and undiagnosed disorders, responding to the needs reported by patients, families, professionals and
all those somehow related to this problematic. Raríssimas is an NGO, founded in 2002 by a group of mothers of rare
diseases patients. Today , Raríssimas has several delegations along the country, namely 2 rehabilitation centres - one
in Oporto (North Delegation) and another on the Pico Island (Azores Delegation). Casa dos Marcos is the most recent
and more expressive project, gathering health and social services, as well as a training centre - Trace RD with activities designed for patients, families/carers, professionals, volunteers, students, the clinical and the scientific communities.
Casa dos Marcos is the first Resource Centre for Rare Diseases in Portugal, taking the Eurordis classification as reference. Casa dos Marcos has a total of 68 beds for Rare Disorders patients so it has a valuable stock of information to
be studied. Casa dos Marcos also hosts Raríssimas' helpline - Linha Rara, operating since 2009, receiving calls form
several countries and with a relevant documental repositorium.
MARKET APPLICATION
Health /social services; Universities; Research Units; Industry; NGO's; ...
Similar organizations; Universities/research groups; Observatories interested in the area of Rare Diseases, mental disorders or chronic diseases Exchange of information and experiences, in order to produce knowledge. Consortiums establishing for new projects Professionals' Interchange programs
Page 374 of 487
Poland
Rehabilitatus
Organisation Name
Country
Poland
City
Gdansk
Street
Grunwaldzka
Website
rehosystem.com
Phone
0048698645252
Organisation Type
SME
Person
Name
Mateusz Bonecki
Email
[email protected]
Job Position
CTO
Rehabilitatus is research and development company in IT industry that provides e-health solutions. One of them is
tele-medicine IT system using noninvasive and markerless motion capture technology for traumatic orthopaedic rehabilitation and support of physical activity of elderly people which enables patients to recover while exercising at
home.
Areas of Activity
(PCP)
(PPI)
population
Methods and data
records (PPI)
Offer: Markerless telerehabilitation system to be integrated in comprehensive program/
platform of services dedicated to ageing population
Page 375 of 487
Turkey
Research Center for Rejenerative and Restorative Medicine
(REMER) in Istanbul Medipol University
Organisation Name
Country
Turkey
City
İstanbul
Street
Ekinciler cad No: 19
Website
http://remer.medipol.edu.tr/
Phone
Organisation Type
R&D Institution
Person
Name
Hakan Cangul
Email
[email protected]
Job Position
Head of Department
REMER (Research Center for Regerenative and Restorative Medicine; www.remer.medipol.edu.tr) is newly built $50Mworld class biomedical research facility within the Istanbul Medipol University funded by the Ministry of Development
(TR). It provides access to state-of-the-art laboratory accommodation with the latest top-of-the-range technology and
equipment (details available on the web-site). Currently there are 21 senior academic staff and 43 research fellows,
PhD students and technicians within the Center. There is a stimulating mix of clinical and basic scientists investigating
the human physiology, pathogenesis of diseases and novel therapeutical approaches using a wide range of methodologies. Core facilities include: (i) Cell Culture and Sorter Lab, (ii) Molecular Biology and Histology, (iii) Proteomics, (iv)
Genomics, (v) Bioinformatics, (vi) Advanced Microscopy (vii) Dental Research and Biomechanics, (viii) Pharmaceutical
Chemistry and Pharmacognosy, (ix) Electrophysiology and Optogenetics, (x) Brain Research and Microsurgery, (xi) Analytical Chemistry, and (xii) Animal Facilities.
Prof Cangul is recruited in Genomics Section of the Center and has full-access to all facilities above. Within the Genomics section all necessary equipment for conventional molecular genetics (DNA extractors, PCR and RT-PCR machines, set-up robots, electrophoresis equipment, Sanger sequencer) are available along with two new next generation sequencing machines (Illumina NextSeq 500 and MiSeq). Other machinary relevant to his projects include:
Molecular Biology and Histology Labs
•
•
•
•
•
•
Equipments for immunohistochemistry.
In vivo and in vitro electroporation device.
Western blot systems including high end gel imaging station.
Multiplate reader.
Conventional and real time PCR systems.
Clean lab space and hood for DNA and RNA isolation
Cell Culture and Cell Sorter Labs
•
•
•
•
•
•
•
•
•
•
Class II cell culture hoods
Regular and cooled incubators with CO2 and O2 regulation
Inverted microscope with fluorescene attachment and intracellular injection system.
Automated cell monitoring and analysis system
Cell viability test instrument
All other equipment needed for working with primary cells and cell lines
Advanced cell sorter with five lasers: 355, 405, 488, 561, 640 nm
Theoretical capacity to sort 14 colors.
Simultaneous sorting through six different channels.
Housed in class II cabinet
Page 376 of 487
Turkey
Advanced Microscopy Lab:
• Two photon microscope with two femtosecond infraded lasers and live animal imaging stage.
• Confocal microscope with five visible and one femtosecond infrared lasers, based on an inverted microscope.
• Spinning disk microscope with two EM, one cooled cameras, advanced incubation equipment, providing ultra
fast and long term time lapse imaging.
• Fluorescence zoom microscope for imaging large specimens at high magnification.
• Additional Equipment and software for FRAP, FLIP, FLIM and FRET analyses.
• Laser microdissection and optical tweezer combi system with incubation equipment.
• Scanning electron microscope with TEM capability and EDS.
• Several operation microscopes.
Medipol Group also owns a five-hospital chain affliated with the University . The hospital chain has a capacity of 1000
beds and 5000 daily out-patient registrations in total. This sizable capacitiy will facilitate the recruitment of patients
into Prof Cangul’s reserch projects. He has already contacted key clinicians in these hospital, who are also affliated
with the University, and they are keen to collaborate with Prof Cangul in his area of research.
These studies range from gene identification to functional analysis of gene products, and there is expertise in all of
the techniques required for this project within the Section.
Areas of Activity
diseases
Methods and data
Offer: Identification of novel causative genes and therapies for autosomal recessive rare
diseases
Autosomal recessively inherited diseases are an important cause of morbidity and mortality, particularly in communities where consanguineous relationships are common. Worldwide at least 1 billion people live in communities where
consanguinity rates are >20% and Rare Disease Research is one of the main themes of H2020. We have a proven
tract record for discovering causative genes for rare diseases. Identification of disease genes allows reliable diagnostic and carrier testing to be offered to at risk families and often provides novel insights into fundamental biological
processes. These discoveries also lead to the development of new diagnostic markers and novel treatment approaches.
Identification of novel disease genes invariably leads to the discovery of novel molecular mechanisms leading to disease development. Once the mechanisms underlying a disease are uncovered, novel therapeutic targets become visible. Therefore our studies are likely to lay ground for invention of new drug developments. Our main advantage in Autosomal Recessive Disease Research is that Turkey has one of the highest consanguinity rates, an average level of
25% and regionally rising up to 40%, compared to the other European countries and thus has much higher frequency
of autosomal recessive rare diseases. Therefore we are well placed to recruit many relevant patients into our research
projects. Lately, we brought together the largest cohort of congenital hypothyroidism (CH) patients born to consanguineous families in the literature. In this cohort we were able to identify two novel disease genes and based on discoveries, studies for the development of alternative diagnostic tools and theurapatic agents are currently underway.
Page 377 of 487
Turkey
MARKET APPLICATION
The high translational potential of our research to medical diagnostics and drug development constitutes the intersectorial aspects of our potential collaborations. Our studies have merits to provide links between the sectors of academic research, medical diagnostics, and pharmaceutical companies.
Expertise: Rare diseases, bioinformatics, biomarkers, drug development Type: University, Research Institution, Hospital, Diagnostic or Pharmaceutical Companies, Country: Any European or associated country. Tasks: Patient recruitment, basic molecular genetic analyses, clinical analysis of large genomic data, drug design, production of diagnostic
tests.
Offer: Discovery of novel genetic factors, molecular mechanisms and new therapies for
Alzheimer's disease
We investigate the genetic factors and molecular mechanisms leading to Alzheimer's disease (AD). For this purpose,
we brought together a cohort of patients with autosomal dominant AD (ADAD). In this cohort, we aim to exclude
known genetic causes of AD and discover novel causative genes as well as to investigate the relationships between
clinical, cognitive and imaging data, genetic and biomarker characteristics; to detect mutations in known-causative
genes; to unravel yet unknown molecular mechanisms causing the disease; to describe novel therapeutic targets; to
participate in clinical trials of newly developed drugs; and to design novel drugs based on molecular mechanisms we
aim to discover. For the implementation of new therapies we have become a Trial Unit within Washington University's
Dominantly Inherited Alzheimer Network (DIAN). We also have a group in our Center specialised on drug design.
There are not many studies in the literature combining comprehensive data to uncover the pathogenesis of AD. Within our work we paln to integrate and interrogate genomics, transcriptomics, proteomics, and metabolomic data with
clinical, cognitive and imaging characteristics of AD patients. Morover, working with ADAD patients gives us the advantage of efficiently identify novel genes, gene products and molecular mechanisms playing role in the development
of the disease. We are well placed to achieve these aims we have both the expertise and many facilities in our Center
to execute the relevant tasks such as a highly established medical genetics and neurosicence teams and facilities;
large access to ADAD pateints and monitoring facilities through hospital chain of our parent Group; genomics and proteomics labs; cell culture and animal facilities; advanced microscopy and imaging facilities; and drug discovery team
and facilities.
MARKET APPLICATION
Our studies have a very high translational potential as to production of new diagnostic, prognostic, therapeutic markers and targets for AD. In terms of novel services, our work may lay basis for the development of new risk assesment
and monitoring methods as well as of novel preventive measures and alternative treatment approaches.
Expertise: Clinical characterisation of AD and recruitment of ADAD patients; Type: University, Hospital, Clinical Centre;
All Europe Expertise: Systems biology and bioinformatics; Type: University, Private Research/Bioinformatics Company/
Institution; All Europe; Tasks: Integration and interpretation of OMICS, clinical, imaging and life-style data. Expertise:
Medical Genetics and Molecular/Cell Biology; Type: University, Research Labs, Pharmaceutical Companies; All Europe;
Taks: Identification of novel disease genes, execution of functional studies for disease causing-genes and molecular
pathways underlying the disease processes. Expertise: Drug discovery and design; Type: University, SMEs, Pharmaceutical Companie; All Europe; Tasks: Drug design based on newly discovered disease pathways and targets.
Request: Systems Medicine: Integration of genomics data with other omics-data for the
risk assesment, prevention and treatment of common diseases
We aim to establish a new strategy for risk assesment, monitoring, personalised prevention and treatment of common
diseases like cancer, heart diseases, diabetes, dementia etc. Towards this purpose, we will combine genomics data
with transcriptomics, proteomics and metabolomics data. On an individual basis, we will obtain whole genome data
and collect longitidunal systems biology data. For longitidunal assessment, today it is posssible to mesure about 2500
non-classical parameters in the plasma of an individual. Among these are cell free DNA and RNA, proteins and
metabolites providing specific information about certain organs. These are present in trace amounts but detectable
with latest technology such as mass spectrometry, and their concentrations vary in orders of magnitude during disease processes. Having a person's whole genomic data showing apparent health risks and annual measurements of
non-classical biomarkers in blood will allow catching disease development at the very beginning, personalised prevention or early traeatment based on molecular disease mechanisms specific to a particular person.
Page 378 of 487
Turkey
Solution for the development of this sophisticated and complicated strategy, we need to desrcibe the non-classical
biomarkers in plasma to be measured annually. Also, expertise in bioinformatics is needed to create algorithms for integration and clinical interpretation of massive data. Expertise in 4P and Digital Medicine would be most helpful.
Expertise: Systems Biology; Type: University, Research Institution, Private lab; Country: All Europe; Tasks: Description
and collection of whole OMICS data. Expertise: Bioinformatics; Type: University, SMEs, Private Companies; All Europe;
Tasks: Integration and interpretation of OMICs, clinical and life-style data.
Request: Personalised Medicine for Heart: Integration of clinical, genetic and life-style information for risk assessment, tailored prevention and therapy of heart diseases
This project is an analytic platform to deliver genetic-‐based personalized care in Cardiovascular Diseases. It will impact health-‐based risk and cost of care for individuals in real-‐time. In addition, it will enable physicians, hospitals,
health networks, health insurance companies, and others involved in population management to become predictive-‐first.
We seek expertise in the areas below matched to the tasks of the project: 1. Designate the Participating Physicians
and Study Coordinator 2. Select the Participating Patients 3. Patient Consultation 4. Study Coordinator Enrolls the Patients 5. Collect Saliva Sample For Genotyping 6. Order Lab work 7. Genotype Analysis & Results 8. Lab Results 9. Enter Patient’s Lab & Clinical Data 10. Secure Data Integration 11. Risk & Recommendation Platforms 12. Present Disease Risk Assessment
Expertise: Systems Biology; Type: University, Research Institution, Private lab; Country: All Europe; Tasks: Description
and collection of whole OMICS data. Expertise: Bioinformatics; Type: University, SMEs, Private Companies; All Europe;
Tasks: Integration and interpretation of OMICs, clinical and life-style data.
Page 379 of 487
Romania
ROPARDO
Organisation Name
Country
Romania
City
Sibiu
Street
Recontructiei 2A
Website
www.ropardo.ro
Phone
0040269231037
Organisation Type
Large Company
Person
Name
Ciprian Hategan
Email
[email protected]
Job Position
Business Developer
ROPARDO is one of the leading and growing IT companies in Romania with a 20-year tradition in delivering offshore,
near-shore and on site projects. We specialize in software engineering covering the full and continuous process: development and implementation of complex software solutions, maintenance of software/IT systems, and full Oracle EBS
and SAP consultancy for worldwide customers operating in a wide range of industries.
Ropardo "R&I" Department (Research and Innovation) is constantly engaged in research and development projects,
being selected as the expert with the necessary skills and resources to implement innovative solutions in the public
sector and various industries. eHealth is an area of expertise for R&I Department having successfully developed a series of results (algorithms, architectures) to serve health purposes in various life areas: work, physical activities, fun.
Areas of Activity
Preventing disease
Initiative
(PCP)
(PPI)
Methods and data
policies
records (PPI)
Health ICT SMEs
Offer: ZivaCare : Cloud Health Parameter Monitoring System
Following the IoT model, ZivaCare provides a secure Cloud environment to gather, store, and exploit body/health data. Beside Cloud, ZivaCare is made of mobile applications and the web portal for users' data analysis and intelligence.
The users are free to use any smart/wearable devices (pedometers, blood pressure monitors, blood glucose monitors,
weight scales) to gather body/health data. From this point on, the data collected is used in a variety of purposes: be
prepared for emergencies, stay fit, manage specific health conditions. ZivaCare has the following characteristics: • allows easy tracking of different body parameters, capture and interpret them • ensures data privacy and secure access • is available from anywhere, anytime • provides configurable alert thresholds • is equipped with trend charts
that help tracking your progress by hour, day, week or even month & year • comes with a website populated instantly
with data collected by the mobile apps • allows integration of all existing and future-to-be devices
Page 380 of 487
Romania
The great thing about ZivaCare is that, once the body data is gathered, it can be used anytime. The Cloud data becomes valuable in that it helps the user stay motivated, analyze trends, set alerts and emergency contacts, and receive education and recommendations, to keep health condition at its best. ZivaCare brings innovation in the following: - normalizes data: data coming from multiple data sources is normalized, using intelligent data retrieval (retrieves, cleans, and structures data from all of sources) - powerful APIs : data are available through powerful, but
easy-to-access APIs - HIPAA compliant cloud security: users' data is secured with SSL transport, AES256 encryption,
logging, and monitoring - scalable infrastructure: ZivaCare provides scalable infrastructure and reliable uptime, considering the rapidly growing number of users - seamless authentificaiton for users: end-users are enabled to connect
their data streams without leaving the mobile/web application - adds specific apps : SDK and libraries are provided to
get up and run quickly with our plug-and-play integration process ZivaCare developed more than an individual model,
but a software product that allows integration of all existing and future-to-be devices, ensuring the innovation factor
for business like gym, clinics and hospitals, insurance companies.
MARKET APPLICATION
ZivaCare interfaces various technologies to create a social and global network for a real time monitoring of the entire
user healthcare system, for data exchange and access to on-line services. The system has a modular architecture,
both horizontally and vertically, to enable an easy communication between its different pieces. ZivaCare developed
more than an individual model, but a software product that allows integration of all existing and future-to-be devices,
ensuring the innovation factor for business like gym, clinics and hospitals, insurance companies.
Our expertise has been around projects as follows : ZivaCare platform is being tested in real life conditions in partner
schools from 3 European regions in Lombardy (Italy), Catalonia (Spain) and England (UK), gathering more than 300
teenager students. ZivaCare is integrated with the regional public health system giving real time access to patient data (similar to the Romanian national patient electronic file). End-user applications resulting from ZivaCare: - Prepared
for Emergency: Using powerful algorithms, the app automatically detects an emergency and sends a signal to a predefined list of contacts. The emergency message contains healthcare data and GPS position. - Fit 4 Fun: Using Zivacare, end-users capture and understand body parameters during fitness programs. They also create personalized
workout types or use one from a standard list, and connect the body parameters to selected workout. Further on,
workout performance is checked and compared using the mobile / web apps. - Manage Specific Health Condition: Data from specific sensors is captured and stored in a private account. Different body parameters (blood pressure, blood
oxygenation, respiration rate and others) are tracked for specific medical conditions. They can be shared anytime with
the healthcare team, family or friends, or just exported / printed.
Page 381 of 487
United Kingdom
ROYAL Society for Public Health
Organisation Name
Country
United Kingdom
City
London
Street
59 Mansell Street
Website
www.rsph.org.uk
Phone
02072657300
Organisation Type
Other
Person
Name
Heather Davison
Email
[email protected]
Job Position
DIRECTOR EDUCATION AND
DEVELOPMENT
RSPH is charitable status organisation based in the UK. It's mission is to optimise health and wellbeing
for all. It does this through its education, training and community based projects and sharing best practice and knowledge exchange. It has a network of practice members of circa 6000 individuals and 800
study centres. It advises on health policy direction and implementation including prevention and protection interventions and working with communities and modernising the health and care workforce.
Areas of Activity
EU level
Preventing disease
young
(PCP)
(PPI)
population
Methods and data
Health ICT SMEs
Request: Youth health Champions
This is an innovative project that is running in schools in England and encourages young people 12 upwards to get involved in sharing and leaving about health and wellbeing. Each organisation and setting whether schools or youth
centres, YOIs or apprenticeship schemes puts in place and supports a defined set of activities and this is led by and
for young people.
Page 382 of 487
United Kingdom
Similar schemes in European countries to share best practice and benchmarking. Potential collaborators around curriculum and ICT support and innovation around a communication platform.
Offer: Health Champions
HEALTH CHAMPIONS and health trainers are a significant feature in providing health and well being advice and support in England. Champions are normally volunteers and Health Trainers are paid roles. Both work as part of public
health teams and increasingly across public and voluntary services. There are around 3000 health trainers at last
labour market audit and an estimated 40000 Champions.
Rsph is providing the education pathway that supports these roles so the product and content is in place and it is in
no H face to face training and e learning format. Rsph is a regulated Awarding Body and the pathway is a set of credit
based Awards that sit on the England and reciprocal countries national qualifications are tons frameworks. They therefore are competency based and meet all quality assurance standards. There is an opportunity to transfer the concept
and programmes across European partners who are invested in this type of approach or to share learning with similar
system level interventions The opportunity to further develop mobile information and signposting health advice and
geo data is significant as is the potential to gather target population health data.
MARKET APPLICATION
Education, ICT, Gvt and public services
Interested in hearing from experts from different sectors and countries who are either involved in similar activities or
see potential.
Page 383 of 487
France
Sanofi
Organisation Name
Country
France
City
94250
Street
82 avenue Raspail
Website
Phone
Organisation Type
Large Company
Person
Name
Jean-Marc Bourez
Email
[email protected]
Job Position
Sanofi is a global healthcare leader focused on patients’ needs engaged in the research, development, manufacturing
and marketing of innovative therapeutic solutions. Sanofi has core strengths in healthcare around diabetes and cardiovascular solutions, human vaccines, oncology and rare disease, consumer healthcare
Areas of Activity
(PCP)
(PPI)
Request: Identify assets within companies dedicated to e-health and integrated care solutions.
Companies could have a software as well as a connected object. We are looking for mature solutions linked to our
main therapeutic domains
Page 384 of 487
Switzerland
Saphetor
Organisation Name
Country
Switzerland
City
Lausanne
Street
EPFL Innovation Park – Bâtiment C
Website
Phone
+41787332361
Organisation Type
SME
Person
Name
Monica Albarca Aguilera
Email
[email protected]
Job Position
Customer Operations Manager
Saphetor is a precision medicine company whose goal is to improve outcomes for patients by offering clinicians and
researchers, data-driven solutions for making better diagnoses and selecting optimal therapies. Saphetor is pioneering the automation of the currently laborious and disparate processes required for genome-scale analyses and annotation of data from next-generation sequencing (NGS).
Saphetor’s technology platform automatically discovers, annotates and classifies variants. We have aggregated and
regularly update about 10 billion annotations from a wide range of databases. This allows end users to efficiently navigate their NGS data, rapidly identify the most relevant variant(s) and explore what is known about each variant in order to facilitate the most accurate diagnosis and optimal therapeutic choices, as well as research and pharmaceutical
applications.
Areas of Activity
the immune system
diseases
Methods and data
policies
Offer: Next generation sequencing (NGS) data analysis, germline and somatic human
variants discovery, annotation and classification.
Saphetor, is a Switzerland based SME bioinformatics company whose goal is to offer clinicians and researchers a datadriven solution for making accurate molecular diagnoses, choosing the right therapies and thereby improving patient
outcomes. The company achieves this by pioneering the automation of the currently laborious and disparate processes required for genome-scale analyses and annotation of data from NGS – Next Generation Sequencing – of large
“panels” of hundreds or thousands of genes, exome (i.e. important sequences from all genes) or whole genome sequencing data. Saphetor has developed a web based bioinformatics platform which provides: 1. Analysis of multiple
NGS files in a time record. 2. Genetic variation analysis of individuals, families or cohorts. 3. A secure web portal,
Page 385 of 487
Switzerland
which offers tool for exploring variant annotation. 4. Quality and summary report for each patient. 5. Support from
molecular geneticists. The variant discovery platform can help to: - Development of new fast and accurate genetic
tests. - Stratify patients for clinical trials, by confirming genetic variation(s) being targeted. - Perform sub-population
analysis to improve drug development, by identifying variations that correlate with differences in efficiency/tolerability. - Discover/validate new drug targets and/or biomarkers for diagnostics, by identifying variants that correlate with
phenotype(s) or disease. - End “diagnostic odyssey” by facilitating accurate diagnoses of diseases that had previously
been difficult to identify. - Allow selection of optimal/targeted therapies by identifying genetic pathways causing disease.
The advantages of the variants discovery platform are: - variant and annotation visualization in a secure web page, no bioinformatics knowledge is needed, - “software as a service” - no need for installation of any software by the user,
- effective integration of data from a large variety of sources available at the user’s fingertips - possibility to apply
custom filters, - easy to create custom reports, - possibility to share variant data with other platforms
MARKET APPLICATION
Medical/health software Oncology Molecular diagnosis Prenatal diagnostic Medical genetic engineering applications
Hospitals/Clinics, Academic/Research Institutions or Biotechnology/Pharmaceutical companies that work with human
NGS genomic data and are interested in using a platform to help with data analysis and interpretation through a commercial agreement with technical assistance. Saphetor is also open for research cooperation agreements including
joint co-development of specific applications and pipelines on the platform, where the partner specifies requirements
and assists with own domain knowledge.
Page 386 of 487
France
SAS REVINAX
Organisation Name
Country
France
City
Montpellier
Street
14 rue du faubourg saint jaumes
Website
www.surgevry.com
Phone
+33967442697
Organisation Type
SME
Person
Name
Jean-Vincent TRIVES
Email
[email protected]
Job Position
CEO
Révinax/Surgevry aims to deliver fully immersive medical training adapted to the technical specifications of your
products into virtual reality.
Viewing through the eyes of a surgeon or a theatre nurse (for 10 to 20 minutes), the users of our training suite can
quickly acquire knowledge and skills specific to your medical apparatus.
In order for the solution to be tailored to each of appliances, companies will have at their disposition a team trained
and specialised (lead by Dr Maxime ROS) in the acquisition of data which will be transcribed into the training software.
In terms of advanced training (whether internal or for external suppliers/customers), we are working of innovating
technologies prioritising virtual reality such as the setting up of virtual classes (based on MOOC – Massive Online
Open Course). This technique increases the efficiency of the learning process by taking advantage of cognitive phenomenon such as “Mirror Neurons” thus increasing emotional engagement, all the while reducing geographical and
logistical constraints.
Well-qualified and at the forefront of the market in terms of training via virtual reality, we are looking for reliable partnerships with well-established medical private or public laboratories .
Jean-Vincent TRIVES | Head of Sales, Project Lead REVINAX
Dr. Maxime ROS | Neurosurgeon, Project Lead REVINAX
Rémi ROUSSEAU | CEO Surgevry
Areas of Activity
(PCP)
Health ICT SMEs
Methods and data
Page 387 of 487
France
records (PPI)
Offer: enhance training technic
Using new mobile technologies with virtual reality, we are able to design in a first person perspective, a new way to
learn.
Our model is composed of a new way for acquiring datas and knowledge, to transmit it thanks to an apps working on
mobile. Main advantages are a better understanding of technical process thanks to immersion and a better memorization.
MARKET APPLICATION
We are specialized in personal and professional healthcare training, available for private and public hospital. It can be
promotional and pedagogic content for companies working on medical devices, for practitioners or patients.
Public health safety expert, Europe, to target pedagogic priorities
Page 388 of 487
France
Semperego
Organisation Name
Country
France
City
Paris
Street
121 avenue des Champs Elysées
Website
www.semperego.com
Phone
Organisation Type
SME
Person
Name
Alban Quefeulou
Email
[email protected]
Job Position
CEO
Semperego is a French biotechnology company (SME) based in Paris and member of the Medicen Paris Region Biomedical cluster. Our technology is dedicated to DNA preservation at room temperature. By offering an uncompromising and innovative alternative to the dependence on cold technologies for the storage of the DNA sample, our main
objective is to increase and accelerate the human biomedical researches.
Areas of Activity
the immune system
diseases
EU level
Preventing disease
Initiative
Offer: Technology for stabilisation / preservation of biomolecules at room temperature
Biomedical research is facing two majors problems : quality and costs of biological samples. Sempergo’s technology
has overcome these problems on DNA samples. This solution could be applied on other biomolecules such as proteins, vaccines and cells.
Room temperature technology allows the long term storage with highest quality and allow savings at all stages of
sample lifecycle. The management, transport and use of samples are also simplified. Our Expertise : Stabilisation of
biomolecules / Room temperature preservation / Medical device design
MARKET APPLICATION
Our first technology is dedicated to biobanking field.
All
Page 389 of 487
France
Skappy
Organisation Name
Country
France
City
MONTREUIL
Street
74 RUE KLEBER
Website
http://www.skappy.co
Phone
0637733549
Organisation Type
Other
Person
Name
Laetitia Heslouis
Email
[email protected]
Job Position
PDG
Skappy is a self-learning coaching App, a personal online assistant that offers brain training sessions to help people develop their stress face resistance.
These brain training programs are run in the form of entertaining games based on revisited staff development techniques by professionals to make them accessible to the greatest number .
How it works ? To improve personalization, we have developed a behavioral learning algorithm that learns to know our
users to fit their lives and their needs in a much preventive and predictive .
In just 10 minutes a day, 3 to 5 days per week , our users will quickly see measurable results in weeks of workouts.
• Market: Wellness / Health
• Primary Targets: B2C
• Secondary Targets:B2B2C
Skappy serving all:
• Skappy adresses insurance agencies to optimize sick leave or reduce the consumption of health
care and medicines.
• Skappy is for companies as a motivational tool to improve performance at work and come within the
framework of RSE plan (Social Responsibility).
By combining learning and fun aspect of preventive aspect, Skappy also serves the healthcare professionals in order to better support adherence and therapeutic monitoring.
Areas of Activity
Preventing disease
young
Methods and data
Request: Commercial ans scientific cooperation
SKAPPY is looking for two types of cooperation 1. Commercial cooperation in order to develop our business in Europe
with a company working on the digital sector, ideally in the areas of personal development 2. Scientific cooperation
Page 390 of 487
France
with university laboratories or start-ups working on data processing and scientific algorithms in predictive behavioral
and / or psychological to develop new applications or scientific algorithms
To define with company or laboratrory profile
Europeans Companies, Start-ups and Universitary Laborotories
Page 391 of 487
France
SLEEP APNEA BIOTECH INNOVATION
Organisation Name
Country
France
City
Orsay
Street
Boulevard Dubreuils
Website
Phone
Organisation Type
SME
Person
Name
Didier EDOUGA
Email
[email protected]
Job Position
CEO
SLEEP APNEA BIOTECH INNOVATION is a start-up/SME which main goal is to introduce a personalised approach in
treating and managing cardiovascular diseases associated to intermittent hypoxia of sleep apnea disorder. The ambition of the company is to have a leading position in the world for the next decade. Therefore, our plan is to develop
during the next 3 years an unique portefolio of genes-markers of intermittent hypoxia in the heart with a strong IP.
Areas of Activity
Request: Evaluation of clinical potentiel of biomarkers
Our Company, Sleep Apnea Biotech Innovation have an ambitious R&D program for the next three years which aim is
to set up an unique portefolio of specific genes-markers of intermittent hypoxia of sleep apnea. Therefore, we would
like to cooperate with a potential partner who is able to bring an expertise in the evaluation of the clinical potential of
those markers in a view to invest in a strong IP.
The expertise seeking is essentially the ability to evaluate very well the clinical potential of biomarkers.
We looking for either a start-up/SME or an academic
Page 392 of 487
France
SOCOSUR Chem
Organisation Name
Country
France
City
Suresnes
Street
19B rue de Verdun
Website
www.socosur.eu
Phone
+33147720075
Organisation Type
SME
Person
Name
Matthieu CHAREYRE
Email
[email protected]
Job Position
Managing Director
Socosur Chem. is a distribution company focused on Active Pharmaceutical Ingredients, especially in Antibiotics, Cardiology, Ophtalmic and Oncology therapeutics.
It was established in 1990 with a mission to be a reference European importation and distribution company.
Solution provider for Biotech companies looking to industrialize their Active Pharmaceutical Ingredients.
Distribution and agency activities for peptides and fine chemicals producers for pharmaceutical and veterinary use
over the European markets.
Exclusive agent in France for AbbVie Global Pharmaceutical Operations APIs
and in Europe for Shandong Boyuan Pharmaceuticals.
European regulatory filings development and marketing support services.
Sourcing and offering generic and innovative oncology finished products and dossiers for export outside the European
Union.
Areas of Activity
Health ICT SMEs
Offer: H2020-SMEINST-2016-2017 - Active Pharmaceutical Ingredients supply solutions for
H2020 projects
Socosur Chem has been duly inspected again by ANSM last August 2015 for importation and distribution inside EU We
can help you to indentify, source and import directly with industrial scale active pharmaceutical ingredients with appropriate regulatory support to your needs for future commercial developments of biotech or innovative generics
products
25 years of experience in identifying and securing API supplies with Supply and Quality Agreements Strong support in
Regulatory support and Quality Assurance for specifications design to speed up international MA registrations
Page 393 of 487
France
MARKET APPLICATION
Already engaged in such partnership with a French JEI to prepare international licensing scenarios, especially North
America, Japan and East Asia Any H2020 project located in European Union is eligible
Any young biotech company scaling up its pharmaceutical operations manufacturing activities or as soon as preparing the ground for clinical trials with a reliable API manufacturer
Request: SC1-PM-09-2016 - H2020 partnership for new MoA in OsteoArthritis clinical trials
As part of an engaged H2020 SME program, we are seeking European partners with established experience in musculoskeletal disorders that can boost clinical trials to be started along 2016.
- European or international CROs with established osteoarthritic patients pool - Innovative companies with biomarkers
to monitor disease progression and treatment efficacy experienced in musculoskeletal disorders
Multinational experienced company in the musculoskeletal degenerative field
Page 394 of 487
France
Soladis
Organisation Name
Country
France
City
Paris
Street
94 rue Saint Lazare
Website
www.soladis.fr
Phone
0607262269
Organisation Type
SME
Person
Name
Anthony PERRUSSEL
Email
[email protected]
Job Position
Business Manager
Soladis is a statistical consulting company founded in 2000, with a main focus on data analysis in the fields of Life Science, Industry and Services. Soladis is an expert in giving the most of value to its collected data. Soladis brings in its
know-how in form of R&D, production and/or marketing plans provided by data scientists on site. Furthermore, we offer externalized management of your projects if desired. For the general support and improvement of your operational business activity, we propose you training sessions to improve for example your statistical knowledge.
We claim to provide double closeness to our clients on a geographical and functional level. Geographically speaking,
we dispose of four branches in France - Lyon, Paris, Roubaix, and Sophia-Antipolis – as well as of branches in Basel,
Switzerland and Brussels, Belgium. Regarding the functional level, we attach high value to maintain a good, stable relationship with our clients in order to guarantee a long-term partnership. Our staff members give your team a hand by
fulfilling an advisory function during your missions. All our services are especially focused and tailored according exactly to your needs and wishes.
In addition to our statistical offer, we created a department devoted to the conduct of Clinical Trail Management
(Phase I-IV) by the acquisition of a full-service CRO with nearly 25 years of experience. This brings in a combination of
statistical and medical services to the Life Science actors to back their clinical, -omic, or personalized medicine projects. Actors are for instance laboratories, the food processing industry in general, as well as the cosmetics industry.
We also cover the field of preclinical studies and clinical development. By combining our medical can statistical expertise to profit from synergy effects, Soladis Clinical Studies, supports your projects from protocol writing to its publication.
Areas of Activity
the immune system
diseases
population
Methods and data
policies
Page 395 of 487
France
Offer: Clinical and Statistical services
Soladis provides its expertise to companies in need of clinical (protocole writing, data managmeent, monitoring, medical writing), and statistical (for clinic, data mining, big data, personalized medicine,..) services during their projects.
The added value of a the double expertise (Medical/Clinical + Statistics) is that both thoughts are bounded while
thinking about indicators or endpoints in studies.
MARKET APPLICATION
Statistics are required while conducting R&D (lab or clinical), Production, or Marketing actions. Life Science fields are
all involved in those actions, from pharmaceutical labs to biotechnology start-ups, including Meddev, agro-food, cosmetics,... These companies face statistical issues while conducting their projects, and Soladis successfully supports
them thanks to its expertise.
Page 396 of 487
France
Sorbonne Universities, University Pierre and Marie Curie
Organisation Name
Country
France
City
Paris
Street
91, bd de l'Hopital, #205
Website
https://www.lib.upmc.fr/?lang=en
Phone
+33633774267
Organisation Type
University
Person
Name
Daniel RACOCEANU
Email
[email protected]
Job Position
Research team Director
The Biomedical Imaging Lab (LIB – Laboratoire d’Imagerie Biomédicale) specializes in fundamental research and applications of biomedical imaging methods for morphologic, functional and molecular exploration of small animals and
humans. The main investigation foci are are among the twenty-first century public health priorities: bone, cancer, cardiovascular and neurological diseases. We develop new diagnosis and treatment methodologies in our main field of
investigation, including bright light microscopy, ultrasound, MRI, CT and SPECT-PET.
Areas of Activity
the immune system
EU level
Preventing disease
Initiative
Methods and data
policies
Offer: Scalable biomedical imaging/engineering for massive data analytics
Our present fields of interest include scalable imaging methods for quantitative and qualitative diagnosis / prognosis
assistance using probabilistic detection approaches, graph-based mathematical morphology, as symbolic cognitive visual algorithms for high-content biomedical image exploration. Our on-going projects concern new protocols for cancer diagnosis and prognosis in digital histopathology and tele-pathology, as well as novel approaches for tumour heterogeneity and tumour growing modelling.
Scalable and parallelizable stochastic algorithms allowing non-supervised detection of complex structures in nD.
Mathematical morphology methods on sparse architectures. Spatial positioning. Semantic-driven high-content image
analysis.
Page 397 of 487
France
MARKET APPLICATION
Digital Pathology High-content biomedical image analysis / screening. Big biomedical (including imaging) data.
Medical knowledge and annotated data. Concrete focused medical challenge. High parallel computing capabilities and
knowledge.
Request: Parallel computing for high-content imaging (big data)
We initiated successful efforts related to
Parallelizing stochastic (nD) image analysis methods in high-content image analysis. Paralelization of specific imaging
algorithms in Digital Pathology. Scalability for big data.
High parallel computing capabilities and knowledge.
Request: Medical challenge and knowledge
We are continuously looking for exiting medical challenges, related to precise medical expertise and know-how. Let's
go together for the next generation of technologies in biomedical image and engineering.
Medical and biomedical practitioners able to provide knowledge, data and annotations.
Offer: Massive Data Analysis
We elaborated a novel framework enabling the integration of prior knowledge into kernel machines / classifiers. Deep
learning used for a very effective pattern recognition and video summarisation.
Scalable algorithms for massive data analysis and interpretation. Use of prior knowledge to increase classification relevance. Deep learning.
MARKET APPLICATION
All industries, including pharmaceutical.
All industries which need a clear vision of their strategy/policy in a very complex heterogeneous and dynamic environment. or Refining a precise and focused target necessitating massive data mining.
Page 398 of 487
France
Sparks & Co
Organisation Name
Country
France
City
Paris
Street
66 avenue des Champs-Elysées
Website
www.sparksandco.com
Phone
0768350060
Organisation Type
SME
Person
Name
Camille Cocaud
Email
[email protected]
Job Position
CEO
Sparks & Co is a communication and dissemination agency specialised in Horizon 2020 projects. Under Horizon
2020, he European Commission now specifically requires projects to have a communication and dissemination strategy, to both maximise the projects impact by targeting stakeholders and promote them to a wide range of audiences.
Our agency is ready to take full responsability for your WP on maximising your project's Impact. Our team of experienced communicators will help you write your Impact section of the proposal and implement the communication
and dissemination strategy during the project.
VISIT WEBSITE
Areas of Activity
the immune system
diseases
EU level
Methods and data
policies
Preventing disease
young
Health ICT SMEs
Page 399 of 487
France
population
Offer: Impact - Communication and Dissemination of your research
Sparks & Co is a communication and dissemination agency specialised in Horizon 2020 projects. Under Horizon 2020,
he European Commission now specifically requires projects to have a communication and dissemination strategy, to
both maximise the projects impact by targeting stakeholders and promote them to a wide range of audiences. As the
European Union Horizon 2020 funding programme unrolls, communication and dissemination activities are set to be
more prevalent in each research project. Because we believe European research projects should get the best impact
on all audiences, our team of experienced science communicators will gather its talents to be wholly dedicated to
their needs. Indeed, the Impact section of your project now weights 1/3 on your total mark. Making sure you have an
experienced communication company with a good track record on your side will show the evaluators you care about
the translation of your project and its impact. Moreover, the Horizon 2020 scheme is very competitive. Including communication experts in your consortium might be the winning factor that will distinguish the project amongst the others. Make sure you give your project the best chance of funding by working with professionnals! // Our work process
PROPOSAL STAGE We enter consortia at the proposal stage as a partner. Our team works with you towards completing
the Impact section and takes the lead on the Work Package dedicated to Communication, Dissemination and Exploitation of results. PROJECT EVALUATION Within 5 months, the project is evaluated. The Impact section is now weighing 1/
3 of the total mark awarded to the project under Horizon 2020. See evaluation criteria on Participant Portal. PROJECT
IMPLEMENTATION During the implementation of the project, our team leads the Work Package on Communication,
Dissemination and Exploitation of results. We create the project's communication strategy and implement all the activities described below. Throughout the project's duration, we monitor the results' impact on: researchers, policymakers, media, industry and general public. Finally, we adapt our communication strategy yearly to maximise the
project's global Impact. // Our services VISUAL IDENTITY Project branding: logo, design chart, completed with various
document templates SOCIAL MEDIA Clever use of social media to optimise project networking, news and events monitoring COMMUNICATION MATERIALS Leaflets, flyers, brochures, videos, infographics, newsletters, presentations,
posters, photo bank… PRESS RELATIONS Mutli-national broad spectrum press relations, in collaboration with partners’
press teams WEBSITE Project website with regular updates, maintenance, up to 3 years after project end IMPACT
MONITORING Impact monitoring of communication and dissemination activities, yearly revision of global communication strategy
FROM PROPOSAL TO IMPLEMENTATION Our team of experienced communicators will write your Impact section and
implement the communication strategy of your project during its duration. COST 0€ All our costs are covered by EU
funding Maximise your chances of getting funded! The Impact section of your proposal now account for 1/3 of your
evaluation mark. Give your project the best chance of funding by allowing communication experts to handle this strategy.
MARKET APPLICATION
All projects will benefit from having communication experts on board, both for project evaluation and implementation.
Contact us to know how we can help your research project get the Impact it deserves!
Consortia with a proposal looking to improve their Impact section by giving their communication and dissemination
strategy the attention it deserves.
Page 400 of 487
Spain
SPECIPIG
Organisation Name
Country
Spain
City
Barcelona
Street
Autovía de Castelldefels C-31. Km 190.5
Website
www.specipig.com
Phone
Organisation Type
SME
Person
Name
Begoña Ondiviela
Email
[email protected]
Job Position
Business Development Manager
SPECIPIG, Breeding and Biomedical Reserch Centre is a preclinical CRO (Contract Research Organization),
specialized in breeding genetically selected pigs (miniature pig model).The company is located in the metropolitan
area of Barcelona where is a strong cluster in life sciences. It is currently the only EU company offering a comprehensive service for biomedical research with this animal model.The facilities are suitable for housing and carrying out
both short- and long-term studies and include an experimental operating room that is fully equipped to
meet the needs of our users. We have an expert team for toxicology studies and concept testing of new drugs, validation doctors, surgeons and research training of new surgical techniques devices.
Swine model is widely used as an experimental model in biomediacl research due to the physiological, physical and
behavioural similarities between pigs and humans. SPECIPIG is working on a project to breed SPECIPIG miniature
pigs weighing about 35 kg in adulthood and with a very specific genetic composition and high standard of health
(SPF - Specific Pathogen Free), bred specifically to cover the needs of biomedical research. The company can conduct
individual studies to customer specification and provide complete consultative design and execution.
Areas of Activity
diseases
(PPI)
Offer: CRO Pre-clinical Services, Breeding center (miniature pigs) for biomedical research
The company is working on a project to breed “specipig” miniature pigs weighing about 35 kg in adulthood and with a
very specific genetic composition. These animals are particularly suitable for long-term studies. Our experimental services and procedures include: Physiopathological models on demand (for ex. Atherosclerosis model) Ocular studies
Acute Dermal Irritation/Corrosion studies Experimental surgeries: organs and tissues obtaining, permanent catheters
implants, endoscopy, etc… Medical devices testing Nutrition studies Cardiovascular studies Pharmacokinetic studies
Offer: SPECIPIG as partner for Pre-clinical research in therapeutic areas in which miniature
pig is a choice model:
We cover all key stages in Pre-clinical development: R&D and Regulatory (Technological revisions, 'in vivo' animal
studies for proof of concept, validation prototypes, medical devices testing) and also Clinical phase (Feasibility studies, surgical techniques, Clinical efficacy, complications and risks linked to MD procedures). We can also be a partner
Page 401 of 487
Spain
for 'in vivo' studies in pre-launch phase: clinical benefits - therapeutic strategy. As a CRO we can help companies with
protocol design and experimental plan execution.
We have our own models in: - DENTAL (Oral and Dental models) - ORTHOPEDICS / BONE REGENERATION - SPINAL
PATHOLOGIES - SKIN / WOUND PATHOLOGIES - OPTHALMIC PATHOLOGIES - CARDIOVASCULAR PATHOLOGIES - THORACIC PATHOLOGIES - URETHRAL IMPLANTS - GASTRIC IMPLANTS - OBESITY - ATHEROSCLEROSIS - DIABETES - METABOLIC SYNDROME - OSTHEOPOROSIS MODEL - NEUROPATHOLOGY - OTHER
We are looking for Research Centers, Hospitals, Medical Devices, Pharma Companies, CROs who search a Pre-Clinical
Contract Research Organisation specialised in swine model (miniature pigs). Our Business model is: - Research on
contract basis - Services company - Delivering high miniature pigs with high health status (breeding center)
Offer: SPECIPIG as partner for Pre-clinical research in therapeutic areas in which miniature
pig is a choice model:
We cover all key stages in Pre-clinical development: R&D and Regulatory (Technological revisions, 'in vivo' animal
studies for proof of concept, validation prototypes, medical devices testing) and also Clinical phase (Feasibility studies, surgical techniques, Clinical efficacy, complications and risks linked to MD procedures). We can also be a partner
for 'in vivo' studies in pre-launch phase: clinical benefits - therapeutic strategy. As a CRO we can help companies with
protocol design and experimental plan execution.
We have our own models in: - DENTAL (Oral and Dental models) - ORTHOPEDICS / BONE REGENERATION - SPINAL
PATHOLOGIES - SKIN / WOUND PATHOLOGIES - OPTHALMIC PATHOLOGIES - CARDIOVASCULAR PATHOLOGIES - THORACIC PATHOLOGIES - URETHRAL IMPLANTS - GASTRIC IMPLANTS - OBESITY - ATHEROSCLEROSIS - DIABETES - METABOLIC SYNDROME - OSTHEOPOROSIS MODEL - NEUROPATHOLOGY - OTHER
We are looking for Research Centers, Hospitals, Medical Devices, Pharma Companies, CROs who search a Pre-Clinical
Contract Research Organisation specialised in swine model (miniature pigs). Our Business model is: - Research on
contract basis - Services company - Delivering high miniature pigs with high health status (breeding center)
Page 402 of 487
France
STAB XTOM
Organisation Name
Country
France
City
Trappes
Street
46 avenue des Freres Lumière
Website
Phone
+33685741846
Organisation Type
SME
Person
Name
Jean DUMAS
Email
[email protected]
Job Position
CEO
We are medical devices manufacturers like blood pressure monitor, ECG, thermometer etc...Our product road map is
now focused on smart (IoT) devices, especially designed for home healthcare management.
Areas of Activity
(PCP)
Offer: Smart healthcare devices provider
Blood pressure monitor, oxymeter, spirometer, ECG
MARKET APPLICATION
home healthcare management
Page 403 of 487
Spain
Starlab Barcelona SLU
Organisation Name
Country
Spain
City
Barcelona
Street
Av Tibidabo 47b
Website
http://www.starlab.es/neuroscience/
Phone
Organisation Type
SME
Person
Name
Aureli Soria-Frisch
Email
[email protected]
Job Position
R&D Manager
Established in 2000 Starlab is an independent, private R&D SME. Starlab Barcelona develops innovative sensor concepts as well as software products and consulting services. The Neuroscience Business Unit has extensive experience
in brain stimulation and electrophysiology, advanced data analysis, and basic/applied research for both institutional
and industrial clients.
Relevant areas of expertise
• Algorithm and Model development: EEG signal processing, Computational Intelligence, Machine learning,
Data-mining, Big-Data, Biomarker evaluation, Multi-modal and Multi-sensory data fusion
• Electroencephalography (EEG) and neuroimaging: Protocol design, experimental and clinical trials, biomarker
discovery, real-time and off-line data analysis, visualization and reporting.
• Software development: End-to-end systems, application layer, and cloud-based data management and analysis.
Expertise Description
Starlab Neuroscience brings scientific rigor to the provision of neuroscience data analysis services to clinical and professional applications while leveraging medical grade hardware provided by our spin-off Neuroelectrics. Starlab Neuroscience capability is based on a unique combination of expertise in different stages of the data analysis pipeline
from the signal acquisition through EEG signal processing to the final application of advanced machine learning techniques. Our methodological approach allows the evaluation and statistical validation of electrophysiological and neuroimaging biomarkers at subject individual level, which paves the path for its extensive application in clinical decision
support systems for diagnosis, prognosis, and treatment monitoring. Our biomarker discovery techniques have been
developed for both spontaneous and event-related EEG protocols. The integration of the analytical framework in cloud
repositories allows a smooth clinical trial data management as well as the automate report generation for giving a
clear insight of results to our clients.
Project Involvement
• HIVE (EU FP7, Coordinator – 3M5€) - Design, develop and test advanced brain stimulation technologies.
• BEAMING (EU FP7, Coordinator - 11M€) - Emotional subject response characterization.
• INTERGROWTH (private, subcontracted by U. Oxford): EEG integration and ERP data analysis in a broad international project on children developmental indices.
• Machine Learning for PD biomarkers I & II (Michael J Fox Foundation, Principal Investigator - 75K$ & 340 K$):
Use machine learning in biomarker discovery for PD diagnosis and prognosis.
• StarProbe (private, Biogen): tCS-based protocol development and analysis.
Areas of Activity
Methods and data
Page 404 of 487
Spain
EU level
policies
Preventing disease
Initiative
young
(PCP)
population
Request: Starlab Barcelona: Your SME partner for electrophysiology, BigData, and neurotechnology
Starlab Neuroscience brings scientific rigor to the provision of neuroscience data analysis services to clinical and professional applications while leveraging medical grade hardware provided by our spin-off Neuroelectrics. Starlab Neuroscience capability is based on a unique combination of expertise in different stages of the data analysis pipeline
from the signal acquisition through EEG signal processing to the final application of advanced machine learning techniques. Our methodological approach allows the evaluation and statistical validation of electrophysiological and neuroimaging biomarkers at subject individual level, which paves the path for its extensive application in clinical decision
support systems for diagnosis, prognosis, and treatment monitoring. Our biomarker discovery techniques have been
developed for both spontaneous and event-related EEG protocols. The integration of the analytical framework in cloud
repositories allows a smooth clinical trial data management as well as the automate report generation for giving a
clear insight of results to our clients.
We would like to join a building consortium
Organizations coordinating a proposal
Page 405 of 487
France
Stimul
Organisation Name
Country
France
City
Paris
Street
5 rue des messageries
Website
www.stimulme.com
Phone
Organisation Type
SME
Person
Name
Marc-Antoine Brochard
Email
[email protected]
Job Position
President
Stimul is a healthcare startup designing high-touch intervention programs delivered through our online platform that
provides everybody with the capacity to build healthy lifestyle habits thanks to human coaching, personalization,
tracking, pedagogical knowledge and flexibility.
Areas of Activity
(PCP)
Stimul designs high-touch intervention programs delivered through our online platform that provides everybody with
the capacity to build healthy lifestyle habits (related to physical activity and/or nutrition) thanks to human coaching,
personalization, tracking, pedagogical knowledge and flexibility. It enables corporations/insurance-providers/pharma
companies to implement evidence-based health & wellness programs with real engagement and savings over time.
Our value proposition there is to improve the health of our users, reduce healthcare costs for employers and insurers,
move from curation to prevention and drive productivity economics. We were recently selected by Deloitte as one of
the 15 startups with the potential to disrupt the e-health and insurance industries:
http://www.deloittedigitaldisruptors.com/disruptors/ and look forward to working with innovative partners all over Europe.
Ready-to-roll-out high-touch behaviour-change interventions encompassing human coaching, connected trackers and
evidence-based curriculums. Very high engagement rates thanks to a user experience that delights. Health-as-a-service (flexible, no setup fee, fast).
MARKET APPLICATION
Corporate health & wellness, insurance, pharmaceutical market
Key accounts that want to roll out a pilot with some of their population (pre-diabetes, inactive people, post-treatment
cancer patients, overweight people, ...etc) -> Stimul can help in the screening phase. Investors for the European expansion. Research labs for the co-design of new programs tackling other behaviour-related conditions. Hospitals to
perform trials with some patients and assess the results.
Page 406 of 487
France
Stimul
Organisation Name
Country
France
City
Paris
Street
5 rue des messageries
Website
Phone
Organisation Type
SME
Person
Name
Etienne Dormeuil
Email
[email protected]
Job Position
Stimul, a behavior change tech company.
Stimul is a healthcare startup designing high-touch intervention programs delivered through our online platform that
provides everybody with the capacity to build healthy lifestyle habits thanks to human coaching, personalization,
tracking, pedagogical knowledge and flexibility.
Areas of Activity
population
Stimul designs high-touch intervention programs delivered through our online platform that provides everybody with
the capacity to build healthy lifestyle habits (related to physical activity and/or nutrition) thanks to human coaching,
personalization, tracking, pedagogical knowledge and flexibility. It enables corporations/insurance-providers/pharma
companies to implement evidence-based health & wellness programs with real engagement and savings over time.
Our value proposition there is to improve the health of our users, reduce healthcare costs for employers and insurers,
move from curation to prevention and drive productivity economics. We were recently selected by Deloitte as one of
the 15 startups with the potential to disrupt the e-health and insurance industries:
http://www.deloittedigitaldisruptors.com/disruptors/ and look forward to working with innovative partners all over Europe.
Ready-to-roll-out high-touch behaviour-change interventions encompassing human coaching, connected trackers and
evidence-based curriculums. Very high engagement rates thanks to a user experience that delights. Health-as-a-service (flexible, no setup fee, fast).
MARKET APPLICATION
Corporate health & wellness, insurance, pharmaceutical market
Key accounts that want to roll out a pilot with some of their population (pre-diabetes, inactive people, post-treatment
cancer patients, overweight people, ...etc) -> Stimul can help in the screening phase. Investors for the European expansion. Research labs for the co-design of new programs tackling other behaviour-related conditions. Hospitals to
perform trials with some patients and assess the results.
Page 407 of 487
United Kingdom
Strata Health Europe
Organisation Name
Country
United Kingdom
City
Dartford
Street
Victory Way, Admirals Park
Website
www.stratahealth.co.uk
Phone
Organisation Type
SME
Person
Name
Clint Schick
Email
[email protected]
Job Position
Managing Director and
Chairman European Council
Strata Health continues to work with healthcare providers to change things for the better; achieving greater operating
efficiencies; increased productivity; and more positive outcomes for patients through intelligent electronic management of patient transitions into the right care, at the right time.
Strata Health works with healthcare providers to change things for the better: achieving greater operating efficiencies; increased productivity; and more positive outcomes for patients through intelligent electronic management of
patient transitions into the right care, at the right time.
Strata Health was formed over a decade ago by healthcare and business professionals committed to finding a way of
using technology to manage the flow of patients into and across the care continuum. To this day, caregivers continue
to be taken away from caring for patients to coordinate care transitions manually by phone, fax and email. They’re often working with an incomplete picture of their patients’ statuses, and even fewer relevant details about available referral options. It is an inefficient process, prone to error. Patients, caregivers and the healthcare system all suffer as a
result.
Working with healthcare leaders, clinicians, and IT specialists, Strata Health has pioneered the development of powerful software tools that have revolutionise patient flow, benefiting patients, caregivers and healthcare organisations
alike. Today, our proprietary intelligent referral technology has positive effects right through the care system – we
make beds and referral options available sooner. Primary care physicians can better match their patient to an available specialist or programme and specialist referrals happen sooner. Waiting times for emergency care are cut. Patients are transferred from accident and emergency faster. Patients, when they’re assessed ready for discharge, are
provided optimal out of hospital care sooner. Hospital readmissions because of discharge to inappropriate care options are reduced. Healthcare professionals spend less time doing paperwork, and have more time to actually care for
their patients.
Areas of Activity
EU level
Methods and data
records (PPI)
(PCP)
(PPI)
Page 408 of 487
France
Strata Health Solutions Europe
Organisation Name
Country
France
City
Paris
Street
74, rue du Faubourg Saint-Antoine
Website
www.stratahealth.com
Phone
0153462631
Organisation Type
SME
Person
Name
Geoffrey Haas
Email
[email protected]
Job Position
Country manager France
Strata Health leverages web-based technology to enable bespoke requirements for local patient transitions covering
all clinical pathways; enabling best-suited intervention to be identified AND delivered through a comprehensive,
transparent e-referral & patient hand-off process across all stakeholder organisations.
Strata Pathways™ Resource Matching and eReferral (RM&R) is an innovative cloud technology solution that matches
patients’ clinical needs and preferences to available and appropriate resources across the entire care ecosystem, in
real time.
Our patient-focused solutions transform health care regions. At Strata Health, eReferrals are not about direct messaging with attachments. They revolutionize patient journeys. We harness the resources of health jurisdictions, making
them accessible to health care professionals and allowing them to match patient needs to downstream options according to transparent eligibility criteria.
To ensure clinicians worldwide adopt a new system and optimal workflow, Strata Health solutions can be configured to
each region’s individual needs, at an International level, and integrates seamlessly with existing IT assets.
By enabling patient transitions across organizational boundaries, Strata underpins four core pillars in health and social
care: Better patient outcomes, better patient safety, asset management/optimization, and cost savings. With 100%
customer retention, Strata Health works with clients on an ongoing basis to ensure sustained outcomes are maintained over time. We have 14 years of experience providing SaaS solutions for global implementations. Each and
every one of our customers has achieved stringent SLAs, met legislative requirements and policies for transitions of
care and for eReferral systems, and met every privacy requirement. Our existing HIS, EMR, EHR and HIE vendor partnerships and integration with other health IT systems ensure streamlined clinician workflow and solution adoption.
Our solutions empower health care regions and health care professionals to provide superior patient care.
Areas of Activity
Methods and data
records (PPI)
Page 409 of 487
France
Request: Strategic partnership to build an integration logic to improve care coordination
across a regional care ecosystem
Relevant topic and areas of collaboration: Care coordination at the regional of healthcare territory level. Patient navigation and orientation at hospital discharge to Long Term Care, Community Care, rehab care, mental health and addictions, palliative care, chronic diseases, home care and from GP to specialist care.
- Health regions, regional health authorities, health territories, Hospital/Acute care centres groups and Community facilities. - Strategic, sales and technology partnerships with: HIS, EMR, EHR vendors and technologies facilitating clinicians collaboration. - Countries: Germany, France, Ireland, Spain, EU countries in general.
Offer: Resource Matching and eReferral technology
Strata PathWays™ makes it easier to intelligently transition patients between care settings. PathWays™ is an innovative cloud technology designed to match patients’ clinical needs and preferences to available and appropriate resources across the care continuum, in real time. Clinicians are presented with up to the minute information on the patient, available care options and wait times. Patients can then be matched to the most ideal individual or package of
health programs, services or specialties. Strata PathWays™ is configurable to each health region’s individual needs.
The solution integrates seamlessly to existing IT assets, ensuring optimal workflow and clinician adoption.
Improve care coordination, clinician collaboration and facilitate patients transitions across the care ecosystem.
MARKET APPLICATION
Regional healthcare authorities, hospital groups, GP to Specialist referrals.
Page 410 of 487
France
STREAMVISION
Organisation Name
Country
France
City
PARIS
Street
9 rue Notre-Dame de Lorette
Website
www.streamvision.fr
Phone
0142810416
Organisation Type
SME
Person
Name
Myriam Blouin
Email
[email protected]
Job Position
Marketing Director
Created in March 2003 in France, StreamVision is a key enabler in the emerging market of digital video broadcast and
rich media applications in proposing to audiovisual, educational and hospitality markets very performing and evolving
interactive offers and products.
StreamVision is also specialized in the design and implementation of quick medical diagnosis systems enabling the
capture of body information and medical analysis via non-invasive sensors.
More info on www.streamvision.com
Areas of Activity
(PCP)
(PPI)
interactive offers and products. StreamVision is also specialized in the design and implementation of quick medical diagnosis systems enabling the capture of body information and medical analysis via non-invasive sensors. StreamVision was awarded in the Worlwide Innovation Challenge in July 2014 as well as in H2020 - Sme Instrument Phase 1 in
March 2015. More info on www.streamvision.com
Academic health partners or organisms (clinic, hospitals, remote health center, etc..): We are looking for health partners who would accept to test our armchair in the frame of a national or international project. Being part of several
H2020 projects, we are good at answering European projects. We're in the process of stepping from the prototype to
the product and are looking for e-health sensor partners to complement our prototype as well as e-health product
manufacturer who would like to extend their offer in the manufacturing of part of the e-health chair. We would also
like to partner with an e-health data base editor for the data processing and result analysis.
see paragraph above
capture of body information and medical analysis via non-invasive sensors. Combining the mastering of the complete
Page 411 of 487
France
signal processing chain with the evolving needs of the silver economy, StreamVision has developed a quick medical
diagnosis armchair, called Check@flash, enabling the quick capture of body information and medical analysis via noninvasive sensors. Check@flash armchair’s triple aim is first to provide a performing and quick answer to medical regional deserts by bridging the gap between the remote location and the nearest medical center, second to reassure
or avoid the possible health problems of a dynamic and always more autonomous population and third to provide a
convenient medical data capturing tool of elderly people in nursing homes for an easier medical follow-up. Placing the
e-health armchair in nursing homes or in emergency department will allow medical helpers to spend less but more
qualitative time on patient. The complete chain of care and medical follow-up will also be optimized. It also gives freedom thanks the remote accessibility of medical data from the patient to the doctor. The StreamVision Company was
awarded in July 2014 by the Worldwide Innovation Challenge for its e-health armchair as well as in March 2015 by the
H2020 SME instrument Phase 1 program.
We're looking for health private or public health organisms (Clinic, hospital, remote centers, etc..) to test our armchair
in the frame of a national or international project. We are running already some european projects and are well versed
in the making -out of proposals. The objective would be to measure the added-value of our prototype in health centers and enrich it with the gained experimentation's results. We're in the process of stepping from the prototype to
the product and any help in the manufacturing of parts of the armchair (arms, 3D drawers) would be appreciated. We
are also looking for e-health industrial partners to complement our e-health armchair (sensors manufacturers, health
data base editors). We would also be glad to partner with e-health product manufacturers interested in extending
their e-health offer.
see above
Page 412 of 487
France
STREAMVISION
Organisation Name
Country
France
City
PARIS
Street
9 rue Notre-Dame de Lorette
Website
www.streamvision.fr
Phone
0142810416
Organisation Type
SME
Person
Name
Mohamed Rebiai
Email
[email protected]
Job Position
Chairman
interactive offers and products.
capture of body information and medical analysis via non-invasive sensors.
More info on www.streamvision.com
Areas of Activity
(PCP)
(PPI)
Page 413 of 487
Switzerland
SUPSI
Organisation Name
Country
Switzerland
City
Manno
Street
Galleria 2
Website
http://www.supsi.ch/isin_en/ricerca-servizi/ICT4Health.html
Phone
004158666 6596
Organisation Type
University
Person
Name
Francesca Faraci
Email
[email protected]
Job Position
Senior Lecturer
ICT4Health (Information Communication Technology for Health) is a Research Unit focused on
ICT applications in the health domain. It is part of the Institute for Information Systems and
Networking (ISIN).
The research topics are mainly:
• Brain Computer Interface (BCI) and Brain Neural Machine Interface (BNMI) in rehabilitation with the aim at
helping people recovering from a neurological disease, as for instance stroke patients, or supporting them in
substituting the loss of functionality (e.g. paraplegic, tetraplegic);
• Mobile Health and Personal Health Systems for continuous monitoring, treatment and prediction of risky disease episodes (e.g. hearth attacks, stroke, bipolar disorder episodes), and for personalized medicine, especially in elderly with comorbidities;
• Intelligent Assistive Technologies for supporting the elderly to prolong as long as possible their life at home;
• Automatic Data Management Systems (ADMS) for supporting hospitals and health care centers to optimize
the health data record management and the personnel work flow organization.
Areas of Activity
(PPI)
Preventing disease
young
Methods and data
policies
Request: Big Data for Social Health
Our Idea is to develop a top down approach to Medicine and to Social Health. Starting from the real data extracted
from EHR or digitalised documents is possible to extract important information about the impact (medical and economical) of a certain treatment, about the spreading of certain disease. It is possible to offer a global vision in Europe
of the prices of certain treatment and of the impact of certain disease. But more innovative we intend to apply the
EVM principle and try to improve the physician diagnosis.
Our Idea is to develop a top down approach to Medicine and to Social Health. Starting from the real data extracted
from EHR or digitalised documents is possible to extract important information about the impact (medical and economical) of a certain treatment, about the spreading of certain disease. It is possible to offer a global vision in Europe
Page 414 of 487
Switzerland
of the prices of certain treatment and of the impact of certain disease. But more innovative we intend to apply the
EBM (evidence based medicine) principle and try to improve the physician diagnosis. The tool will be at the service of
Health Authorities, offering high quality reccomendations.
We actually have two small SME dedicated at ICT for Health, --- Health Authorities from all EU countries are welcome -- Business and Social Health Researcher are welcome -- EBM expert physicians, hospitals .... --- we need a Coordinator !!
Page 415 of 487
France
SWAF
Organisation Name
Country
France
City
Paris
Street
9 Rue René Boulanger
Website
www.swaf.io
Phone
0633401775
Organisation Type
SME
Person
Name
Jacques Rossard
Email
[email protected]
Job Position
CEO
SWAF is a startup which offers the solution for proper hydration. This solution is present throughout the value chain:
from the final user with an IoT glass for drinking until policimakers with a Business Intelligence solution based on Big
data. Between, a range of services hosted in a cloud computing for caregivers, nurses and doctors accessible by
smartphone or web technology.
SWAF is oriented for the elderly, sportive people or any person aware of his good health.
We have strong partnerships with global corporations who believe in our solution in the areas of health, insurance,
food, nutrition or sports.
We would be honored to present to you in more detail our solution SWAF.
Areas of Activity
(PCP)
Offer: Hydration solution
SWAF is a startup which offers the solution for proper hydration. This solution is present throughout the value chain:
from the final user with an IoT glass for drinking until policimakers with a Business Intelligence solution based on Big
data. Between, a range of services hosted in a cloud computing for caregivers, nurses and doctors accessible by
smartphone or web technology. SWAF is oriented for the elderly, sportive people or any person aware of his good
health. We have strong partnerships with global corporations who believe in our solution in the areas of health, insurance, food, nutrition or sports. We would be honored to present to you in more detail our solution SWAF.
Page 416 of 487
Poland
SWPS University of Social Sciences and Humanities
Organisation Name
Country
Poland
City
WARSAW
Street
UL. CHODAKOWSKA
Website
Phone
Organisation Type
University
Person
Name
Szymon Wichary
Email
[email protected]
Job Position
assistant professor
SWPS University of Social Sciences and Humanities is a modern research and higher education institution which offers
interdisciplinary studies in social sciences and humanities in the main Warsaw campus and branch-campuses in
Sopot, Wroclaw, Poznan and Katowice. SWPS University is the first center of psychological education in Poland which
has received the highest mark of distinction from the National Accreditation Commission. SWPS University has been
granted the right to award doctoral degrees in the following disciplines: psychology, sociology, cultural studies, and
law. SWPS Univesrity is among the best scientific institutions in Europe, carrying out research in the fields of social
sciences and humanities. The university is one of the major beneficiaries of the funds from the Polish science budget.
As the only non-public higher education institution in Poland, SWPS University regularly receives grants from Ministry
of Science and Higher Education for statutory R&D activities. SWPS University has been involved in European Union
projects, including 6th and 7th European Framework Projects and it participates in the Joint Programing Initiative established by the European Commission. At present it has almost 14 500 students.
Areas of Activity
Preventing disease
young
(PCP)
(PPI)
population
Request: Relieving stress to enhance reproduction: Cognitive Behavior Therapy and
blended intervention for the treatment of Functional Hypothalamic Amenorrhea. A randomized clinical trial with reproductive hormone measures as outcomes.
Aim of the project The aim of this project is to design, implement and evaluate a cost-effective therapeutic intervention to help reduce the symptoms associated with infertility of unexplained origin, increase the levels of reproductive
hormones and restore ovulation. Societal Challenge and Background Ageing of European population has two sides. On
one side, increasing longevity and life expectancy, and on the other side decreasing fertility, both contribute to this
societal trend. As reported in “Fertility statistics (Eurostat report; http://ec.europa.eu/eurostat/statistics-explained/in-
Page 417 of 487
Poland
dex.php/Fertility_statistics), fertility rates are steadily decreasing in Europe. Although these changes are caused to
some degree by changing lifestyle factors and individuals’ conscious choices, infertility also plays a large part in this
process. As estimated by European Society for Human Reproduction, “one in six couples worldwide experience some
form of infertility problem at least once during their reproductive lifetime. The current prevalence of infertility lasting
for at least 12 months is estimated to be around 9% worldwide for women aged 20-44. 20-30% of infertility cases are
explained by physiological causes in men, 20-35% by physiological causes in women, and 25-40% of cases are because of a problem in both partners. In 10-20% no cause is found. Infertility is also associated with lifestyle factors
such as smoking, body-weight and stress. The unexplained cases of infertility are often referred to as functional hypothalamic amenorrhea (FHA). FHA is a form of anovulation that is caused by psychological factors such as trauma,
work stress, family stress, poor social support and inadequate coping strategies. Importantly, FHA is a reversible condition. The above psychological factors can be targeted by therapeutic and corrective interventions. Previous research
showed that ovulation in women diagnosed with FHA and treated with Cognitive Behavior Therapy (CBT) can be restored. CBT intervention leads to the increase in reproductive hormone levels and to improvement in other hormone
measures, particularly decreased levels of stress hormones. Increased reproductive hormone levels translate to higher probability of conception and implantation.
We are seeking partners with expertise in eHealth and ICT solutions for internet based interventions, as well as mental health specialists willing to participate in designing and conducting the above mentioned intervention.
We are looking for researchers and ICT specialists.
Page 418 of 487
Germany
Synchem UG & Co. KG
Organisation Name
Country
Germany
City
Felsberg
Street
Am Kies 2
Website
www.Synchem.de
Phone
+49 5662 408730
Organisation Type
SME
Person
Name
Felix Jäger
Email
[email protected]
Job Position
CEO
We are a producer of special chemicals in a laboratory scale. Founded in 1997 we deliver to the Pharmaceutical Industry, resesearch organisations and analytical laboratories.
Areas of Activity
diseases
Offer: Synthesizing new molecules for the research on active substances
We want to offer our service as a manufacturer of small organic molecules. In a project of the Horizon2020 programme we will synthesize new molecules, which will be tested on the biological activity by other partners of the project.
We have a broad range of knowledge in the field of synthetic organic chemistry. In a forgoing research programm, we
have received a patent on a new class of pharmaceutical active ingredients (EP 2486923). For our work on customer
syntheses as well as for the work on our own catalog of compounds, we have also made a patent for the synthesis of
pyridine boronic acids (DE 102008063243).
MARKET APPLICATION
We deliver building blocks for the pharmaceutical industry, biochemcials and analytical standards. In the market of
special chemicals, we are keen on the synthesis and marketing of new unique molecules.
We are looking for partners, which can complete the chain in the search for new API`s. Beginning from experts in finding of new lead structures, there must be partners, which are active in the field of testing the biological activity of the
the compounds. Partners may be SME`s, universities and all kinds of research organisations.
Page 419 of 487
France
Systematic Paris Region
Organisation Name
Country
France
City
palaiseau
Street
8, avenue de la Vauve - Bât. 863 - CS 70005
Website
http://www.systematic-paris-region.org/
Phone
+33674509192
Organisation Type
Other
Person
Name
Salma ESSAFI
Email
[email protected]
Job Position
EU & International Project
Manager
At the heart of digital and software development infrastructures, Systematic, a French innovation and technology
cluster, brings together more than 800 key players and asserts its place in 8 major industries and services sectors
(Transport, Energy, Telecoms, Security, Health, Smart Cities, Information Systems and the Factories of the Future) and
two areas of technology (Free & Open Source Software and Complex Systems).
Through its nine Technology Groups, Systematic Paris-Region manages a whole community and deploys its expertise
to encourage collaborative innovation. To date, Systematic Paris-Region has facilitated the development of more 510
R&D projects, representing an overall R&D investment of 2.6 billion euros and a total of 950 million euros in subsidies
from the French State, development agencies (ANR, EUREKA, FEDER, bpifrance) and territorial bodies.
Systematic Paris-Region is also committed to increasing the attractiveness of the region, the Cluster, its area of specialization and its key players to foreign investors in order to attract skills and companies, encourage and support export initiatives by member SMEs and ensure that the Cluster and its members play a key role in developments at European level.
Areas of Activity
Methods and data
policies
records (PPI)
Health ICT SMEs
Offer: Collaboration with partners working in ICT and Healthcare technologies within
H2020 projects
If you are looking for partners for national and international projects, Systematic Paris Region has a strong network of
SMEs and researchers within the following areas: digital healthcare technology, electronics/embedded software systems. Systematic Paris Region can also be partner in international events and projects with a focus on innovation and
internationalization.
Page 420 of 487
France
Systematic is coordinating an FP7 european project. Our organisation offers an innovative network in ICT domains
(800 ICT members: SME/ Large Companies/Research Institutions)
MARKET APPLICATION
ICT for market applications on Health, Telecommunication, Smart Cities...
• Partners for cluster-to-cluster collaboration, primarily within ICT&Healthcare and big data. • Organizations in EU
countries, to develop projects on internationalization, innovation and networking.
Page 421 of 487
France
Team8
Organisation Name
Country
France
City
Pré Saint Gervais
Street
11 avenue Faidherbes
Website
Phone
Organisation Type
SME
Person
Name
Stephane Daucourt
Email
[email protected]
Job Position
CEO
Team8 is a connectable watch for children (6 to 12). Kids can completely create, play and oppose their super-hero living in the watch. BUT those heroes will need kid's energy to be use, this way we will motivate kids to do exercice and
have a healthier life style.
The watch will have also diet option, reminders if they need to take medication, with the included camera they can
read the barcode and make sure they can eat a product if they are allergics.
Parent can also control their schedules, send them short messages, have their localisation for safety and much more.
Areas of Activity
Methods and data
policies
Preventing disease
Initiative
Request: Team8, the connectable watch for kids for fun, health and safety.
Team8 is a connectable watch for children (6 to 12). Kids can completely create, play and oppose their super-hero living in the watch. BUT those heroes will need kid's energy to be use, this way we will motivate kids to do exercice and
have a healthier life style. The watch will have also diet option, reminders if they need to take medication, with the included camera they can read the barcode and make sure they can eat a product if they are allergics. Parents can also
control their schedules, send them short messages, have their localisation for safety and much more.
Team8 is a big project regrouping many skills. We are developing hardware and software but would be open to any
kind of partnership helping us to move faster on that and to industrialise it.
Team8 can really help kid's obesity, it became a major global health problem all over the world. So we need partner to
help us develop world wide our solution.
Page 422 of 487
France
tebu-bio
Organisation Name
Country
France
City
Le Perray en Yvelines
Street
39 rue de Houdan
Website
www.tebu-bio.com
Phone
0130463971
Organisation Type
SME
Person
Name
Nadia Normand
Email
[email protected]
Job Position
R&D Manager
tebu-bio based near Paris, provide solutions in life sciences throughout Europe with a full range of products and services. We are focusing on innovative approaches and partnering with experts for the development of novel assays
and new tools for the discovery of active molecules.
An important focus of the company is to work on alternatives to animal models with the development of models on
specific primary human cells and the production of recombinant variant proteins and therapeutic antibodies.
tebu-bio offers its expertise in physiological environments for cellular models in controlled oxygen conditions. We are
working on the characterisation of compounds and ingredients activity through in vitro functional and quantitative assays and a wide range of profilings for identification and validation of biomarkers in translational projects.
Areas of Activity
the immune system
Request: Generic technologies for in vitro assays and physiological fluid analysis
Working on innovative multiplex approaches for the development of novel assays and new tools for the discovery of
active molecules
We would be interested in hearing from experts involved in: - Big data analysis for biomarker profiling (proteins, mRNA & miRNA) - 3D cellular models for biomarker validation - Quantitation of molecules activity for biomarker validation - Molecular biology tools for cell line engineering for screening
Seeking a partner having a technology with a high potential for co-development of R&D tools and their commercialisation in translational projects. We can provide our input in both the technological development and the commercialisation.
Offer: In vitro alternatives to animal models
Expertise in physiological environment for cellular models in controlled oxygen conditions. Characterisation of compounds and ingredients activity through a wide range of functional and quantitative assays and profilings for identification and validation of biomarkers in translational projects.
Apart from our above technical expertise, we have our own European network for the distribution of new products and
services in life sciences with a reliable logistics department.
Page 423 of 487
France
MARKET APPLICATION
Translational research
Partner with a technlogy to develop We can provide our input in both the technological development and the commercialisation
Page 424 of 487
Spain
Tecnologias Avanzadas Inspirala SL
Organisation Name
Country
Spain
City
Madrid
Street
Calle Estrada 10B
Website
www.inspiralia.com
Phone
Organisation Type
R&D Institution
Person
Name
Eric Fiklocki
Email
[email protected]
Job Position
Innovation Process Manager
Inspiralia is a New Product Development company based in Madrid and founded in 2005. It is a successful NPD
company which offers a 360º service that covers concept generation, innovation strategy, technology and product development, finishing with Market launch. Most of its projects are financed by the H2020 European Framework Programme.
We have wide expertise in preparing winning proposals, either from the inception of the idea or editing and improving
ongoing ones and are market leader in our field.
Inspiralia is built on 3 markets: Health, Energy and Industry.
Our Innovation Process Managers from the Health Unit are going to be present on this event and look forward to
meeting you.
Offer: Financing your project with the leader - H2020 Framework Program for SME´s in
HEALTHCARE
Inspiralia is a Research & Innovation Center from Madrid working with companies over all Europe focusing on the development of innovative products and solutions. We are European leader in the organization of funds through the European Commission and the Framework Progamme H2020. I would be happy to discuss funding opportunities. All together we were able to fund over 90 projects in the SME Instrument. Looking forward to hearing from you! Eric Fiklocki
- Leadership in funding through the H2020 Framework Programme - Technical Development in our facilities and laboratories - 31% PHD´s - Client References - Own products funded and in development
MARKET APPLICATION
- SME´s in the healthcare sector looking for funding for R&D / Market launch
Page 425 of 487
Turkey
Teknopar
Organisation Name
Country
Turkey
City
Ankara
Street
Hacettepe Teknokent İvedik OSB
Website
http://teknoparbilisim.com/
Phone
Organisation Type
R&D Institution
Person
Name
İrem Aksoy
Email
[email protected]
Job Position
Senior R&D Engineer
Teknopar is a technology company with a 20 years track record based in Ankara. Our company is a professionally
managed high-end automation solutions company with its state-of-the-art implementation, integration, development
and customization services to its partners and customers. Its major focus is on industrial and energy automation with
abilities on hardware and embedded software design and delivery. We provide mobile and web solutions for IS, on
business intelligence and decision support systems, and ICT, particularly for health sector, focusing on Big Data and
M2M.
Areas of Activity
(PCP)
(PPI)
Health ICT SMEs
Methods and data
policies
Request: Telemedicine, telehealth and home care services
Teknopar Information Technologies is a technology company experienced in Information Systems, M2M, Mobile and
Web solutions. We are looking for collaborations to deploy our expertise in personalized medicine.
We are searching for academic, SME or other industrial partners to cooperate in the following areas: -M2M and IoT
platform solutions -Telemetry and sensor networks
Page 426 of 487
Turkey
Teknopar
Organisation Name
Country
Turkey
City
Ankara
Street
Mekih Gokcek Bulvarı 61/23
Website
http://teknoparbilisim.com/
Phone
Organisation Type
SME
Person
Name
Perin Unal
Email
[email protected]
Job Position
Vice President, ICT
Teknopar is a technology company with its 20 years track record that is based in Ankara. Our company is a professionally managed high-end automation solutions company with its state-of-the-art implementation, integration, development and customization services to its partners and customers. Its major focus is on industrial and energy automation with abilities on hardware and embedded software design and delivery. We also have mobile and web solutions
for ICT, particularly for health sector, focusing on Big Data and M2M.
Areas of Activity
(PCP)
(PPI)
population
Methods and data
policies
records (PPI)
Request: ICT solutions for active and healthy ageing and management of health data
Teknopar is a technology company with a 20 years track record based in Ankara. Our company is a professionally
managed high-end automation solutions company with its state-of-the-art solutions in sensor networks and M2M
Telemetry platforms. Its major focus is on industrial and energy automation with abilities on hardware and embedded
software design and delivery. We also have mobile and web solutions for IS, on business intelligence and decision support systems, and ICT, particularly for health sector, focusing on Big Data and M2M.
We are looking for collaboration on ICT research and innovation projects for 2016-2017 calls on personalized medicine. We are particularly interested in topics that address active and healthy ageing for adults. Effectiveness of
healthcare interventions, personalised computer models, personalised coaching for ageing population, big data and
analytics solutions are the main topics we are interested in. Relevant coordination and support actions are also wellcome.
Page 427 of 487
Turkey
Universities, research institutes, companies, SMEs with skills in research & development
Page 428 of 487
United Kingdom
The University of Manchester
Organisation Name
Country
United Kingdom
City
Manchester
Street
Oxford Road
Website
www.manchester.ac.uk
Phone
Organisation Type
University
Person
Name
Claire Faichnie
Email
[email protected]
Job Position
EU Funding Manager
The University of Manchester is one of the world's top 50 university.
Areas of Activity
the immune system
diseases
Preventing disease
Initiative
young
population
Methods and data
policies
Request: Looking to partner with the University of Manchester
The University of Manchester carries out research across the breadth of biomedical sciences and undertakes discovery science as well as clinicial translational work. On behalf of the University I will be presenting project ideas under
the personalised medicine call. I will update with details as I receive them from our researchers.
Offer: Universty of Manchester colleagues are interested in joining a consortium for
SC1-PM-02-2017: New concepts in patient stratification;
The Manchester Collaborative Centre for Inflammation Research (MCCIR) performs explorative research leading to
step changes in our understanding of the molecular basis of immune health and its dysregulation in inflammation. Established in October 2012, the MCCIR addresses current priorities in inflammatory disease in an open innovation, precompetitive collaboration with GlaxoSmithKline, AstraZeneca. Our mission is to bring together clinical, industrial, and
Page 429 of 487
United Kingdom
academic scientists – and innovate at this interface. We are connected to a rich diversity of patient cohorts with
chronic respiratory disease, rheumatoid arthritis and ageing.
Patient stratification aims at grouping patients into disease sub-groups, where the specific pathological processes involved are better defined (clinical/molecular phenotypes). This will lead to the development of targeted therapies, optimizing the intervention to individual patients, thus achieving greater success in treating or curing the patient.
Page 430 of 487
France
TheFamily
Organisation Name
Country
France
City
Paris
Street
25 rue du Petit Musc
Website
http://www.thefamily.co
Phone
0609623913
Organisation Type
Other
Person
Name
antoine zins
Email
[email protected]
Job Position
Healthcare Venture Partner
THEFAMILY NURTURES ENTREPRENEURS THROUGH EDUCATION, UNFAIR ADVANTAGES & CAPITAL. WE HAVE MULTIPLE
ACTIVITIES BUT A SINGLE MISSION: EMPOWERING ENTREPRENEURS IN THEIR QUEST FOR A REPEATABLE, SCALABLE &
PROFITABLE BUSINESS MODEL.
Areas of Activity
(PCP)
(PPI)
population
Methods and data
Request: The Future Of Aging Care
How we can make homecare more efficient and a better experience for aging patients.
Looking for any expertise in aging care;
Any country in Europe. Someone that knows well the ecosystem around aging care.
Page 431 of 487
Ireland
Tonix Pharma Limited
Organisation Name
Country
Ireland
City
Dublin
Street
65 Adelaide Road
Website
Phone
0035316617940
Organisation Type
SME
Person
Name
Marlis Dunne
Email
[email protected]
Job Position
Manager, Ireland
Tonix Pharmaceuticals develops next-generation medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden.
Tonix's lead product candidate, TNX-102 SLAttribution (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic
stress disorder (PTSD). Product candidate TNX-201Attribution (dexisometheptene mucate) is in development for
episodic tension-type headache, the most common form of headache.
Tonix is currently conducting the Phase 3 AFFIRM study of TNX-102 SL in fibromyalgia as well as the Phase 2 AtEase
study of TNX-102 SL in PTSD. Tonix plans to begin a Phase 2 study of TNX-201 in episodic tension-type headache in
the second quarter of 2015.
Areas of Activity
Tonix is interested in using advanced knowledge for a further phase I-II study with one of our drug candidates in new/
wider target patient groups with a chronic CNS disorder with a large socio-economic impact. We seek R&D partners
and clinical centres for such an innovative clinical study. We are a global bio-pharma company (SME), with a portfolio
of projects already in clinical phase (I - III) for 3 unmet medical need indications (new approaches to common CNS disorders). Most of our R&D is outsourced to strategic partners all around the world. Tonix seeks partners for a consortium to submit a proposal towards SC1-PM-09-2016.
We seek expertise in human clinical trials in Europe.
CNS disorder, pharmacology, innovation, clinical studies, target patient groups, large healthcare burden, patient involvement
Page 432 of 487
United States
Tonix Pharmaceuticals Holding Corp.
Organisation Name
Country
United States
City
New York
Street
509 Madison Avenue - Suite 306
Website
Phone
Organisation Type
SME
Person
Name
Bruce Daugherty
Email
[email protected]
Job Position
Chief Scientific Officer
Tonix Pharmaceuticals develops next-generation medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden.
Tonix's lead product candidate, TNX-102 SLAttribution (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic
stress disorder (PTSD). Product candidate TNX-201Attribution (dexisometheptene mucate) is in development for
episodic tension-type headache, the most common form of headache.
Tonix is currently conducting the Phase 3 AFFIRM study of TNX-102 SL in fibromyalgia as well as the Phase 2 AtEase
study of TNX-102 SL in PTSD. Tonix plans to begin a Phase 2 study of TNX-201 in episodic tension-type headache in
the second quarter of 2015.
Areas of Activity
Tonix is interested in using advanced knowledge for a further phase I-II study with one of our drug candidates in new/
wider target patient groups with a chronic CNS disorder with a large socio-economic impact. We seek R&D partners
and clinical centres for such an innovative clinical study. We are a global bio-pharma company (SME), with a portfolio
of projects already in clinical phase (I - III) for 3 unmet medical need indications (new approaches to common CNS disorders). Most of our R&D is outsourced to strategic partners all around the world. Tonix seeks partners for a consortium to submit a proposal towards SC1-PM-09-2016.
We seek expertise in human clinical trials in Europe.
CNS disorder, pharmacology, innovation, clinical studies, target patient groups, large healthcare burden, patient involvement
Page 433 of 487
Finland
TraceRay Oy
Organisation Name
Country
Finland
City
Turku
Street
Lemminkäisenkatu 14-18A
Website
Phone
Organisation Type
SME
Person
Name
Julia Kulkova
Email
[email protected]
Job Position
CEO
TraceRay Oy – established in April 2015 as a result from the research activities at the University of Turku, Finland. We
have over 20 years’ experience related to biomaterials, biomechanics and medical implants.
Areas of Activity
EU level
Health ICT SMEs
(PCP)
(PPI)
Request: Sophisticated technological platform for bone regeneration in humans and animals
We are developing a sophisticated technological platform for bone regeneration in humans and animals. Patent is
pending. The company's technology allows the creation of bioresorbable and bioactive devices. The technology is totally unique and will fill an existing need in the medical procedure by improving upon standing ones, and by designing
a product to serve a need that is clearly defined and acknowledged by medical professionals. All the components of
the proposed novel bioactive implantable system are approved for the clinical use in human patients. The components of the system are available on the market and could be obtained from subcontractors and/or produced by the
company with low investment. Who would buy the product? • Veterinary surgeons • Orthopaedic surgeons – Adult Reconstructive – Foot & Ankle – Hand – Orthopeadic Oncology – Orthopaedic Trauma – Pediatric Orthopaedics
1. 3D printing 2. Biomedical Polymer Chemistry 3. Veterenary Companies 4. Companies which are interested in bone
graft substitues delivery platforms
1. 3D printing 2. Polymer Synthesis 3. Collaboration
Page 434 of 487
Spain
Traza consultores
Organisation Name
Country
Spain
City
Murcia
Street
C. Mayor 55, Poligono Camposol
Website
www.trazaconsultores.com
Phone
+34 968 93 23 12
Organisation Type
SME
Person
Name
Rafael Jiménez
Email
[email protected]
Job Position
food safety
TRAZA is a Spanish company (SME) formed by professionals with over 15 years experience in Food Safety Management, Public Health, Nutrition and Healthcare. We are involved in more than 500 companies as external audit and
consultant, including nursing homes, schools, hospitals and other institutions related to Public Health.
TRAZA is internationally-certified Auditing for Food Safety and Public Health management, Nutritional studies, Enviromental and Healthcare management, food and water analysis lab, Quality consultancy & Management and teaching
for training courses.
In TRAZA we have a multidisciplinary team which includes professionals in Public Health & Nutrition and Dietetics
(which some of them have broad experience management in research projects as PhD), intervening in the management of those food operators where this discipline is relevant to daily operational (school canteens, nursing homes,
catering and group catering industries, special lines food manufacturing industries, etc.).
• Among others, we accomplish different kind of tasks in the field of health and nutrition:
• Analysis of the menus and their rotations, including complete nutritional studies (macro and micronutrients).
• Rating and establishing balanced menus with nutritional brainstorming, suggesting those modifications considered necessary according to the criteria of the international reference organizations.
• Control of specific diets for eating disorders (diabetes, food intolerance, celiac ..) in different groups of the
population (children, teenager, the elderly..)
• Control of other specific diets: kidney, liver, hypertension, disphagia and other nervous condition that affects
the nervous system (stroke, head injury), dementia, mouth cancer, oesophageal cancer, gastro-oesophageal
reflux disease (GORD) and others
• Anthropometrical studies and preventing in obesity and overweight.
We are involved in Health Management for all stages of food chain and in all its activities. Our Authorized Lab of Public Health and Agrifood, provides the means for determining any microbiological, nutritional and physicochemical food
analysis.
Other Credentials
Thanks to our proposal and our proactive work, Molina de Segura was awarded with the National Prize from the Ministry of Health- NAOS Strategy for the promotion of healthy eating habits under the programme “Prevention of child
and youth obesity and diabetes”.
TRAZA received an award from the Murcia Royal Academy of Medicine & Surgery on its Bicentenary, for its various
Page 435 of 487
Spain
training activities in Health field, like for food safety promotion, prevention of diabetes and prevention of childhood
obesity.
Areas of Activity
population
Offer: PM-15-2017 - Personalised coaching for ageing population
TRAZA is a Spanish company (SME) formed by professionals with over 15 years experience in Food Safety Management and Nutrition involved in more than 500 food companies as external audit and consultant. TRAZA is
internationally-certified Auditing for Food Safety, Nutritional studies, food and water analysis lab & Quality Company.
In TRAZA we have a multidisciplinary team which includes professionals in Nutrition and Dietetics (which some of
them have broad experience management in research projects as PhD), intervening in the management of those food
operators where this discipline is relevant to daily operational (school canteens, nursing homes, catering and group
catering industries, special lines food manufacturing industries, etc.).
Among others, we accomplish different kind of tasks in the field of health and nutrition: • Analysis of the menus and
their rotations, including complete nutritional studies (macro and micronutrients). • Rating and establishing balanced
menus with nutritional brainstorming, suggesting those modifications considered necessary according to the criteria
of the international reference organizations. • Control of specific diets for eating disorders (diabetes, food intolerance,
celiac ..) in different groups of the population (children, teenager, the elderly..) • Control of specific diets: kidney, liver, hypertension ... • Anthropometrical studies and preventing in obesity and overweight.
MARKET APPLICATION
We can help to reach: -school canteens -nursing homes, -catering and group catering industries, -special lines food
manufacturing industries
We are looking for collaborate in a strong consortium in order to help with our experience in the fields of nutrition,
food safety and teaching among others.
Page 436 of 487
Spain
Traza consultores
Organisation Name
Country
Spain
City
Murcia
Street
C. Mayor 55, Poligono Camposol
Website
www.trazaconsultores.com
Phone
+34 968 93 23 12
Organisation Type
SME
Person
Name
Vicente de Pablos
Email
[email protected]
Job Position
Managing Director
TRAZA is a Spanish company (SME) formed by professionals with over 15 years experience in Food Safety Management, Public Health, Nutrition and Healthcare. We are involved in more than 500 companies as external audit and
consultant, including nursing homes, schools, hospitals and other institutions related to Public Health.
TRAZA is internationally-certified Auditing for Food Safety and Public Health management, Nutritional studies, Enviromental and Healthcare management, food and water analysis lab, Quality consultancy & Management and teaching
for training courses.
In TRAZA we have a multidisciplinary team which includes professionals in Public Health & Nutrition and Dietetics
(which some of them have broad experience management in research projects as PhD), intervening in the management of those food operators where this discipline is relevant to daily operational (school canteens, nursing homes,
catering and group catering industries, special lines food manufacturing industries, etc.).
• Among others, we accomplish different kind of tasks in the field of health and nutrition:
• Analysis of the menus and their rotations, including complete nutritional studies (macro and micronutrients).
• Rating and establishing balanced menus with nutritional brainstorming, suggesting those modifications considered necessary according to the criteria of the international reference organizations.
• Control of specific diets for eating disorders (diabetes, food intolerance, celiac ..) in different groups of the
population (children, teenager, the elderly..)
• Control of other specific diets: kidney, liver, hypertension, disphagia and other nervous condition that affects
the nervous system (stroke, head injury), dementia, mouth cancer, oesophageal cancer, gastro-oesophageal
reflux disease (GORD) and others
• Anthropometrical studies and preventing in obesity and overweight.
We are involved in Health Management for all stages of food chain and in all its activities. Our Authorized Lab of Public Health and Agrifood, provides the means for determining any microbiological, nutritional and physicochemical food
analysis.
Other Credentials
Thanks to our proposal and our proactive work, Molina de Segura was awarded with the National Prize from the Ministry of Health- NAOS Strategy for the promotion of healthy eating habits under the programme “Prevention of child
and youth obesity and diabetes”.
TRAZA received an award from the Murcia Royal Academy of Medicine & Surgery on its Bicentenary, for its various
Page 437 of 487
Spain
training activities in Health field, like for food safety promotion, prevention of diabetes and prevention of childhood
obesity.
Areas of Activity
Preventing disease
young
Offer: PM-07-2017 - Mental health and well-being in the young
TRAZA is a Spanish company (SME) formed by professionals with over 15 years experience in Food Safety Management and Nutrition involved in more than 500 food companies as external audit and consultant. TRAZA is
internationally-certified Auditing for Food Safety, Nutritional studies, food and water analysis lab & Quality Company.
In TRAZA we have a multidisciplinary team which includes professionals in Nutrition and Dietetics (which some of
them have broad experience management in research projects as PhD), intervening in the management of those food
operators where this discipline is relevant to daily operational (school canteens, nursing homes, catering and group
catering industries, special lines food manufacturing industries, etc.).
Among others, we accomplish different kind of tasks in the field of health and nutrition: • Analysis of the menus and
their rotations, including complete nutritional studies (macro and micronutrients). • Rating and establishing balanced
menus with nutritional brainstorming, suggesting those modifications considered necessary according to the criteria
of the international reference organizations. • Control of specific diets for eating disorders (diabetes, food intolerance,
celiac ..) in different groups of the population (children, teenager, the elderly..) • Control of specific diets: kidney, liver, hypertension ... • Anthropometrical studies and preventing in obesity and overweight.
MARKET APPLICATION
We can help to reach: -school canteens -nursing homes, -catering and group catering industries, -special lines food
manufacturing industries
We are looking for collaborate in a strong consortium in order to help with our experience in the fields of nutrition,
food safety and teaching among others.
Page 438 of 487
Germany
TU Darmstadt
Organisation Name
Country
Germany
City
Darmstadt
Street
Hochschulstraße 10
Website
www.esa.informatik.tu-darmstadt.de
Phone
Organisation Type
University
Person
Name
Andreas Engel
Email
[email protected]
Job Position
Research Assistant
The Embedded Systems and Applications group of the Computer Science department at the Technical University of
Darmstadt (Germany) focuses on application-specific architectures for low-energy and high-performence copmputing.
Our current research focus is on how to efficiently provide computing performance in situations where the capabilities
of a standard microprocessor do not suffice, or its energy requirements would be excessive.
As an alternative, we propose adaptive computers: combining a smaller, low-power microprocessor with a highly optimized reconfigurable compute unit. The structure of the latter can then be optimally adapted to the precise needs of
the current application, and thus provide the required compute power with reduced energy consumption.
To achieve this goal, we realize hardware demonstrators for such computer architectures (including the required operating system ports), and evaluate these using practical applications from a variety of fields. After very promising results, we have now concentrated on making the potential of such computers available even to developers who lack
the skills in hardware design that are still required to program such systems. To this end, we have been working on a
complete compile flow for partitioning a program in a software high-level programming language for separate execution on the two compute units. The part assigned to the reconfigurable compute unit is then processed further using
techniques from hardware synthesis and physical chip design (mapping, placement, routing).
Areas of Activity
(PCP)
(PPI)
Methods and data
policies
Offer: Application-specifc computing architectures
We provide energy-efficient high-performance computing architectures. These can range from battery-powered mobile diagnostic systems with enhanced encryption capabilities, up to high-speed simulations for in-silico trials and personalized medication.
By combining reconfigurable hardware with traditional software-processors, we provide heterogeneous computing architectures, that are highly energy-efficient but also runtime-adaptable to dynamic requirements.
MARKET APPLICATION
Wearable diagnostic systems, high-performance simulations (e.g., of biochemical processes)
Page 439 of 487
Germany
Medical diagnostics SMEs from outside Germany
Page 440 of 487
Turkey
TUBITAK
Organisation Name
Country
Turkey
City
Ankara
Street
Bilkent
Website
Phone
Organisation Type
Other
Person
Name
ayşenur okatan
Email
[email protected]
Job Position
TUBITAK ( The Scientific and Technological Research council of TURKEY ) is a kind of research center having many institutes for different areas like health, security. Also, It has Horizon2020 coordination office where people work as National Contact Points whom separately dedicated to all Horizon2020 areas. TURKEY has attended in 6th Framework
Programmes as Association country having same rights as Member State countries and had many successful projects. Now, TURKEY is ready for new projects of Horizon2020 and waiting for cooperation.
Areas of Activity
the immune system
diseases
EU level
Preventing disease
young
(PCP)
(PPI)
population
Methods and data
policies
records (PPI)
Offer: TUBITAK
TUBITAK ( The Scientific and Technological Research council of TURKEY ) is a kind of research center having many institutes for different areas like health, security. Also, It has Horizon2020 coordination office where people work as Na-
Page 441 of 487
Turkey
tional Contact Points whom separately dedicated to all Horizon2020 areas. TURKEY has attended in 6th Framework
Programmes as Association country having same rights as Member State countries and had many successful projects.
Now, TURKEY is ready for new projects of Horizon2020 and waiting for cooperation.
Page 442 of 487
Turkey
TUBITAK MARMARA RESEARCH CENTER
Organisation Name
Country
Turkey
City
Gebze
Street
Dr. Zeki Acar Cad. Baris Mah.
Website
Phone
+902626772000
Organisation Type
R&D Institution
Person
Name
Fevzihan Basarir
Email
[email protected]
Job Position
Senior Researcher
The Scientific and Technological Research Council of Turkey (TUBITAK) is the leading govermental agency for management, funding and conduct of research in Turkey. It was established in 1963 with a mission to advance science and
technology, conduct research and support Turkish researchers. TUBITAK is responsible for promoting, developing, organizing, conducting and coordinating research and development in line with national targets and priorities.
Marmara Reseach Center (MRC), which is the host organization, is one of the 15 reserach centers of TUBITAK. It has
been established in 1972 and it continues to perform its research activities with 330 researchers and 187 PhD holder
senior researchers in Gebze campus. It is dedicated to become a leader in Turkey as well as in Middle East countries
in the field of nanoscience related to materials, energy, genetic and environment. All institutes of MRC have received
ISO 9001:2000 Quality Management System and ISO 14001:2004 Environment Management System Certification in
2001. Most of the test and analysis done by MRC have been accredited by DAR/DAP.
Areas of Activity
Preventing disease
Initiative
Methods and data
(PCP)
Request: Suport of Turkish Initiative on Human Biomonitoring on European Initiative
Each individual is today exposed to a large number of chemicals in their environment, including the workplace,
through the air, food, water and consumer products. For many of the chemicals, the health impact, including longterm, is still unknown. Innovative approaches are needed to enable us to decipher the potential causal associations
between exposures and health effects over a lifetime and, where such links are identified, to understand the underlying mechanisms.
Page 443 of 487
Turkey
- a platform providing support for field sampling and analytical work - a data infrastructure - a research programme to
assess the impact of chemical exposure on human health - an activity focused on translation of programme results into policy
- coordination of HBM initiatives at national and EU level, with a special focus on linking research to evidence-based
policy making - build on European excellence in the field and promote capacity building and the spread of best practice - provide a platform through which harmonised and validated information and data collected at national level can
be accessed and compared - support research and innovation in various ways
Page 444 of 487
Portugal
UCP - CREATING HEALTH - Research and Innovation Funding
Organisation Name
Country
Portugal
City
Lisboa, Portugal
Street
Palma de Cima
Website
http://creatinghealth.ics.lisboa.ucp.pt/en/
Phone
00351918722434
Organisation Type
University
Person
Name
Joana Camilo
Email
[email protected]
Job Position
Executive Director
CREATING HEALTH, Research and Innovation Funding is an Office that provides support for applying to Health
Innovation and Research (R&I) funding, initially targeting the European Union framework programme, Horizon 2020,
and under the coordination of the Public Health area of the Institute of Health Sciences, at the Catholic University of
Portugal.
This initiative was launched with the support of multiple institutions and distinguishes itself by providing a public university based, non-profit service, specialized in Health Research and Innovation Funding, open to support any institution.
Areas of Activity
the immune system
diseases
EU level
Preventing disease
Initiative
young
Methods and data
policies
records (PPI)
Page 445 of 487
Portugal
• PM-12-2016
(PCP)
• PM-13-2016
(PPI)
• PM-14-2016
• PM-15-2017
population
Offer: Ophiomics - an SME Partner for SC1-PM-01-2016: Multi omics for personalised therapies addressing diseases of the immune system
Ophiomics is a molecular diagnostics and innovation company enabling preventive and personalised medicine. It develops and commercialises genetic and genomic tests focused on specific clinical decisions. It also develops research
& development activity aimed at developing better services in support of a precision medicine. Ophiomics offers advanced genetic and genomic tests in support of diagnostic, prognostic, pharmacogenomics and clinical follow up in
cancer and other chronic diseases. Ophiomics was born from a collaboration between scientists and clinicians with a
common purpose of bringing the latest advances in genomics, bioinformatics and clinical research in support of a precision medicine.
Ophiomics offers added value molecular diagnostics in support of a precision medicine, basing its offer on an intensive Research & Development activity. Ophiomics aims to support the clinicians in implementing a precision medicine,
allowing them to support their patients in choosing the best lifestyles tailored to their genetic background, in defining
personalised strategies for early detection of disease, in implementing tailored therapies and in following therapeutical response.
Offer: HELP U2B IT, LDA (HUBIT) - A Partner for research and development of machine
learning for correlations between health improvement programs and health outcomes,
promoting healthier lifestyles.
HELP U2B IT, LDA (HUBIT) was founded in March 2013, as a company envisioning a new way of thinking about health.
Hubit has been incubated at UPTEC (http://uptec.up.pt/en/company/wymbe), the Science and Technology Park of University of Porto. Our focus is the patient empowerment to manage health and wellness, by bringing best state-of-theart behavioral methodologies and communication tools that improve collaboration with healthcare professionals. Our
team has extensive international experience (over 13 countries). Our behavioral approach to health is based on the
team background and certifications in Coaching, Neuro-Linguistic Programming and Gamification. These fields of
knowledge have been proving to be extremely effective to design human behavior and show impacting outcomes.
With so many evidences and with our field experience both in behavioral science and Health IT, we found a great opportunity to provide our knowledge in these methodologies to healthcare professionals as a mean for increasing patient compliance and, by doing so, tackling the increasing costs in healthcare. Other of the key aspects for HUBIT was
to include healthcare professionals in a broader sense. We consider important to involve not only medical doctors and
nurses but also the increasing community of professionals that are joining the global quest for improving health and
wellbeing. Our understanding is that making a shift for a patient centric approach requires multi-sided and multisourced platforms from which the patient can interact with different healthcare professionals. Our company is a member of Building Global Innovators from MIT (http://www.mitportugal.org/innovation-and-entrepreneurship/buildingglobal-innovatores.html) and has been a service provider for the Portuguese Ministry of Health, PRIMAVERA BSS and
Health Insight. We operate both in Portugal and Brazil. Our most recent product, WYMBE, allows Healthcare and Wellness professionals to deliver their services in a customizable platform, create health improvement programs for their
patients, provide daily interaction, as well as enable them to track and document changing habits. WYMBE uses
Coaching, Neuro-Linguistic Programming and Gamification to positively impact the patient’s trigger motivation and
thereby provide step-by-step pathways through small, easy-to-follow actions, which are critical aspects for reducing
healthcare costs as we are offering patients an opportunity to connect with several healthcare promoters, while having all the information saved and stored in a single place. Video: https://youtu.be/MEvDeCGs8TM
PPT:https://www.dropbox.com/s/8n268te8u2fb3ps/WYMBE_Presentation.pdf?dl=0
WYMBE’S technology provides a more comprehensive solution that not only incorporates customization but also,
through machine learning provides increasingly more instructive data on which solutions work for multiple demographics, including: - Health Improvement Programs Store - Actionable Health Improvement Programs; - Remote
Follow-up and communication with Health Promoters; - Social support through private social networks; - Analysis for
Page 446 of 487
Portugal
individual and population management; - Correlation between lifestyle and heath outcomes, with science based evidence. We can: - Make available experience in changing lifestyle and creating healthier habits by creating Health Improvement Programs based on Coaching. Neuro-Linguistic Programming and Gamification. - Perform studies with patients to increase engagement and compliance. - Create analytics correlations betweens Health Improvement Programs and Health Outcomes. - Provide a marketplace for Health Promoters (doctors, nurses, coaches, nutritionist) to
deliver their Health Improvement Programs (business model innovation)
MARKET APPLICATION
We are targeting Health Promoters, including medical doctors, nurses, coaches, nutritionists, physiologists and/or other self-employed therapists working for health organizations.
We are very keen on integrating consortia preparing proposals for accelerating market introduction of ICT solutions for
Health, Well-Being and Ageing Well, and specially interested in joining proposals for submission to the
“SC1-PM-15-2017: Personalised coaching for well-being and care of people as they age” topic. We are also looking for:
- Research institutions to perform studies on professionals and patients; - Content Providers to create Health Improvement Programs; - Service Providers to deliver health counseling through WYMBE; - Mobile Carriers to raise demand for
those services and contents.
Page 447 of 487
France
UK Science and Innovation Network
Organisation Name
Country
France
City
Paris
Street
35 rue Faubourg St Honore
Website
https://www.gov.uk/government/world/organisations/uk-science-and-innovation-network
Phone
Organisation Type
Person
Name
Alison MacEwen
Email
[email protected]
Job Position
Senior Science and Innovation Adviser
The UK's Global Science and Innovation Network is funded by the Foreign and Commonwealth Office and the Department for Business, Innovation and SKills and is based at UK Embassies around the world. We work with the local science and innovation community to promote beneficial science partnerships and inform science policy.
Page 448 of 487
France
Umanlife
Organisation Name
Country
France
City
Paris
Street
2 rue meissonier
Website
Www.umanlife.com
Phone
Organisation Type
SME
Person
Name
Cyril Grospiron
Email
[email protected]
Job Position
Business Advisor
Umanlife is a platform of services where the user can follow and manage all his health and wellbeing.
We collect the data manualy or from the differents connected devices and Mobile App.
Therefore we are giving added value to rough data with an algorithm that will send to the user the good advice at the
right time, according to all his data and objectives.
Areas of Activity
Preventing disease
Initiative
young
(PCP)
(PPI)
population
Methods and data
policies
Health ICT SMEs
Request: Umanlife, platform of prevention to follow and manage his health and wellbeing
Umanlife is a platform of services where the user can follow and manage all his health and well being safely. Umanlife
is a unique platform to centralize all its health and wellbeing data from Mobile applications and connected devices.
Umanlife gives added-value to raw data thanks to complex algorithm, medically validated by our ethic committee, in
order to provide the good advice at the right time. Umanlife is your personalized digital coaching. We have the ambition to allow the user to become the actor of his life !
Partnership to develop our solution in other countries Partnership to build an offer New type of clients to propose a
personal service Partnership for a case study
Page 449 of 487
France
UNICANCER
Organisation Name
Country
France
City
Paris
Street
101 rue de tolbiac
Website
http://www.unicancer.fr/
Phone
+33 1 44 23 55 50
Organisation Type
R&D Institution
Person
Name
Aude Sirven
Email
[email protected]
Job Position
Head of Strategic program
development
UNICANCER is an hospital group entirely devoted to fighting cancer. It groups together 20 French Comprehensive Cancer Centers (FCCC), which are private, non-profit establishments with a threefold mission of patient care, research
and oncology teaching.
UNICANCER, national academic leader for clinical research on cancer in France, works directly with more than 210
health institutions (French Comprehensive Cancer Centres, public hospitals and private clinics) in France and abroad.
Its main objective is to promote and accelerate the development of clinical research in oncology in order to facilitate a
quick transfer of innovation to the patient’s bed and achieve a better global care of all cancer patients. This is particularly important for the pathologies and therapeutic areas poorly covered by industry such as rare cancers, surgery, radiotherapy, epidemiology…
In addition to its clinical research activity, UNICANCER is also missioned to encourage and facilitate basic and preclinical research to be realized in the 20 FCCC in order to achieve a better knowledge and understanding of cancer.
In 2014 and 2015, UNICANCER continued its focus on personalized medicine, with the launch of three new emblematic clinical trials divided in two types of design:
• An “umbrella” design : one pathology, a molecular map to determine which of several drugs to administrate
(launched in 2014: SAFIR 02 Lung and SAFIR 02 Breast trials)
• A “basket” design: one drug, several pathologies but one single test to determine the possibility to administrate the drug (launch in 2014: AcSé vemurafenib)
UNICANCER also started the ESME program, a completely new concept to provide a clear vision of the real therapeutic
practices. The compilation in one single database of clinical and therapeutic information will allow the identification of
best strategies leading - in the long term- to a better caring for the patients. This large-scale medical economic approach began with a metastatic breast cancer project, gathering the information of 18 000 patients by 2015.
Areas of Activity
the immune system
diseases
Methods and data
policies
EU level
Page 450 of 487
France
population
Offer: Real life data
UNICANCER started the ESME (Epidemio -strategy medico economy) program, a completely new concept to provide a
clear vision of the real therapeutic practices. This program iscompiling in one single database the clinical and therapeutic information (included in several databases, structured or not) of patients treated in several hospitals. This
database will allow the identification of best strategies leading - in the long term- to a better caring for the patients.
This large-scale medical economic approach began in 2014 with a metastatic breast cancer project, gathering the information of 14 000 patients (as of june 2015) from the 20 French comprehensive cancer centers. UNICANCER, is willing to continue its work on other cancer and as the european level.
Structured centralised database including information from several databases (structured or not) and several hospitals. real life data Academically controlled.
MARKET APPLICATION
the health authorities are interested to analyse the best practice and evaluate the cost/benefit ratio of medicine The
pharmaceutical industry needs this information to complete the evaluation files for the Health authorities The analysis
can identify holes in the treatments or best practices
We can cooperate with any type of consortia to perform (establish , collect, curate, manage and analyse the database) such an program in the field of cancer, either in France or at the european level.
Offer: Clinical trial for cancer
UNICANCER, national academic leader for clinical research on cancer in France, works directly with more than 210
health institutions (French Comprehensive Cancer Centres, public hospitals and private clinics) in France and abroad.
Its main objective is to promote and accelerate the development of clinical research in oncology in order to facilitate a
quick transfer of innovation to the patient’s bed and achieve a better global care of all cancer patients. This is particularly important for the pathologies and therapeutic areas poorly covered by industry such as rare cancers, surgery, radiotherapy, epidemiology… Through UNICANCER, you can also have access to the 20 French Comprehensive Cancer
Centers, which are the leaders for the inclusion of patients in clinical trials (18% of patients treated in CLCC are included in one clinical trial). UNICANCER is particularly active in the fields of breast, gastro-intestinal, urogenital,
Head&neck cancers and sarcoma, with dedicated expert groups working actively one those subjects. UNICANCER is
also particularly active in personalised medicine, radiotherapy, geriatry and early phase trial.
Dedicated team for trial management and promotion. quality control International promotion experience Access to
our expert groups and to the 20 FCCC High level of inclusion in clinical trials in the 20 FCCC.
MARKET APPLICATION
Oncology.
UNICANCER can be the promoter of your clinical trial in Europe or in France Through UNICANCER and its expert groups
you can make contact easily with the 20 French comprehensive cancer centers.
Offer: interoperable electronic health record for translational research
UNICANCER is developing the CONSORE program, a IT project with aim to give access and exploit big data in cancer
(research as well as treatment data). This project is developing semantic, ontology research bringing together Physicians, biologists, bioinformaticians, databases managers and IT specialists. The final aim is to facilitate the interaction
between researchers and clinicians to accelerate the development of cancer therapies.
Page 451 of 487
France
Interoperability, semantic Web big data non-structured data security / no transfer of data
MARKET APPLICATION
Health, pharmaceutical, big data
Any type
Page 452 of 487
Portugal
UNINOVA-CTS
Organisation Name
Country
Portugal
City
Caparica
Street
Quinta da Torre
Website
Phone
Organisation Type
R&D Institution
Person
Name
Ricardo Goncalves
Email
[email protected]
Job Position
The Instituto de Desenvolvimento de Novas Tecnologias (UNINOVA) is a multidisciplinary, independent and non
for profit research institute employing around 180 persons, located in the metropolitan area of Lisbon. It was formed
in 1986 by the Faculty of S&T of the University Nova de Lisboa (FCT-UNL - www.fct.unl.pt), a group of industrial associations, a financial holding, and up to 30 companies. It is an active partner of Madan Parque
(www.madanparque.pt), a business facilitator and accelerator, incubating Micro and SME’s through several layers of
support to entrepreneurial activity.
The main aim of UNINOVA is to pursue excellence in scientific research, technical development, advanced
training and education. By working closely with industry and universities, technological innovations are transferred
into profitable business concepts and, existing products further developed to match new industrial requirements.
Due to its tight connection with the University and Madan Parque, UNINOVA has, since its foundation, hosted
and supported the development several PhD thesis, as well as the creation of several successful spin-offs.
Specialist areas of expertise of UNINOVA can be summarised as follows, organized in 2 major research centers:
The Centre of Technology and Systems (CTS) aims to develop theoretical and applied research and encourages technology transfer mostly supported by spin offs and deep involvement in international R&D projects. The scientific results are expected to contribute to improve the graduate training in the academia and contribute to the internationalization.
The Centre (CEMOP) is specially equipped for Research & Development, service providing and training activities in
five main areas: microelectronic and optoelectronic devices' conception/production technologies and processes; tribologic and optic coatings; system project and conception; material and device characterization; and also device simulation/modeling.
Health areas activity, as indicated below, is among the several application domains that UNINOVA excels.
Areas of Activity
Preventing disease
Initiative
young
(PCP)
Health ICT SMEs
Page 453 of 487
Portugal
(PPI)
population
Methods and data
policies
records (PPI)
Offer: UNINOVA
CONTRIBUTE TO SEAMLESSLY INTEROPERATE WITH OTHERS THROUGHOUT RESEARCH DEVELOPMENT OF FOCAL
IDEAS, BY REMOVING BARRIERS TO INTEROPERABILITY, FOSTERING A NEW NETWORKED CULTURE AND TRANSFERING
AND APPLYING THE RESEARCH RESULTS IN APPLICATIONS.
INTEROPERABILITY OF COMPLEX SYSTEMS IS A TRANS-DISCIPLINARY AREA OF APPLIED RESEARCH THAT ADDRESSES
THE PROBLEMS RELATED WITH THE LACK OF SYSTEMS AND APPLICATIONS' INTEROPERABILITY IN ORGANISATIONS,
PROPOSING NOVEL SOLUTIONS. IT EMBRACES HIERARCHICAL DESIGN FOR MODELLING COMPLEX AND DISTRIBUTED
SYSTEMS, WHICH REQUIRES A CONSISTENT SUPPORTING FRAMEWORK, USING PREVIOUS DEVELOPMENTS ON STANDARDS AND META-STANDARD ARCHITECTURES. SEMANTIC INTEROPERABILITY COMPLEXITY AND CYBER PHYSICAL
SYSTEMS THEORIES HAVE BEEN TAKEN AS A REFERENCE TO MOVE BEYOND THE STATE OF THE ART IN THIS AREA. IT
CONTRIBUTES TOWARDS THE VISION OF THE H2020 EUROPEAN UNION RESEARCH AND INNOVATION PROGRAMME.
THE PRINCIPAL OBJECTIVE IS TO BE A CATALYZER FOR THE SCIENTIFIC ADVANCES AND TECHNOLOGY TRANSFER TO
THE INDUSTRY IN THE AREA OF INTEROPERABILITY OF SYSTEMS AND APPLICATIONS. GRIS AIMS TO ASSURE THE RESEARCH GROUP MAINTAINS THE EXCELLENCE AND VISIBILITY AT NATIONAL AND INTERNATIONAL LEVEL, AND IT PROVIDES IMPACT THROUGH EXTENSIVE PARTICIPATION IN SOUND RESEARCH CONSORTIA, AND OUTREACH AT SCIENTIFIC
AND SOCIETY LEVEL. THIS INCLUDES PURSUING REFERENTIAL ACTIVITIES AT INTERNATIONAL, EUROPEAN AND NATIONAL LEVEL, LIKE RESEARCH PROJECTS AND SCIENTIFIC NETWORKS INTEGRATED IN EXCELLENT CONSORTIA, PUBLICATIONS OF RESEARCH IN REFERENTIAL JOURNALS AND CONFERENCES, TECHNOLOGY TRANSFER AND CLOSER SYNERGIES WITH THE SOCIETY.
MARKET APPLICATION
Horizontal markets
Page 454 of 487
Spain
Universidad complutense
Organisation Name
Country
Spain
City
Madrid
Street
C/ Rosa de Lima, 32
Website
www.ucm.es
Phone
0034678318848
Organisation Type
University
Person
Name
Clara Garcia
Email
[email protected]
Job Position
Phd candidate
The Complutense University of Madrid (Spanish: Universidad Complutense de Madrid or Universidad de
Madrid, Latin: Universitas Complutensis) is a public research university located in Madrid, and one of the oldest universities in the world. The university enrolls over 86,000 students, and consistently ranks as one of the top universities in Spain.It is located on a sprawling campus that occupies the entirety of the Ciudad Universitaria district
of Madrid, with annexes in the district of Somosaguas in the neighboring city of Pozuelo de Alarcón.
In the course of over seven centuries, the University of Madrid has provided invaluable contributions in the sciences,
fine arts, and political leadership.
Areas of Activity
Methods and data
policies
Preventing disease
young
(PCP)
Offer: Advise on Health systems cohesión mechanisms
I have carried an European research on Health systems cohesión mechanisms
To know which are the cohesión mechanisms of each system will make easier to identifybest practicas at our own
MARKET APPLICATION
Health systems
Health authority at state level
Page 455 of 487
Spain
Request: Access to Health
A research project on Health access
To uncover the mechanisms towards Health access
Researchers
Page 456 of 487
France
University Hospital of Montpellier
Organisation Name
Country
France
City
Montpellier
Street
80, Augustin Fliche avenue
Website
Phone
+33467339510
Organisation Type
Other
Person
Name
Christina PSOMAS
Email
[email protected]
Job Position
Senior Registrar
I am a Senior Registrar in a large French Department of Infectious Diseases (Head Prof Jacques Reynes). I am responsible of Clinical and Translational Research mainly concerning our 1900 HIV-infected patients that are followed-up in
our unit. Clinical Research concerns interventional therapeutic studies of phases II and III. Translational research is realized with collaboration of the Institute of Human Genetics (CNRS UPR 1142) and the Immunology and Virology Departments of the University Hospital of Montpellier.
The main advantage of our position is the direct access to indoor and ambulatory patients, as well as a quality research structure, combining our research engineers, as well as biology structures with a recognized expertise.
Areas of Activity
the immune system
Offer: Persistent Immune Activation in patients followed-up for a chronic disease and
emerging comorbidities
HIV infection causes generalized immune activation. Combinated AntirRetroviral Therapy (cART) reduces but does not
abolish immune activation that fuels non-AIDS comorbidities, such as liver steatosis, atherothrombosis, osteoporosis,
metabolic syndrome, kidney impairment, frailty, cancers, and neurocognitive disorders. Characterization of different
profiles of immune activation can determine different risks of presenting specific comorbidities. Immunopathogenic
mechanisms concerning HIV-infected patients, other chronically followed-up patients (with autoimmune or rhumatismal diseases), as well as natural ageing, may be very similar.
Page 457 of 487
Switzerland
University of Applied Sciences Northwestern Switzerland
Organisation Name
Country
Switzerland
City
Muttenz
Street
Gruendenstrasse 40
Website
Phone
Organisation Type
University
Person
Name
Michael de Wild
Email
[email protected]
Job Position
University of Applied Sciences Northwestern Switzerland
School of Life Sciences
Institute for Medical and Analytical Technologies
The Institute for Medical and Analytical Technologies carries out research and development in the innovative environment of medicine, industry and academia in the areas of material and implant development, in vivo diagnostics and
therapeutic systems.
Our work is focussed on patient-specific solutions and the analysis of medical data. In cooperation with our partners
we tackle issues in the field of medicine and develop innovative solutions, from the first idea to functional models.
The industry experience of our staff results not only in innovative research, but is also integrated in the teaching program.
Research fields
• Implants and Surgical Systems
• Biomedical IT Systems
• Medical Image and Signal Processing
Request: Additive Manufacturing of Smart Implants
Our institute has a strong background in smart 3D implant development. We are aiming to realise application-oriented, scientific research projects with you.
We are actively searching for partners to cooperate in H2020 health projects.
Page 458 of 487
Italy
University of Bologna
Organisation Name
Country
Italy
City
Bologna
Street
Via Zamboni33
Website
Phone
Organisation Type
University
Person
Name
Gianluca Storci
Email
[email protected]
Job Position
Almost 1000 years old, the Alma Mater Studiorum – Università di Bologna (UNIBO) is known as the oldest University of
the western world. Nowadays, UNIBO still remains one of the most important institutions of higher education across
Europe and the second largest university in Italy with 11 Schools, 33 Departments and more than 84.000 students; it is organized in a multi-campus structure with 5 operating sites (Bologna, Cesena, Forlì, Ravenna and Rimini),
and, since 1998, also a permanent headquarters in Buenos Aires. With regard to the international reputation, UNIBO has been awarded the use of the logo "HR Excellence in Research” and is among the top 5 Italian universities in
the main International rankings, e.g., 1st Italian university (182nd worldwide position in 2014/2015 and 69th for
Academic Reputation) in the international QS - World University Rankings since 2010; 4th Italian university (128th
worldwide position in 2014) in the National Taiwan University Ranking; 1st Italian University (86th worldwide position
in 2015) in the Ranking Web of World Universities. With regard to the ability of attracting funding, UNIBO is very
active both at National and European level. At European level, with 87.5 million Euro from FP7 (275 projects funded in
2007-2013; in 58 of them UNIBO was coordinator) UNIBO is the 2nd Italian university (37th position) in the ranking
of top 50 Higher or secondary education organizations in FP7 signed grant agreements in terms of counts
of participations (Seventh FP7 Monitoring Report 2013). In Horizon 2020, UNIBO is involved in 49 funded projects – in
9 of them UNIBO is coordinator – with 16.095 million Euro. At National level UNIBO ranks second for competitive research funding from the Italian Government. At UNIBO, activities related to European funding programs are supported
by the European Research and Innovation Office, which has more than 10 years experience with European projects. With about 30 people, organized in 4 thematic units plus another unit specifically devoted to ERC and Marie
Curie programs, the office assists research groups in the whole project lifecycle: networking and lobbying, consortium
building, proposal preparation, negotiation and project management. With reference to FP7, the office managed more
than 130 projects, of which 30 coordinated by the University of Bologna. The European Research and Innovation Office steadily cooperates with the Knowledge Transfer Office, which supports protection, management and exploitation of intellectual property of project results (patents and other IPR, licensing, spin-off companies, etc.), and with the
Research Communication Office, devoted to enhance visibility of the research activities carried out within the Alma Mater Studiorum – Università di Bologna (communication material targeted to local, national and European media,
planning and organization of research related events and support in the participation to external dissemination
events, etc.). The cooperation among these three offices maximizes the impact of project results, both in terms of exploitation and high quality communication and dissemination.
Areas of Activity
the immune system
population
Methods and data
Page 459 of 487
Italy
diseases
EU level
Preventing disease
Initiative
young
policies
Offer: Societal challenges. Health, demographic change and wellbeing
University of Bologna is one of the leading Italian Universities for obtaining European funding for research. The university of Bologna school of medicine and surgery is hosted and structured in the S.Orsola-Malpighi University hospital.
The Polyclinic is organized in 9 departments with 86 operative units. Tha main research fields cover: -Cardiothoracic
and vascular treatments and surgery (pediatric and adult); -Clinical and experimental hematology; -Organ diseases
and transplantation; -Regenerative medicine; -Bone marrow transplantation; -Hepato-gastroenterology; -Chronical intestinal diseases; -Highest security for bioterrerosim and SARS; -HIV-AIDS; -Immunogenetics; -Medical genetics; Neonataology; -Diabetology; -Endocrinology; -Medical oncology Every year the S.Orsola-Malpighi University hospital
handles 70.000 admitted cases and an estimated 4.000.000 outpatients visits by medical specialists.
The University of Bologna has a wide range of research expertise in the medical and biomedical field, ranging from
bioengeneering to all medical sciences, supported by a long history of EU project management.
MARKET APPLICATION
H2020-Societal challenges-Health, demographic change and wellbeing
Public and private research institution looking for H2020 partnerships for medical and biomedical project.
Page 460 of 487
Spain
Organisation Name
Country
Spain
City
Bilbao
Street
Avenida Universidades 24
Website
Phone
+34619967223
Organisation Type
University
Person
Name
Begoña Garcia-Zapirain
Email
[email protected]
Job Position
The University of Deusto has a long and well established teaching and research tradition. Founded in 1886, and since
2009 recognised as an International Excellence Campus, the University is a hub of thirty-nine research teams belonging to six faculties (Psychology and Education, Social Sciences and Humanities, Engineering, Law, Economic and Business Sciences, and Theology) situated across three different campuses in Bilbao, San Sebastian, and Madrid. In 1987
the University embarked upon a strategy of internationalisation which has led Deusto to join ninety-four international
networks, and to sign over 700 cooperation agreements with universities and research centres from around the globe.
At present, it coordinates or participates in fourteen on-going collaborative research projects funded by the European
Commission.
DeustoTech-Life Research Group (eVida), a research group within the University of Deusto Engineering Faculty, is
an experienced, dynamic and diverse team of telecommunications, electronics and software engineers, physicists,
mathematicians and psychologists. Founded in 2002, the group is committed to research on and development of ICTbased tools, systems and interventions for psychological, social and physical health. Over the last decade,
DeustoTech-Life have established close working relationships with key local stakeholders including hospitals, charities,
other research groups and ICT companies.
DeustoTech-Life conduct applied research in two main areas. In the field of ICTs for Well-Being, DeustoTech-Life research, design, develop and test tools and systems which enable disabled people and the elderly to live more independent lives. DeustoTech-Life is currently involved in creating apps and devices for informal learning and informal
learning follow-up services, programmes for person-centred care, and various tele-medicine and tele-monitoring systems. Work in this area has included applied research aimed at assisting groups such as people with intellectual disabilities, people with autism, people with visual impairments, people with hearing impairments, and people with multiple sclerosis. In the field of health, DeustoTech-Life specialise in creating diagnostic tools and systems and interventions for people with health problems such as skin and lung cancer, laryngectomy, epilepsy, migraines, dyslexia and
bed sores. This work is based on long term research in the processing of: speech, ECG, EMG and EEG signals, and MRI
(colon and lung cancer, articulatory description...), neuro fMRI, dermoscopy, pressure ulcers and stroboscopy images.
Areas of Activity
Preventing disease
Initiative
young
Methods and data
Page 461 of 487
Spain
• PM-12-2016
(PCP)
• PM-13-2016
(PPI)
• PM-14-2016
• PM-15-2017
population
policies
diseases
Offer: Collaboration in the areas of Personalised Medicine, ICTs for Health and Wellbeing,
and Active Ageing
DeustoTech-Life Research Group (eVida), a research group within the University of Deusto Engineering Faculty, is an
experienced, dynamic and diverse team of telecommunications, electronics and software engineers, physicists, mathematicians and psychologists. Founded in 2002, the group is committed to research on and development of ICT-based
tools, systems and interventions for psychological, social and physical health. Over the last decade, DeustoTech-Life
has established close working relationships with key local stakeholders including hospitals, charities, other research
groups and ICT companies.
DeustoTech-Life conduct applied research in two main areas. In the field of ICTs for Well-Being, DeustoTech-Life research, design, develop and test tools and systems which enable disabled people and the elderly to live more independent lives. DeustoTech-Life is currently involved in creating apps and devices for informal learning and informal
learning follow-up services, programmes for person-centred care, and various tele-medicine and tele-monitoring systems. Work in this area has included applied research aimed at assisting groups such as people with intellectual disabilities, people with autism, people with visual impairments, people with hearing impairments, and people with multiple sclerosis. In the field of health, DeustoTech-Life specialise in creating diagnostic tools and systems and interventions for people with health problems such as skin and lung cancer, laryngectomy, epilepsy, migraines, dyslexia and
bed sores. This work is based on long term research in the processing of: speech, ECG, EMG and EEG signals, and MRI
(colon and lung cancer, articulatory description...), neuro fMRI, dermoscopy, pressure ulcers and stroboscopy images.
MARKET APPLICATION
Personalised Medicine, ICTs for Health and Wellbeing, and Active Ageing
Universities, research Groups, Patient Associations, ICT Companies
Request: Seeking partners interested in projects on Machine Learning, Data Mining and
Biomedical Signal Processing
DeustoTech-Life Research Group (eVida), a research group within the University of Deusto Engineering Faculty, is an
experienced, dynamic and diverse team of telecommunications, electronics and software engineers, physicists, mathematicians and psychologists. Founded in 2002, the group is committed to research on and development of ICT-based
tools, systems and interventions for psychological, social and physical health. Over the last decade, DeustoTech-Life
has established close working relationships with key local stakeholders including hospitals, charities, other research
groups and ICT companies.
We are seeking companies interested in projects on Machine Learning, Data Mining and Biomedical Signal Processing,
applied to health and wellbeing
Companies who want to collaborate applying our knowledge, by private contracts or H2020 funding calls
Page 462 of 487
Spain
Organisation Name
Country
Spain
City
Bilbao
Street
Avenida Universidades 24
Website
www.evida.deusto.es
Phone
Organisation Type
University
Person
Name
Amaia Mendez Zorrilla
Email
[email protected]
Job Position
The University of Deusto has a long and well established teaching and research tradition. Founded in 1886, and since
2009 recognised as an International Excellence Campus, the University is a hub of thirty-nine research teams belonging to six faculties (Psychology and Education, Social Sciences and Humanities, Engineering, Law, Economic and Business Sciences, and Theology) situated across three different campuses in Bilbao, San Sebastian, and Madrid. In 1987
the University embarked upon a strategy of internationalisation which has led Deusto to join ninety-four international
networks, and to sign over 700 cooperation agreements with universities and research centres from around the globe.
At present, it coordinates or participates in fourteen on-going collaborative research projects funded by the European
Commission.
DeustoTech-Life Research Group (eVida), a research group within the University of Deusto Engineering Faculty, is
an experienced, dynamic and diverse team of telecommunications, electronics and software engineers, physicists,
mathematicians and psychologists. Founded in 2002, the group is committed to research on and development of ICTbased tools, systems and interventions for psychological, social and physical health. Over the last decade,
DeustoTech-Life have established close working relationships with key local stakeholders including hospitals, charities,
other research groups and ICT companies.
DeustoTech-Life conduct applied research in two main areas. In the field of ICTs for Well-Being, DeustoTech-Life research, design, develo

Participants Catalog

Transcription

Similar documents

Technical Information

Rosato – Leggero 9° – Light wine

Act No. 26 of 1997

Iraq Country Office Overview

Rosso – Leggero 9° – Light wine

The Art of Ageing

FestusManor Good News Gazette Update

Lanvera Borland-Groover Clinic Case Study

FamaLaser4 - Video HT Ltd.

Burlington County Times - Solar - color.indd